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Summary of Thesis  
 
To help mitigate the escalating prevalence of Type 2 Diabetes (T2D) and alleviate 
society of its associated morbidity and economic burden on health care, it is 
crucial to understand its aetiology. Both genetic and the environmental risk 
factors are known to be involved. Healthy diets have been proven to reduce the 
risk of T2D in primary prevention trials, however, which components and exact 
mechanisms are involved is not fully understood, in particular, the role of 
macronutrient intake. Body weight, glycaemic markers and T2D are all to some 
extent genetically regulated. There may also be genetic influences on how people 
digest, absorb or metabolise macronutrients. This poses the possibility that the 
interplay between genes and our diet may help us unravel T2D’s aetiology.  
 
The aim of this PhD was to investigate gene-diet interactions on the risk of 
incident T2D, focusing primarily on macronutrient intake as the dietary factor. 
First, I systematically evaluated the current evidence before taking a step-wise 
approach (hypothesis driven to hypothesis-free) to interrogate gene-
macronutrient interactions. This identified 13 publications, with 8 unique 
interactions reported between macronutrients (carbohydrate, fat, saturated fat, 
dietary fibre, and glycaemic load derived from self-report of dietary intake and 
circulating n-3 polyunsaturated fatty acids) and genetic variants in or near 
TCF7L2, GIPR, CAV2 and PEPD (p<0.05) on T2D. All studies were observational 
with moderate to serious risk of bias and limitations that included lack of 
adequate adjustment for confounders, lack of reported replication and 
insufficient correction for multiple testing.  
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Second, these reported interactions did not replicate in a large European multi-
centre prospective T2D case-cohort study called EPIC-InterAct. We concluded 
that the heterogeneity between our results and those published could be 
explained by methodological differences in dietary measurement, population 
under study, study design and analysis but also by the possibility of spurious 
interactions. 
 
Third, given the paucity of gene-macronutrient interaction research using genetic 
risk scores (GRS), we examined the interaction between three GRS (for BMI (97 
SNPs), insulin resistance (53 SNPs) and T2D (48 SNPs)) and macronutrient 
intake (quantity and quality indicators) in EPIC-InterAct. We did not identify any 
statistically significant interactions that passed multiple testing corrections 
(p≥0.20, with a p value threshold for rejecting the null hypothesis of 0.0015 
(based on 0.05/33 tests)). We also examined 15 foods and beverages identified as 
being associated with T2D, and no significant interactions were detected. Lastly, 
we applied a hypothesis-free method to examine gene-macronutrient interactions 
and T2D risk by using a genome-environment-wide-interaction-study. 
Preliminary findings showed no significant interactions for total carbohydrate, 
protein, saturated fat, polyunsaturated fat and cereal fibre intake on T2D. 
 
In conclusion, the consistently null findings in this thesis using a range of 
statistical approaches to examine interactions between genetic variants and 
macronutrient intake on the risk of developing T2D have two key implications. 
One, based on the specific interactions examined, this research does not confirm 
evidence for gene-diet interactions in the aetiology of T2D and two, this research 
suggests that the association between macronutrient intake and the risk of 
developing T2D does not differ by genotype.  
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1. Chapter 1 Introduction 
 
In 1932, Lancelot Hogben a zoologist and medical statistician claimed that 
variability  
‘arises from the combination of a particular hereditary constitution with 
a particular kind of environment.’[1] 
The variability in disease traits and the contribution of nature vs nurture to this 
variability has fascinated scientists for centuries. Certainly, for Type 2 Diabetes 
Mellitus (T2D), a major global public health challenge of the 21st century, 
variability in development, manifestation and progression have underpinned the 
many discussions about its definition and classification.[2] This is important in 
correct and timely diagnosis and treatment but also understanding what drives 
variability in disease development offers crucial insights to better target 
prevention efforts. Therefore, to better understand this variability and T2D 
aetiology, it led me to study the interplay between our genes and dietary intake 
(i.e. interplay between nature and nurture).   
Apart from helping to unravel the aetiology of T2D, it is believed that knowledge 
about gene-diet interactions may translate into identifying individuals most likely 
to benefit from preventative dietary interventions.[3] This is of great public health 
interest, particularly in the setting of scarce healthcare funding. However 
currently, it is unclear what the evidence is for gene-diet interactions in the 
development of T2D. That is, are there any convincing interactions that may 
support this ambition? Studies suggesting gene-diet interactions for T2D 
certainly exist, including between dietary fibre and genetic predisposition for T2D 
via TCF7L2[4] (strongest genetic locus for T2D),[5] however, findings have been 
sporadic and inconsistent. Secondly, the literature on gene-environment 
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interactions harbours many methodological limitations that devalue the quality of 
studies used to evaluate the evidence. This includes problems inherent to the 
observational nature of studies, such as chance, confounding and bias, as well as 
concerns regarding the lack of statistical power because of the relatively small 
magnitude of interaction effects and publication bias. Hence, would studies 
designed to overcome such limitations provide a clearer answer? 
The overall aim of this PhD thesis was therefore to address these two questions 
about gene-diet interactions in the context of preventing T2D, in order to 
understand if these are important in the aetiology of T2D as well as the value for 
dietary public health interventions. This was achieved using observational 
epidemiological methods applied to large-scale population-based and T2D case-
cohort studies.  
This thesis begins by introducing the background that motivated this piece of 
research in Chapter 2, ending with the aims and specific objectives. Next, the 
concepts and application of statistical interactions used within this PhD will be 
explained before a description of the main case-cohort study that was used within 
this PhD: EPIC-InterAct (Chapter 3). In Chapter 4, the literature on gene-
macronutrient interactions and T2D was reviewed and to assess the validity of 
reported interactions an attempt was made to replicate these in EPIC-InterAct. 
Gaps in research were identified, one of which was a lack of non-candidate gene 
approaches to examine interactions. Therefore, in Chapter 5 and 6, genetic risk 
scores were used to investigate interactions with macronutrients and with foods 
and beverages in relation to the development of T2D. A genome-environment-
wide-interaction-study to examine gene-macronutrient interactions was also 
conducted and will be discussed in Chapter 7.  
Lastly, in Chapter 8, a discussion of the strengths and limitations will be made in 
the context of the current literature, including a discussion about the impact of 
genetic risk information on behaviour change which together with the findings on 
gene-diet interactions helps to evaluate the public health value of genetically 
stratified nutritional interventions. Finally, a discussion about what the findings 
mean for future research and public health nutrition draws the thesis to a close. 
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2. Chapter 2 Background and literature review 
 
 
This chapter highlights the urgent need to tackle the rising prevalence of Type 2 
Diabetes Mellitus (T2D). I also explain how prevention strategies may be 
optimised by improving our understanding of whether the risk of diet-induced 
T2D differs genetically between people. I will examine the evidence which 
motivated the research within this PhD.   
2.1 Definition, classification and diagnosis of Type 2 Diabetes Mellitus 
 
According to the World Health Organization (WHO) the term "diabetes mellitus" 
describes, ‘a metabolic disorder of multiple aetiology characterised by chronic 
hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism 
resulting from defects in insulin secretion, insulin action, or both.’[6] T2D is often 
distinguished from other forms of diabetes by β-cell deterioration or dysfunction 
and results in an imbalance between insulin secretion and insulin sensitivity. 
Individuals with T2D may not require external insulin to survive, as depicted in 
the figure below from the American Diabetes Association (ADA) (Figure 2-1).  
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Figure 2-1: Classification of diabetes (American Diabetes Association)[7] 
Diagnosing T2D involves either an examination of plasma glucose or 
haemoglobin A1c (HbA1c). With the former, this may be via fasting glucose or an 
oral glucose tolerance test followed by a plasma glucose test after 2 hours. The 
diagnostic criteria recommended by the WHO and the International Diabetes 
Federation (IDF) are provided in Table 2-1.[8,9] Concordance between the tests is 
imperfect and there are benefits and limitations of each. For example, HbA1c 
tests are the most stable to day-to-day perturbations and convenient but HbA1c is 
affected by factors that influence haemoglobin glycation independent of 
glycaemia, such as age, race and anaemia.[9] It appears that 2 hour plasma glucose 
during an oral glucose tolerance test diagnoses more people with diabetes. For 
diagnosing clinical diabetes, the ADA recommends that a second confirmatory 
test using a new blood sample is required when the patient is asymptomatic and 
test results exceed normal thresholds.[10] Classic symptoms of T2D include 
frequent urination, excessive thirst, fatigue, blurred vision and/or possible 
unexplained weight loss. 
Table 2-1: T2D diagnostic criteria 
Test Threshold above which diabetes is 
diagnosed 
Fasting plasma glucose ≥7mmol/L 
2 hour plasma glucose during an oral 
glucose tolerance test 
≥11.1mmol/L 
HbA1c ≥48mmol/mol (or ≥6.5%) 
Patient with classical symptoms of 
hyperglycaemia, a random plasma 
glucose 
≥11.1mmol/L 
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Even within T2D, based on current diagnostic criteria, presentation and the rate 
of progression of hyperglycaemia can vary between individuals. This 
heterogeneity may result in misdiagnosis or underdiagnosis in the clinical setting 
and/or misclassification for research purposes. Tuomi and colleagues described 
how the true spectrum and distinct forms of diabetes are still to be clarified and 
how factors such as the age of onset and genetics may contribute to this 
heterogeneity as well as may explain why there are patients presenting with 
features overlapping multiple types of diabetes.[2]  Although this discussion is 
beyond the scope of this thesis, it suggests that there is much-needed research in 
dissecting the genetic contribution to this variation as it may help to elucidate a 
better understanding of the aetiology of T2D to improve the precision and 
timeliness of diagnosis and treatment. 
2.2 Epidemiology of diabetes   
 
Worldwide prevalence of diabetes has more than doubled for men (from 4.3 to 
9.0%) and increased by 60% for women (from 5.0 to 7.9%) from 1980 until 2014 
and was estimated to affect more than 420 million people in 2014.[11] The fastest 
rise has been observed in low- and middle-income countries. In 2015, the average 
prevalence of diabetes in Europe was 9.1%, where 87-91% of these were cases of 
T2D.[12] Figure 2-2 illustrates the prevalence across Europe. According to the IDF, 
among European countries in 2015, 23.5 million people with diabetes (39.3%) 
were unaware of their condition, with T2D making up almost all those 
undiagnosed.[12] Untreated or poorly managed diabetes can contribute to 
significant morbidity, reduced quality of life and premature death, including 
microvascular complications such as retinopathy which increases the risk of 
blindness, nephropathy, neuropathy and macrovascular complications such as 
cardiovascular disease, which is the world’s leading cause of mortality.[13] Women 
with gestational diabetes have higher risk of pregnancy complications such as 
pre-eclampsia and eclampsia but more devastating are the transgenerational 
impacts on the child. Studies have shown that children of women with gestational 
diabetes are at greater risk of developing T2D later in life because of shared 
genetics and intrauterine conditions that may cause ‘fetal programming’ due to 
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excessive placental transfer of glucose.[14] Every year, diabetes and its 
complications result in more than 2 million deaths, globally.[11] On top of this 
debilitating impact on human function and wellbeing, diabetes also poses 
immense economic burden. A recent systematic review estimated that the global 
economic cost of diabetes in 2015 was US$13.1 trillion, reflecting both direct (e.g. 
hospitalisation and medication) and indirect costs (e.g. loss of productivity due to 
morbidity and premature mortality).[15]  
 
Figure 2-2: Variation in prevalence of diabetes across Europe, IDF 2015[12] 
The sheer scale and disabling impacts of diabetes therefore identifies it as one of 
the four priority noncommunicable diseases within the 2011 Political Declaration 
on the Prevention and Control of Noncommunicable Diseases requiring urgent 
action by world leaders. It is also one of the key targets within the WHO Global 
Action Plan 2013-2020, which is a set of strategic actions towards the prevention 
and control of noncommunicable diseases.[16] 
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2.3 Pathophysiology and aetiology of type 2 diabetes 
 
T2D is multifactorial and polygenic and arises after the failure of insulin secretory 
function to maintain normoglycemia (β cell dysfunction) in the face of insulin 
resistance, often secondary to obesity.[17] Progressive β cell dysfunction 
characterises the glucose impairment classic of T2D.[17] This affects metabolism 
within three major tissues being the liver, muscle and adipose tissues (Figure 2-
3).[18] Given that the brain and red blood cells’ primary source of energy is 
glucose, the body tries to maintain sufficient levels of this. A lack of intracellular 
glucose signalling leads firstly to increased glucose production either by hepatic 
glycogenolysis or gluconeogenesis coupled with decreased glucose uptake by 
insulin-dependent GLUT4 of adipose tissues and muscle. This may lead to 
hyperglycaemia and subsequent microvascular conditions. Second, a reduction in 
carbohydrate utilisation may shift energy production from carbohydrate to 
another source such as fatty acids (increase lipolysis and decrease triglyceride 
synthesis) which may increase plasma lipids and macrovascular disease. Thirdly, 
muscle protein may be used as a source for gluconeogenesis and may lead to 
muscle wasting. Subsequently, hyperglycaemia and raised lipids may worsen 
insulin resistance.  
31 
 
 
Figure 2-3 Pathophysiology of hyperglycaemia and increased circulating fatty acids in type 2 diabetes[18] 
Fortunately, T2D can be prevented but in order to develop effective prevention 
strategies, we need to understand its aetiology. The risk factors for T2D and 
associated poor glucose homeostasis can be classified broadly as those that 
pertain to i) the individual’s bio-physiology, ii) behaviours and iii) external 
influences of the environment or social context (Figure 2-4). There is overlap and 
interplay between these risk factors. 
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Figure 2-4: Causal diagram of risk factors in the development of T2D (not an exhaustive list) 
* Represents factors illustrated in the Figure: Barriers and opportunities for healthy eating, available in Mozaffarian et 
al., 2016[19] 
 
Within the domain of bio-physiological and behavioural factors, some are 
modifiable and some non-modifiable. Non-modifiable factors include ethnicity, 
age, sex, family history of diabetes and genetic predisposition, which will be 
discussed in section 2.4. Noticeably, a striking difference in diabetes prevalence 
exists between those under 40 and those over 50 years old, likely because T2D is 
heavily influenced by the accumulation of lifestyle factors over time. Such 
differences were also evident in the prevalence between men (9%) and women 
(7.9%) (Figure 2-2).[11,12]  
Being overweight or obese drastically increases the risk of developing T2D. A 
meta-analysis of 11 cohort studies revealed significantly higher risk of T2D among 
those who were obese and metabolically healthy (defined by normal insulin 
sensitivity, normoglycaemia, low inflammation and higher cardiorespiratory 
fitness) (RR: 4.03, 95%CI: 2.66, 6.09) as well as those who were obese and 
metabolically unhealthy (RR: 8.93, 95%CI: 6.86, 11.62) compared to healthy 
normal-weight adults.[20] These individual factors (e.g. adiposity, blood glucose 
homeostasis, blood lipids and blood pressure) are responsive to lifestyle change 
(e.g. smoking, physical activity, sedentary time and diet) and thus are crucial 
factors to target for T2D prevention.  
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Wider societal influences including inequalities in access (financial, physical 
distance and comprehension), differing levels of acceptance and adherence to 
healthy lifestyles also affects risk of T2D. Those from socioeconomically 
disadvantaged backgrounds are particularly vulnerable to a poor diet and 
subsequent risk of T2D.[21] This was evident from a large UK-based cohort study, 
which found that individuals who consumed a greater diversity of foods (from five 
major food groups) had 30% lower risk of T2D than those consuming a diet with 
three or fewer food groups.[22]  However, the group consuming a greater dietary 
diversity were often those who could afford to pay more.[22]  These external 
factors, therefore, may either support healthy behaviours or create what some 
have coined an ‘obesogenic environment,’ that is not conducive to preventing 
T2D. These factors are the individual’s social-cultural-geopolitical context and 
include the workplace, family environment, food production and industry 
interests, the country’s nutrition policies, health care system, culture, and so on. 
This framework is in part underpinned by the Social-Ecological Model of health 
promotion, which recognises that human behaviours and well-being are a product 
of both their social, institutional and cultural context and the interaction with 
personal characteristics of the individual.[23]  
It is through understanding the mechanisms of how our behaviours and 
environment shape our risk of T2D, in the context of our biological 
predispositions, that we can define more effective prevention strategies. Indeed, 
the importance of focusing on both individual and population level strategies is 
recognised in recommendations for prevention of T2D by the National Institute 
for Health and Care Excellence.[24] Among these many facets of risk factors 
involved in T2D development, my PhD focuses on the interplay between two of 
these, namely diet and genes (Figure 2-4). Next, these will be discussed separately 
before explaining the connection between the two. 
2.4 Genetic epidemiology of T2D 
 
The heterogeneous development and clinical manifestation of T2D may in part be 
explained by biological differences between individuals, including their genes. 
Studies indicate that T2D is strongly heritable, with 61-78% of T2D variance 
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explained by genetics (estimated in >30,000 same-sex twin pairs aged ≥45 
years)[25,26] with the genetic component for T2D often stronger than for type 1 
diabetes.[12] Advancements in genetic epidemiology including recent meta-
analyses of genome-wide association studies (GWAS) in >100,000 individuals 
have led to the discovery of many common genetic variants robustly associated 
with T2D (>70 single nucleotide polymorphisms- SNPs),[5,27] and related traits 
including 97 SNPs for body mass index,[28] 36 for fasting glucose, 19 for fasting 
insulin[29] and 53 for insulin resistance.[30] There is expected overlap in the 
genetic architecture of these traits, likely reflecting intermediate processes along 
the causal pathway for T2D.[31] The most commonly studied class of genetic 
variations are SNPs, which result in single nucleotide changes in the DNA 
sequence. For example, rs7903146 is a SNP in the TCF7L2 gene, which encodes a 
high mobility group box-containing transcription factor involved in the Wnt 
signalling pathway, and is to date the most strongly associated SNP with T2D 
across multiple ethnicities (estimated odds ratio- OR per risk allele=1.45).[32,33]   
The majority of SNPs have smaller effects, with OR for T2D less than 1.20 per risk 
allele.[5]  
Taken together, these genes only account for approximately 6% of the variance in 
T2D susceptibility,[5] which beg the question about missing heritability in further 
understanding the aetiology of T2D. We now know that low-frequency variants 
(0.1%<minor allele frequency<5%) play a smaller role in T2D compared to their 
common counterparts (2.9% vs 6.3% of the variance for T2D by rare vs common 
variants, respectively).[34] Therefore gene-environment interactions, including 
with our diet, are hypothesised to explain some of this missing heritability and 
has been of immense research interest.[35] Next, the evidence for diet will be 
appraised before the literature relating to gene-diet interactions will be 
summarised. 
 
2.5 Diet and the prevention of Type 2 Diabetes 
 
Lifestyle interventions entailing dietary and physical activity modification have 
been proven to prevent T2D in randomised controlled trials. Among those with 
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impaired glucose tolerance, the incidence of T2D was halved in the dietary 
intervention group (e.g. populations in the United States of America, Finland and 
China),[36–38] and in some populations these benefits were sustained up to 20 
years post-intervention.[37]  The US Diabetes Prevention program (DPP), where 
3,234 high-risk participants were randomised to either placebo, Metformin or 
lifestyle intervention (including reduction in fat and energy intake), 
demonstrated that lifestyle intervention reduced the incidence of T2D by 58% 
after 2.8 years of follow-up and was more effective than Metformin (31% risk 
reduction).[39] Although impressive and clinically significant, from these trials it is 
difficult to distinguish the relative contribution of benefit from diet versus 
physical activity, which is important in understanding the mechanism to enable 
fine-tuning and more effective and cost-efficient planning of future interventions. 
It is also not possible to tease out the underlying dietary factor/s involved. 
Dietary modification has been a public health priority in preventing T2D.[19,40,41] 
However, the optimal dietary profile is still a mystery. What is known is that for 
those who are overweight or obese, a dietary intake which achieves weight loss is 
effective in preventing T2D. Next, a brief summary of the evidence for diet in T2D 
prevention will be presented, at different ‘levels’ of the dietary exposure 
spectrum, from dietary patterns to foods and beverages to nutrients. 
Macronutrient intake was the primary dietary exposure of interest within this 
thesis.  
2.5.1 Dietary patterns 
Several patterns of eating, underpinned by specific combinations of dietary 
components, have been demonstrated to reduce the risk of developing T2D. This 
includes the Mediterranean dietary pattern, the Alternate Healthy Eating Index, 
and the Dietary Approaches to Stop Hypertension (DASH) diet, to name a few for 
the prevention of T2D.[42] The longest running randomised controlled trial 
investigating the Mediterranean dietary pattern (median follow-up of 4.8years, 
N=3,541) found that compared to controls (advice on a low-fat diet), those 
consuming a Mediterranean dietary pattern with extra-virgin olive oil showed 
40% lower risk (95%CI: 15-57%) of developing T2D.[43] Although understudied, 
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the benefits of these dietary patterns must be in some way also influenced by their 
methods of preparation as well as how, when and where they are consumed.  
 
2.5.2 Foods and beverages  
A wealth of evidence from both intervention and observational studies highlights 
a range of foods and beverages associated with T2D, which shows commonalities 
with the aforementioned dietary patterns, when disaggregated.[19,42] Table 2-2 
lists these according to their reported association with T2D from recently 
published meta-analyses. 
Table 2-2: Foods and beverages associated with Type 2 Diabetes 
Association with T2D Foods and beverages (reference to published 
meta-analysis) 
Inversely associated Fruits[44] 
 Green leafy vegetables[44] 
 Root vegetables[44] 
 Wholegrain bread and cereals[45] 
 Nuts and seeds[46] 
 Legumes[46] 
 Fermented dairy[47,48] 
 Coffee[49] 
 Tea[50] 
Association inconsistent or null Fish[51] 
 Egg and egg products[52] 
Positively associated Sugar Sweetened Beverages (SSB)[53] 
 Rice[54] 
 Unprocessed red meat[55] 
 Processed meat[55] 
 
There are reasons for research investigating dietary exposures at different ‘levels’ 
of the dietary exposure spectrum (i.e. from nutrients to foods to diets). Figure 2-5 
illustrates this spectrum using carbohydrates. Certainly, research that provides 
messages about foods and dietary patterns enables improved public 
understanding and easier uptake of dietary advice.[19] Another reason relates to 
potential synergism between nutrients and non-nutritive constituents which 
would suggest that the sum of the whole food and/or beverage may act 
independently to the individual nutrients it is composed of.[19,56] The same applies 
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to dietary patterns. Nutrients are not consumed in isolation, however, 
understanding disease aetiology and biological mechanisms underpinning the 
association between higher level dietary factors and T2D requires examination at 
the level of nutrients. At the molecular level, catabolised nutrients such as 
glucose, amino acids, fatty acids and micronutrients may directly interact with 
transcription factors, ligands, DNA, etc. For example, the vitamin D receptor 
(VDR) is a transcription factor that triggers a cascade of cellular signalling post-
DNA-binding, which controls serum calcium levels, metabolism, cellular growth 
and immune functions.[57] Like a lock and key, the nutrient 1α,25(OH)2D3 
(vitamin D) needs to bind to the VDR to initiate this process. Therefore, there is 
merit in researching nutrients to help understand the molecular aetiology of T2D, 
as in the case of gene-diet interactions which will be discussed in section 2.6.  
Next, a summary of the latest literature regarding energy and macronutrient 
intake in relation to the risk of developing T2D, will be provided. The majority of 
published literature with T2D as an outcome is observational in nature because of 
the longer follow-up required in identifying the development of T2D. Other 
factors that may make it challenging to study dietary factors using an RCT design 
include motivation for long term adherence to a dietary intervention, drop outs, 
difficulty in blinding and cost which may contribute to bias. Since adiposity and 
glucose homeostasis are likely mediators between diet and T2D the literature on 
RCTs pertaining to these intermediate traits were also examined to gain a more 
complete picture of the impact of diet on T2D development. 
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2.5.3 Energy intake affects weight whereas macronutrient composition affects 
glucose homeostasis 
 
It has been conventional clinical practice to prevent excessive weight gain by 
managing energy balance (i.e. energy intake vs energy expenditure). Energy 
reduction, regardless of macronutrient composition leads to weight loss, as 
exemplified in a meta-analysis of 48 weight loss interventions.[58] However, 
macronutrients have been shown to differentially influence T2D risk via their 
effects on glucose homeostasis and insulin resistance, in addition to how their 
palatability may influence adherence to the diet. Figure 2-6 summarises the 
observational literature, whereas Table 2-3 summarises the evidence from RCTs.    
Figure 2-5: Nutrition spectrum (designed by SL using a photo from bicycling.com) 
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Figure 2-6: Association between macronutrient intake and Type 2 Diabetes (observational literature). 
This figure was compiled after reviewing the literature on this topic (non-systematic). Where possible, the most 
recently reported meta-analysis has been reported and the estimates from the most adjusted models have been used. 
Example of interpretation: the risk of developing T2D is 23% lower when replacing 5% total energy intake from protein 
(decrease intake) with carbohydrate intake (increase intake) (Schulze et al., 2008). ‘Replace’ means, to reduce this 
macronutrient. CHO- carbohydrate, SFA- saturated fat, MUFA- monounsaturated fat, PUFA- polyunsaturated fat, TEI: 
total energy intake, M- men, W- women. 
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 2.5.3.1 Macronutrient quantity 
Macronutrient quantity can be measured as a proportion of total energy 
intake (i.e. % of total energy intake: TEI).  
Total fat intake 
Among all the large diabetes prevention trials, which involved an intensive 
lifestyle intervention consisting of exercise and dietary behavioural change, 
from my knowledge, only the Finnish Diabetes Prevention Study investigated 
macronutrient intake and the risk of developing T2D.[59] In 500 participants at 
high risk for T2D (overweight or obese with impaired glucose tolerance), those 
reported to be consuming >37% TEI from total fat had a higher risk of 
developing T2D than those with <30%TEI from total fat (HR: 2.14, 95%CI: 
1.16, 3.92).  
Within meta-analyses of clinical trials for intermediate traits there is 
inconsistency in the effect of total fat intake on weight change, among 
overweight, obese and/or normal weight individuals (for weight 
maintenance).[60–62] Whilst Hooper et al., noted an overall weight reduction in 
favour of lower fat diets in a meta-analysis of 33 RCTs (every 1% decrease in 
energy from total fat led to 0.19kg decrease in body weight compared to no 
change in fat intake),[61] a more recent meta-analysis of 53 RCTs concluded no 
statistically significant difference in weight loss between low fat and higher fat 
dietary interventions of similar intensity (i.e. time and resources or support 
provided by study staff) (weighted mean difference in weight loss: 0.36, 
95%CI: -0.66 to 1.37).[62] Tobias and colleagues suggest that the difference 
observed with Hooper et al., may relate to confounding by the intensity of 
dietary interventions among studies of longer than one year in duration. 
Weight loss trials have shown that adherence to allocated diets diminishes 
with increasing duration, so it is unclear to what extent this influenced the 
reported findings. Tobias et al., used triglyceride levels at follow up as a proxy 
for adherence to a low fat diet,[62] however, it is questionable how well this 
captures adherence to a low fat diet, given that exercise, alcohol intake and 
medications can also influence triglyceride levels.  
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Observational cohort studies do not support a major influence of total dietary 
fat on the risk of T2D[63] but allude to the differential effects of fat subtypes 
(i.e. SFA, MUFA, PUFA), which will be discussed under the section titled 
‘macronutrient quality’.[42] 
Total carbohydrate intake 
Low carbohydrate diets have been popular but also controversial. The 
definition of a ‘low carbohydrate diet,’ varies, with studies including diets 
from 20g/d such as the Atkins diet[64] to <45% of total energy from 
carbohydrate intake,[65] and advocating restriction or avoidance of certain 
foods. For example, the South Beach diet is based on the philosophy of 
training your body to use fat as the main source of energy, starting off with 
avoidance of sugar and refined carbohydrates as well as fruits and whole 
grains.[66] The Banting diet recommends avoidance of gluten containing grain 
products.[67] To my knowledge, there is no published systematic review of 
clinical trials investigating the effect of carbohydrate intake on the risk of 
developing T2D.  
Two meta-analyses demonstrated that there is little difference in the change in 
blood glucose levels between those who consumed low carbohydrate (<45% 
energy) compared to low fat diets (<30% energy).[64,65]  
Two meta-analyses have shown that low carbohydrate diets results in greater 
weight loss compared to low fat diets.[62,64] For example, Tobias and 
colleagues found that among 18 RCTs, those on a low carbohydrate diet 
experienced a larger weight reduction than those on a low fat diet (weighted 
mean difference of 1.15kg more in weight reduction, 95%CI:0.52-1.79).[62] 
Whereas other meta-analyses have shown little difference in weight loss 
between a low carbohydrate diet compared to either a low fat diet or those 
with a moderate macronutrient composition.[58,65,68]  A major caveat of studies 
that compare low carbohydrate and low fat diets is that, under isocaloric 
conditions, low carbohydrate diets may also represent an increase in fat or 
protein intake or an equal increase in both. Therefore, the independent effect 
of reducing carbohydrate intake cannot be deduced from these studies. 
Moreover, low carbohydrate diets have been shown to increase LDL 
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Cholesterol,[64,65,68] yet also favourably increase HDL Cholesterol and decrease 
triglyceride levels.[64,65,69] However, it is unclear whether there are other non-
metabolic adverse consequences with low carbohydrate diets and at what level 
of carbohydrate intake would they manifest.  
In the observational setting, total carbohydrate intake is not associated with 
T2D.[63] However, in over 27,000 Germans, there was a suggestion of an 
inverse association when 5%TEI from protein was modelled to be replaced by 
carbohydrate intake (HR: 0.77, 95%CI: 0.64, 0.91).[70] It is unclear, however, 
to what extent this observed association was related to carbohydrate quality 
such as whether the carbohydrate was from whole- or refined-grain products.  
Total protein intake 
The definition of a, ‘high protein diet,’ varies but typically is >20% energy 
from protein intake. It has been purported to increase body fat mass loss, 
attenuate fat free mass loss, increase satiety and improve cardiometabolic 
profile. Among short term RCTs (<6 months duration), the effect of high 
protein diets on plasma insulin in healthy individuals is inconclusive whereas 
amongst those who are overweight or obese, high protein diets do not appear 
to improve insulin sensitivity over and above the effect of weight loss.[71]  
For weight loss, high protein diets appear to be beneficial, at least in the short 
term.[72] Santesso and colleagues found that when 38 trials comparing high 
(ranging from 16-45% of total energy intake) to low protein diets (ranging 
from 2-23% of total energy intake) were meta-analysed, there was a 
statistically significant larger weight loss in those consuming high protein 
diets (SMD of 0.36kg, 95%CI: 0.17, 0.56 greater), albeit high heterogeneity 
was also evident (I2=77%).[72] Other measures of adiposity, including BMI and 
waist circumference showed directionally similar effects in favour of a high 
protein diet, at three months.[72] However, the benefits attenuated when 
examining findings for studies of longer than three months in duration.[72] 
This was corroborated by the findings from two other meta-analysis, one 
comparing high with standard protein diets (N=13 studies)[73] and another 
comparing high with low protein diets (N=13 studies).[74] It appears that the 
benefits of high protein diets are temporary, however, it is unclear whether 
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this benefit may be confounded by the simultaneous reduction in glycaemic 
load whilst consuming a high protein diet. Similarly with low carbohydrate 
diets, there is improvement in HDL-Cholesterol and reduction in triglycerides 
but some have reported adverse gastrointestinal symptoms including bloating, 
constipation and diarrhoea.[72]  
Another systematic review showed that among prospective observation 
studies, those who consumed the highest amount of total protein had a 9% 
higher risk of developing T2D (95%CI: 6, 13%), compared to those who 
consume the lowest.[75] When modelling replacement of total protein for total 
fat or carbohydrate intake, findings did not materially change.[76,77]  
2.5.3.2 Macronutrient quality 
Fat subtypes 
A meta-analysis of clinical trials concluded that glycaemic indices, including 
plasma glucose, HbA1c and HOMA-IR improved when unsaturated fats 
(either monounsaturated or polyunsaturated fat) were consumed instead of 
saturated fat or carbohydrate.[78] This confirms the importance of fat subtypes 
in glucose homeostasis and subsequent T2D propensity. It also highlights that 
the replacement fat is as crucial as the type of fat being replaced. Two meta-
analyses, one of 20 cohort studies (RR: 1.03, 95%CI: 0.98, 1.07)[79] followed by 
another of 12 observational studies (RR: 1.06, 95%CI: 0.95, 1.17)[80] both 
showed that SFA was not associated with coronary disease risk. However, 
their inferences suffered criticism after evidence was brought forward about 
differential associations between SFA and CHD, depending on the 
macronutrient SFA was being replaced by, which may mask an association 
when looking at SFA by itself. For example, a meta-analysis of eight RCTs 
found that the overall risk of CHD was reduced by 10% (95%CI: 3-17%) when 
5%TEI from SFA was replaced by PUFA.[81] Similarly, observational studies 
demonstrated similar benefits, of a reduction in CHD risk, when SFA was 
replaced with PUFA (HR: 0.75, 95%CI: 0.67, 0.84), MUFA or complex 
carbohydrates.[82]  Whereas, CHD risk was not associated with SFA when it 
was replaced with intake of simple carbohydrates.[82] This differential 
association was evident because the researchers modelled isocaloric 
44 
 
macronutrient substitution, which will be explained in more detail in Chapter 
3, and highlights the importance of this method as well as macronutrient 
quality when investigating macronutrient intake and disease relationships.  
 
 Table 2-3: Association between macronutrient intake and Type 2 Diabetes (from RCTs) 
Direction of 
association 
Outcome Macronutrient (reference to published meta-
analysis) 
Inversely associated Glycaemia and IR MUFA replacing SFA[83] 
PUFA replace SFA[83] 
PUFA replace CHO[83] 
 Obesity Total protein (short term <3months)[72–74] 
Total protein replace CHO (but increases mortality 
and cardiovascular disease risk)[60,68] 
   
Association 
inconsistent or null 
T2D 
Glycaemia and IR 
 
 
Obesity 
SFA[59] 
SFA replacing CHO[83] 
PUFA replace MUFA[83] 
Total CHO[64,65] 
Total fat [62] 
Total CHO[60,65,68] 
Total Protein[60] 
Different macronutrient compositions show little 
difference between each other[58] 
   
Positively associated T2D 
Obesity 
Total fat[59] 
Total fat[60,61] 
Total CHO (low carbohydrate diet increase weight 
loss)[62,64] 
 
Abbreviations: RCT- randomised controlled trial, T2D - Type 2 Diabetes, IR- insulin resistance, MUFA- 
monounsaturated fatty acids, SFA- saturated fatty acids, PUFA- polyunsaturated fatty acids, CHO- carbohydrate 
 
Animal versus plant protein 
A meta-analysis of 13 RCTs reported glycaemic benefits (HbA1c, fasting 
glucose and insulin) of replacing animal protein with plant protein.[84] 
However, these studies were among participants with established diabetes, 
some on medication, and 85% of the studies were of poor quality and of <12 
weeks in duration. A meta-analysis of 11 cohort studies also find that animal 
protein is positively associated with T2D (RR: 1.19, 95%CI: 1.11, 1.28) whereas 
a null association was observed for plant protein intake (RR: 0.95, 95%CI: 
0.89, 1.02).[75] In the Nurses’ Health Study and Health Professionals Follow-
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up Study, researchers found that modelling replacement of 5% energy from 
animal with plant protein intake lowered T2D risk by 23% (95%CI: 16-
30%).[85] They also revealed that beyond the classification of animal and plant 
protein, the source of animal protein that is being replaced can significantly 
alter this relationship. That is, in a meal with refined grains and potatoes, 
when a serving of processed red meat was modelled to be replaced by a 
serving of plant protein-based food (wholegrains, legumes, nuts) this resulted 
in a 21% lower risk of developing T2D (95%CI: 16-26%), whereas this effect 
was non-significant when modelled to replace a serving of dairy (HR: 0.98, 
95%CI: 0.96, 1.00).[85] These suggest that protein quality and food source 
differentially influences T2D risk. 
Dietary fibre 
Evidence from a meta-analysis of cohort studies reported that consuming 
more dietary fibre, in particular, cereal fibre was associated with a lower risk 
of T2D (RR of T2D comparing high vs low consumers of cereal fibre: 0.75, 
95%CI: 0.65,0.86).[86] This included results from the EPIC-InterAct study 
(HR: 0.81, 95%CI: 0.70, 0.93, which was attenuated after adjusting for 
BMI).[86] Similarly, clinical trials providing grains such as rye, barley, oats and 
fibre supplements including psyllium (insoluble fibre) have noted clear 
benefits to acute postprandial blood glucose and insulin as well as long-term 
insulin sensitivity.[87] A meta-analysis investigating the isolated effect of 
psyllium among euglycaemic individuals in clinical trials ranging from 2 to 26 
weeks discovered a directionally consistent lower postprandial blood glucose 
(-12.4 mg/dL, 95%CI: -17.5, -7.3, 11 publications) and insulin (-126.8 mg/dL, 
95%CI: -219.5, -34.1, 6 publications) compared to placebo.[88]  There is less 
consistency in the effect of dietary fibre for preventing obesity, with 
hypothesised mechanisms related to satiety and appetite still unclear.[87] 
There is also a lack of association between fibre intake from fruit and 
vegetable sources and T2D.[86,89]  
In summary, evidence for macronutrient intake and T2D as well as for 
intermediate traits is clearly complex. Although it is reasonably clear that total 
energy intake affects weight, macronutrient intake and more importantly which 
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substitutions appear to differentially drive glucose homeostasis to the detriment 
of T2D development remains to be fully elucidated. The current trial evidence for 
total macronutrient composition with body weight and glucose homeostasis is 
inconsistent. Notably, trial data show that the quality indicators of macronutrient 
intake, including PUFA, plant protein and cereal fibre intake appear to improve 
glycaemia. Whereas, observational studies investigating the risk of T2D show 
inconsistent associations with macronutrient composition, except for total and 
animal protein and dietary fibre. From the literature, three key issues were 
highlighted:  
1. A key limitation that prevents clear comparison between trials comparing 
diets with different macronutrient compositions is that many of these trials 
report insufficient information about the relative proportions of energy 
from each macronutrient (e.g. does a low-fat diet represent a diet high 
carbohydrate and protein or only higher in protein?). Therefore, this 
makes clinical interpretation difficult. 
2. Diets which were very restrictive are unlikely to be sustainable in the long 
term because of the difficulty in adherence. Adherence is currently poorly 
measured in most trials using ad-libitum diets. Additionally, few studies 
report adverse consequences of dietary interventions, but this is important 
in helping to identify thresholds for macronutrients intake (both minimum 
and maximum) to minimise health risk beyond deficiency in essential 
nutrients (e.g. essential amino acids or fatty acids). For example, a low 
carbohydrate diet which may also be high in protein is likely to be low in 
dietary fibre and may increase the likelihood of renal complications or 
electrolyte imbalance but this remains to be studied.[90] Indeed, a study 
which analysed such diets (e.g. Atkins), albeit only over three days, 
discovered that six micronutrients (e.g. vitamin B7, E and iodine) were 
either insufficient in meeting nutrient requirements or non-existent.[91] 
This raises concerns about potential long term micronutrient deficiencies. 
3. Macronutrient quality and food source. 
The inconsistencies in response to macronutrient intake on the risk of developing 
T2D between studies beg the question about whether biological differences such 
as those from genetic variants may play a role. That is, can gene-regulated 
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Box1: Definitions  
Nutritional genomics is an umbrella term, encompassing both nutrigenetics and nutrigenomics.  
Nutrigenetics investigates how genetic variation affects nutrient requirements as well as the interaction 
with nutrients on disease development. This may be due to genetic polymorphisms encoding enzymes or 
transporters involved in nutrient ingestion, digestion, absorption, metabolism and/or elimination.  
Nutrigenomics examines how nutrients may alter the genome, proteome and metabolome.[92] 
Nutrigenomic studies may contribute to discussion of my findings as they aid in the broader aetiological 
understanding of nutrient-gene interactions but will not be specifically examined as this is out of the 
scope of my PhD. 
mechanisms of digestion, absorption, metabolism and distribution of 
macronutrients affect nutrient bioavailability and therefore downstream effects 
on glucose control and T2D risk differently between study participants and 
between studies? There is emerging research that tries to evaluate this within a 
field of study known as gene-diet interactions.   
 
2.6 The interplay between genetics and diet in the prevention of type 2 
diabetes  
2.6.1 Definitions 
The notion that a multifactorial condition such as T2D is a likely result of the 
interplay between our genes and environment is well accepted but the exact 
mechanism is unknown. Within the broad scope of research that examines the 
interplay between genes and environment I focused my investigation on gene-
environment interactions with a particular lens on gene-diet interactions. In 
some fields of research this overlaps with ‘nutritional genomics’ (see Box 1), 
specifically ‘nutrigenetics,’ which examines how genetic variation influences the 
effect of diet on disease or on nutrient requirements. This is distinct from 
‘nutrigenomics.’[92] Within this thesis, I will use the term ‘gene-diet interactions’ 
or a variant of this. More details relating to the statistical concepts of interaction 
will be provided in Chapter 3.   
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2.6.2 Motivation for studying gene-diet interactions  
There are two primary reasons motivating research in gene-diet interactions 
within T2D: 
1. Improve the understanding of T2D aetiology: 
a. Investigating gene-diet interactions, alongside epistasis (gene-gene 
interactions) may help to explain the ‘missing heritability’ of 
T2D.[35]  
b. Help to identify novel genetic variants without any marginal effects 
that may be masked by environmental exposures such as dietary 
intake. Conversely, this can also help identify novel environmental 
factors that are only evident among those with particular genetic 
susceptibility.[35]  
c. Statistically, modelling the combined contribution of genes, 
environment and their interplay on T2D development, will more 
accurately explain the effect of each of these factors.[93] 
 
2. Improve the method of identifying those at risk of T2D and therefore 
better prevent it: a classic example of gene-diet interaction is 
phenylketonuria (PKU), which only manifests in those who consume 
phenylalanine whilst possessing a recessive mutation in the gene 
phenylalanine hydroxylase. Children with this condition avoid neurological 
damage when adhering to well-established dietary interventions based on 
knowledge of this interaction.[94] This is a monogenic condition. Since 
then, advancements in genetic technology and the sequencing of the 
human genome are enabling gene-diet interaction research on polygenic 
and multifactorial disorders, such as T2D. This may aid in identifying 
individuals in a population who respond well to dietary interventions that 
prevent T2D, those who do not (non-responders) as well as those who 
experience worse outcomes (adverse responders), assuming similar levels 
of adherence. Although appealing, whether this may translate into 
genetically stratified approaches for optimising identification and 
provision of more effective dietary interventions in preventing T2D, is yet 
unknown.[35,92,95]  
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This vision for translation, for which currently there are no concrete and 
experimentally validated examples for T2D, [96]  has been coined by some as 
‘personalised’ or ‘precision’ nutrition.[97–99] It has gained much attention, often 
secondary to a parallel field called personalised medicine, which in recent times 
both the UK and US government have invested large amounts of public funding 
to its research.[100,101] Within the dietetics profession, personalised nutrition was 
identified as a ‘change driver’ by the Dietetics Workforce Supply and Demand 
Future Scan.[102]  
 
Some of the public health benefits envisaged from genetics based personalised 
nutrition include: 
1. Refinement of targeting dietary interventions to people most likely to 
respond well to them; 
2. Improvement in cost and health effectiveness of existing preventive 
strategies and treatments related to diet (e.g. medical nutrition therapy);  
3. Minimising adverse effects related to dietary interventions;  
4. Improvement in patient adherence to clinical recommendations; and  
5. Discovery of novel dietary interventions that are beneficial only in a 
defined genetic subgroup of the population.[95]  
 
How these may be implemented into practice is under considerable discussion 
and research. This includes whether it is administered in person with a health 
professional or online (e.g. the Food4Me Study); how genetic risk itself should be 
communicated to optimise comprehension and behaviour change; can it operate 
safely, ethically and equitably through private health services or does it need to be 
via public health services; and what level of scientific evidence is sufficient for 
translation? Real life examples from commercial companies are provided in table 
2.5.    
2.6.3 Examples of gene-environment interactions in multifactorial conditions 
Cancer epidemiology has elucidated some of the most replicated gene-
environment interactions to date and is considered a leader in genetic-
personalisation of diagnosis and treatment. For example, given that not everyone 
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who smokes tobacco develops cancer, it was hypothesised that certain 
polymorphisms such as that in the NAT2 gene (rapid or intermediate vs slow 
acetylators) which has a role in detoxification of carcinogens may modify cancer 
risk from tobacco smoking. Indeed, a case-only meta-analysis (n=22 studies) 
found that smokers who were genetically predisposed to slow acetylation had a 
significantly higher risk of bladder cancer compared to those who were 
intermediate or rapid acetylators (interaction OR: 1.2, 95%CI: 1.1-1.5, 
pinteraction=0.008).[103] In psychiatry, examples such as whether a polymorphism in 
the 5-HT T genetic locus differentially influences how stressful life events and 
childhood maltreatment predicts depression has caused much controversy.[104] 
This interaction has had one of the highest attempted replications, with mixed 
results, so conclusions are still under intense debate and scrutiny.[105]   
Within the cardoiometabolic literature, a meta-analysis of >200,000 European 
and North American adults investigated one of the most replicated 
interactions.[106] Authors found that the effect of the strongest obesity-associated 
locus (FTO) on obesity risk was attenuated among those who were physically 
active by 0.4kg/minor allele when compared to those who were sedentary. This 
was also observed within UK Biobank (N~ 120,000),[107] and the Food4Me study 
which used objective measures of physical activity (n=1,280).[108] However, an 
individual participant meta-analysis of 8 RCTs (n=9,563) which had investigated 
either dietary, drug or lifestyle intervention (diet and physical activity) on body 
weight, did not observe differences in response when individuals were stratified 
by FTO genotype.[109] The discrepancy between observational and trial data, in 
this case, may be explained by i) possible measurement bias in self-reported 
physical activity and the cross-sectional nature of some observational studies (e.g. 
UK Biobank) and ii) the trials did not study the independent effects of physical 
activity and may be underpowered to examine this interaction.  
Several dietary interventions with varying macronutrient composition also 
suggest a genetic contribution to variation in weight loss response.[60] Similar 
genotype-specific responses to dietary interventions have also been reported for 
insulin resistance,[110] and T2D risk,[111] though not all findings have been 
consistent.[112,113] For example, in a weight loss trial of 737 overweight adults, Qi et 
al., observed a significantly greater improvement in glucose homeostasis (fasting 
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glucose, insulin and HOMA-IR) among those possessing the TT genotype of 
rs2287019 (GIPR locus) and consuming a low fat diet compared to a high fat diet 
at 6 months follow-up.[114] Whereas for those with either the CC or CT genotype, 
the choice between low and high-fat diets did not matter.[114] Additionally, 
whether individuals with the genetic variant in the APOE locus, that are 
predisposed to coronary heart disease (E4+), are more sensitive to the lipid 
raising effects of dietary fat intake have also been of interest. In an adequately 
powered feeding trial, with participants recruited based on APOE genotype 
(N=88, duration=8 weeks), authors reported a significantly greater decrease in 
circulating triglyceride levels in APOE4 carriers compared to non-carriers 
following a low fat intervention (0.48±0.11mmol/L and 0.22±0.06mmol/L, 
respectively).[115] Whereas this response was not observed for changes in total 
cholesterol in a large multi-centre European ad-libitum dietary intervention trial 
(N=1,466, Food4Me, follow-up=6months).[116] This begs the question of, if genetic 
variation establishes an individual’s baseline risk for developing T2D could diet, a 
known modifiable modulator of this risk, accentuate, attenuate or even abolish 
T2D risk?[117] This instigated further questions about whether there are indeed 
replicated, validated and clinically useful interactions that may challenge our 
current one-size-fits-all nutritional recommendation for the prevention of T2D. 
2.6.4 Current methodological challenges facing the field of gene-diet 
interactions 
Despite these intriguing research questions, several reviews on gene-lifestyle 
interactions for cardiometabolic conditions do not highlight any specific 
interactions that have been replicated or with a magnitude that is clinically 
relevant to take forward for application.[96,118] Several reviews also present the 
methodological challenges that make researching gene-environment interactions 
difficult and these challenges may help to explain the current state of 
evidence.[95,105,119,120] These are summarised in Table 2-4, including a brief 
introduction to the approaches taken within this PhD to overcome some of these. 
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Table 2-4: Key limitations of current gene-diet interaction studies on T2D and methods that 
have been proposed to overcome these 
Key 
challenges 
Explanation What have I done to address 
this 
Sample size In general, common SNPs have modest effects on 
multifactorial outcomes (on average below 20% 
higher risk). Therefore, large studies, often in the 
tens of thousands of individuals are needed to 
detect these effects. Subsequently, the number of 
people needed to study interactions between 
genetic variants and diet would be even 
larger.[120,121] This also depends on the minor allele 
frequency of the genetic variant of interest. 
Increasing sample size, using a 
large prospective cohort with 
incident T2D cases[119] 
 
Publication 
bias 
Often novel, interesting gene-diet interactions are 
published without replication of findings. 
Conversely, negative results are often unpublished. 
Attempt to publish all 
interaction analyses, regardless 
of findings. 
Measurement 
bias of dietary 
exposures 
How accurately we can estimate a population’s 
intake using self-reported methods e.g. 
questionnaires are a well-known problem in 
nutritional research. Participant burden is balanced 
against the precision of measurement.[120,122] 
Sample sizes could be reduced 
by 30 fold with increased 
precision of exposure 
measurement, such as by using 
objectively measured data.[122] 
Possible 
selection of 
inappropriate 
genetic 
targets  
i) simple interaction analyses based on single 
candidate variants may not reflect the complex 
biology of living systems nor the polygenic nature 
of T2D, where epistasis may exist,[123] ii) genetic 
variants without demonstrable marginal effects on 
T2D may exhibit synergistic interaction under 
environmental influence.[124]   
Genetic risk scores (GRS) has 
enhanced power in detecting 
interactions.[35,125] Also, 
hypothesis-free based genome-
wide interaction analysis 
(GEWIS) will aid in discovering 
novel interactions at potentially 
unexpected genetic loci.[35]   
Confounding In studies of interaction, both sets of confounders 
for each exposure are equally important to 
account for. Few studies have accounted for 
population stratification and confounding relating 
to dietary exposures, which may lead to spurious 
findings.[120,126,127] Nor have they addressed 
potential confounding between genetic or dietary 
exposures and covariates.[128] 
Adjustments for population 
stratification and other key 
confounders. 
Multi-
collinearity  
Multicollinearity between exposures and their 
interaction variables can lead to inflated estimated 
variances of the interaction coefficient. 
A simple method of mean 
centring of continuous 
exposure variables has been 
shown to reduce covariance 
and correlations between main 
exposures and the interaction 
term.[129]  
Dynamics of 
interactions 
Exposures and therefore interactions may change 
over the lifetime of an individual and 
population.[120] 
Beyond the scope of this PhD 
Limited 
reproducibility 
Influenced partly by the above factors, many 
reported gene-diet interactions have failed to be 
replicated in similar populations. This questions 
the validity of such interactions.  
Attempt to replicate reported 
interactions available in the 
current literature but also 
conduct replication if I identify 
any statistically significant 
interactions. 
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2.6.5 Current societal and commercial backdrop 
With genotyping and genome sequencing becoming faster and more affordable, a 
number of commercial companies are providing direct-to-consumer lifestyle tests 
and dietary advice, predicated on the evidence of gene-diet interactions, and have 
been under immense scrutiny by regulatory agencies.[130,131] Some examples have 
been listed in table 2-5. Although conflicting findings have been reported for its 
clinical utility (research examining whether genetic risk information and/or 
based dietary advice leads to change in dietary behaviours) and validity (research 
examining gene-diet interactions), particularly in the area of T2D prevention, the 
overall evidence taking into account the quality of studies is yet to be determined. 
Whereas the ethical, social and legal issues of these ‘personalised nutrition’ 
services, including whether genetic test results induce psychological harm, has 
also been called into question and requires further investigation.[132] Therefore, 
investigating gene-diet interactions is urgently needed to confirm or refute 
unambiguously the current clinical validity of genetic-based personalised 
nutrition. Findings may provide timely evidence and advice for healthcare 
professionals and policy makers to better guide and safeguard the public.  
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Table 2-5: Examples of commercial organisations providing ‘personalised nutrition’ advice 
Company name, 
Headquarters and 
founding year 
Tests offered for the following,  
Number of genes this is based on 
More information, including costs and their values 
on science 
Website  
Nutrigenomix 
Canadian 
Founded in N/A 
Cardiometabolic health 
Nutrient metabolism 
Weight management 
Food intolerances 
Eating habits 
Physical activity 
Injury risk 
Based on 45 genetic markers 
DNA analysed via saliva sample 
Operates through dietitians 
 
Price: N/A 
 
‘Genetic tests are based on the most robust scientific 
evidence.’ 
https://www.nutrigenomix.com/  
DNAnalysis 
South-African 
Founded in 2007 
Obesity risk/insulin resistance: FTO 
Binge eating: DRD2 
Carbohydrates and obesity: ADRB2 
Fat absorption: FABP2 
And other genes not listed on their website 
Operates through a health care professional 
 
Equivalent to £100 
 
‘DNA Diet is designed to assist the healthcare 
practitioner in the design of a personalised healthy 
eating plan based on individual genetic differences’ 
http://dnalysis.co.za/dna-diet/ 
 
DNAFit 
UK 
Founded in 2013 
 
Diet type recommendation 
Carbohydrate response 
Saturated fat response 
Lactose intolerance 
12 week recipe guide 
Genotype specific shopping list 
Detoxification genetics 
Anti-oxidant needs 
Omega-3 need 
Vitamin B need 
Vitamin D need 
Alcohol sensitivity 
Caffeine sensitivity 
Salt sensitivity  
20 genes listed on their website 
DNA analysed via saliva sample 
Direct to consumer 
 
£99-199 
 
‘(genes included)... in the DNAFit reports only once 
the evidence is clear regarding an easily modifiable 
gene x environment interaction with a positive 
outcome, and that this effect is shown in multiple 
studies.’ 
https://www.dnafit.com/diet 
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Vitagene 
USA 
Founded in N/A 
 
Obesity risk 
Alcohol metabolism 
Cholesterol levels 
Triglyceride levels 
Lactose sensitivity 
Gluten sensitivity 
Emotional eating 
Weight regain after dieting 
Fat intake 
Sodium intake  
Supplementation test: which supplements to 
take 
Supplemental service: uses genetic results from 
other genetic testing companies (e.g. 23andMe) to 
provide a secondary analysis service that advises on 
dietary intake. 
 
Equivalent to £38 
https://vitagene.com/products/  
Personalised eating 
restaurant 
 
VITA MOJO 
UK 
Founded in 2016 
VITA MOJO and DNAFit teamed up to provide 
menus created based on ‘personalised 
nutrition,’ advice provided by genetic testing 
from DNAFit. 
 
Website allows you to adjust how much of the 
dish you choose to purchase, to match the 
macronutrient composition that is presumably 
recommended by your DNAFit results. 
 https://www.vitamojo.com  
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 2.7 PhD framework, aims and objectives 
 
The current literature demonstrates strong epidemiological evidence for the 
individual effects of genetics and of diet in the development of Type 2 Diabetes 
(T2D). Theoretically, gene-environment, including gene-diet, interactions plays a 
role in T2D development, however, few robustly replicated empirical examples 
exist for cardiometabolic diseases, including T2D. There is a need to understand 
if and how gene-diet interactions contribute to T2D risk. This is set against the 
background of rising public and commercial interest in translating gene-diet 
interactions into ‘personalised nutrition’ advice. It is therefore timely to 
systematically evaluate the current evidence for gene-diet interactions in T2D 
aetiology, particularly focusing on macronutrient intake. Moreover, there are 
many methodological challenges currently hindering our epidemiological 
understanding of whether reported gene-diet interactions are in fact real. 
Therefore, by addressing some of these methodological challenges and by 
systematically and comprehensively assessing gene-diet interactions using a 
battery of methods, it is hoped that the aim and objectives below could be 
achieved. This is illustrated in Figure 2-7. The methods used within this PhD 
spanned the spectrum of methods for studying gene-diet interactions, from 
hypothesis driven genetic variant selection (biological candidate genes) to 
hypothesis-driven analysis based on hypothesis-free selection of genetic variants 
(genetic risk scores using BMI, IR and T2D associated loci) to completely 
hypothesis-free analysis of interaction using genome-environment-wide-
interaction-study (GEWIS) that examines interaction without restriction on the 
genetic exposure.  
Aim: 
Investigate the contribution of gene-diet interactions to the aetiology of 
T2D. Indirectly this may help evaluate the potential for using this insight 
to identify population subgroups that differ significantly in their response 
to dietary interventions.  
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Objectives:  
1. Conduct a systematic review of gene-macronutrient interactions and T2D 
(described in Chapter 4) to understand the available literature on a specific 
aspect of gene-diet interactions in the development of T2D. 
 
2. Attempt to replicate identified interaction/s in a large prospective case-
cohort study (EPIC-InterAct) to evaluate the validity and reproducibility of 
these identified interactions (Chapter 4).    
 
3. To examine interactions between macronutrient intake and genetic risk 
scores in the development of T2D (Chapter 5).    
 
4. To examine interactions between food and beverage intake and genetic risk 
scores in the development of T2D (Chapter 6).    
 
5. To examine interactions between macronutrient intake and genetic 
variants on T2D, across the entire genome (Chapter 7).    
 
6. Appraise the literature as to whether there is clinical utility for providing 
genetic risk information on dietary behaviour change. This is described in 
the discussion (Chapter 8).    
The ‘analytic validity, clinical validity, clinical utility and associated ethical, legal 
and social implications’ (ACCE) framework for evaluating genetic tests,[133]  which 
share similar broader goals for public health to our work helps to place my aims 
and objectives into context. This framework illustrates the critical areas that are 
important for evaluation, which is relevant for both genetic testing and the 
potential use of genetic tests to personalise dietary interventions (the potential 
application for researching gene-diet interactions). 
Hypothesis:  
We hypothesised that based on prior literature we would detect gene-diet 
interactions between specific dietary macronutrients and genetic variants on the 
incidence of type 2 diabetes. 
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Figure 2-7: Visual representation of the aims and objectives of my PhD, with links to the ACCE framework.[6] 
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Chapter 3 Methods for interaction analyses and 
cohort descriptions 
 
3.1  Interaction analysis  
3.1.1 What is an interaction? 
A distinction must be made between biological and statistical interaction, the 
latter of which is the focus within this thesis. Biological or mechanistic 
interactions often refer to a physical or chemical reaction between two 
compounds such as when iron inhibits gastrointestinal calcium absorption. 
Rothman describes it as synergism or antagonism in the ‘sufficient cause 
framework’ or ‘causal pie.’[134] Synergism occurs when either two or more factors 
cannot independently result in an outcome but do when present simultaneously, 
such as when two people who have complementary skills work together to achieve 
a task that could not be achieved alone. Whereas, antagonism is when a risk 
factor must be absent for the sufficient cause to exist, for example when native 
bacterial flora out competes with foreign bacteria to prevent infections.[134] 
Statistical interactions are purely statistical. Some mechanistic interactions can 
be picked up statistically and others not. Conversely, sometimes even if a 
statistical interaction is present a mechanistic one may not be and therefore 
functional studies are often required to follow up on statistical interactions.[135] 
In the realm of statistical interactions, the term ‘effect modification’ is often 
confused with ‘interaction’. Attempts to clarify terminology include the 
distinction made by VanderWeele:[136]  
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Effect modification: the causal effect of the primary exposure (A) differs across 
strata of another factor of interest (exposure B). This, therefore, involves only one 
hypothesis and one set of confounders for the primary exposure (A). Figure 3-1.i. 
Interaction: the causal effect requires both exposures (A and B) and therefore 
involves two hypotheses and two sets of confounders for each exposure. Figure 3-
1.ii. 
 
Figure 0-1: Distinction between statistical (i) effect modification and (ii) interaction 
Within this thesis, the premise is to investigate ‘interactions.’ If these are found, 
further analyses would be conducted to distinguish whether it is purely an 
interaction or an effect modifier by examining strata-specific effects of each 
exposure one at a time.  
3.1.2 Interaction scales 
Interactions can be estimated by introducing a product term between the two 
exposures in the statistical model. Below provides an example of this modelled for 
the interaction between G and SFA (main exposures), their interaction term (G x 
SFA) and covariates (C) (Equation 1). 
f(T2DM)= β0 + βGG + βSFASFA + βG·SFAG  X SFA + ∑βCCx    
 (1) 
Statistical interactions can be assessed on one of two common scales, 
multiplicative or additive. Whilst there continues to be debate over the pros and 
cons and when to use either, Table 3-1 shows a summary of the differences 
between these two scales. 
  
 
 
61 
 
Although VanderWeele recommends reporting interactions on both scales 
because additive interactions can exist independent of multiplicative 
interactions,[139] the decision on interaction scale was guided by the objective of 
the specific project. That is, when examining the contribution that gene-diet 
interactions have on the aetiology of disease, the multiplicative scale was adopted. 
Whereas when dietary exposures already have public health implications (e.g. 
sugar-sweetened beverage intake is detrimental for T2D),[53] this also justified 
examining additive interactions.   
3.1.3 Methods in studying gene-diet interactions 
Approaches to examining gene-diet interaction can be broadly classified into 
hypothesis-driven or hypothesis-free approaches and both entail methodological 
limitations. Hypothesis-driven approaches may include examining i) single 
genetic variants, using either a candidate gene approach or GWAS-derived 
genetic variant/s, or ii) a combination of variants such as a GRS or haplotype. 
Table 0-1: differences between the two interaction scales 
Scale Multiplicative  Additive[137–139] 
Primary aim of 
examining interaction 
Understanding of aetiology and biology. 
Using just the multiplicative interaction 
scale can indicate the wrong subgroup to 
treat, as demonstrated by Markowitz and 
colleagues.[140] 
Help identify which group in 
the population to target 
finite healthcare resources 
to. More relevant for public 
health. 
What it measures Relative risk of different groups  
(relative ratio) 
Difference in number of 
individuals at risk (absolute 
rate) 
Regression model 
suitable 
Multiplicative models e.g. Cox regression Additive models e.g. 
attributable risk 
Further explanation  Combined effect of the two exposures (i.e. 
genetic variants and diet) would be larger 
or smaller than the product of the 
individual effects [HRGRS x diet/(HRGRS x 
HRdiet)] <1 or >1 
Whether an absolute 
incidence rate due to the 
combined exposures (i.e. 
genetic variants and diet) 
would be larger or smaller 
than the sum of incidence 
rate due to each individual 
exposure [ HRGRS x diet – HRGRS 
– HRdiet + 1] 
How it is calculated OR11/ (OR10 x OR01) 
 
P11 - (P01 + P10) + P00   
(if P00= 1) 
= P11 - P01 - P10 + 1   
 
Strength Computationally faster. 
Relative ratios are less heterogeneous 
than absolute rates. 
 
Caveat Must interpret with knowledge of the 
main effects of each exposure. 
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Taking a hypothesis-free approach involves investigating possible interactions 
across the whole genome, where interaction is tested between an exposure and 
every measured or imputed genetic variant across the genome. This is known as 
GEWIS. [35]  All these three methods have been used in this thesis. Table 3-2 
provides an explanation of these methods and others, including their strengths 
and limitations. 
3.1.4 Quality criteria for evaluating interactions 
Currently, there is no well-accepted published recommendation on determining 
the quality of reported gene-diet interactions, or of gene-environment 
interactions in general. A common and accepted list of recommendations is 
needed to overcome concerns relating to the methodological limitations already 
discussed and it can also aid in helping the scientific community come to a 
consensus about the validity of specific gene-diet interactions. There needs to be a 
level of scientific rigour and standard that all studies examining interactions 
should aspire towards, which may be also instigated by such a list. Although 
several authors have made suggestions about reporting of interactions and 
publication of null findings,[141,142] currently a set of consistent recommendations 
does not exist for journals and readers to a) establish standards of practice in 
examining interactions and b) to help with evaluating the quality of an interaction 
study. 
A set of guiding principles does currently exist for GWAS studies: ‘Strengthening 
the Reporting of Genetic Association Studies (STREGA)- An Extension of the 
STROBE Statement.’[143] Boffetta et al. also published a proposed guideline for 
assessing gene-environment interactions that may help contribute to this 
effort.[144] Until one becomes available for gene-diet interactions, to aid my 
evaluation of the literature, I developed a ‘quick-to-use’ checklist informed by the 
following: Boffetta,[144] STREGA,[143] recommendations for evaluating GWAS 
studies for systematic reviews from HuGENet,[145] recommendations by Pearson 
and Manolio[146] on how to interpret a GWAS as well as concepts relevant to 
nutritional epidemiology (Appendix A).   
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Table 0-2: Types of approaches used to study gene-diet interactions  
Type of method What is this? Example Strength Limitation 
Candidate gene-diet 
interaction studies 
Examines one or more genetic 
variants (e.g. candidate genes or 
haplotypes), which may have often 
been chosen because of a biological 
hypothesis. This has been the 
predominant method of published 
gene-diet interaction studies to date. 
Alternatively, using single candidate 
genes identified in GWAS meta-
analyses of traits of interest. 
The interaction between folate status and a 
single C677T polymorphism in the MTHFR 
genetic locus on risk for stroke. This SNP 
reduces enzyme efficiency for processing folic 
acid within the folate-mediated one carbon 
metabolism, thereby lowering circulating 
folate levels and increasing homocysteine. 
Individuals with a T risk allele (CT or TT 
genotype) were found to have higher stroke 
risk only if residing in countries with low levels 
of folate in the food supply  (i.e. in Asia, where 
there are no policies in folic acid fortification). 
This suggests that the effects of MTHFR on 
stroke risk may only become apparent under 
conditions of low folate intake.[147] 
Simple to examine The effect size of 
individual SNPs is 
sometimes too small to 
detect. Often it is 
difficult to determine 
the causal variant. 
Genetic risk score- 
diet interaction 
studies 
 
GRS are where several individual 
SNPs are combined. 
The interaction between sugar-sweetened 
beverage (SSB) intake and a GRS composed of 
32 SNPs associated with BMI, at genome-wide-
significance (p<5x10-8) on the risk for obesity. 
Researchers found that for individuals with a 
high genetic predisposition for obesity (high 
BMI GRS), having higher intakes of SSB led to a 
marked higher risk for obesity than compared 
to individuals with lower intakes of SSB.[148]  
Combining multiple SNPs 
can improve the variance 
explained by ‘genes’ on 
predicting disease, 
particularly for common 
diseases with low 
penetrance SNPs. It may 
also be used to better 
reflect the polygenic nature 
of common multifactorial 
diseases such as T2D.[149] 
Individual genetic 
variants may have 
differing individual 
interactions with dietary 
exposures on T2D, which 
may be masked when 
aggregated.[150] Also, this 
aggregation may make it 
more difficult to 
evaluate the underlying 
aetiology.  
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Genome-
environment-wide-
interaction studies 
(GEWIS) 
 
GEWIS studies apply a hypothesis-
free approach to examining gene-
diet interactions. It does this by 
examining the interaction between a 
dietary factor and every genetic 
variant in the genome, for an 
outcome of interest. Few GEWIS 
studies in nutritional genomics have 
been conducted because the 
extremely large sample sizes that 
they require have until recently been 
unfeasible. 
 
A GEWIS was conducted for alcohol intake and 
cigarette smoking and colorectal cancer. An 
interaction was identified between alcohol 
intake and variants in the 9q22.32/HIATL1 
region (p=1.76E-08 ;permuted p=3.51E-08). 
This suggests that the effect of alcohol intake 
on colorectal cancer risk may differ by genetic 
subgroups but results are yet to be 
replicated.[151] 
Given the limited 
reproducibility of many 
candidate gene-diet 
interaction studies, it has 
been hoped that GEWIS 
may be able to help identify 
novel interactions at 
unexpected genetic loci.[35]  
Methods to overcome 
the statistical power 
limitations with high 
multiple testing and the 
need for efficient 
methods to sieve 
through results have 
been proposed.[35] In 
their reviews, they 
suggest methods such as 
a joint meta-analysis 
with 2 degrees of 
freedom and others that 
prioritise variants 
through multi-stage 
analyses. The latter is 
less favourable because 
interaction testing 
should not be limited to 
only genetic variants 
identified in GWAS of 
marginal gene effects.  
Dietary interventions 
that recruit 
participants by 
genotype (also 
known as ‘genotype-
based recall’ or 
‘recall by genotype’ 
Participants undergo a dietary 
intervention to investigate an 
outcome but are recruited based on 
their genotype for a genetic variant of 
interest. Often this study design is 
used to clarify specific gene-diet 
interactions that have been widely 
An example of a study examined the 
interaction between fat intake and APOE on 
blood lipids. The researchers discovered that 
there was a significant difference in how 
participants’ triglyceride responded to the 3 
dietary interventions, depending on their 
genotype.[115]  
Useful to confirm the 
function of disease-
associated genetic variants. 
Enables more statistical 
power in the context of a 
smaller number of 
participants compared to a 
Conditional on the 
identification of robust 
interactions and 
therefore genetic 
variants to recruit by. 
Several ethical concerns 
prevail, with the primary 
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studies) 
 
but inconsistently reported in 
observational studies. 
standard RCT.  concern being the 
potential to violate 
participant’s privacy and 
right not to know their 
genetic information. 
More is discussed in a 
review.[152] 
Individual participant 
meta-analysis of 
gene-diet 
interactions 
Given the small effects of gene-diet 
interactions, it is often difficult to 
investigate these interactions in 
studies with small populations. To 
overcome this, several research 
groups have come together to answer 
a shared research question using a 
meta-analysis approach where results 
are pooled.  
CHARGE nutrition consortium, an offshoot 
from the Cohorts for Heart and Aging Research 
in Genetic Epidemiology consortia which were 
originally set up to investigate genetic variants 
associated with coronary related outcomes.  
An example has been their investigation into 
GRS and dietary pattern interactions in obesity 
where they did not find any interactions.[153]    
By adopting a standardised 
analysis plan, this tries to 
ensure that there is as 
much similarity in the 
analysis as possible. This 
includes harmonisation of 
exposure measurements 
and analysis between 
studies. Therefore, this de 
novo interaction meta-
analyses have been 
favoured over literature 
based approaches.[154] 
Difficult to pool studies 
with heterogeneous 
designs, especially in the 
measurement of dietary 
exposures. 
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3.2  The EPIC-InterAct study 
 
3.2.1 Cohort description 
 
The European Prospective Investigation into Cancer and Nutrition (EPIC) is a 
prospective cohort study representing 519,987 participants from 23 centres in 10 
European countries (Denmark, France, Germany, Greece, Italy, The Netherlands, 
Norway,  Spain, Sweden, and the UK).[155] It was initiated in the late 1980s and is 
on-going. The EPIC-InterAct Study is a case-cohort study nested within EPIC, 
including all countries except Greece and Norway. Most participants were 
recruited from the general population, with some exceptions as follows: only 
women who were members of a health and insurance scheme for school and 
university employees were included in France; some blood donors were included 
in Turin and Ragusa (Italy) and Spain; those in Utrecht (The Netherlands) and 
Florence (Italy) were recruited via a breast cancer screening programme; and 
most participants within Oxford (the UK) were vegetarian. The design and 
methods have been detailed previously.[156]  
Briefly, the case-cohort design of EPIC-InterAct combines the methodological 
advantages of i) prospective assessment of exposures which avoids recall bias and 
reverse causality with ii) the efficiency from needing fewer controls (Figure 3-2). 
From the above 8 countries eligible for InterAct (N=455,680), 340,234 
participants with stored blood were eligible. A random sub-cohort of 16,835 
participants was selected. After excluding individuals with prevalent T2D at 
baseline (1991-1997), post-censoring diabetes or unknown T2D status, a total of 
27,779 EPIC-InterAct participants were included, with 12,403 incident T2D cases 
and a random subcohort of 16,154 participants (with the subcohort including 778 
T2D cases that developed T2D during follow up, according to the design of a case-
cohort study). The mean age at baseline was 55.6 years. Mean BMI in men was 
29.4kg/m2 and in women it was 30.1kg/m2. 49.7% of participants were men.[156] 
Ethical approval was obtained at each centre and all participants provided 
informed consent.  
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The EPIC-InterAct study was designed to improve the understanding of the 
interplay between genes and the environment in the development of T2D, so it 
presents a richly phenotyped platform for investigating gene-diet interactions.[157] 
 
Figure 0-2: Study design of EPIC-InterAct and countries and centres represented 
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3.2.2 Type 2 diabetes ascertainment 
 
Cases of clinical incident T2D were ascertained in each centre using multiple 
sources for verification. This included information about the participant from at 
least two of the following sources and was recorded at a date after the baseline 
visit: self-report, linkage to primary-care registers, secondary-care registers, 
medication use, hospital admissions and mortality data. In Denmark and Sweden, 
cases were considered verified because they were ascertained via local and 
national diabetes and pharmaceutical registers. Censoring occurred at the date of 
diagnosis, end of 2007 or date of death, whichever was the earlier.   
 
3.2.3 Assessment of dietary intake 
 
Habitual self-reported dietary data was collected at baseline using country-
specific self or interviewer-administered dietary questionnaires, which were 
developed and validated within each country to estimate usual intake of 
participants during the past 12 months. This contained up to 260 food items. 
They were either quantitative or semi-quantitative. The semi-quantitative food 
frequency questionnaire (FFQ) asked participants to choose from nine options for 
frequency of consumption from ‘never or less than once per month,’ to ‘6+ per 
day.’ For example, the UK based FFQ in the EPIC-Norfolk study included major 
food groups and contained foods including meat, fish and poultry; bread and 
savoury biscuits; cereals (including porridge); potatoes, rice and pasta (including 
composite foods such as lasagne); dairy products, eggs and egg products and fats 
(such as butter or vegetable oil spreads); sweets and snacks (including cakes, ice-
cream, chocolate, candy, chips and nuts); soups, sauces and spreads; drinks 
(including alcoholic and non-alcoholic beverages); fruit (including fresh, tinned 
and dried) and vegetables (including legumes and pulses). It concluded with 
open-ended questions asking about items relevant to consumption including the 
type of milk used, type of fat, the frequency of fried food consumption, takeaway, 
cooking methods (e.g. grilling or roasting meat), added salt and use of dietary 
supplements. A copy of this is in Appendix B. Some centres collected dietary data 
via diet histories. The EPIC-SOFT software was used to help harmonise country-
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specific data through the collection of 24-hour dietary recalls in a representative 
sample of EPIC (N=32,063). This was then used to help correct for systematic 
between-centre over- or underestimations in dietary assessment.[155] Food 
composition was then derived from a standardised nutrient database called the 
EPIC Nutrient DataBase (ENDB), which contains 550 to 1500 foods depending 
on the country, standardised for unit, mode of expression, definition and 
chemical method of analysis.[158] Country-specific FFQs demonstrated moderate 
validity against a 16 day weighed food record and biomarkers for energy (doubly 
labelled water) and protein intake (urinary nitrogen) (Spearman correlation 
coefficients of 0.43 to 0.55 for macronutrients).[159–161]  
 
3.2.4 Measurement of plasma phospholipid fatty acids 
 
Objective dietary measures may help to overcome recall and reporting bias. The 
fatty acid composition of plasma phospholipids were available and could be used 
as nutritional biomarkers of  n3, n6, total PUFA and individual and total SFA, 
represented as a percentage of total measured phospholipid fatty acids 
(mol%).[162] They were profiled using a validated high-throughput automated 
method, including hydrolysis and trans-methylation to produce volatile free fatty 
acids before separation by gas chromatography, as previously described.[163] 
Samples were processed randomly and laboratory staff blinded during analysis.  
3.2.5 Other measurements 
 
All participants completed baseline health and lifestyle questionnaires to obtain 
data on diet, physical activity, smoking, family history of diseases and socio-
economic status variables and trained nurses collected data on anthropometry 
(e.g. weight, height, body circumferences), clinical measures (e.g. blood pressure) 
and biological samples (e.g. blood).[155] In France and Oxford, weight and height 
were self-reported by some participants.  
3.2.6 Genetic data 
 
Methods for DNA extraction from blood samples and genotyping have been 
previously described.[156] Genotyping was performed on the Illumina 660W-Quad 
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BeadChip or Illumina HumanCore Exome chip arrays  and harmonised, with 
imputation to the Haplotype Reference Consortium using IMPUTE v2.3.2.  All 
SNPs met quality control criteria for genotyping call rate (≥95%) or were well 
imputed (info≥0.99). After these evaluations, 22,492 participants had genetic 
data available for analysis. Samples that were genotyped on the 660 W-Quad 
BeadChip were randomly chosen, with the number of participants from each 
centre being proportional to the percentage of total cases in that centre. All 
centres had samples genotyped with the 660 W-Quad BeadChip array except for 
those from Denmark. The remaining samples were genotyped on the Illumina 
HumanCoreExome. There were no obvious differences in participant 
characteristics by array. 
3.2.7 Statistical analysis 
 
Given the case-cohort design and the over-representation of cases, a modified Cox 
regression (Prentice-weighted) was elected to be used as a way of analysing time 
to event data in case-cohort study designs. Cases within and outside the 
subcohort were weighted differently.[156,164]  Age was used as the underlying 
timescale.  
 
Specification of exposure variables: 
- Genes were modelled additively, according to an increase in risk alleles (0, 
1 or 2 risk alleles) and per standard deviation for GRS. 
- Dietary exposures were modelled as continuous densities of total energy 
intake, to avoid losing statistical power from arbitrary categorisation. For 
macronutrients, this was for example, per 5% of total energy intake (TEI) 
from carbohydrate intake and for dietary fibre per 1g/1000kcal. 
- Total energy intake was calculated by summing the energy contribution 
from carbohydrate, fat, protein and alcohol intake. 
 
Model construction for interaction analyses: 
 
The observational nature of this research and complexity of T2D aetiology meant 
that understanding the possible confounders and biases was important to help 
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minimise the impact of these on the findings. Therefore a directed acyclic graph 
(DAG)[165] of the causal path from the exposures (genetic, macronutrient intake) 
to the outcome, T2D, was developed to visualise this (Figure 3-3).  
 
 
Figure 0-3: Directed acyclic graph for the interaction between macronutrient intake and genetic variants on the risk 
of developing Type 2 Diabetes (T2D), including confounders for each set of exposures. M: macronutrient exposure, 
G: genetic exposure. 
 
Unless otherwise specified, the covariates were chosen if a) considered a known 
confounder between genetic variants and T2D, b) considered known confounders 
between dietary macronutrient and T2D from the literature (i.e. age, sex, 
geographical location, population stratification, physical activity, socioeconomic 
status, smoking, alcohol intake, total energy intake and BMI) or c) dietary factors 
that may be potential confounders (e.g. magnesium) were included within the 
interaction model and backward deletion was undertaken to eliminate those that 
did not make a notable difference to the β co-efficient of the interaction term 
(≤10% change) and/or induced multicollinearity until a parsimonious model was 
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established.[166] Regarding the rationale for the decision about the selected dietary 
factors to include as covariates, both ‘nutrients’ and ‘foods or beverages,’ were 
chosen if they had a significant association with T2D in the literature.[42] 
Additionally, ‘food or beverage’ covariates were then filtered to include only those 
composed minimally of macronutrients (i.e. leafy vegetables and tea and coffee). 
The reason for this was to preserve the variation of the macronutrient being 
examined. That is, if the interaction between PUFA and genetic variants on T2D 
was of interest, and if fish intake was included in the model (a likely confounder), 
it would be hard to interpret findings if the source of the variation in PUFA intake 
has been removed. This modelling is listed below. BMI was not adjusted in the 
models examining BMI GRS because the association between BMI GRS and T2D 
may be secondary to the association with BMI. Although a family history of T2D 
is a possible confounder, this data was available only in 52% of participants in 
EPIC-InterAct. Therefore, to avoid losing statistical power, we tested this as a 
sensitivity analysis, described below.  
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Where appropriate, models were adjusted for the following covariates 
based on the DAG in Figure 3-3: 
 
• Age (as the underlying timescale) 
• Sex 
• BMI  
• Centre 
• Principal components for population 
stratification 
• Physical activity (inactive, moderately 
inactive, moderately active and 
active) 
• Highest level of education (none, 
primary school, 
technical/professional school, 
secondary school, longer education 
such as University) 
 
• Smoking (never, former, current 
smoker) 
• Sex-specific alcohol categories 
(none; light drinking: 0.1-6 g; 
moderate: women 6.1-12 g and 
men 6.1-24 g; heavy: women >12 
g and men >24 g of alcohol/d) 
• Lifestyle factors and dietary 
factors previously found to be 
associated with T2D and 
macronutrient intake: total 
energy intake, season of FFQ 
completion which has been 
associated with accuracy of recall, 
other macronutrients, dietary 
fibre, magnesium, iron, vitamin C 
and a selection of foods and 
beverages that did not contain or 
contained minimal amounts of 
macronutrients 
Plus isocaloric macronutrient substitution  
 
 
Sensitivity analysis: 
Where a statistically significant interaction is identified, the following are a list of 
sensitivity analyses that were planned:  
- Exclusion of those with implausible energy intakes according to thresholds 
used by a similar population of the Nurses’ Health Study (women <500 or 
>3500kcal/day) and Health Professionals’ Follow-up Study (men <800 or 
>4000kcal/day).[167]  
- Adjustment for family history of T2D, only in those with available data 
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Separate adjustment for possible confounders and/or mediators: 
- Blood lipids (total cholesterol, high-density lipoprotein, low-density 
lipoprotein, triglycerides) and lipid-lowering medication  
- Hypertension and antihypertensive medication 
- Prevalent cardiometabolic conditions (e.g. myocardial infarction or stroke)  
 
Where additional methods were used for a particular project, these are described 
in the respective chapters. 
Crude and multivariable-adjusted Prentice-weighted Cox regression models were 
constructed within country and by genotyping chip, to account for variation in 
genetic and dietary exposures between countries and variation in genotyping by 
chip. Chip-specific HRs were pooled within each country using random-effects 
meta-analysis. Country-specific HRs were then also combined using random-
effects meta-analysis. Between-country heterogeneity was assessed with 
Cochran’s Q statistic and quantified by the I2 value and P for heterogeneity was 
derived from a Chi-squared test. Stata v14 (StataCorp LP, Texas, USA) was used 
for analysis. 
Isocaloric macronutrient substitution 
 
The importance of isocaloric macronutrient substitution modelling was described 
in section 2.5.3.2. In relevant analyses, multivariate nutrient density model with 
isocaloric substitution described by Willet et al., have been applied.[168] In brief, 
this method assumes an isocaloric model, which means that TEI is held stable. 
Within such a model, when energy intake is increased from a particular 
macronutrient (e.g. carbohydrate), this subsequently leads to a reduction in TEI 
from another macronutrient (e.g. fat) to ensure TEI remains constant. Therefore, 
the interpretation would be ‘what is the effect of decreasing a proportion of 
energy from fat intake when replacing it with the same proportion of energy from 
carbohydrates intake?’ Specifically, the modelling in Equation 2 helps to answer 
this question for T2D. The absence of ‘fat density’ in the model below implies a 
substitution effect. 
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f(T2DM)= β0 + βCCarbohydrate density + βPProtein density+ βAAlcohol + ∑βCCx 
 (2) 
Please note that TEI was treated as a separate confounder adjusted within the 
model. Indeed, nutrient density models do capture TEI (relative measure) but 
they do not account for energy as a confounder which may reflect differences in 
body size and nutritional requirements. In fact, if TEI is a confounder, converting 
macronutrients into %TEI does not reduce this confounding, it simply induces 
confounding in the opposite direction for the macronutrient of interest because 
TEI will be the denominator.  Moreover, as a density variable, if low TEI is 
associated with disease, macronutrient densities will have a positive association 
with the disease because of the presence of TEI in the variable even when there is 
no association. Therefore, to avoid this artefact, TEI was further adjusted in the 
model. 
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3. Chapter 4 Systematic literature review of gene-
macronutrient interactions and T2D with attempted 
replication in EPIC-InterAct 
 
 
This chapter addresses objectives 1 and 2 (see Chapter 2). Here I systematically 
reviewed interactions reported for genetic variants and macronutrient intake in 
the development of Type 2 Diabetes and attempted to replicate these within 
EPIC-InterAct. These interactions adopted the use of candidate genetic variants.  
 
This Chapter has been published: 
Li SX, Imamura F, Ye Z, Schulze MB, Zheng J, Ardanaz E, et al., Interaction 
between genes and macronutrient intake on the risk of developing type 2 
diabetes: systematic review and findings from EPIC- InterAct. Am J Clin Nutr 
2017;106(1):263-75 
 
4.1 Abstract     
 
Background: Gene-diet interactions have been reported to contribute to the 
development of type 2 diabetes (T2D). However, to date, few examples have been 
consistently replicated. To identify existing evidence for gene-macronutrient 
interactions on the risk of developing T2D, and to examine the reported 
interactions in a large-scale study. 
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Methods: We systematically reviewed studies reporting gene-macronutrient 
interactions and T2D that were identified using electronic databases including 
MEDLINE, HuGENet and the WHO clinical trials registry (to October 2015). 
Eligibility criteria included assessment of macronutrient quantity (e.g. total 
carbohydrate) or indicators of quality (e.g. dietary fibre) by use of self-report or 
objective biomarkers of intake. Interactions from the review were subsequently 
examined in the EPIC-InterAct case-cohort study (n=21,148 with 9,403 T2D 
cases; 8 European countries). Prentice-weighted Cox regression was used to 
estimate country-specific HRs, 95%CI and pinteraction, which were then pooled by 
random effects meta-analysis. A primary model was fitted using the same 
covariates as reported in the published study, and a second model adjusted for 
additional covariates and estimated the effects of isocaloric macronutrient 
substitution.  
 
Results: Thirteen observational studies met eligibility criteria (n<1,700 cases). 
Eight unique interactions were reported to be significant between macronutrients 
(carbohydrate, fat, saturated fat, dietary fibre, and glycaemic load derived from 
self-report of dietary intake and circulating n-3 polyunsaturated fatty acids) and 
genetic variants in or near TCF7L2, GIPR, CAV2 and PEPD (pinteraction <0.05). We 
found no evidence of interaction when trying to replicate previously reported 
interactions. Additionally, no interactions were detected in models with 
additional covariates. 
 Conclusions: Eight gene-macronutrient interactions on the risk of T2D were 
identified from the literature. These interactions were not replicated in the EPIC-
InterAct study which mirrored the analyses undertaken in the original reports. 
Our findings highlight the importance of independent replication of reported 
interactions. 
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4.2 Background 
 
As a first step in examining gene-diet interactions and T2D, macronutrient intake 
was chosen because of its importance in public health nutrition and its likelihood 
to interact biologically at the molecular level. A Genome-wide Complex Trait 
Analysis of interactions with several macronutrients across the genome also 
demonstrated that gene-carbohydrate interactions may explain around 25.1% 
(SE:14%) of the variance for fasting insulin and 24.2% (SE:13.9%) for HOMA-
IR.[169]  Although large confidence intervals are evident and only a few 
interactions reached genome-wide significance in this analysis, likely due to the 
small sample size of this preliminary study, the results nevertheless signify the 
potential value of investigating gene-macronutrient interactions in helping to 
understand the aetiology of T2D.  
There is currently sparse confirmatory evidence for gene-macronutrient 
interactions and T2D. The most widely reported example is the interaction of 
TCF7L2 and dietary fibre and related dietary factors (i.e. wholegrain intake), as 
markers of carbohydrate quality, on T2D risk.[4,112,170–172] In addition to several 
narrative reviews, [95,117,142] a systematic review examined lifestyle-gene 
interactions for T2D and highlighted the poor quality of evidence available in 
2007 due to factors such as small sample size and the use of cross-sectional 
designs.[173] Larger prospective studies have since been published, and far more 
genetic loci associated with T2D risk have been identified. Furthermore, there are 
several important gaps in knowledge about gene-macronutrient interactions. 
First, past studies have not adequately controlled for confounding (e.g. by 
population stratification and total energy intake)[127,174,175] or considered effects of 
isocaloric macronutrient substitution. Second, objective biomarkers of 
macronutrient intake (e.g. circulating levels of polyunsaturated fatty acids- 
PUFA) have also not been investigated systematically. Finally, replication has 
been limited to date and there is potential publication bias.[142] To understand the 
currently available evidence and these issues, a systematic review of gene-
macronutrient interactions is warranted. In synthesising summary evidence on 
interactions, our group had previously demonstrated that high heterogeneity 
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between studies prevents meaningful meta-analyses so a narrative approach was 
undertaken.[154] 
Our first aim was to systematically review the literature relating to gene-
macronutrient interactions and T2D, including both self-reported and objective 
markers of macronutrient intake and dietary fibre. Specifically, we planned to 
identify relevant interactions, assess their validity, reliability, biological 
plausibility, clinical relevance and to identify research gaps. Our second aim was 
to investigate the interactions identified from the literature-based systematic 
review in a large prospective study, EPIC-InterAct,[156] to address research gaps 
relating to replication, confounding and isocaloric macronutrient substitution. 
 
4.3 Methods 
 
4.3.1 Systematic review 
 
This systematic review conformed to the guidelines proposed for Meta-analysis of 
Observational Studies in Epidemiology [176] and that of the Human Genome 
Epidemiology Network (HuGENet).[141,145]  
Firstly, the literature was scanned for any systematic review and/or meta-
analyses on this topic to assess whether a new or an update was needed for a pre-
existing systematic review. Both the published literature and on-going systematic 
reviews on the international prospective register of systematic reviews 
(PROSPERO) were examined.[177]  
Selection criteria  
Studies were eligible if they reported incident or prevalent T2D as an outcome, 
and statistical interaction between any genetic exposure (e.g. single nucleotide 
polymorphisms: SNPs, genetic risk score) with macronutrient intake. 
Macronutrient intake included both quantity (total carbohydrate, fat and protein 
intake) and indicators of quality (dietary fibre, glycaemic index (GI), glycaemic 
load (GL), free sugars, SFA, MUFA, trans- fatty acids and PUFA, dietary 
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cholesterol, ratio of SFA/PUFA, linoleic acid and alpha-linolenic acid, animal and 
plant protein). In defining the scope for ‘macronutrient intake,’ the following 
criteria were developed: 
 
For macronutrient quantity, it must be an essential macronutrient for 
physiological function and included in population dietary recommendations. 
This, therefore, included total carbohydrate, fat and protein. Ethanol intake was 
not eligible because it does not fulfil either of the above criteria. 
 
For macronutrient quality, it can satisfy either or all of: 
- included in population dietary recommendations 
- evidence of an association with T2D 
- is of reasonable contribution to the macronutrient quantity of interest  
 
For example, the essential fatty acids linoleic acid (LA) and alpha-linolenic acid 
(ALA) contribute little to total energy intake (5.1% and 1% respectively), however, 
they are included for three reasons. Firstly, they contribute the most to commonly 
consumed dietary PUFA sources in the UK (e.g. meat, dairy, cereal products),[178] 
and PUFA is a quality indicator of fat intake. Secondly, often studies may 
represent PUFA as LA or ALA rather than total PUFA, so including these two fatty 
acids ensures that PUFA intake is adequately captured. Thirdly, they are essential 
fatty acids which have an important physiological function. 
 
No restrictions were placed on language, age, date of publication or study design. 
 
Exclusions included wholegrain intake. Although wholegrain intake is often 
associated with fibre intake because wholegrain foods are a key contributor to 
fibre consumption,[179] currently there is an inconsistent definition of wholegrains 
to accurately assess its conferred health benefits, and using it as an indicator of 
fibre intake is highly confounded as it contains many other bioactive compounds 
(B vitamins, zinc, magnesium and phytochemicals) that may affect T2D.[180,181] 
Moreover, it is a group of various grains such as rye, rice, oats, etc. Therefore, it 
cannot be categorised as a single nutrient and therefore is beyond the scope of 
this review. In this study, ‘macronutrient’ refers to both indicators of intake 
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(quantity and quality) as well as both methods used to assess intake (self-report 
and biomarker- e.g. circulating n-3 PUFA, urinary nitrogen), unless otherwise 
specified. Studies that assessed other forms of diabetes (e.g. type 1, gestational), 
examined nutrigenomics, quantitative glycaemic traits or examined the 
interaction between gene-lifestyle interventions without macronutrient 
assessment were excluded (Table 4-1).   
 
Table 3-1: Systematic review selection criteria  
Inclusion Exclusion 
Macronutrient exposure:   
Carbohydrate quantity (grams or percentage of energy 
intake: %E) or quality: free sugars, non-starch 
polysaccharides (dietary fibre), GI, GL 
 
Macronutrients which will provide both 
caloric and nutritive value so ethanol 
will not be included in this review   
Protein quantity (grams or %E intake) or quality: meat 
versus plant sources  
Other environment- gene interactions 
e.g. physical activity, smoking, pollution; 
non-macronutrient: foods and dietary 
patterns i.e. wholegrain intake; or 
lifestyle interventions without 
macronutrient on its own 
Fat quantity (grams or %E intake) or quality: SFA, 
MUFA, trans and PUFA, dietary cholesterol, ratio of 
SFA/PUFA 
Essential fatty acids: Linoleic acid (LA), alpha-linolenic 
acid (ALA), n-6/n-3 ratios 
 
(both self-reported and objective biomarkers of intake 
was eligible) 
 
Genetic exposure: any single variant, haplotype or 
combined risk score 
 
Outcome: incident or prevalent T2D Other forms of diabetes: such as type 1 
diabetes, gestational diabetes, MODY 
Study design Nutrigenomic studies, ecological, 
reviews or commentaries 
 
Search strategy and data extraction 
Following a pre-defined protocol, electronic searches were performed using 
MEDLINE, EMBASE, Cochrane Library and HuGENet up to 31st October 2015 
(an example is available in Appendix C). To minimise publication bias, the 
following were also searched: the WHO clinical trials registry, the grey literature 
(e.g. GreyNet), names of key authors and diabetes trials, and hand-searched 
relevant reviews. Medical Subject Headings and specific terms (i.e. title, abstract 
and keywords) were also used wherever possible to ensure sensitivity within 
respective databases. Authors of three published [172,182,183] and an unpublished 
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study (ClinicalTrials.gov ID: NCT01168297) were contacted to either assess 
eligibility or collect further data to conduct the review. Subsequently two studies 
(n= 1 published.[183] 1 unpublished) were determined ineligible. Studies were 
screened by title and abstract for eligibility for full-text review. From each 
publication meeting eligibility criteria, the following information were extracted 
using an agreed data extraction form on cohort characteristics (e.g. study design, 
sample size, ethnicity, etc), covariates, statistical analyses, estimates of 
associations between 1) macronutrient intake and T2D, 2) genetic variant and 
T2D and 3) gene-macronutrient interactions and T2D.  
Assessment of study quality 
Assessment for confounding, bias (selection, measurement, attrition, outcome 
and reporting) and genetic-specific issues (genotyping quality, population 
stratification, multiple testing) were undertaken using a modified version of the 
Cochrane guidelines for non-randomised studies of interventions to incorporate 
genetic issues highlighted by the HuGE Network.[145,184] This broadly classified 
studies as being of low, moderate, serious or critical risk of bias. 
 
Two authors (Sherly Li and Zheng Ye) independently undertook every stage of 
screening, selection, data extraction and quality assessment in duplicate and 
resolved any disagreements by a discussion with two other authors (Nita Forouhi 
and Robert Scott). 
 
Data analysis 
 
A narrative synthesis was undertaken. Studies were heterogeneous in reporting of 
interaction results, therefore for consistency, results were analysed and presented 
according to categories of macronutrient intake where possible. The large extent 
of heterogeneity made any form of standardisation impossible. For the same 
reason, publication bias could not be quantitatively assessed. 
   
 
 
 
 
83 
4.3.2 EPIC-InterAct Study 
 
To investigate the reproducibility of the statistically significant interactions 
identified from this systematic review, these were examined in a large-scale study 
(EPIC-InterAct), which had informed consent and approved ethics.[156] The 
cohort, genotyping and imputation, dietary assessment and estimation of 
macronutrient intake have already been described in the Methods Chapter 
(Chapter3). In addition to the general method taken for statistical analyses, 
described in the Methods chapter, below are some specific methods for this piece 
of work. 
 
Additional method for genetic data 
 
For quality control, the Hardy-Weinberg equilibrium (HWE) was estimated for 
the SNPs of interest within EPIC-InterAct. Theoretically, allele frequencies 
should be stable within a population due to the random assortment in mating if 
there are no perturbations. This is demonstrated in equation 3 below which 
shows how in a population, the sum of the homozygotes for the p allele, 
homozygotes for the q allele and the heterozygotes should equate to 1. Therefore, 
deviation from equilibrium within the healthy control group is commonly tested 
within genetic epidemiology and can signal possible selection bias, population 
stratification or genotyping error.[185] Typically, this is not tested in the cases 
because of obvious non-random selection based on their disease state. However, 
reliability has been debated because it is underpinned by the assumption that 
there is no perturbation in this equilibrium including genetic drift, migration, 
mutations, non-random mating and natural selection, which does happen in 
reality. There is also concern about misleading results when power for HWE 
testing is limited.[185] With these limitations in mind, the HWE was therefore 
chosen as a preliminary test in flagging possible errors. 
 
                                                         p2+2pq + q2=1     (3) 
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Additional methods for statistical analysis  
 
Additive models for all genetic variants were assumed unless previously 
published studies demonstrated a more appropriate alternative. Each 
macronutrient was categorised based on the distribution of the macronutrient 
intake within the subcohort sample, excluding outliers (±3 standard deviations 
from the mean). To account for between-country variations in dietary intake, 
categorisation was performed per country and then country-specific Cox 
regression was conducted. Since categorisation was performed in each country, 
the pooled category-specific ranges may appear to overlap. However, individuals 
are mutually exclusive within each category by country. The pooled 
macronutrient percentiles are given below and shown as median (minimum, 
maximum): 
 
Macronutrient Category 1 2 3 4 5 
Dietary fibre 
(grams/1000kcal) 
 
7.5 
(2.4-9.5) 
9.5 
(7.3-11.0) 
10.9 
(8.7-12.3) 
12.4 
(10.0-
14.0) 
15.0 
(11.5-
37.0) 
Glycaemic load 
(grams of 
carbohydrate) 
 
87.8 
(14.1-118.5) 
123.6 
(100.6-
161.1) 
165.6 
(132.8-
436.6) 
  
Carbohydrate 
(%total energy 
intake) 
 
37.2 
(12.6-43.2) 
44.0 
(38.4-
49.1) 
50.6 
(44.1-73.9) 
  
Fat (%total 
energy intake) 
 
 
29.3 
(5.1-34.0) 
34.7 
(31.0-
38.6) 
40.2 
(35.7-64.9) 
  
Circulating n-3 
PUFA (%total 
phospholipid 
fatty acid) 
5.4 
(0-7.5) 
7.8 
(5.2-23.1) 
   
 
Two approaches to modelling were taken: a ‘replication model’ and a ‘modified 
model.’ The ‘replication model,’ tried to mirror the interaction model as reported 
by the original publication as much as possible, to ensure comparable results. 
This included whether macronutrients were treated as continuous or categorical 
variables, whether an additive or codominant genetic model was applied, as well 
as selection of the effect allele and of covariates. P value for interaction was 
estimated with SNP and macronutrient variables treated as either categorical or 
continuous as per that reported in the previous publication. Whereas, the 
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‘modified model’ accounted for isocaloric macronutrient substitution and 
additional confounders that may bias the interaction results. This was to address 
the previously demonstrated risk of inflation of type I error under the inadequate 
control of environmental or genetic confounders.[127] Given that physical activity, 
education, smoking and alcohol intake are known confounders between 
macronutrient intake and T2D, these were included in the model. Similarly, 
population stratification is a well-recognised confounder for genetic exposures, as 
demonstrated by Sul et al., and should be included in gene-macronutrient 
interaction analyses.[126] In addition to confounding, the issue of isocaloric 
macronutrient substitution has already been discussed and have been thus far 
neglected in the observational literature on gene-macronutrient interactions and 
cardiometabolic diseases. Therefore, to improve the precision of our estimates 
and aid interpretation of results on macronutrient intake, modelling was based on 
that described in the Methods Chapter. However, please see Appendix D for a full 
covariate list for each respective macronutrient. P value for interaction was 
estimated with SNP and macronutrient variables both treated as continuous 
variables unless otherwise specified. 
 
For two replication analyses, we excluded EPIC-InterAct centres Potsdam and 
Malmo, which contributed to previous analyses.[4,186] This included the 
interaction between CAV2 and total fat and SFA which was identified by Fisher et 
al., and conducted in EPIC-Potsdam, so Potsdam was excluded from the present 
EPIC-InterAct analysis. Also, the interaction between dietary fibre and TCF7L2 
was identified by Hindy et al., in a population including participants from Malmo, 
so this centre was excluded in the present EPIC-InterAct analysis. 
 
For sensitivity analysis, the interaction between dietary fibre and TCF7L2 was 
examined using a dietary fibre variable which was calibrated to account for 
different degrees of measurement bias between centres. This is because some 
centres asked about non-white bread rather than specifically wholegrain bread 
intake. This may have resulted in different degrees of misclassification of dietary 
fibre, by centre, if non-white bread included for example malted brown bread 
which is not higher in fibre than white bread. Certainly, previous EPIC authors 
have shown that measurement bias in protein intake differs in magnitude and 
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direction across countries.[187] To try and address this differential measurement 
bias, analysis using a calibrated dietary fibre variable was examined. This was 
created by calibrating dietary fibre estimated from diets measured by FFQ with 
dietary fibre estimated from a single measure of 24-hour recall.[188] 
 
The software QUANTO (http://biostats.usc.edu/Quanto.html) was used to 
evaluate the statistical power for EPIC-InterAct to detect the specific interactions 
of interest.  
 
Complete case analyses were undertaken so that those with missing 
macronutrient intake, genetic data or covariates were excluded. Stata version 14 
(StataCorp LP, Texas, USA) was used for all analyses with p-value for interaction 
of <0.05 judged as statistically significant on the basis that each interaction was 
considered an independent replication attempt.  
4.4 Results 
4.4.1 Systematic review 
4003 publications were screened and 13 publications were included in this review 
(Figure 4-1). Participants had a mean age of 50 years and were on average 
overweight (mean BMI: 27kg/m2). Characteristics are provided in Table 4-2. 
Study designs included four which were cross-sectional,[182,189–191]  two case-
control,[172,192] one family-based association study [193] and six prospective (cohort 
or case-cohort) studies.[4,170,186,194–196] Sample sizes ranged from 805 [191] to 24,840 
[194] participants (n=165 to 1,649 cases). Dietary assessment method included self-
reported diet (n=12) and one which measured erythrocyte phospholipid n-3 
PUFA.[192] Across the studies examined, all macronutrients were represented 
except for protein quality (animal or plant protein).  Interactions were examined 
with SNPs from nine candidate genetic loci (TCF7L2, GIPR, IRS1, PPARγ, 
APOA2, CAV2, FABP1/2/3/4, PGC-1α, PEPD) and a GRS comprising variants in 
15 T2D-associated loci.[189] There was high heterogeneity in macronutrient 
categorisation, which foods used to estimate certain macronutrients such as 
cereal fibre, genetic model, statistical interaction method and reporting was 
evident.  
 
 
87 
 
Figure 3-1: Flow diagram of the systematic review for gene-macronutrient interactions and the risk of Type 2 
Diabetes 
Abbreviations: GI: glycaemic index; GL: glycaemic load; SFA: saturated fatty acid; MUFA:  monounsaturated fatty acid; 
PUFA: polyunsaturated fatty acid. Numbers are not mutually exclusive.  
a not including exploratory studies which examined many candidate genetic variants 
 
Gene-macronutrient interactions from the systematic review 
 
Eight interactions between SNPs and macronutrients were reported to be 
significant. These included interactions between two SNPs in the Transcription 
Factor 7-Like 2 (TCF7L2) gene with dietary fibre,[4,170] another TCF7L2 variant 
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with GL,[172] a genetic variant in Gastric Inhibitory Polypeptide Receptor (GIPR) 
with total fat and carbohydrate intake,[194] a genetic variant in Caveolin 2 (CAV2) 
with total fat and SFA,[186] and a genetic variant in Peptidase (PEPD) with 
erythrocyte phospholipid n-3 PUFA.[192] These are summarised in Table 4-2 
(magnitude of effects in Appendix E) and are described next. 
        
Several studies examined variants in or near TCF7L2, the common variant with 
the strongest association with T2D.[27] This gene encodes for a high mobility 
group box-containing transcription factor with a role in the Wnt signalling 
pathway and blood glucose homeostasis. In this current review, the interaction 
with dietary fibre was the most widely examined (by four studies), albeit 
inconsistently replicated. One study reported that the effect of the T allele of 
rs7903146 (within TCF7L2) on T2D risk was significantly increased with higher 
intakes of total dietary fibre,[4] which was corroborated by another study 
investigating cereal fibre.[170] However, the results of two other studies were 
discordant.[172,189] Moreover, Cornelis et al., observed another interaction among 
US women, where T allele carriers demonstrated increased odds of T2D with 
diets higher in GL.[172] Dietary fibre was also the subject of interaction analyses 
with the following genes but no statistical interaction was found, GIPR, IRS1 or 
PPARγ or a T2D GRS. 
One study reported that carriers of the A allele for SNP rs10423928 (GIPR)  had a 
lower 12-year incidence of T2D only if also consuming a diet higher in fat or lower 
in carbohydrate.[194] GIPR was chosen based on the hypothesis that it encodes the 
receptor for the incretin hormone gastric inhibitory polypeptide,[194] which 
stimulates insulin release in the presence of elevated glucose.  
Another study followed up CAV2 (rs2270188) for interaction with fat intake after 
exploratory analysis. This gene encodes a protein found on the surface of caveolae 
(small invaginations of cellular plasma membranes) and may be involved in lipid 
metabolism. It has not been previously associated with T2D (OR: 0.99, 95%CI 
0.97, 1.01, p= 0.49).[5] When individuals with the GG genotype were compared to 
those with TT genotype, those with the TT genotype had a higher risk of T2D 
when consuming diets higher in total fat and SFA.[186]  
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In a Chinese case-control study, Zheng et al. reported an interaction between 
circulating n-3 PUFA and PEPD,[192] which encodes a peptidase involved in 
proline recycling and collagen production. Within the gene, PEPD, rs3786897 has 
been associated with T2D in Asians.[197] It has not been associated with T2D in 
Europeans within DIAGRAM (OR of T2D: 0.97; 95%CI: 0.95,0.99; p:0.04). 
Individuals with a GA or AA genotype were found to be at higher risk of T2D, 
compared to those with a GG genotype, only among adults possessing lower levels 
of n-3 PUFA (≤ 5.33% of total circulating phospholipid fatty acids).   
Three large cohort studies examined protein intake and SNPs in/near TCF7L2, 
GIPR and IRS1 for interaction on T2D. However, no interactions were reported 
for protein intake.  
Four studies investigated the interaction between fatty acid intake and SNPs in or 
near PPARγ on T2D risk but none were statistically significant.  
Assessment of risk of bias and quality of evidence 
All studies included in the review were observational and rated either at moderate 
(n=8) or serious risk of bias (n=5) (Appendix E for more information). Of the 6 
studies reporting interactions, three did not account for multiple testing 
corrections (α<0.05) when examining several macronutrients and/or SNPs (e.g. 
an exploratory study examining 64 SNPs with 4 fatty acids; total 256 
tests).[4,186,194] Two studies which published a statistically significant interaction 
included accompanying replication results.[186,190] Many studies do not adjust for 
known confounders. Confounders including total energy intake, physical activity 
and population stratification were frequently ignored,[192,196,198] in particular the 
last was considered in only one study.[182] Other concerns included the validity 
and reliability of the dietary measurement tool [170,189,191,196] and possible selective 
analysis and reporting.[182,191] 
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Table 3-2: Summary of all eligible studies within the systematic review of gene-macronutrient interactions and T2D  
Genetic locus and 
variant 
Reference and 
study name 
(n=cases/total) 
Country and population 
characteristics (age in years, 
BMI in kg/m2) 
Macronutrient  Interaction results  
(p value for interaction) 
Quality assessment  
TCF7L2 
rs7903146 
Hindy, 2012 [4] 
(MDCS cohort 
n=1649/24799) 
Sweden, European 
Age: 58.1±7.6 
39%M 
BMI: 25.7±3.9 
Carbohydrate 
Fat 
Protein 
Total fibre 
Dietary fibre ˟ TCF7L2 
(p=0.049). 
↑ fibre ↓ T2D risk in CC 
genotype. 
↑ fibre ↑ T2D risk in T allele 
carriers. 
Moderate 
Large sample size with 
validated measurement tools 
and adjustment for 
confounders. Multiple testing 
not accounted for (4 tests). 
rs7903146 
rs4506565 
Wirstrom, 2013 
[170] (SDPP cohort 
n=165/5477) 
Sweden, European 
Age: 47.2 
42%M 
Cereal fibre rs7903146 (p=0.005)  
↑ fibre ↓ T2D risk in CC 
genotype. 
rs4506565 (p=0.006) 
↑ fibre ↓ T2D risk in AA 
genotype. 
Moderate 
Exposure is not 
comprehensively measured and 
study with small sample size.    
 rs12255372 Cornelis, 2009 [172] 
(NHS case-control 
n=1140/3055) 
USA, European 
Age: 47.5±6.9 
0%M 
BMI: 24.5±4.6 
Carbohydrate 
GI 
GL 
Cereal fibre 
GL ˟ TCF7L2 (p=0.003) 
*interaction disappeared after 
adjusting for family history 
(p=0.13) 
Moderate 
Well conducted study. 
GIPR 
  
rs10423928 
Sonestedt, 2012 
[194] (MDCS cohort 
n=1541/24840) 
Sweden, European 
Age: 58±7.7 
39%M 
BMI: 25.7±4 
Carbohydrate 
Fat 
Protein 
Fibre 
Sucrose 
Carbohydrate ˟ GIPR (p=0.001) 
Fat ˟ GIPR (p=0.002) 
↑ fat and ↓ carbohydrate 
reduce T2D in A allele carriers. 
The opposite composition for T 
allele carriers. 
Moderate 
Large sample size, validated 
measurement tools and 
comprehensive analyses, with 
adjustment for key 
confounders. Multiple testing 
not accounted for (5 tests). 
IRS1 
rs2943641 
Ericson, 2013 [195] 
(MDCS cohort 
n=1567/24841) 
Sweden, European 
Age: 58±7.7 
39%M 
BMI: 25.6±4 
Carbohydrate 
Fat 
Protein 
Fibre 
No significant interaction 
(p=0.59) 
(p=0.40) 
(p=0.28) 
(p=0.92) 
Moderate 
Large sample size with 
comprehensive dietary 
measurement. Multiple testing 
was not accounted for. 
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Genetic locus and 
variant 
Reference and 
study name 
(n=cases/total) 
Population characteristics 
(age in years, BMI in kg/m2) 
Macronutrient  Interaction results  
(p value for interaction) 
Quality assessment 
rs7578326 
rs2943641 
Zheng, 2013 [190] 
(GOLDN, BPRHS 
cross-sectional 
n=419/1664) 
USA, Hispanic, African, 
European, Native American 
Age: 53.5±13.2 
38%M 
BMI: 30.3±6.4 
Carbohydrate 
Fat 
SFA 
MUFA 
SFA: 
Carbohydrate 
 ratio 
GI GL 
No significant interaction (p= 
not available) 
Moderate 
Conducted replication and 
meta-analysis. Well adjusted for 
confounding.  Small sample 
size. 
PPARγ  
Pro12Ala/rs1801282 
1431C>T 
Lamri, 2012 [196]  
(DESIR cohort 
n=191/4676) 
France, European 
Age: 46.8±10 
49%M 
BMI: 24.7±3.8 
Fat No significant interaction 
(p=0.05) 
Serious 
Dietary questionnaire with 
limited food items may cause 
measurement bias and 
misclassification of fat intake. 
Residual confounding is likely 
due to lack of adjustments for 
key confounders (total energy 
intake, physical activity, etc). 
 Pro12Ala Cornelis, 2009 [172] 
(NHS case-control 
n=1140/3055) 
USA, European 
Age: 47.5±6.9 
0%M 
BMI: 24.5±4.6 
Carbohydrate 
GI 
GL 
Cereal fibre 
No significant interaction (p= 
not available) 
 
 Pro12Ala 
 
Nelson, 2007 (37) 
(GENI study: 
family-based 
association 
analysis 
n=736/1318) 
USA, Hispanic, European 
Age: 40.9±19.4 
43%M 
BMI: 30.5±6.6 
PUFA 
SFA 
MUFA 
PUFA: SFA ratio 
No significant interaction (p= 
not available) 
Serious 
Family-based association test 
conducted. Several key 
confounders (energy intake, 
BMI, physical activity, etc) not 
considered and possible 
reporting bias. 
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Genetic locus and 
variant 
Reference and 
study name 
(n=cases/total) 
Population characteristics 
(age in years, BMI in kg/m2) 
Macronutrient  Interaction results  
(p value for interaction) 
Quality assessment 
Pro12Ala 
63 SNPs examined with 
only CAV2 and PPARγ 
taken forward for 
confirmation 
Fisher, 2011 [186] 
(EPIC-Potsdam 
case-control 576, 
case-cohort 
806/2864) 
Germany, European 
Age: 50.4±8.9 
42%M 
BMI: 26.7±4.6 
Fat 
SFA 
MUFA 
PUFA 
No significant interaction 
(p=0.32) 
(p=0.08) 
(p=0.29) 
(p=0.07) 
Moderate 
Robust assessment, using a 
novel interaction analysis 
approach that maximises 
power. Multiple testing was not 
accounted for in exploratory 
analysis (256 tests). 
APOA2 
  
−265T>C 
Corella, 2011 [182] 
(PREDIMED and 
SNHS are both 
cross-sectional 
n=825/2830) 
Singapore, Asian 
Spain, European 
Age: 44.1±16 
41%M 
BMI: 25±5.3 
SFA 
 
No interaction reported (p= not 
available) 
Moderate 
Potential reporting bias 
evident. 
CAV2 
rs2270188 
63 SNPs 
Fisher, 2011 [186] 
(EPIC-Potsdam 
case-control 576, 
case-cohort 2864) 
Germany, European 
Age: 50.4±8.9 
42%M 
BMI: 26.7±4.6 
Fat 
SFA 
MUFA 
PUFA 
Fat ˟ CAV2 (p=0.02) 
SFA ˟ CAV2 (p=0.002) 
↑ fat and SFA ↑ T2D among TT 
genotype. 
(confirmatory analyses) 
 
FABP1/2/3/4 
  
 
 
rs2197076 
12 SNPs 
 
Mansego, 2012 
[191] (Hortega, 
Segovia 
replication cross-
sectional 
n=174/2022) 
Spain, European 
Age: 52.8±11.2 
45%M 
BMI: 27.5±4.1 
Fat 
SFA 
PUFA 
No significant interaction post 
multiple testing corrections 
(p=0.03) 
Serious 
Replication conducted. The 
interaction was neither 
examined in 1/3 of the 
population (without reason) nor 
examined in SNPs without the 
main effect on T2D. Most 
confounders were not 
accounted for and selective 
reporting was evident. 
 
 
93 
Genetic locus and 
variant 
Reference and 
study name 
(n=cases/total) 
Population characteristics 
(age in years, BMI in kg/m2) 
Macronutrient  Interaction results  
(p value for interaction) 
Quality assessment 
PGC-1α 
  
Gly482Ser 
Thr612Met 
Thr528Thr 
Nelson, 2007 (37) 
(GENI study: 
family-based 
association 
analysis 
n=736/1318) 
USA, Hispanic, European 
Age: 40.9±19.4 
43%M 
BMI: 30.5±6.6 
PUFA 
SFA 
MUFA 
PUFA: SFA ratio 
No significant interaction (p= 
not available) 
 
PEPD 
 
rs3786897 
9 SNPs examined 
Zheng, 2015 [192] 
(case-control, 
n=622/915) 
China, Asian 
Age: 51.1±13.2 
51%M 
BMI: 24.5±2.7 
Circulating 
erythrocyte 
membrane 
phospholipid n-3 
PUFA 
n-3 PUFA ˟ PEPD (p=0.027) 
↓ n-3 PUFA ↑ T2D among A 
allele carriers 
↑ n-3 PUFA is not associated 
with T2D among A allele 
carriers  
Serious 
Several likely confounders may 
explain the associations 
observed that were not 
adjusted for (BMI, blood lipid 
status, etc) and incomplete 
reporting of participant 
characteristics. 
GRS  
Based on 15 T2D 
genetic loci, weighted 
score 
Villegas, 2014 
(32) (NHANES 
cross-sectional 
n=1337/13120) 
USA, European 
Age: 51.1±13.2 
51%M 
BMI: 24.5±2.7 
Carbohydrate 
 
Fibre 
 
No significant interaction (Non-
Hispanic whites p=0.53) 
(p=0.09) 
Serious 
Dietary measurement tool was 
not validated and how T2D 
status was obtained was not 
described, therefore bias may 
be likely. The study reported a 
lack of statistical power to 
detect interactions. 
For the magnitude of effects (e.g. OR and 95%CI), refer to Appendix E. 
Abbreviations: M: male, GL: glycaemic load, GI: glycaemic index,  MDCS: Malmo Diet and Cancer Study, SDPP: Stockholm Diabetes Prevention Program, NHS: Nurse’s Health Study, 
GOLDN: Genetics of Lipid Lowering Drugs and Diet Network, BPRHS: Boston Puerto Rican Health Study, GENI: Gene-Environment Interactions study, EPIC: European Prospective 
Investigation into Cancer and Nutrition-Potsdam, PREDIMED: Prevención con Dieta Mediterránea trial, SNHS: , Singapore National Health Survey, NHANES: National Health and Nutrition 
Examination Survey. 
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4.4.2 Findings in EPIC-InterAct  
The population of EPIC-InterAct used for this analysis was broadly similar to the 
average of the cohorts from the systematic review. The mean age at baseline was 
52.3years and 55.7years in non-cases and cases of T2D, respectively and 
overweight (mean BMI: 25.8kg/m2 and 29.7kg/m2 in non-cases and cases, 
respectively) (Table 4-3). Associations between the SNPs we attempted to 
replicate and T2D were comparable with the genome-wide meta-analysis of 
genetic variants for T2D previously published (Table 4-4).[5] 
Table 3-3: Baseline characteristics of the participants from EPIC-InterAct (based on 
complete case analysis) 
Characteristics Mean/% SD/n Mean/% SD/n 
% 
missing 
 Subcohort non-cases Incident cases  
Number  11745   9403   
Total: 
21148^ 
Average years of 
follow-up 12.2   6.9     
Age (y) 52.3 9.2 55.7 7.6 0 
Sex (%male) 37.9 4452 50.0 4704 0 
PA level (%) 
 
  
 
  1.1% 
inactive 22.4 2636 29.5 2778   
moderately inactive 33.7 3956 33.0 3102   
moderately active 23.1 2712 20.3 1909   
active 20.8 2441 17.2 1614   
Highest school level (%) 
 
  
 
  1.7% 
none 6.8 802 9.2 862   
primary school 32.1 3772 41.8 3928   
technical/professional 24.4 2863 24.9 2339   
secondary school 15.1 1773 10.7 1005   
longer education (inc. 
university) 21.6 2535 13.5 1269   
Family history of 
diabetes (%) 
 
  
 
  47.8% 
Yes 18.1 1105.0 35.9 1748.0   
No 81.9 5006.0 64.2 3128.0   
BMI (kg/m2) 25.8 4.0 29.7 4.7 0.6% 
HbA1c (mmol/mol) 36.0 4.2 43.6 10.6 2.0% 
Total cholesterol 
(mmol/L) 5.9 1.1 6.2 1.2 5.2% 
LDL (mmol/L) 3.8 1.0 4.0 1.0 7.7% 
HDL (mmol/L) 1.5 0.4 1.2 0.4 5.2% 
TAGs (mmol/L) 1.3 0.9 2.0 1.3 5.2% 
Smoking status (%) 
 
  
 
  1% 
never 46.6 5477 40.4 3798   
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former 27.1 3178 31.2 2935   
current smoker 26.3 3090 28.4 2670   
Energy intake (kcal/d) 2137.3 635.1 2176.0 674.9 3.4%* 
Fat (%E) 34.8 5.8 34.8 6.0 3.4%* 
Saturated fat (%E) 13.4 3.4 13.3 3.5 3.4%* 
Monounsaturated fat 
(%E) 13.1 3.4 13.1 3.3 3.4%* 
Polyunsaturated fat (%E) 5.5 1.8 5.6 1.9 3.4%* 
Protein (%E) 16.9 3.0 17.2 3.2 3.4%* 
Animal protein (%E) 10.5 3.3 11.0 3.4 3.4%* 
Plant protein (%E) 5.0 1.3 4.9 1.3 3.4%* 
Carbohydrate (%E) 44.0 7.0 43.6 7.2 3.4%* 
Fibre (g/1000kcal) 10.9 3.1 10.7 3.2 3.4%* 
Fibre- vegetable 
(g/1000kcal) 2.0 1.3 1.9 1.4 0.0% 
Fibre- fruit (g/1000kcal) 2.1 1.7 2.1 1.7 1.3% 
Fibre- cereal 
(g/1000kcal) 4.2 2.1 4.2 2.1 0.0% 
Glycaemic Load (g of 
carbohydrate) 131.6 45.4 132.8 47.1   
Alcohol intake (sex-
specific g/d) 
 
  
 
  3.4%* 
none 13.6 1601 16.4 1539   
light drinking (0.1-6g) 34.9 4093 33.2 3123   
moderate drinking 
(men: 6.1-24g, women: 
6-12g) 23.6 2770 24.3 2286   
heavy drinking 
(men>24g, women>12g) 27.9 3281 26.1 2455   
Circulating fatty acid (% 
total phospholipid fatty 
acid) Subcohort non-cases Total incident cases 1.3% 
  12336   9937   
Total: 
22273^ 
total PUFA 42.5 3.5 41.9 3.5   
n3 PUFA 6.7 2.0 6.8 2.1   
n6 PUFA 35.7 3.7 35.1 3.7   
* represents % missing based on total sample of 27,779 
All other missing % based on a sample of 21900 (after exclusion of individuals with missing macronutrient n=736 and 
genetics data n=5,287). ^ total sample size and descriptive statistics: based on complete case analyses after exclusion 
of those with missing exposure and covariates. Abbreviations: PA: physical activity; BMI: body mass index; LDL: low-
density lipoprotein; HDL: high-density lipoprotein; TAGs: triglyceride; g: grams; E: total energy intake; SFA: saturated 
fatty acids, MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids 
 
There were no significant interactions for any of the replication analyses in EPIC-
InterAct that were comparable to the model specifications in the published 
literature. Figure 4-2A  shows that compared to the original report (pinteraction= 
0.049) (1,649 cases of T2D/24,799 total),[4] in EPIC-InterAct we failed to 
replicate the significant interaction between TCF7L2 rs7903146 and dietary fibre 
intakes on incident T2D (pinteraction = 0.97) (8,012 cases of incident T2D/ 18,292 
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total). The covariates included in each model are detailed in the figure legend. No 
interactions were observed in EPIC-InterAct by sub-types of dietary fibre (cereal, 
vegetable or fruit fibre) (pinteraction ≥0.27) (Figure 4-3). Figure 4-2B shows no 
replication of the interaction  between TCF7L2 and GL on T2D (pinteraction = 0.58)  
as previously detected by Cornelis et al.,[172] Similarly, in EPIC-InterAct no 
significant interactions were detected between rs10423928 (in GIPR) and 
carbohydrate or fat intake on incident T2D (pinteraction = 0.79 and 0.25, 
respectively)[194] (Figure 4-4). At CAV2, where an interaction had been reported 
between both total fat and SFA intake with rs2270188, [186] there was no evidence 
to support this in EPIC-InterAct (pinteraction = 0.76 and 0.95, respectively) (Figure 
4-5). In additional analysis, however, a significant interaction was detected when 
Potsdam was analysed independently, the centre originally analysed in the 
previous publication,[186] (pinteraction = 1.01E-6 and 0.001 for total and SFA, 
respectively) (Figure 4-6). The interaction between rs3786897 (within PEPD) and 
circulating n-3 PUFA reported by Zheng et al.,[192] was also not observed in EPIC-
InterAct (pinteraction = 0.58) (Figure 4-7). 
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Table 3-4: EPIC-InterAct results for the association between SNPs of interest and incident T2D 
SNP rsid chr 
nearest 
gene call rate 
info 
score HWE 
effect 
allele HR for T2D lower CI Upper CI p-value I2 (%) p_het 
DIAGRAM results 
(OR;95%CI; p) 
rs7903146 10 TCF7L2 >95% NA 0.44 T 1.33 1.24 1.43 1.74E-16 53 0.04 1.39;1.35,1.42;1.2E-139 
rs122255372 10 TCF7L2 >95% NA 0.78 T 1.29 1.20 1.38 2.37E-12 56 0.03 1.33; 1.30,1.37; 1.2E-12 
rs10423928 19 GIPR >95% 1.00 0.4 A 1.03 0.98 1.08 0.19 0 0.49 1.05; 1.02,1.08; 0.00 
rs3786897  19 PEPD >95% 1.00 0.03* A 1.06 1.01 1.10 0.01 0 0.64 0.97; 0.95,0.99; 0.04 
rs2270188 7 CAV2 >95% 0.99 0.48 T 0.96 0.92 1.01 0.13 29 0.20 0.99; 0.97,1.01; 0.49 
SNPs imputed using Haplotype Reference Consortium 
Abbreviations:  info: information content metric; HWE: Hardy-Weinberg equilibrium; HR: hazard ratio; T2D: type 2 diabetes; CI: confidence interval; p_het: p-value for heterogeneity 
Pooled HR for T2D, with adjustment age (=underlying time scale), sex, centre and eigenvectors (first 5 principle components for population stratification) 
DIAGRAM results from Morris et al., Nat Genet, 2012 
*HWE p-value threshold for rejecting the null p<0.01 (5 SNPs) 
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Figure 3-2: Interaction between genetic variants within TCF7L2 and dietary fibre or glycaemic load: comparison 
between the study by Hindy et al., 2012 and Cornelis et al., 2009 with EPIC-InterAct 
 A) Odds ratio (OR) from Hindy et al., 2012[4] (above) and pooled hazard ratios (HR) from EPIC-InterAct (below) for 
type 2 diabetes (T2D) per T allele of rs7903146 (TCF7L2) and quintiles of dietary fibre (g/1000kcal). Hindy et al., 
adjusted for age, sex, body-mass index (BMI), total energy intake, season and method (dietary intake assessment 
method); EPIC-InterAct replication model adjusted for age (=underlying time scale), sex, centre, BMI, total energy 
intake, and season, excluding the EPIC-InterAct centre: Malmo.   
B) OR from Cornelis et al., 2009[172] and HR from EPIC-InterAct for T2D per T allele of rs12255372 (TCF7L2) by tertiles 
of glycaemic load (g). In women only. Cornelis et al. adjusted for age, BMI, smoking, alcohol, coffee, menopausal 
status, physical activity, energy-adjusted ratio of PUFA/SFA and trans fat and cereal fibre; EPIC-InterAct adjusted for 
age (=underlying time scale), centre, BMI, smoking, alcohol, coffee, menopausal status, physical activity, energy-
adjusted ratio of PUFA/SFA and cereal fibre. Given that Cornelis et al., evaluated this interaction in a female cohort 
(Nurses’ Health Study), the EPIC-InterAct analysis was conducted in women only.  
Pinteraction for EPIC-InterAct: estimated by treating macronutrient and SNPs as continuous variables. In EPIC-InterAct, 
heterogeneity between countries was not significant (I2=0% in A and 1% in B). 
These two SNPs (rs7903146 and rs12255372) are in moderate linkage disequilibrium (CEU r2=0.7). 
Please see methods for an explanation of the range of country-specific dietary intake percentiles used. 
Total sample size for EPIC-InterAct analysis of the interaction between dietary fibre and TCF7L2 interaction:  18292; 
GL and TCF7L2: 11992 (women only). 
Statistical test: multiplicative interaction analysis using Prentice-weighted Cox regression 
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Figure 3-3: Interaction between genetic variants within TCF7L2 and dietary fibre or glycaemic load under the 
modified model with EPIC-InterAct 
1. EPIC-InterAct meta-analysis of the hazard ratio (HR) of T2D per T allele of rs12255372 (TCF7L2), stratified by 
percentiles of glycaemic load (g) with adjustment for age (=underlying time scale), sex, centre, eigenvectors (first 5 
principal components for population stratification), physical activity, education, smoking, sex-specific alcohol 
categories, total energy intake, season of intake assessment, dietary intake (protein, magnesium, iron, vitamin C, 
coffee, tea, leafy vegetables and artificially sweetened beverage) and BMI. Heterogeneity between countries was 
moderate (I2=44%). 
2. EPIC-InterAct meta-analysis of the HR of T2D per T allele of rs7903146 (TCF7L2), stratified by percentiles of 
dietary fibre intake (g/1000kcal) with adjustment for age (=underlying time scale), sex, centre, eigenvectors (first 5 
principal components for population stratification), physical activity, education, smoking, sex-specific alcohol 
categories, total energy intake, season of intake assessment, dietary intake (carbohydrate, protein, saturated fat, 
mono-unsaturated fat, poly-unsaturated fat, magnesium, iron, vitamin C, coffee, tea, leafy vegetables and artificially 
sweetened beverage) and BMI. Heterogeneity between countries was not significant (I2=13%). 
3-5. EPIC-InterAct meta-analysis of the relative hazard ratios (RHR) for incident T2D per increase in T allele (TCF7L2 
rs7903146) and per 1g/1000kcal of dietary fibre. By fibre sub-types. 
with adjustment for age (=underlying time scale), sex, centre, eigenvectors (first 5 principal components for 
population stratification), physical activity, education, smoking, sex-specific alcohol categories, total energy intake, 
season, dietary factors (carbohydrate, protein, SFA, MUFA, PUFA, magnesium, iron, vitamin C, coffee, tea, leafy 
vegetables and artificially sweetened beverage) and BMI. All models for different subtypes of fibre are mutually 
adjusted. Heterogeneity I2 between countries differed for vegetable fibre xTCF7L2: 51%; fruit fibre xTCF7L2: 71% and 
cereal fibre xTCF7L2: 0% 
Pinteraction: estimated by treating macronutrient and SNPs as continuous variables 
*relative hazard ratio  
Statistical test: multiplicative interaction analysis using Prentice-weighted Cox regression 
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Figure 3-4: Hazard ratio (HR) of incident T2D per A allele of rs10423928 (GIPR) by tertiles of macronutrient intake: 
comparison between the study by Sonestedt et al., 2012 and EPIC-InterAct. 
For both A) total carbohydrate intake and B) total fat intake, HR  from Sonestedt et al., 2012[194] (above) and pooled 
HR from EPIC-InterAct (below). Sonestedt et al., adjusted for age, sex, physical activity, education, smoking, sex-
specific alcohol categories, season, total energy intake (TEI), method and BMI. EPIC-InterAct replication adjusted for 
age (=underlying time scale), sex, centre, physical activity, education, smoking, sex-specific alcohol categories, 
season, total energy intake and BMI  
Pinteraction for EPIC-InterAct: estimated by treating macronutrients and rs10423928 as continuous variables. 
In EPIC-InterAct, heterogeneity between countries was not significant (I2=17% in A; 19% in B)  
Please see methods for an explanation of the range of country-specific macronutrient intake percentiles used.  
Total sample size for EPIC-InterAct analysis: 21148. 
Statistical test: multiplicative interaction analysis using Prentice-weighted Cox regression 
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Figure 3-5: Hazard ratio (HR) of incident T2D per 1% total energy intake (TEI) increase in macronutrient intake, 
stratified by CAV2 rs2270188 genotype: comparison between the study by Fisher et al., 2011 and EPIC-InterAct. 
For both A) total fat intake and B) saturated fat intake, HR from Fisher et al.,[186] (above) and pooled HR from EPIC-
InterAct (below). Fisher et al., adjusted for sex, age, total energy intake, and BMI (pinteraction using results from the 
confirmatory case-cohort study under the additive genetic model). EPIC-Interact replication model adjusted for age 
(=underlying time scale), sex, centre, total energy intake, BMI, excluding the EPIC-InterAct centre: Potsdam.   
Note: the classical interaction model was adopted, not the genotype-specific model reported in Fisher et al., because 
of the stated equivalence of the 2. 
Pinteraction: estimated by treating macronutrients and rs2270188 as continuous variables. 
In EPIC-InterAct, heterogeneity between countries was moderate (I2 =41% in A; 34% in B). 
Please see methods for an explanation of the range of country-specific macronutrient intake percentiles used.  
Total sample size for EPIC-InterAct analysis: 19477. 
Statistical test: multiplicative interaction analysis using Prentice-weighted Cox regression 
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Figure 3-6: Relative Hazard Ratio (RHR) for incident T2D per 1% total energy increase in total fat intake and per T 
allele  of rs2270188 (CAV2) in 2 German centres within EPIC-InterAct. 
  
  Centre                   RHR (95%CI)       
weight 
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Figure 3-7: Interaction between genotypes for rs3786897 (PEPD: GA vs GG) and percentage of total phospholipid 
fatty acid (TPFA) that is circulating n-3 PUFA: comparison between the study by Zheng et al., 2015 and EPIC-
InterAct. 
Odds ratio (OR) from Zheng et al., 2015[192] (above) and pooled hazard ratio (HR) from EPIC-InterAct (below) for T2D. 
Zheng et al., adjusted for age and sex. EPIC-InterAct replication model adjusted for age (=underlying time scale), sex, 
centre.  
Pinteraction: estimated by treating circulating n-3 PUFA as dichotomous and PEPD rs3786897 as continuous variables. 
In EPIC-InterAct, heterogeneity between countries was not significant (I2 =15%). 
Please see methods for an explanation of the range of country-specific circulating n-3 PUFA percentiles used.  
Abbreviation: TPFA: total phospholipid fatty acid. 
Total sample size for EPIC-InterAct analysis: 22273. 
Statistical test: multiplicative interaction analysis using Prentice-weighted Cox regression 
 
There was also no evidence of any significant interaction in the more detailed 
analysis that accounted for additional potential confounders and isocaloric 
macronutrient substitution (Appendix D, Figures 1 to 3). 
For the interaction between dietary fibre and TCF7L2 on incident T2D, there 
was no material difference between the analysis using calibrated and 
uncalibrated dietary fibre (Figure 4-8). 
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Figure 3-8 Interaction between genetic variants within TCF7L2 and dietary fibre: comparison between analysis by 
Hindy et al., analysis in EPIC-InterAct with original fibre variable (uncalibrated) and analysis in EPIC-InterAct with 
calibrated fibre variable. 
 A) Odds ratio (OR) from Hindy et al., 2012[4],  B) pooled hazard ratios (HR) from EPIC-InterAct (below) for type 2 
diabetes (T2D) per T allele of rs7903146 (TCF7L2) and quintiles of dietary fibre (g/1000kcal) using uncalibrated 
dietary fibre and C) pooled HR from EPIC-InterAct for T2D per T allele of rs7903146 (TCF7L2) and quintiles of dietary 
fibre (g/1000kcal) using calibrated dietary fibre. Hindy et al., adjusted for age, sex, body-mass index (BMI), total 
energy intake, season and method (dietary intake assessment method); EPIC-InterAct replication model adjusted for 
age (=underlying time scale), sex, centre, BMI, total energy intake, and season, excluding the EPIC-InterAct centre: 
Malmo.   
Pinteraction for EPIC-InterAct: estimated by treating macronutrient and SNPs as continuous variables.  
Statistical test: multiplicative interaction analysis using Prentice-weighted Cox regression 
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4.5 Discussion 
 
13 papers reporting gene-macronutrient interactions on T2D were identified 
from this systematic review but we did not find any consistently replicated 
evidence for gene-macronutrient interaction in the aetiology of T2D. Next, given 
the nature of these findings, a general discussion about the shared issues which 
arose from this review, rather than a discussion about specific interaction 
findings, will be presented. 
Challenges in identifying and replicating gene-macronutrient 
interactions  
 
The differences between findings from the published studies and EPIC-InterAct 
re-emphasise the challenges in studying gene-diet interactions. We believe that 
selective reporting through limited consideration for multiple testing in studies 
examining multiple SNPs and/or macronutrients, without a justified predefined 
hypothesis and lack of replication are among several possible methodological 
explanations for this inconsistency. There are also other factors that may explain 
why we find different results to that of the published studies, which include 
heterogeneity in dietary measurement, population under study, study design or 
in analysis and reporting, as discussed in previous reviews.[119,142,199,200] 
In hypothesis-free genetic epidemiological analyses, given the large number of 
variants tested on a genome-wide scale, stringent correction for multiple testing 
has attempted to minimise the false positive rate.[201] However, approaches to 
address multiple testing for interaction studies have been less consistent. We 
found in our review that studies often used a nominal p<0.05 as the threshold 
for rejecting the null, even when performing many tests,[4,170,172,186,194] including 
one study that performed an exploratory analysis of 256 gene-macronutrient 
interactions and used p<0.05 for rejecting the null.[186] Two of the six studies 
that reported significant interactions would have passed multiple testing 
corrections after Bonferroni correction,[170,194] whereas only one study adopted 
Bonferroni corrected p values.[192] Therefore, we consider false positive reports 
as a potential explanation for the discordant findings between EPIC-InterAct 
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and published reports. Whilst debate continues about whether an optimal p-
value threshold should exist for interaction studies,[202] in the future researchers 
should account for potential inflation of a false positive rate when conducting 
multiple interaction analyses (e.g. by using methods such as the ‘effective 
number of independent tests’),[203] preferably with independent internal 
replication in additional studies. As evidenced by genome-wide association 
studies, the design of genetic studies allows for relatively straightforward in 
silico replication, yet few gene-macronutrient interaction studies that report 
finding a significant interaction have been followed by independent 
replication.[4,170,172,192,194] Arguably, variations in dietary assessment methods 
introduce more difficulty in identifying suitable replication sources. For 
instance, although four independent studies included in our review examined 
the interaction between TCF7L2 and dietary fibre or related fibre 
subtypes,[4,170,172,189] it is arguable how comparable their methods are.  This 
includes differences in relation to dietary assessment and degree of 
measurement bias: two studies used an FFQ,[170,172] one used a 24-hour recall[189] 
and one used a combined FFQ, diet history and 7-day diary.[4] Moreover 
regarding study design: two studies were prospective,[4,170] and two were cross-
sectional,[172,189] which may be subject to differing levels of bias and ability to 
determine the direction of effect. Lastly, analytic methods varied by whether 
variables were treated as continuous or categorical and what covariates were 
controlled for. Therefore, in the future, researchers should consider internally 
conducted replication as this would reduce variation in the analysis.  
We attempted to mirror the population and analyses conducted in EPIC-
InterAct with that of the published studies reporting an interaction and showed 
comparable characteristics except with one study where the ethnicity was 
different  (an Asian population was examined).[192] However, we cannot exclude 
possible heterogeneity between studies. This may include differences in study 
design (only one published study used a case-cohort study design similar to 
EPIC-InterAct) and unmeasurable inconsistencies in dietary exposures (e.g. food 
composition, preparation methods, measurement tool used, coding of 
exposures) between countries within EPIC-InterAct and between EPIC-InterAct 
and the published studies. Indeed, this was evident for the interaction between 
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CAV2 with total fat and SFA, which showed centre-specificity. Within the 
German centres, an interaction was detected for the EPIC-InterAct centre 
Potsdam but not Heidelberg resulting in an overall lack of interaction for 
Germany (Figure 4-6 shows the interaction results for fat and CAV2 by German 
centres). However, the percentage of total variation due to heterogeneity across 
the countries within EPIC-InterAct was low to moderate for interactions under 
the replication model (I2: 14 to 30%). The consistently null findings across 
different countries of EPIC-InterAct strengthen the inference from this overall 
null finding. Another possible contributor to the disparity between results, for 
instance relating to TCF7L2 and dietary fibre, may be overestimation by certain 
estimation parameters (e.g. odds ratios) which could lead to an inflated 
difference between fibre categories.[204] 
The methodological issues described above highlight difficulties in discerning 
whether type I error or true heterogeneity underlies the inconsistencies we 
observed and are similar to that faced in the broader gene-environmental 
literature.[35,202] For gene-environment interactions, recommendations have 
been made for improving standards in design, analysis and reporting, which are 
also relevant for gene-diet studies.[141,142] For example, Cornelis suggested 
minimising publication bias by publishing both positive and negative interaction 
findings and reporting them in supplemental materials if necessary.[142]  
Strengths and limitations  
A potential limitation of our systematic review is that the heterogeneity between 
the published studies did not enable a quantitative synthesis (e.g. meta-analysis) 
or formal statistical evaluation of publication bias, as previously demonstrated 
and advised against by Palla et al.,[154] We did, however, use a comprehensive 
search strategy and tried to minimise publication bias by contacting authors of 
studies possibly examining interactions (n=4).  
From the literature, EPIC-InterAct, is the largest study of incident T2D cases (>5 
times the number of previous studies) with both genetic data and measures of 
self-reported macronutrient intake as well as objective circulating fatty acids, 
which overall makes it well positioned to examine these reported interactions 
(power calculations in the Table 4-5 below). The prospective design minimises 
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the potential bias due to reverse causality for dietary exposures. Additionally, to 
our knowledge, this is the first study for gene-macronutrient interactions which 
has investigated the effect of isocaloric macronutrient substitution in the 
observational setting. This is important for public health interpretation of 
macronutrient density if total daily energy intake is fixed, as the benefit of 
decreasing one macronutrient may be dependent on which macronutrient/s it is 
replaced by. As exemplified by the interaction between rs10423928 (GIPR) and 
both fat and carbohydrate intake.[194] The authors did not model isocaloric 
macronutrient substitution, so it is unclear whether they demonstrated a lower 
risk of T2D among those possessing an A allele for this genetic variant and 
consuming a diet that is higher in fat and lower in carbohydrate intake reflects a 
substitution effect or independent effects for the respective macronutrient.  
Several limitations need to be considered whilst interpreting the results. These 
analyses only investigated a select number of interactions which have been 
reported in the literature. Hence, this does not preclude the possibility that there 
may be interactions between other dietary (including foods and dietary patterns) 
and/or other genetic variants or combined gene scores. Moreover, our focus was 
on examining possible type I error. Given that we did not examine interactions 
which did not reach statistical significance in published studies (possible type II 
error) we cannot preclude the presence of genuine interactions among those loci 
we did not test. Alternative study designs, such as agnostic GEWIS may be better 
placed to investigate the presence of these interactions.[205] Variations in dietary 
assessment between EPIC-InterAct centres may contribute to potential variation 
in measurement bias for macronutrients. The current literature consists of 
studies primarily from European populations, which limits the generalisability 
of our findings. Another limitation is the uncertainty about between-centre and 
between-country variation in the degree of measurement bias for macronutrient 
intake and how this may affect our interaction results, especially for dietary fibre 
as previously explained. Hence, the interaction between dietary fibre and 
TCF7L2 using a variable calibrated with a single measure of 24-hour recall,[188] 
was examined and found no difference to interaction results using the 
uncalibrated dietary fibre variable. This can be explained by two reasons, i) 
Hoffmann and colleagues cautions that the accuracy of calibrated FFQs depends 
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on the accuracy of the reference method.[188] Although a single 24 hour recall 
measured in <8% of EPIC participants has been validated against 24 hour urine 
nitrogen as a reference method for calibrating protein intake,[187] it is unclear 
how reliable and accurate it would be as the reference method for calibrating 
dietary fibre intake when objective measurements are as yet unavailable for 
dietary fibre. ii) Yet, even if a more accurate reference was available for dietary 
fibre intake since regression calibration only affects the precision of effects, 
when the precision of effects in both strata of a dietary exposure under an 
interaction model is improved, it is unlikely that the significance of interaction 
estimates would be affected. Moreover, no previous interaction studies have 
calibrated their macronutrient intake data. There are alternative suggestions to 
address measurement bias within an interaction framework proposed by 
Midthune and colleagues,[206] but this is beyond the scope of this thesis. 
Table 3-5: Power calculations 
Published 
study 
Interactions 
reported (effect 
allele) 
Effect allele 
frequencies 
(Europeans) 
Marginal effect in 
InterAct 
(gene/macronutri
ent) 
All log-additive 
unless specified 
LogOR for 
interaction 
(highest /lowest 
category of 
intake or 
genotype) 
Power to 
detect 
interaction 
in InterAct 
Hindy et 
al., 2012 
TCF7L2-dietary 
fibre (rs7903146) 
(T) 
0.23 1.3/1  1.26 0.87 
Wirstrom 
et al., 2012 
TCF7L2-cereal 
fibre (rs7903146) 
(T) 
0.23 1.3/0.97  
 
1.72 0.99 
Cornelis et 
al., 2009 
TCF7L2-GL 
(rs12255372) (T) 
0.21 1.3/0.997  1.41 0.99 
Sonestedt 
et al., 2012 
GIPR-CHO 
rs10423928 (A) 
0.17  1/0.98  1.36  0.96 
 GIPR-fat 0.17 1/1  0.73 0.92 
Fisher et 
al., 2011 
CAV2- total fat 
rs2270188 (T) 
0.55  1/1  1.01 0.05  
 CAV2- SFA 0.45 1/1  1.15 0.58 
Zheng et 
al., 2015 
PEPD- circulating 
n-3 PUFA 
rs3786897(A) 
0.59  1/0.88  
Dominant model  
0.29 0.99 
Assumptions for QUANTO (v.1.2.4): InterAct sample size= 9,000 cases, 12,000 non-cases; Prevalence of T2D:  10%; 
macronutrient intake normally distributed; α <0.05; per increase in 1%E from macronutrient intake per risk allele, 
under a log additive model unless specified otherwise 
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Implications for public health and research 
Our systematic review and replication in EPIC-InterAct highlight the importance 
of independent replication in the study of interaction and the need to improve 
standards in conducting and reporting future interactions. Moreover, our review 
reveals a gap in non-candidate gene approaches to examining gene-
macronutrient interactions. This includes GRS and GEWIS. Additionally, there 
is a gap for examining gene-macronutrient interactions in the intervention 
setting. Given that no promising gene-macronutrient interactions were found 
and that genetic variants most relevant for interactions may be those with weak 
or no marginal effects,[95,207] GEWIS may aid in discovering novel interactions at 
potentially unexpected genetic loci. Furthermore, this review highlights that on 
the basis of the interactions examined here, there is no evidence to support 
genetic personalisation of macronutrient intake recommendations as a strategy 
to prevent T2D.  
Recommendations for future research  
A) Within study considerations: (i) specifying the hypothesis of the study and 
accounting for multiple testing, as appropriate; (ii) reporting all interaction 
results and if conducted as pre-planned or post-hoc, regardless of whether 
findings are positive, negative or null; and (iii) where possible, notable 
interaction findings should be accompanied with independent replication and if 
not feasible a discussion should be made about the reasons and validity of non-
replicated findings.  
 
B) General considerations for studies within the field: (i) improving consistency 
and standards in examining and reporting interactions, as advised in several 
previous reviews; [141–143] (ii) conducting studies examining non-European 
populations; and (iii) applying isocaloric macronutrient substitution. 
 
4.6 Conclusion  
 
Whilst there is growing interest in personalised diets to more effectively combat 
cardiometabolic conditions such as T2D, none of the gene-macronutrient 
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interactions currently reported in the literature could be replicated in the large-
scale EPIC-InterAct study. We also do not find evidence to support that the 
specific gene-macronutrient interactions we examined play a significant role in 
the aetiology of T2D. Improving standards in examining and reporting 
interactions, including independent replication, will be vital to making progress 
in this area.  
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4. Chapter 5 Interaction between genetic risk score 
and macronutrient intake on incident T2D in EPIC-
InterAct 
 
 
 
This chapter follows on from the previous chapter by addressing some of the 
major research gaps identified from our systematic review. In particular, it 
contributes to the currently scarce literature on gene-macronutrient interactions 
and T2D, using genetic risk scores. This project relates to objective 3 (Chapter 
2). 
 
This Chapter will soon be published: 
Li SX, Imamura F, Ye Z, Schulze MB, Zheng J, Ardanaz E, et al., Interplay 
between genetic predisposition and macronutrient intake on type 2 diabetes 
incidence: analysis within EPIC-InterAct across eight European countries. 
Diabetologia 2018. doi: 10.1007/s00125-018-4586-2. [Epub ahead of print] 
 
5.1 Abstract    
 
Objective Gene-macronutrient interactions may contribute to the development 
of type 2 diabetes (T2D) but evidence is inconclusive.  
 
 
 
113 
Research design and methods the interactions between three genetic risk 
scores (GRS) and macronutrient intake on the development of T2D was 
examined in EPIC-InterAct, a prospective case-cohort study across eight 
European countries (N=21,900, 9,742 incident T2D cases). GRS were 
constructed for T2D (48 single nucleotide polymorphisms [SNPs]), insulin 
resistance (53 SNPs) and body mass index (97 SNPs) based upon shared biology 
in T2D development. Macronutrient intake was estimated from diets reported in 
questionnaires, including the proportion of energy derived from total 
carbohydrate, protein, fat, plant and animal protein, saturated, mono- and poly-
unsaturated fat and dietary fibre. Using multivariable-adjusted Cox regression, 
country-specific interaction results were estimated under the multiplicative 
scale, which were pooled by random-effects meta-analysis. Secondary analysis 
accounted for isocaloric macronutrient substitution.  
 
Results A significant positive association was observed between total and 
animal protein intake with incident T2D. No interactions were identified 
between any of the three GRS and any macronutrient intake, with low to 
moderate heterogeneity between countries (I2 range: 0-51.6%). Results were 
similar when analyses accounted for isocaloric macronutrient substitution, when 
using weighted and unweighted GRS and when examining individual SNPs.  
Conclusions Genetic susceptibility to T2D, insulin resistance and BMI did not 
modify the association between macronutrient intake and incident T2D. This 
indicates that dietary recommendations for macronutrient intake for preventing 
T2D apply across the population regardless of genetic predisposition to these 
three metabolic conditions. 
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5.2 Background        
 
An emphasis on macronutrient composition has dominated public health dietary 
recommendations for decades, with guidance on optimal percent of energy to be 
consumed from carbohydrate, fat and protein. In addition to guidance relating 
to macronutrient quantity, more recently dietary guidance has evolved to 
acknowledge the importance of macronutrient quality. For instance, evidence 
supporting cardiometabolic benefits when replacing dietary saturated fat with 
polyunsaturated fat has led to emergence of guidance concerning fat subtype or 
quality.[81,208] Similarly, there is evidence on the importance of carbohydrate 
quality such as higher dietary fibre intake,[86] which is reflected in guidance on 
preventing T2D.[10]  
Genetic susceptibility to T2D is also well documented, with heritability 
estimated to be between 40% and 80% and meta-analyses of genome-wide 
association efforts have now identified over 70 genetic variants associated with 
increased risk of T2D, that explain around 6% of its variance.[25,27] With this, 
there has been increasing interest in whether this genetic susceptibility may 
differentially influence how macronutrient intake affects the development of 
T2D (gene-macronutrient interaction) and whether this may support the rising 
popularity of ‘personalised’ or ‘precision’ nutrition.[95] However, evidence for 
this from a recent systematic review for interactions between genetic 
predisposition and macronutrient intake for T2D is far from conclusive.[209] 
Genetic risk scores (GRS), composed of multiple single nucleotide variants, are 
of interest because they may better reflect the polygenic nature of T2D.[125] It is 
known that insulin resistance (IR), often secondary to obesity, is involved in the 
aetiology of T2D and susceptibility genetic loci have been identified for T2D, IR 
and Body Mass Index (BMI) [5,28,30]. Moreover, GRS for T2D, IR, and BMI may 
help to explain more variance for T2D than candidate genetic variant 
approaches and may improve statistical power to detect potential interactions. 
Yet, there is a paucity of studies examining gene-macronutrient interaction 
using a GRS approach.  
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We aimed to increase understanding about the aetiology of T2D by investigating 
potential interactions between genes and macronutrient intake on the incidence 
of T2D using GRS for each of these three traits: T2D, IR and BMI. 
5.3 Methods 
 
The EPIC-InterAct cohort, genotyping and imputation, dietary assessment and 
estimation of macronutrient intake and statistical analyses have already been 
described in the Methods Chapter (Chapter 3). In addition to these general 
methods, below I describe some specific methods for this piece of work. 
 
Cohort 
 
This current study is based on 21,900 adults with available genome-wide 
genotyping and dietary data (9,742 cases and 12,158 non-cases) from EPIC-
InterAct.  
 
Computation of genetic risk score  
 
Unweighted GRS for T2D, IR and BMI were generated by summing up the 
number of risk alleles for each trait [125]. SNPs from loci reaching genome-wide 
significance for the respective traits in published meta-analyses investigating 
European populations were used (48 for T2D after excluding BMI raising alleles 
FTO and MC4R so as to reduce overlap with the BMI GRS; 53 for IR and 97 
SNPs for BMI).[5,28,30] An additive genetic model was assumed for each SNP. 
Taking the T2D GRS (48 SNPs) as an example, an individual could carry 0, 1, or 
2 risk alleles for each genotyped SNP or a continuous dosage for imputed SNPs 
(the possible range for T2D GRS: 0 to 96). The results of these analyses were 
also compared with interactions examined using weighted GRS based on the 
beta coefficients from published meta-analyses of GWAS for the respective traits 
(available for BMI and T2D).[5,28] 
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Imputation of missing covariates 
 
In situations where data is missing at random but not completely at random, 
conducting complete case analyses may be biased. Additionally, where there may 
be different degrees of missingness across several covariates, this may result in a 
loss of precision and power. Since the difference between missing at random or 
completely at random is difficult to disentangle statistically, covariates at <30% 
missing (Table 5-1) were imputed using Multiple Imputations by Chained 
Equations (MICE) in Stata.[210]  In brief, practically this method involved the 
inclusion of covariates needing imputation as well as the outcome and predictors 
of all missing covariates. Firstly, all continuous covariates and predictors were 
normalised to enable prediction based upon a known distribution. Based on the 
predictors in the model MICE uses a Bayesian approach to create a specified 
number of datasets in addition to the original, with the plausible imputed values 
in place of those that were previously missing within each dataset. 20 datasets 
are usually sufficient to allow for uncertainty in imputation so that the datasets 
would capture the supposed ‘real’ value within the variation of imputed values. 
The method explained by White and colleagues involved running the analysis 
model for each imputed dataset independently after which results from each 
analysis would be then pooled into one estimate using Rubin’s rules. However, 
for each of the interaction analyses in EPIC-InterAct, this was conducted by 
country and genotyping chip before being meta-analysed. At the time of 
conducting this analysis, there was no function within MICE to incorporate this 
additional complexity. Therefore, for computational efficiency, a single imputed 
dataset was used for all analyses, after confirming no obvious between-
imputation variation across twenty multiple-imputation datasets[210] (Figure 5-1 
provides an example analyses across all 20 datasets). The total variation, being 
the sum of the within dataset variation (3.89E-05) plus the between-study 
variation (1.32E-07) was very small. Therefore, all datasets were deemed 
comparable. Dataset number 15 was therefore chosen, at random, for all 
analyses presented in this paper. With many imputation methods, there are 
limitations related to MICE, including the possibility of misleading results 
driven by systematic differences in missing values. Therefore complete-case 
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analysis was also performed as a sensitivity analysis to compare with the results 
from MICE.[211] 
 
Table 4-1: Imputed baseline variables from EPIC-InterAct 
Characteristics % missing Imputed 
Number    21900 
Age (y) -   
Sex (%male) -   
PA level (%) 1.1% Y 
inactive     
moderately inactive     
moderately active     
active     
Highest school level (%) 1.7%  Y 
none     
primary school     
technical/professional     
secondary school     
longer education (inc. university)     
BMI (kg/m2) 0.7% Y 
Waist hip ratio  7.9% Y 
Smoking status (%) 1% Y 
never     
former     
current smoker     
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Beta coefficient of the interaction between fibre and T2D GRS on incident T2D 
Figure 4-1: Comparison between 20 imputed datasets for the interaction between total fibre intake and T2D 
genetic risk score on incident T2D.     
Beta co-efficient for the interaction term adjusted for age (=underlying time scale), sex, centre, TEI, eigenvectors 
(first 5 PC for population stratification), physical activity, education, smoking, sex-specific alcohol categories, 
carbohydrate, SFA, MUFA, PUFA intake, magnesium, iron, vitamin C, leafy vegetable, tea, coffee, BMI 
Statistical analyses 
 
Main effect analyses 
The associations between macronutrient intake and T2D were estimated by 
treating macronutrient exposures as continuous variables (per SD difference in 
percentage of total energy intake). Potential outliers were Winsorised at the 1st 
and 99th percentile. 
Crude and multivariable-adjusted Prentice-weighted Cox regression models 
were constructed within country. For consistency, modelling was based as 
closely as possible on those used in previous EPIC-InterAct analyses for 
carbohydrate,[212] protein[213] and dietary fibre.[86] For dietary fat and subtypes 
(not previously published in EPIC-InterAct), models adjusted for age 
(underlying time scale), sex, centre (nominal categorical), total energy intake 
(Kcal/d), physical activity (inactive, moderately inactive, moderately active, 
active), education (none, primary school, technical/professional, secondary 
school, longer education (including university)), smoking (never, former, 
current smoker), sex-specific alcohol intake (none, light drinking: 0.1-6g/d, 
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moderate drinking: men 6.1-24g/d and women 6.1-12g/d, heavy drinking: 
men>24g/d and women>12g/d) and other dietary confounders (dietary fibre, 
magnesium, iron, vitamin C, green leafy vegetables, tea and coffee in mg or 
g/day). The covariates used can be found in the legend of Table 5-2. Country-
specific hazard ratios (HR) for each macronutrient intake were combined across 
countries using random-effects meta-analysis.  
 
For the association between GRS and T2D, the GRS were treated both as 
continuous (per SD difference) and dichotomised exposures (as high and low 
GRS estimates based on being above or below the median estimates among 
those in the subcohort) (Table 5-3). Prentice-weighted Cox regression models 
were constructed within country and by genotyping chip. Genotype chip-specific 
and then country-specific estimates were combined using random-effects meta-
analysis. Analyses were adjusted for age (underlying time scale), sex, centre, the 
first 5 principal components for population stratification and BMI. 
 
Interaction analyses 
For the interaction analyses between each macronutrient intake and each GRS 
on the risk of developing T2D, both exposures were treated as continuous 
variables (GRS per SD difference and macronutrient as densities, being 5% of 
total energy intake/day and 1g/1000kcal/day for dietary fibre) to avoid loss of 
statistical power from categorisation. Multiplicative interaction was evaluated by 
fitting a product term between the GRS and macronutrient exposures [135].  
Regression models were constructed in the same way as in analysis of the 
association between GRS and incident T2D, and the list of covariates included in 
the models were the same as for the main associations between macronutrient 
intake and T2D (described above), with addition of the first 5 principal 
components for population stratification. Between-country heterogeneity was 
quantified by the I2 value and P for heterogeneity was derived from the Cochran-
Q test.  BMI was a covariate in the interaction analysis for IR and T2D GRS only.   
 
For visualisation, the estimated HR for each dietary factor was stratified by high 
and low GRS groups (Figure 5-2).  
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Given that GRS may mask interactions with individual SNPs, further secondary 
interaction analysis was conducted for each SNP within all 3 GRSs. The potential 
effect of whether substitution of a macronutrient for another was modified by 
genetic predisposition while energy intake was held constant (i.e. isocaloric 
macronutrient substitution using the multivariate nutrient density model),[168] 
was also examined. This was performed for energy-bearing macronutrients (not 
dietary fibre), with the modelling strategy provided in Appendix F. 
Stata v14 (StataCorp LP, Texas, USA) was used for analysis. Numerical p value 
for interaction were reported in tables and figures, however, the threshold for 
determining statistical significance for interactions between GRS and 
macronutrient intake (without isocaloric macronutrient substitution) was 
≤0.0015 (0.05/33 tests) to account for the effective number of independent tests 
among correlated exposures (see Table 5-4 for correlations).[203] The threshold 
for determining statistical significance for interactions under the substitution 
model was ≤0.0006 (0.05/81 tests). 
 
5.4 Results  
 
At baseline, the mean age of participants in the subcohort was 52.3 years (SD= 
9.3 years) and median follow-up was 10.9 years. A statistically significant 
association was observed between proportion of energy from protein intake and 
incident T2D (HR per 1 SD =1.10; 95%CI: 1.03, 1.18) and from animal protein 
intake and incident T2D (HR per 1 SD =1.10; 95%CI: 1.01, 1.18) (Table 5-2). 
Those with higher genetic risk for T2D, IR or BMI (i.e. in the ‘high GRS’ group) 
were at a significantly higher risk for developing T2D than those in the lower 
genetic risk group (Table 5-3). There was little correlation between the GRS and 
macronutrients (Table 5-4). 
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Table 4-2: Association between macronutrient intake and the incidence of type 2 diabetes: EPIC-InterAct study 
 
No. Cases/Total Mean (SD)  Mean (SD)  HR (95%CI) per SD* 
    Subcohort non-cases Total incident T2D cases 
 Median years of follow up 9742/21900 12.3  6.8  
 Age at baseline(y) 
 
52.3 (9.3) 55.7 (7.6) 
 Sex (%male) 
 
37.9% 49.9% 
 Macronutrient intake     
Carbohydrate (%TEI) 9742/21900 44.1 (6.9) 43.7 (6.9) 0.97 (0.92,1.02) 
Protein (%TEI) 9742/21900 16.9 (3.0) 17.2 (3.0) 1.10 (1.03,1.18) 
Animal protein (%TEI) 9742/21900 10.5 (3.2) 10.9 (3.2) 1.10 (1.01,1.18) 
Plant protein (%TEI) 9742/21900 5.00 (1.3) 4.9 (1.3) 1.074 (0.999,1.150) 
Fat (%TEI) 9742/21900 34.8 (5.7) 34.7 (5.7) 1.03 (0.99,1.08) 
Saturated fat (%TEI) 9742/21900 13.4 (3.3) 13.3 (3.3) 0.99 (0.93,1.06) 
Monounsaturated fat (%TEI) 9742/21900 13.1 (3.4) 13.0 (3.4) 1.04 (0.97,1.12) 
Polyunsaturated fat (%TEI) 9742/21900 5.5 (1.8) 5.6 (1.8) 1.066 (0.999,1.137) 
Fibre (g) 9742/21900 22.7 (7.5) 22.6 (7.6) 0.92 (0.84,1.02) 
Fibre-cereal (g) 9739/21891 8.8 (4.9) 8.9 (4.9) 0.96 (0.86,1.07) 
Fibre-fruit (g) 9608/21611 4.3 (3.2) 4.2 (3.2) 0.86 (0.73,1.02) 
Fibre-vegetable (g) 9737/21893 4.1 (2.6) 34.0 (2.6) 0.99 (0.94,1.04) 
Hazard Ratios (HR) for macronutrients (per SD) and incident Type 2 Diabetes (T2D):  Carbohydrate intake adjusted for age (=underlying time scale), sex, centre, 
education, physical activity, smoking status, sex-specific alcohol categories, BMI, total energy intake, dietary protein, PUFA:SFA ratio, dietary fibre (attempt to 
replicate model 3 in  Sluijs et al., 2013); Protein intake and subtypes adjusted for age (=underlying time scale), sex, centre, physical activity,  smoking status, sex-
specific alcohol categories, BMI, waist hip ratio, total energy intake, dietary fibre, SFA, MUFA, PUFA, soft drinks, tea, and coffee (not adjusted for carbohydrates; 
i.e., a substitution model), education (attempt to replicate model 4 in van Nielen et al., 2014); Fat intake and subtypes  adjusted for age (=underlying time scale), 
sex, centre, physical activity, smoking status, sex-specific alcohol categories, BMI,  total energy intake, dietary fibre, magnesium, iron, vitamin C, leafy vegetables, 
tea, coffee, education; Dietary fibre and subtypes  adjusted for age (=underlying time scale), sex, centre, physical activity, smoking status, sex-specific alcohol 
categories, total energy intake, dietary carbohydrates, magnesium, saturated fatty acids, education level. Fibre subtypes were mutually adjusted (attempt to 
replicate model 3 in Aune et al., 2015). 
*SD calculated based on the whole population 
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Table 4-3: Association between genetic risk scores for BMI, IR and T2D and the incidence of type 2 
diabetes: EPIC-InterAct Study 
Unweighted genetic risk score N HR (95%CI) 
  
 
Model 1 Model 2 
T2D  
 
  
   per SD (4.3 risk alleles) 
 
1.42(1.32,1.52) 1.49(1.37,1.63) 
   High (≥52 risk alleles) 12033 1.75(1.55,1.98) 1.85(1.58,2.16) 
   Low (<52) 9867 1 [Reference] 1 [Reference] 
IR  
 
  
   per SD (4.5 risk alleles) 
 
1.11(1.08,1.14) 1.14(1.09,1.20) 
   High (≥55) 11303 1.18(1.12,1.25) 1.23(1.12,1.35) 
   Low (<55) 10597 1 [Reference] 1 [Reference] 
BMI  
 
  
   per SD (6.3 risk alleles) 
 
1.07(1.04,1.10) NA 
   High (≥91) 11230 1.12(1.06,1.19)  
   Low (<91) 10670 1 [Reference]  
 
Interaction between genetic risk scores and macronutrient intake on 
incident T2D 
The association between the proportion of energy derived from the intake of each 
macronutrient and incident T2D did not differ significantly by T2D GRS (lowest 
pinteraction=0.20) (Figure 5.2 and Table 5.5). No significant interactions were found 
with GRS for IR (lowest pinteraction =0.21) or BMI (lowest pinteraction=0.22) (Figure 
5.2 and Table 5.5). There was low to moderate heterogeneity between countries in 
EPIC-InterAct (I2 range: 0-51.6%) (Table 5.5). Results did not change 
substantially when GRS were weighted by the beta coefficient of each SNP on 
their respective trait from published GWAS meta-analyses (data not presented).  
Similarly, no interactions were detected when modelling isocaloric macronutrient 
substitution for the GRS-based analyses (pinteraction ≥0.17) (Appendix F, model 5).  
Hazard Ratio (HR) for genetic risk scores and Type 2 Diabetes (T2D):   
Model 1: age (=underlying time scale), sex, centre, first 5 principal components (PC) for population stratification  
Model 2: model 1 + BMI 
Abbreviations: T2D- type 2 diabetes, BMI- body mass index, IR- insulin resistance, SD- standard deviation  
Number of SNPs: T2D (48 as per Morris et al., Nature Gen, 2012), BMI (97 as per Locke et al., Nature, 2015), IR 
(53 as per Lotta et al., Nature Gen, 2016)  
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Figure 4-2: Association between macronutrient intake (per SD) and the incidence of type 2 diabetes, which were stratified by high or low genetic risk scores: EPIC-InterAct Study 
Macronutrients are modelled per standard deviation difference in intake (see Table 5-1 for the standard deviation for each macronutrient)  
Carbohydrate intake adjusted for age (=underlying time scale), sex, centre, education, physical activity, smoking status, sex-specific alcohol categories, BMI, total energy intake, dietary 
protein, PUFA:SFA ratio, dietary fibre and first 5 principal components (PC) for population stratification; Protein intake and subtypes adjusted for age (=underlying time scale), sex, 
centre, physical activity,  smoking status, sex-specific alcohol categories, BMI, waist hip ratio, total energy intake, dietary fibre, SFA, MUFA, PUFA, soft drinks, tea, and coffee (not 
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adjusted for carbohydrates; i.e., a substitution model), education and first 5 principal components (PC) for population stratification; Fat intake and subtypes  adjusted for age 
(=underlying time scale), sex, centre, physical activity, smoking status, sex-specific alcohol categories, BMI,  total energy intake, dietary fibre, magnesium, iron, vitamin C, leafy 
vegetables, tea, coffee, education and first 5 principal components (PC) for population stratification; Dietary fibre and subtypes  adjusted for age (=underlying time scale), sex, centre, 
physical activity, smoking status, sex-specific alcohol categories, total energy intake, dietary carbohydrates, magnesium, saturated fatty acids, education level and first 5 principal 
components (PC) for population stratification. Fibre subtypes were mutually adjusted. 
Interaction analysis for BMI GRS does not adjust for BMI. 
Interactions were considered statistically significant if p< 0.0015 (0.05/33 tests) 
There were also no statistically significant multiplicative interactions between any macronutrient and GRS, when treating them as continuous exposures (see Table 5.5). 
Filled in black dots= high genetic risk score, Unfilled white dots= low genetic risk score 
Example of interpretation: the HR of 1 SD difference in fruit fibre on incident T2D is 1.03 in those who have the highest genetic predisposition for T2D and 1.01 for those with lower 
genetic predisposition for T2D. There was no statistically significant difference between those with different genetic predispositions for T2D. 
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Table 4-4: Correlations between dietary exposures within the EPIC-InterAct Study 
Exposures 
T2D 
GRS 
IR 
GRS 
BMI 
GRS fat sfa mufa pufa prot prota protp cho fb fb_veg fb_fruit fb_cereal 
fat 0.01 0.01 0.00   0.71 0.70 0.40 0.01 0.13 0.37 0.61 0.30 0.03 0.20 0.29   
sfa 0.01 0.01 0.01   0.21 0.11 0.21 0.04 0.57 0.31 0.35 0.27 0.30 0.05   
mufa 0.00 0.00 0.00     0.03 0.15 0.21 0.12 0.52 0.26 0.03 0.01 0.41   
pufa 0.00 0.01 0.02     0.01 0.01 0.03 0.25 0.06 0.15 0.11 0.00   
prot 0.00 0.00 0.03       0.04 0.04 0.32 0.17 0.37 0.18 0.15   
prota 0.00 0.00 0.02       0.25 0.47 0.05 0.24 0.11 0.25   
protp 0.01 0.00 0.01         0.30 0.63 0.36 0.24 0.36   
cho 0.01 0.00 0.02         0.37 0.07 0.24 0.35   
fb 0.01 0.00 0.01           0.53 0.52 0.43   
fb_veg 0.01 0.01 0.01           0.32 0.13   
fb_fruit 0.02 0.00 0.01             0.13   
fb_cereal 0.01 0.00 0.00 
 
              
                 Strength of correlation 
          0  
           0.3      
           0.5      
           0.7      
           1      
           
 
     
           Spearman’s Rho, without direction of correlation. 
Abbreviations: sfa- saturated fatty acid, mufa- monounsaturated fatty acid, pufa- polyunsaturated fatty acid, prota- animal protein, protp- plant protein, cho- carbohydrate, fb- fibre, 
fb_veg: vegetable fibre, fb_fruit: fruit fibre, fb_cereal: cereal fibre. 
All variables treated as continuous variables 
Correlations calculated based on subcohort population only (N=12749) 
Effective number of independent tests:[203]  for the interaction between genetic risk scores and macronutrient interactions (without isocaloric macronutrient substitution):  10.9776  
(variance of the observed eigenvalues: 1.12). This estimates the independent number of tests, accounting for any correlated macronutrients. 
 
 
126 
Table 4-5: Multiplicative interaction between macronutrient and unweighted genetic risk scores: EPIC-InterAct Study 
Macronutrient 
intake (5% total 
energy intake) Model 
GRS for body mass index (per 6.3 risk 
alleles)% 
GRS for insulin resistance (per 4.5 risk 
alleles) 
GRS for type 2 diabetes (per 4.3 risk 
alleles) 
  
Beta (95% CI) P I2 (%) Beta (95% CI) P I
2 
(%) Beta (95% CI) P I
2 (%) 
Carbohydrate Sluijs et al., 2013 0.001(-0.034,0.035) 0.971 50.2 0.001(-0.03,0.031) 0.970 19.1 0(-0.028,0.027) 0.976 0.0 
Total protein van Nielen et al., 2014 -0.032(-0.1,0.036) 0.351 0.0 0.062(-0.035,0.16) 0.210 37.9 -0.06(-0.162,0.042) 0.249 43.4 
Animal protein van Nielen et al., 2014 -0.022(-0.083,0.039) 0.475 0.0 0.055(-0.048,0.158) 0.293 51.6 -0.05(-0.145,0.045) 0.302 45.5 
Plant protein van Nielen et al., 2014 -0.057(-0.206,0.091) 0.451 0.0 0.004(-0.241,0.249) 0.975 49.0 -0.022(-0.185,0.142) 0.793 0.0 
Total fat model 4 0.01(-0.017,0.036) 0.471 0.0 -0.004(-0.048,0.041) 0.869 41.2 0.011(-0.021,0.043) 0.497 0.0 
SFA model 4 0.031(-0.019,0.08) 0.228 0.0 -0.015(-0.089,0.058) 0.687 22.8 0.027(-0.034,0.089) 0.384 0.0 
MUFA model 4 0.014(-0.044,0.073) 0.634 0.0 0.023(-0.087,0.133) 0.685 48.5 -0.016(-0.097,0.065) 0.699 15.3 
PUFA model 4 -0.042(-0.155,0.072) 0.471 30.5 0.01(-0.139,0.16) 0.895 40.4 0.072(-0.039,0.182) 0.204 2.2 
Total dietary 
fibre (g/1000kcal) Aune et al., 2015 0.004(-0.006,0.015) 0.408 0.0 -0.004(-0.019,0.011) 0.623 44.7 -0.001(-0.011,0.01) 0.919 0.0 
Vegetable fibre 
(g/1000kcal) Aune et al., 2015 0(-0.029,0.028) 0.973 6.8 -0.012(-0.053,0.028) 0.548 46.4 0.007(-0.021,0.035) 0.634 0.0 
Fruit fibre 
(g/1000kcal) Aune et al., 2015 0.013(-0.008,0.033) 0.222 0.0 -0.007(-0.036,0.022) 0.632 40.8 -0.001(-0.029,0.026) 0.927 30.2 
Cereal fibre 
(g/1000kcal) Aune et al., 2015 -0.005(-0.022,0.012) 0.568 0.0 -0.002(-0.02,0.015) 0.799 0.0 0.004(-0.018,0.025) 0.735 21.5 
Abbreviations: SFA- saturated fatty acid, MUFA- monounsaturated fatty acid, PUFA- polyunsaturated fatty acid, GRS- genetic risk score 
Beta-coefficient for the interaction between each of the genetic risk score and respective macronutrients on incident T2D, adjusted for the following covariates (as per previously 
published EPIC-InterAct study, see methods). 
Carbohydrate age (=underlying time scale), sex, centre, education, physical activity, BMI, smoking status, sex-specific alcohol categories, total energy intake, dietary protein, PUFA:SFA 
ratio, dietary fibre, first 5 principal components (PC) for population stratification 
Protein and subtypes  
age (=underlying time scale), total energy intake (TEI), centre, and sex, smoking, education, physical activity, sex-specific alcohol categories, dietary fibre, SFA, MUFA, PUFA, soft drinks, 
tea, and coffee (not adjusted for carbohydrates; i.e., a substitution model), BMI, waist hip ratio, first 5 PC for population stratification 
Fat and subtypes  
Model 1: age (=underlying time scale), sex, centre, TEI, first 5 PC for population stratification 
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Model 2: model 1 + lifestyle factors- physical activity, education, smoking, sex-specific alcohol categories 
Model 3: model 2+ dietary covariates (dietary fibre, magnesium, iron, vitamin C, leafy vegetables, tea, coffee) 
Model 4: model 3+ BMI  
Dietary fibre and subtypes  
age (=underlying time scale), sex, smoking status, physical activity, education level and sex-specific alcohol categories, total energy intake, dietary carbohydrates, magnesium, saturated 
fatty acids, first 5 PC for population stratification, types of fibre were mutually adjusted 
Trying to replicate model 3. 
& interactions with BMI GRS does not adjust for BMI 
IR GRS and protein intake interaction does not adjust for centre because of convergence issues 
Example of interpretation: the beta-coefficient of the interaction between total fat and BMI GRS was 0.010 for incident T2D.  
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In the analysis examining interactions with each individual SNP (N tests=5,265) 
and isocaloric macronutrient substitution, none of the interactions tested was 
statistically significant (Figure 5-3 and Appendix G).  
 
 
 
Figure 4-3: QQ plot of pvalues for the interactions between individual SNPs for each of the genetic risk scores and 
macronutrients or dietary fibre on T2D (with isocaloric macronutrient substitution): EPIC-InterAct Study 
All interactions are based on the most adjusted models (previously reported in Appendix F). None of the individual 
SNP interactions were significant after accounting for multiple testing. P value for interaction threshold for 
significance <9.50E-6 (0.05/5265 tests). 
Please note that each individual GRS graph contains multiple sets of interaction analyses, therefore the expected p 
values may be conservative due to correlated analyses. That is, for the interaction between fibre intake and T2D GRS, 
this includes interactions between T2D GRS and total fibre, T2D GRS and cereal fibre, T2D GRS and vegetable fibre and 
T2D GRS and fruit fibre on incident T2D 
A list of SNP x macronutrient interactions with pvalue for interaction<0.05 are available in Appendix G (Excel) 
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Results were similar between the current analysis based on imputed data and a 
complete case analysis (9,403 cases and 11,745 non cases) (Table 5-6 provides an 
example). 
Table 4-6: An example of interaction findings comparing multiple imputation and complete 
case analysis 
Unweighted T2D 
GRS (per SD) x 
Macronutrient 
(g/1000kcal) 
 
 
Multiple imputation analysis 
results (9742 cases, 12158 
noncases) 
                   
Complete case analysis results (9403 
cases, 11745 noncases) 
 Beta (se) P Beta (se) P 
Total dietary fibre 0.001(0.006) 0.875 0.001(0.007) 0.839 
     
Cereal fibre 0.006(0.011) 0.606 0.002(0.016) 0.902 
Abbreviation: SSB: sugar sweetened beverage, BMI: body mass index, T2D: type 2 diabetes, GRS: genetic risk score,  
p: p value for interaction 
Modelling the same as that in Table 5.5, model 4. 
Conclusion: no substantial difference in results between analysis 
approaches 
    
5.5 Discussion  
 
In this large, multi-country, population-based study from Europe, no statistically 
significant interactions were observed between three metabolic GRS and 
macronutrient intake on the development of T2D. In other words, based on these 
findings, the association between macronutrient intake and incident T2D does 
not seem to vary by genetic susceptibility for T2D, IR or BMI. The public health 
implication for prevention of T2D of these null findings is that currently dietary 
guidelines on macronutrient intake should apply universally across populations 
that may differ in genetic susceptibility to metabolic indices.[10]  
The literature on gene-macronutrient interaction studies and T2D is limited, with 
a previous cross-sectional study which examined the interaction between a T2D 
GRS and carbohydrate and fibre intake failing to identify interactions for 
prevalent T2D (N= 1,337 cases of T2D).[189] This current analysis is the first to 
examine gene-macronutrient interaction for T2D risk prospectively, investigating 
major macronutrients including quantity and quality indicators of fat, protein 
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and carbohydrate consumption, using a T2D GRS with additional genetic variants 
(48 compared to 15 in the previous work), as well as also examining GRS for BMI 
and IR in a much larger sample (with 9,742 T2D cases). There is an inconsistent 
evidence base for intermediate end points related to T2D (e.g. adiposity and 
glycaemic traits).[214–217] The studies which reported an interaction were limited 
by small sample size (N<715).[216,217] In particular, a study which recruited users 
of a nutrigenetic service and reported interactions between dietary fat intake and 
a GRS composed of obesity and lipid metabolism SNPs on adiposity risk [216] is 
limited by both its cross-sectional design and its likely potential for gene-diet 
dependence. It is unclear whether the GRS used in that study may be correlated 
with fat related dietary exposures given that it included SNPs involved in lipid 
metabolism (e.g. the lipoprotein lipase gene, LPL, which hydrolyses triglycerides 
and mediates lipoprotein uptake into cells). Dudbridge and Fletcher posited that 
gene-environment dependence may result in spurious interactions.[218] That is, if 
an environmental exposure mediates the association between a genetic exposure 
and the outcome, testing the interaction of that environmental and genetic 
exposure on the outcome may lead to a spurious interaction because it is more 
likely that the outcome would occur when both exposures are present. The 
evaluation of the likelihood of such dependence and of possible type I error can 
be facilitated by examining the correlation between the GRS and macronutrient 
intakes, as have been performed in Table 5-4. In this current study, the 
consistency across various methods (adoption of unweighted and weighted GRS 
and a combined GRS as well as single SNPs) collectively strengthens the 
confidence in the null findings for interaction that were observed.  
The null findings may indicate that interactions between the three GRS that were 
examined and macronutrient intake may truly not exist for T2D, or if they do 
potentially exist, the current approach was not able to detect them. There are 
several possible reasons that may contribute to the absence of interactions in this 
study. From a dietary perspective, foods and/or dietary patterns, may offer 
greater insights than nutrients based on the food synergism hypothesis.[219] This 
proposes that biological synergism may occur within the ‘food matrix’ as a whole, 
including with yet potentially unidentified constituents. Indeed interactions have 
been reported between the GRS for BMI and intake of sugar sweetened beverages 
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on risk of developing obesity (pinteraction <0.001).[148,220] Furthermore, foods or 
dietary patterns may be subject to less accumulated measurement bias (i.e. bias 
from self-report of food intake plus error from conversion to nutrients). From a 
genetics perspective there may be other genetic loci, with no or weak marginal 
genetic effects for the traits of interest that may show a significant variation in 
effect between subgroups of the population. Therefore, future agnostic 
approaches such as genome-environment-wide-interaction studies, are of 
interest. Additionally, it may be valuable to examine specific candidate genetic 
variants when biologically plausible hypotheses of specific interactions may 
exist.[209,221] Another possible explanation for null interaction findings may be 
that in certain situations many factors must be present simultaneously for an 
interaction of interest to become apparent.[222] Multi-way interactions have been 
reported but these were not tested in this current study so future research is 
warranted.[195] 
Among strengths, EPIC-InterAct is a large population based study with incident 
T2D and both genetic data and harmonised measures of self-reported 
macronutrient intake. All three GRS were positively associated with incident T2D 
(Table 5-2) [5,28,30] and the associations between macronutrient intake and T2D 
were directionally consistent with previous literature (Table 5-1).[86,212,213,223,224] 
The prospective design minimises the potential bias due to recall bias and reverse 
causality for dietary exposures and the verification of diabetes cases minimises 
possible misclassification bias of the outcome. To our knowledge, this study 
represents the most comprehensive investigation of the interaction between 
multiple GRS and macronutrient intake on incident T2D, to date. An attempt was 
made to address some of the key methodological issues identified from our recent 
systematic review, including multiple testing and inadequate control for likely 
confounders.[209] To reduce the risk of spurious gene-macronutrient interactions, 
it was confirmed that GRS were not correlated with macronutrient intake.[218] To 
our knowledge this is also the first observational study for gene-macronutrient 
interactions within the cardiometabolic literature that has investigated the effect 
of isocaloric macronutrient substitution. This is important for public health 
interpretation of macronutrient density, as the benefit of decreasing one 
macronutrient may be dependent on which macronutrient(s) it is replaced by.  
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Apart from issues of generalisability and the limited dietary and genetic 
exposures that were examined, as discussed above, other limitations merit 
consideration. Despite attempts to reduce confounding, including by controlling 
for population stratification in addition to other known risk factors for T2D,[126] 
the possibility of residual confounding cannot be fully excluded. Given that 
interactions were examined using continuous exposures, the possibility that they 
exist for specific categories of either exposure, cannot be fully excluded. However, 
using continuous exposures aimed to maximise statistical efficiency. The 
generalisability of these findings is limited to European populations and research 
is warranted in different populations. 
In conclusion, within a multi-centre European cohort, we observed no interaction 
between GRSs for type 2 diabetes, insulin resistance and BMI and macronutrient 
intake on the risk for developing type 2 diabetes. These findings suggest that 
currently there is no support for personalised dietary advice on macronutrient 
intake for type 2 diabetes prevention in subgroups of the population defined by 
their overall genetic risk for type 2 diabetes, insulin resistance or BMI.  
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5. Chapter 6 Interaction between genetic risk score 
and food or beverage intake on incident T2D in 
EPIC-InterAct 
 
 
This chapter examines the interaction between genetic risk scores and foods and 
beverages in the development of T2D. It relates to objective 4 (Chapter 2).  
 
6.1 Abstract    
 
Background There has been inconsistent evidence about whether the 
association between foods and beverages with type 2 diabetes (T2D) might differ 
depending on an individual’s genetic predisposition for metabolic disorders. We 
aimed to investigate the interaction between foods and beverages and genetic 
susceptibility on the risk of developing T2D. 
 
Methods and Findings The current analyses included 9,742 incident T2D 
cases and 12,158 non-cases in EPIC-InterAct, a prospective case-cohort study 
across eight European countries. Genetic risk scores (GRS) for body mass index 
(97 single nucleotide polymorphisms: SNPs), insulin resistance (53 SNPs) and 
T2D (48 SNPs) were chosen based upon shared biology in T2D development. 
Fifteen dietary variables that were previously examined with T2D within 
published meta-analyses were identified: fruits, green leafy vegetables, root 
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vegetables, wholegrain breads and cereals, legumes, nuts and seeds, fermented 
dairy, red meat, processed red meat, fish, egg and egg products, sugar sweetened 
beverage (SSB), coffee and tea. Using multivariable-adjusted Cox regression, we 
estimated country-specific interaction results using multiplicative and additive 
scales which were pooled by random-effects meta-analysis. Processed red meat 
and SSB intake were positively associated, whereas coffee and tea intake were 
inversely associated with T2D. After accounting for multiple testing (45 tests, p 
value threshold for significance <0.001), no significant interactions were 
identified between any of the GRS and foods or beverages on incident T2D (p for 
multiplicative interactions≥0.01; for additive interactions≥0.01). 
 
Conclusions Genetic susceptibility for BMI, insulin resistance or T2D did not 
significantly modify the association between food or beverage intake and T2D 
incidence and therefore does not support dietary recommendations stratified by 
metabolic genetic risk for the prevention of type 2 diabetes.  
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6.2 Introduction  
 
Current nutritional guidelines  emphasise consumption of, for example, green 
leafy vegetables and wholegrain foods and a reduction in red and processed red 
meats and sugar-sweetened beverages (SSB) for the prevention of T2D.[10,41]  
The effect of these foods on metabolic risk may be heterogeneous by genotype, 
arguing a case for the presence of interaction between dietary factors and genes. 
For instance, previous research suggests that the adverse consequences of 
habitual SSB intake on adiposity and the risk of developing obesity, a strong 
determinant for T2D, were significantly higher in those with a high compared to 
those with a low genetic predisposition to obesity.[148,220]  Whether the observed 
interaction between SSB and BMI genetic risk score (GRS) is also relevant in the 
aetiology of T2D is currently unknown. If genes contribute to the heterogeneity in 
dietary response, then it is important to consider the potential for personalised 
dietary advice based on genotype for preventing T2D.[3] Studies have reported, for 
instance, that consuming wholegrain bread and cereals and coffee influence T2D 
risk differently depending on an individual’s TCF7L2 gene.[170,171,221]  However, 
there is a gap in knowledge about whether there are interactions for other foods 
and beverages that may be important in the development of T2D (e.g. green leafy 
vegetables, red meat, SSB, among others).   
The advantages of using a GRS has been previously discussed (Chapter 5). 
However, to date, there has been limited evidence for gene-food interactions 
using GRS.[221,225]  
We, therefore, aimed to investigate the interaction between foods and beverages 
and genetic predisposition to these three metabolic traits on the risk of 
developing T2D, by using three GRS.   
 
6.3 Methods 
The EPIC-InterAct cohort, genotyping and imputation, dietary assessment and 
statistical analyses have already been described in the Methods Chapter (Chapter 
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3). In addition to these general methods, below I describe some specific methods 
for this piece of work. 
 
Cohort 
The current analyses were based on 21,900 adults with available genome-wide 
genotyping and dietary data (with 9,742 T2D cases including those in the 
subcohort and 12,158 non-cases).  
 
Genotyping and genetic risk score  
The same GRS as those used in the interaction analyses between GRS and 
macronutrient intake on incident T2D (Chapter 5) were used here.  
 
Self-reported dietary intake  
The habitual consumption of 15 foods and beverages that were previously 
investigated for their association with T2D in published systematic reviews and 
meta-analyses were examined (Table 6-1). Dietary data on habitual consumption 
over the previous year (g/day) was derived from self or interviewer-administered 
country-specific food frequency questionnaires or dietary histories taken at 
baseline. Validity of the instruments to capture habitual diet was assessed in each 
participating cohort.[159,226] All 15 foods and beverages were available in EPIC-
InterAct, except for legume intake which was not available in Denmark. 
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Table 5-1: Definition of foods and beverages included in the analyses: EPIC-InterAct study 
Foods and beverages included 
(reference to published meta-analysis) Definition and examples 
Fruits[44] 
 
 
apples, oranges, grape, stone fruits, mixed fruits (dried fruits, fruit 
salad) 
 
Green leafy vegetables[44] 
 
lettuce, spinach, Swiss chard leaf 
 
Root vegetables[44]  
 
 
carrot, celeriac, radish, parsnip, beetroot. Exclude potato 
 
 
Wholegrain breads and cereals[45] 
 
 
bread and crispbreads (non-white), grains (e.g. couscous, 
semolina, polenta, pearl barley) 
 
Rice[54] 
 
white and brown rice 
 
Legumes[46] 
 
red kidney beans, chickpeas, lentils 
 
Nuts and seeds[46] 
 
nuts and seeds, tree nuts, peanuts, chestnuts 
 
Fermented dairy[47,48] 
 
 
yoghurt and fermented milk (e.g. kefir), cheese (e.g. ricotta, 
cheddar) 
 
Unprocessed red meat[55] 
 
beef, lamb, pork, goat 
 
Processed red meat[55] 
 
bacon, ham, cold meat 
 
Fish[51] 
 
 
fish including oily and white fish but not including crustaceans/fish 
products 
 
Egg and egg products[52] 
 
egg, pickled egg, egg powder 
 
Sugar Sweetened Beverages (SSB)[53] 
 
 
 
 
carbonated, soft, isotonic drinks, diluted syrups (e.g. cola, 
lemonade, sweetened or sugar reduced). Based on the proxy: total 
soft drinks minus artificially sweetened beverages 
 
Coffee[49] 
 
caffeinated, decaffeinated and partially caffeinated 
 
Tea[50] 
 
black and green teas 
 
 
Assessment of covariates 
The method is the same as that described in the interaction analyses between 
GRS and macronutrient intake on incident T2D, in Chapter 5.  
 
Statistical analyses 
Variables with < 30% missing data (BMI, physical activity, education level and 
smoking status: Table 5-1) were imputed using multiple imputation by chained 
equations in Stata, as previously described,[210] to reduce bias from loss of data. 
After confirming no obvious between-imputation variation across 20 multiple-
imputations, a single imputation was used for analyses because of computational 
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efficiency (Figure 6-1). Imputation was based on 21,900 individuals. Potential 
outliers were Winsorised at the 99th percentile.  
 
 
Figure 5-1: Comparison between 20 imputed datasets for the interaction between egg and egg product intake with 
T2D genetic risk score and incident T2D 
Modelling same as that for model 4 within Table 6-4. Here, analysis performed by country and pooled using random 
effects meta-analysis (no chip-specific analysis was undertaken).  
Total variation= within + between study variation is very small. 
Within variance: 0.072 
Between variance: 8.98E-5 
Conclusion: total variation= within + between study variation is very small. Dataset number 15 was therefore 
chosen, at random, for all analyses presented in this paper. 
Abbreviation: MICE: multiple imputation using chained equations, T2D: type 2 diabetes, GRS: genetic risk score 
 
Main effect analyses 
The associations between each of the 15 foods and beverages and incident T2D 
was analysed by treating dietary exposures as continuous variables (per portion of 
intake/day as specified in Table 6-2). Average portion sizes were used to reflect a 
realistic amount of consumption and were derived from consultation of the Food 
Standards Agency ‘Food Portion Sizes’[227] and published meta-analyses of the 
respective foods or beverages and T2D. Crude and multivariable-adjusted 
Prentice-weighted Cox regression models were constructed within country. 
Multivariable-adjusted models were constructed, with model 1 adjusting for age 
(years) as the underlying timescale, sex, centre (nominal categorical), total energy 
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intake (kcal/day), physical activity (inactive, moderately inactive, moderately 
active, active), education (none, primary school, technical/professional, 
secondary school, longer education (including university), smoking (never, 
former, current smoker), sex-specific alcohol intake (none, light drinking: 0.1-
6g/d of pure alcohol, moderate drinking: men 6.1-24g/d and women 6.1-12g/d, 
heavy drinking: men>24g/d and women>12g/d), and mutual adjustment for all 
other foods except legumes (due to data availability) and model 2 additionally 
adjusting for BMI (kg/m2). Country-specific hazard ratio (HR) for each dietary 
exposure and incident T2D was combined using random-effects meta-analysis.  
 
Whereas for the main associations between GRS and T2D, the GRS were treated 
as both continuous (per SD difference) and dichotomised exposures (being high 
and low GRS estimated based on the median estimates from those in the 
subcohort). Prentice-weighted Cox regression models were constructed within 
country and by genotyping chip. Genotype chip-specific and then country-specific 
estimates were combined using random-effects meta-analysis. Models included 
adjustment for age (underlying time scale), sex, centre, the first 5 principal 
components for genetic population stratification and BMI.  
  
Interaction analyses 
All interaction findings and P values for interaction reported in the text and tables 
(Tables 6-4 to Table 6-6) were estimated by treating dietary (per 100g/day 
difference) and GRS exposures as continuous variables (per SD difference). 
Interactions were analysed using two types of statistical interaction approaches 
by introducing a product term between the GRS and dietary exposure. First, a 
multiplicative interaction was considered present if the HR for food or beverages 
and incident T2D differed between GRS groups (i.e. RRGRS x diet/RRGRS x RRdiet <1 
or >1). Second, additive interactions were tested by evaluating relative excess risk 
due to interaction (RERI), which can be useful in public health decision making 
[135]. The RERI examines whether an absolute incidence rate differs between GRS 
groups (i.e. RRGRS x diet – RRGRS – RRdiet + 1 is < or >0).[135] Regression models 
were constructed in the same way as in the analysis of the association between 
GRS and incident T2D, and the list of covariates included in the models were the 
same as for the main associations between dietary exposures and T2D (described 
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above), with addition of the first 5 principal components for population 
stratification. Between-country heterogeneity was quantified by the I2 value and P 
for heterogeneity was derived from the Cochran-Q test. The modelling for the 
multiplicative interaction analyses resulted in four levels, with sequential 
addition of more covariates (Table 6-4). Whereas, in additive interaction 
analyses, only most adjusted multivariable model has been presented (Table 6-5). 
BMI was a covariate in the interaction analysis for IR and T2D GRS only. To 
account for multiple testing for 15 dietary exposures and 3 GRS, the p-value 
threshold was set as 0.001 (0.05/45) for each of the multiplicative and additive 
interaction analyses. To visualise potential interactions, we separately estimated 
the prospective association between dietary exposures and T2D, stratified by 
those possessing low or high genetic risk for each of the three GRS (Figure 6-2).  
 
Given that GRS may mask interactions between diet and individual SNPs, 
secondary interaction analysis was conducted for each of 195 non-overlapping 
SNPs within all 3 GRS and 15 foods and beverages (for which p<1.71E-5 was 
designated as significant). Stata version 14 (StataCorp LP, Texas, USA) was used 
for analysis. 
 
6.4 Results  
 
The demographic data and association between the three GRS and incident T2D 
are the same as that described in Chapter 5 (Table 6-2). In the adjusted analyses, 
there was a positive association between habitual processed red meat intake (HR 
per portion/d: 1.22; 95%CI 1.09,1.37) and habitual SSB intake (HR per can/d: 
1.21;95%CI 1.02,1.43) on incident T2D, whereas habitual coffee (HR per cup/d: 
0.92;95%CI 0.89,0.95) and habitual tea intake (HR per cup/d: 0.95;95%CI 
0.90,0.999) were inversely associated with T2D (Table 6-2). There was an overall 
null association with other dietary factors. There was little correlation between 
the GRS and dietary factors (Table 6-3). 
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Table 5-2: Association between food and beverage intake or genetic risk score with incident T2D: EPIC-InterAct study 
  Mean (SD)  Mean (SD)  HR (95%CI) per portion/d 
  subcohort non-cases total incident cases Model 1 Model 2 
Median years of follow up (y) 12.3 6.8 
  Age at baseline (y) 52.3 (9.3) 55.7 (7.6) 
  Sex (%male) 37.9 49.9 
          Foods or beverages (portion size) Median (IQR)  Median (IQR)  
  Fruit (100 g/d) 187.8(102,307) 178.6(95.9,300.8) 1.02(0.98,1.06) 0.98(0.94,1.03) 
Green leafy vegetables (90 g/d) 12.0(2.6,33.4) 8.6(1.4,30.4) 1.19(0.96,1.47) 1.11(0.99,1.25) 
Root vegetables (80 g/d) 11.9(4.4,28.8) 10.6(3.9,27.3) 0.83(0.71,0.96) 0.90(0.77,1.05) 
Wholegrain breads/cereals (40 g/d) 42.3(2.9,102.5) 44.3(2.5,102.5) 0.99(0.96,1.02) 1.00(0.96,1.04) 
Rice (100 g/d) 15.1(5.3,28.7) 14.3(3.5,26.0) 0.97(0.80,1.18) 0.75(0.48,1.18) 
Fermented dairy (125 ml/d) 73.7(34.5,140.7) 66.6(28.6,131.7) 0.97(0.92,1.01) 0.95(0.90,1.02) 
Nuts and seeds (30 g/d) 0.7(0,3.0) 0.3(0,1.7) 1.00(0.74,1.33) 1.05(0.85,1.29) 
Legumes (35 g/d)* 6.2(0.7,23.1) 6.2(0.5,23.1) 1.14(0.96,1.35) 1.11(0.90,1.37) 
Red meat (144 g/d) 37.7(18.3,65.6) 43.3(22.5,71.2) 1.78(1.36,2.34) 1.20(0.99,1.45) 
Processed red meat (75 g/d) 28.5(14.9,49.5) 32.7(17.6,56.1) 1.46(1.30,1.65) 1.22(1.09,1.37) 
Fish (100 g/d) 5.9(0.6,14.4) 6.6(0.6,14.9) 1.26(0.91,1.75) 1.09(0.82,1.46) 
Egg and egg products (50 g/d) 14.3(6.7,24.4) 15.2(7.0,27.0) 1.26(1.03,1.55) 1.03(0.77,1.38) 
SSB (336 ml/d) 0(0,42.9) 1.2(0,57.1) 1.34(1.13,1.60) 1.21(1.02,1.43) 
Coffee (260 ml/d) 298(98.9,580.2) 300(95.7,600.0) 0.93(0.90,0.97) 0.92(0.89,0.95) 
Tea (260 ml/d) 5.1(0,200.0) 2.5(0,150.0) 0.91(0.87,0.94) 0.95(0.90,0.999) 
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Hazard ratio (HR) for foods and beverages (per portion) and incident Type 2 Diabetes (T2D), adjusted for: Model 1: age (=underlying time scale), sex, centre, total energy intake, 
physical activity, education, smoking status, sex-specific alcohol categories, all foods are mutually adjusted (except for legumes); Model 2: model 1 + BMI 
 
HR for the association between unweighted genetic risk score and incident T2D, adjusted for: Model 1: age (=underlying time scale), sex, centre, first 5 principal components for 
population stratification; Model 2: model 1 + BMI. BMI GRS not adjusted for BMI. 
 
Number of SNPs: T2D (48 SNPs from Morris et al., Nature Gen, 2012), BMI (97 as per Locke et al., Nature, 2015), IR (53 as per Lotta et al., Nature Gen, 2016) 
Abbreviations: T2D- type 2 diabetes, BMI- body mass index, IR- insulin resistance, SD- standard deviation 
 
*Sample size: all dietary exposures: 9,742 incident T2D cases and 21,900 participants in total. Except, for legumes, which had 7,946 incident T2D cases and 18,334 participants in total. 
 
  
 
     
Unweighted genetic risk score 
 
 
Sample size 
 
 
                                                               Model 1 
 
 
     Model 2 
GRS for T2D  
 
   
per SD (4.3 risk alleles) 
 
 1.42(1.32,1.52) 1.49(1.37,1.63) 
High (≥52 risk alleles) 12033  1.75(1.55,1.98) 1.85(1.58,2.16) 
Low (<52) 9867  1 [Reference] 1 [Reference] 
GRS for IR      
per SD (4.5 risk alleles) 
 
 1.11(1.08,1.14) 1.14(1.09,1.20) 
High (≥55) 11303  1.18(1.12,1.25) 1.23(1.12,1.35) 
Low (<55) 10597  1 [Reference] 1 [Reference] 
GRS for BMI  
 
   
per SD (6.3 risk alleles) 
 
 1.07(1.04,1.10) NA 
High (≥91) 11230  1.12(1.06,1.19)  
Low (<91) 10670  1 [Reference]  
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Table 5-3: Correlations between exposures within the EPIC-InterAct study 
  
T2D 
GRS 
IR 
GRS 
BMI 
GRS Fruit 
Leafy 
Veg 
Root 
Veg 
Whole 
grain Rice 
Fermented 
Dairy Legumes 
Nuts 
and 
seeds 
Red 
Meat 
Proce- 
ssed 
Meat Fish 
Egg and 
egg 
products SSB Coffee Tea 
Fruit 0.01 0.00 0.01   0.34 0.11 0.16 0.13 0.08 0.22 0.01 0.04 0.16 0.16 0.06 0.10 0.27 0.07 
Leafy Veg 0.01 0.01 0.00    0.09 0.34 0.20 0.05 0.39 0.05 0.02 0.08 0.09 0.18 0.23 0.40 0.29 
Root Veg 0.00 0.00 0.01     0.24 0.09 0.17 0.19 0.09 0.02 0.10 0.03 0.09 0.13 0.16 0.33 
Wholegrain 0.01 0.00 0.00      0.23 0.18 0.37 0.19 0.09 0.08 0.15 0.03 0.12 0.39 0.36 
Rice 0.01 0.00 0.02       0.04 0.38 0.05 0.05 0.03 0.22 0.09 0.08 0.18 0.10 
Fermented 
Dairy 0.00 0.01 0.00       0.20 0.07 0.07 0.02 0.02 0.05 0.06 0.12 0.10 
Legumes 0.01 0.01 0.00         0.06 0.10 0.06 0.25 0.21 0.20 0.34 0.11 
Nuts and 
seeds 0.01 0.00 0.03         0.01 0.01 0.06 0.03 0.08 0.08 0.21 
Red Meat 0.01 0.00 0.01           0.15 0.18 0.28 0.02 0.17 0.05 
Processed 
Meat 0.01 0.01 0.00           0.09 0.16 0.07 0.11 0.12 
Fish 0.02 0.01 0.01             0.16 0.06 0.08 0.04 
Egg and egg 
products 0.00 0.00 0.01             0.13 0.02 0.16 
SSB 0.02 0.01 0.02               0.17 0.22 
Coffee 0.01 0.00 0.02               0.14 
Tea 0.01 0.00 0.01                 
                   0 
  
Spearman’s rho without direction of correlation, all variables treated as continuous variables.
Abbreviations: Veg- vegetables, SSB- sugar sweetened beverage 
Correlations calculated based on subcohort population only (N=12,749) 
Effective number of independent tests:[203] 14.596 (variance of the observed eigenvalues: 0.433). Therefore, 15 tests conducted per GRS 
http://gump.qimr.edu.au/general/daleN/matSpD/  
This estimates the number of independent tests, given the correlation between exposures (provided in the table above). 
 
0.3 
  0.5 
  0.7 
  
1 
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Interactions between three GRS and food and beverage intake on 
incident T2D 
Under the multiplicative interaction scale, two interactions showed a nominally 
significant interaction (pinteraction<0.05): eggs and egg product intake and T2D 
GRS (pinteraction=0.039); and SSB and BMI GRS (pinteraction=0.012) on T2D risk 
(Figure 6-2 and Table 6-4). The interaction between egg and egg products and the 
T2D GRS showed high heterogeneity between countries (I2:80%). However, no 
interactions passed multiple testing corrections. Results also did not change 
materially after adjustment for different sets of confounders using multivariable 
adjusted models (Table 6-4). Similarly this was the case for when T2D and BMI 
GRS were weighted by the beta coefficient of each SNPs effect on their respective 
trait from published GWAS meta-analyses. On the additive interaction scale, an 
interaction was also noted between SSB and BMI GRS on T2D risk 
(pinteraction=0.02), however no interactions were significant after accounting for 
multiple testing (Table 6-5).  
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Figure 5-2: Prospective associations of food or beverage intake (per portion) with incidence of type 2 diabetes, stratified by genetic risk for the respective metabolic traits: EPIC-
InterAct study 
Adjusted for age (=underlying time scale), sex, centre, total energy intake, first five principal components for population stratification, physical activity, education, smoking, sex-specific 
alcohol categories, body-mass index and mutually adjusted for all other foods (except legumes). See Model 4 of Table 6-4 and methods for more information. Median number of risk 
alleles for genetic risk score (GRS) group: T2D GRS (low<52 risk alleles); IR GRS (low<55 risk alleles); BMI GRS (low<91 risk alleles). Between country heterogeneity (I2) ranged from 0 to 
80% (Table 6-4). There are no statistically significant interactions (p value threshold<0.001 based on 0.05/45 tests). P values for interactions are provided in Table 6-4 and were estimated 
using continuous exposures: per 100g/d of dietary exposure and per SD difference in GRS. The lowest p value for interaction for each respective GRS: between T2D GRS and egg and egg 
product intake (pinteraction=0.039), IR GRS and legume intake (pinteraction=0.056) and BMI GRS and SSB intake (pinteraction=0.012).  
Abbreviations: SSB: sugar sweetened beverage; GRS: genetic risk score; HR: hazard ratio. Black dots: high genetic risk group, white dots: low genetic risk group. 
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Table 5-4: Multiplicative interaction between three metabolic genetic risk scores and food or beverage intakes on incident T2D: EPIC-InterAct study  
(Unweighted GRS) 
Food or 
beverage  
(100 g/d) Model 
GRS for body mass index (per 6.3 risk 
alleles)% 
GRS for insulin resistance (per 4.5 risk 
alleles) 
GRS for type 2 diabetes (per 4.3 risk 
alleles) 
  
Beta (95% CI) P I2 (%) Beta (95% CI) P I
2 
(%) Beta (95% CI) P I
2 (%) 
Fruit model 1 0.013(-0.006,0.032) 0.168 0.0 -0.001(-0.025,0.023) 0.951 25.4 0.006(-0.026,0.039) 0.704 56.2 
 
model 2 0.013(-0.009,0.036) 0.242 16.0 -0.001(-0.026,0.023) 0.926 25.6 0.003(-0.03,0.035) 0.875 55.3 
 
model 3 0.01(-0.012,0.033) 0.355 10.3 0(-0.025,0.024) 0.972 19.8 0.003(-0.032,0.037) 0.881 55.6 
 
model 4 
   
-0.004(-0.037,0.03) 0.830 41.0 0.01(-0.035,0.055) 0.663 67.1 
Green leafy 
vegetable model 1 0.076(-0.024,0.175) 0.137 0.0 -0.074(-0.16,0.011) 0.088 0.0 0.098(-0.182,0.379) 0.493 53.1 
 
model 2 0.082(-0.02,0.185) 0.115 0.0 -0.072(-0.16,0.017) 0.113 0.0 0.044(-0.244,0.332) 0.767 52.8 
 
model 3 0.071(-0.056,0.198) 0.274 2.4 -0.049(-0.142,0.044) 0.298 0.0 0.089(-0.177,0.354) 0.513 39.8 
 
model 4 
   
-0.075(-0.173,0.023) 0.135 0.0 0.351(-0.016,0.718) 0.061 56.3 
Root vegetable model 1 -0.004(-0.12,0.111) 0.940 0.0 0.085(-0.038,0.207) 0.176 0.0 0.001(-0.118,0.119) 0.992 0.0 
 
model 2 0.013(-0.105,0.131) 0.833 0.0 0.065(-0.072,0.202) 0.351 6.2 -0.01(-0.129,0.109) 0.870 0.0 
 
model 3 0.014(-0.108,0.137) 0.819 0.0 0.087(-0.044,0.218) 0.194 0.0 -0.037(-0.16,0.086) 0.553 0.0 
 
model 4 
   
0.061(-0.092,0.214) 0.435 2.4 -0.12(-0.252,0.013) 0.077 0.0 
Whole grain 
breads and 
cereals 
model 1 
0.017(-0.052,0.087) 0.625 29.4 0.001(-0.08,0.083) 0.980 48.6 -0.016(-0.069,0.037) 0.555 0.0 
 
model 2 0.019(-0.047,0.085) 0.566 20.7 -0.014(-0.096,0.067) 0.733 45.8 -0.02(-0.075,0.034) 0.459 0.0 
 
model 3 0.002(-0.068,0.073) 0.951 21.9 -0.017(-0.108,0.074) 0.711 50.4 -0.018(-0.075,0.039) 0.539 0.0 
 
model 4 
   
-0.046(-0.148,0.055) 0.367 49.6 0.003(-0.062,0.067) 0.935 0.0 
Rice model 1 0.051(-0.162,0.264) 0.638 38.9 -0.065(-0.248,0.119) 0.490 29.8 0.062(-0.088,0.211) 0.417 0.0 
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model 2 0.017(-0.186,0.219) 0.871 30.3 -0.086(-0.253,0.082) 0.316 16.5 0.05(-0.102,0.203) 0.517 0.0 
 
model 3 0.061(-0.164,0.286) 0.595 35.9 -0.072(-0.283,0.139) 0.504 37.7 0.063(-0.096,0.221) 0.441 0.0 
 
model 4 
   
-0.003(-0.254,0.248) 0.983 41.8 0.17(-0.051,0.392) 0.132 20.4 
Legumes† model 1 -0.065(-0.219,0.09) 0.413 0.0 0.034(-0.128,0.196) 0.678 0.0 0.011(-0.285,0.307) 0.943 31.4 
 
model 2 -0.084(-0.243,0.076) 0.302 0.0 0.051(-0.118,0.219) 0.557 0.0 -0.03(-0.35,0.29) 0.853 35.4 
 
model 3 -0.064(-0.232,0.104) 0.457 0.0 0.062(-0.112,0.236) 0.488 0.0 -0.059(-0.487,0.369) 0.786 54.3 
 
model 4 
   
0.186(-0.004,0.376) 0.056 0.0 -0.038(-0.67,0.593) 0.905 70.2 
Nuts and seeds 
(per 30 g/d) model 1 0.019(-0.152,0.19) 0.830 6.7 0.08(-0.081,0.24) 0.332 0.0 0.008(-0.15,0.167) 0.917 0.0 
 
model 2 -0.039(-0.233,0.154) 0.692 14.0 0.109(-0.058,0.276) 0.202 0.0 0.031(-0.182,0.245) 0.774 22.7 
 
model 3 -0.086(-0.385,0.212) 0.571 53.2 0.148(-0.026,0.322) 0.096 0.0 0.051(-0.176,0.278) 0.662 22.6 
 
model 4 
   
0.046(-0.156,0.248) 0.655 0.0 -0.073(-0.456,0.309) 0.707 58.8 
Fermented 
dairy model 1 0.002(-0.033,0.036) 0.932 0.6 0.028(-0.041,0.098) 0.427 67.3 0.04(0.005,0.076) 0.024 0.0 
 
model 2 0.009(-0.026,0.044) 0.612 0.0 0.029(-0.045,0.103) 0.441 69.7 0.042(0.006,0.078) 0.023 0.8 
 
model 3 0.011(-0.025,0.047) 0.543 0.0 0.027(-0.053,0.107) 0.514 71.7 0.037(-0.008,0.082) 0.108 19.7 
 
model 4 
   
0.002(-0.064,0.068) 0.956 45.9 0.028(-0.032,0.087) 0.365 33.0 
Red meat model 1 -0.016(-0.103,0.072) 0.725 0.0 0.013(-0.073,0.099) 0.769 0.0 -0.028(-0.118,0.061) 0.536 0.0 
 
model 2 0.002(-0.088,0.093) 0.959 0.0 0.013(-0.076,0.103) 0.767 0.0 -0.043(-0.135,0.049) 0.359 0.0 
 
model 3 0.018(-0.079,0.114) 0.717 0.0 0.015(-0.078,0.108) 0.753 0.0 -0.043(-0.139,0.053) 0.377 0.0 
 
model 4 
   
0.024(-0.081,0.128) 0.660 0.0 -0.082(-0.245,0.081) 0.323 45.3 
Processed red 
meat model 1 0.078(-0.084,0.24) 0.344 55.5 0.006(-0.091,0.103) 0.903 0.0 -0.062(-0.232,0.107) 0.470 58.1 
 
model 2 0.089(-0.074,0.252) 0.286 53.2 0.034(-0.067,0.136) 0.505 0.0 -0.064(-0.22,0.092) 0.420 47.2 
 
model 3 0.094(-0.076,0.265) 0.277 51.6 0.032(-0.074,0.138) 0.551 0.0 -0.08(-0.262,0.102) 0.390 56.3 
 
model 4 
   
0.023(-0.098,0.144) 0.709 0.0 -0.106(-0.319,0.107) 0.330 54.7 
Fish model 1 -0.022(-0.27,0.226) 0.863 0.0 0.2(-0.116,0.517) 0.214 21.9 0.235(-0.231,0.702) 0.323 55.3 
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model 2 -0.033(-0.288,0.221) 0.798 0.0 0.176(-0.214,0.566) 0.376 38.9 0.23(-0.291,0.75) 0.387 61.5 
 
model 3 -0.002(-0.269,0.264) 0.988 0.0 0.223(-0.166,0.613) 0.262 35.4 0.303(-0.251,0.857) 0.283 63.1 
 
model 4 
   
0.407(-0.224,1.038) 0.207 65.5 0.26(-0.542,1.062) 0.525 76.6 
Egg and egg 
products model 1 -0.094(-0.27,0.082) 0.293 0.0 -0.067(-0.36,0.226) 0.655 55.5 0.127(-0.099,0.354) 0.271 16.9 
 
model 2 -0.053(-0.264,0.157) 0.619 15.4 -0.072(-0.395,0.252) 0.663 59.9 0.126(-0.09,0.342) 0.252 7.2 
 
model 3 -0.025(-0.248,0.199) 0.829 15.2 -0.089(-0.415,0.236) 0.590 51.9 0.202(-0.095,0.499) 0.182 36.4 
 
model 4 
   
-0.183(-0.58,0.213) 0.365 56.8 0.638(0.032,1.243) 0.039 79.8* 
SSB model 1 0.027(0,0.053) 0.047 0.0 -0.006(-0.033,0.021) 0.650 0.0 -0.005(-0.035,0.025) 0.729 13.2 
 
model 2 0.027(0,0.055) 0.054 0.0 -0.006(-0.034,0.022) 0.694 0.0 0(-0.042,0.041) 0.982 42.6 
 
model 3 0.037(0.008,0.066) 0.012 0.0* -0.001(-0.031,0.028) 0.931 0.0 -0.001(-0.037,0.036) 0.969 26.9 
 
model 4 
   
0.007(-0.03,0.044) 0.711 13.4 0.001(-0.053,0.056) 0.963 54.0 
Coffee model 1 0.008(-0.007,0.023) 0.314 41.8 0.001(-0.017,0.018) 0.946 58.1 0.017(-0.004,0.038) 0.111 64.9 
 
model 2 0.008(-0.011,0.027) 0.400 55.9 -0.001(-0.016,0.015) 0.938 46.0 0.021(-0.001,0.043) 0.065 65.8 
 
model 3 0.009(-0.01,0.029) 0.347 54.5 -0.002(-0.019,0.015) 0.802 48.3 0.017(-0.007,0.041) 0.161 67.4 
 
model 4 
   
-0.001(-0.023,0.02) 0.891 55.1 0.027(-0.006,0.059) 0.109 76.7 
Tea model 1 -0.006(-0.018,0.006) 0.305 0.0 -0.003(-0.016,0.01) 0.622 0.0 0.004(-0.01,0.017) 0.610 0.0 
 
model 2 -0.006(-0.019,0.006) 0.340 0.0 -0.003(-0.016,0.01) 0.634 0.0 0.003(-0.011,0.017) 0.674 0.0 
 
model 3 -0.009(-0.022,0.005) 0.214 0.6 -0.005(-0.019,0.009) 0.500 0.0 0.003(-0.012,0.018) 0.685 0.0 
  model 4       -0.012(-0.036,0.012) 0.333 24.9 0(-0.024,0.025) 0.971 29.2 
Beta coefficient for the interaction between the respective GRS and foods or beverages on incident T2D, adjusted for : 
Model 1: age (=underlying time scale), sex, centre, total energy intake, first 5 principal components for population stratification; Model 2: model 1 + physical activity, education, 
smoking, sex-specific alcohol categories; Model 3: model 2+ mutually adjusted for all other foods except for legumes; Model 4: model 3+ BMI  
α for significant interaction: 0.001 (0.05/45 tests) 
*p interaction<0.05 
% Interaction analyses using the BMI GRS does not include adjustment for BMI because this would remove the variance explained by the exposure 
† N=7946 incident T2D cases/18334 total participants; Note: model 4 for nut: does not adjust for alcohol intake due to convergence;  model 4 interaction between IR GRS and green 
leafy vegetables, rice or dairy does not adjust for alcohol due to convergence 
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Table 5-5: Additive interactions between three genetic risk scores and foods and beverages on incident T2D: EPIC-InterAct study 
Food or beverage (100 
g/d) 
GRS for body mass index (per 6.3 risk 
alleles)% 
GRS for insulin resistance (per 4.5 risk 
alleles) 
GRS for type 2 diabetes (per 4.3 risk 
alleles) 
 
RERI (95% CI) P I2 (%) RERI (95% CI) P I2 (%) RERI (95% CI) P I2 (%) 
Fruit 0.011(-0.01,0.032) 0.300 0.0 -0.007(-0.04,0.026) 0.670 33.9 -0.003(-0.056,0.05) 0.910 51.5 
Green leafy vegetable 0.058(-0.068,0.183) 0.370 0.0 -0.088(-0.197,0.021) 0.120 0.0 0.246(0.059,0.432) 0.010 0.0* 
Root vegetable -0.015(-0.116,0.087) 0.770 0.0 -0.026(-0.163,0.111) 0.710 6.8 -0.252(-0.478,-0.025) 0.030 34.2* 
Whole grain breads 
and cereals 0(-0.058,0.058) 1.000 0.0 -0.064(-0.134,0.006) 0.070 0.0 -0.021(-0.119,0.077) 0.670 2.2 
Rice 0.019(-0.177,0.214) 0.850 26.3 -0.02(-0.137,0.097) 0.740 0.0 -0.136(-0.418,0.146) 0.340 48.0 
Legumes† -0.089(-0.265,0.087) 0.320 0.0 0.116(-0.081,0.313) 0.250 0.0 -0.094(-0.369,0.18) 0.500 0.0 
Nuts and seeds (per 30 
g/d) -0.084(-0.262,0.093) 0.350 11.0 -0.036(-0.255,0.182) 0.750 0.0 -0.327(-0.637,-0.016) 0.040 23.0* 
Fermented dairy 0(-0.037,0.036) 0.990 0.0 -0.008(-0.054,0.039) 0.750 1.7 -0.018(-0.136,0.1) 0.770 69.6 
Red meat 0.036(-0.098,0.17) 0.590 0.0 0.043(-0.092,0.178) 0.530 0.0 -0.079(-0.257,0.099) 0.390 9.1 
Processed red meat 0.101(-0.208,0.41) 0.520 47.7 0.085(-0.098,0.268) 0.360 0.0 -0.046(-0.263,0.171) 0.680 0.0 
Fish -0.059(-0.372,0.254) 0.710 0.0 0.073(-0.426,0.572) 0.770 9.9 -0.233(-0.969,0.503) 0.530 48.4 
Egg and egg products -0.173(-0.453,0.106) 0.220 2.0 -0.146(-0.351,0.06) 0.160 1.4 -0.223(-0.653,0.207) 0.310 33.3 
SSB 0.039(0.006,0.071) 0.020 0.0* -0.002(-0.04,0.037) 0.930 0.0 -0.028(-0.123,0.067) 0.560 68.5 
Coffee 0.006(-0.014,0.026) 0.540 56.8 -0.008(-0.031,0.014) 0.460 50.6 -0.01(-0.047,0.027) 0.610 58.8 
Tea -0.01(-0.024,0.005) 0.190 0.0 -0.01(-0.028,0.008) 0.250 0.5 0.002(-0.032,0.036) 0.930 29.5 
 
RERI for the interaction between the respective GRS and foods or beverages on incident T2D, adjusted for age (=underlying time scale), sex, centre, total energy intake, first 5 principal 
components for population stratification, physical activity, education, smoking, sex-specific alcohol categories, BMI, mutually adjusted for all other foods except for legumes. 
α for significant interaction: 0.001 (0.05/45 tests) 
*pinteraction<0.05 
% Interaction analyses using the BMI GRS does not include adjustment for BMI because this would remove the variance explained by the exposure 
† N=7946 incident T2D cases/18334 total participants
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In secondary analyses, from 2,925 tests, there were 121 pairs of individual SNP 
and food or beverage interactions that demonstrated a pinteraction <0.05 (Appendix 
H). None of these interactions remained statistically significant after accounting 
for multiple testing using either Bonferroni correction or the False Discovery Rate 
(Figure 6-3).[228]  Moreover, results did not materially differ between our current 
analyses based on imputed data and a complete case analysis (9,403 cases and 
11,745 non cases) (Table 6-6).  
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Figure 5-3: QQ plot of p values for the interactions between individual SNPs for each of the genetic risk scores and food or beverage exposure on T2D: EPIC-InterAct Study 
All interactions are based on the most adjusted models (previously reported for Table 6-4). None of the individual SNP interactions were significant after accounting for multiple testing 
using Bonferroni correction p value threshold of p<1.71E-5 (based on 0.05/2,925 number of tests for 15 dietary exposures and non-overlapping SNPs across all 3 GRS). Please note that 
these analyses were conducted after excluding France (N=9,588 incident cases of T2D/21,418 total). Appendix H includes the results from individual SNP interactions with the respective 
dietary exposures that had a p value for interaction<0.05.
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Table 5-6: An example of interaction findings comparing multiple imputation and 
complete case analysis 
Interaction 
 
 
Multiple imputation analysis results 
(9742 cases, 12158 noncases) 
                   
Complete case analysis results 
(9403 cases, 11745 noncases) 
 Beta (se) P Beta (se) P 
Egg and egg products 
x unweighted T2D 
GRS 0.638 (0.309) 0.039 0.631 (0.317) 0.047 
SSB x unweighted BMI 
GRS 0.037 (0.015) 0.012 0.036 (0.015) 0.017 
Abbreviation: SSB: sugar sweetened beverage, BMI: body mass index, T2D: type 2 diabetes, GRS: 
genetic risk score,  p: p value for interaction 
Conclusion: no substantial difference in results between analysis approaches 
 
6.5 Discussion  
 
In a large prospective study of T2D incidence across eight European countries 
included in EPIC-InterAct, the associations between foods or beverages on the 
risk of developing T2D does not significantly differ between those with low and 
high genetic risk for obesity, IR or T2D.  
There are two main findings from these analyses. The main associations for the 
three GRS and T2D risk was consistent with previous literature.[5,28,30] They 
confirm known biological connections between adiposity and IR with the clinical 
manifestation of T2D. Similarly, the main associations for food and beverage 
intake and incident T2D were either consistent or not significant but directionally 
consistent with previously published EPIC-InterAct analyses and meta-
analyses.[44–52,54,229–234]  
We did not identify any statistically significant interactions between 15 foods or 
beverages and genes on the risk of T2D, on either the relative (multiplicative 
interaction analysis) or absolute (additive interaction analysis) scale. That is, in 
EPIC-InterAct, higher habitual consumption of a portion of processed red meat 
or a can of SSB raised the relative risk of T2D by 22% (HR: 1.22, 95%CI: 
1.09,1.37) and 21% (HR: 1.21, 95%CI: 1.02,1.43) respectively, regardless of 
baseline genetic risk for obesity, IR or T2D (Figure 6-2). For example, even 
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among individuals with a lower genetic predisposition to T2D, those who 
habitually consumed a portion a day of processed red meat had 38% (HR 1.38; 
95%CI: 1.16, 1.64) higher risk of developing future T2D compared to those that 
consumed none (Figure 6-2). This was in contrast to findings from a study among 
2,533 US men[225], which was a smaller study (1,196 cases of T2D) than the 
current analyses with difficulties ascertaining directionality due to its case-control 
design. However, in another larger study (N=16,002 and replication N=21,421) 
examining BMI, a strong risk factor for T2D, the authors found the same adverse 
association between higher habitual consumption of fried food with higher BMI 
even among those with the lowest genetic predisposition for higher BMI.[235] 
Therefore, this suggests that current public health nutrition recommendations to 
reduce processed red meat and SSB intake apply to the whole population, 
irrespective of genetic predisposition. It was noted that the habitual consumption 
of a cup of coffee or tea was inversely associated with the relative risk of T2D by 
8% (HR: 0.92, 95%CI: 0.89, 0.95) and 5% (HR: 0.95, 95%CI: 0.90, 0.999) 
respectively (Table 6-2), regardless of baseline genetic risk for obesity, IR or T2D 
(Figure 6-1). For example, those with a higher genetic predisposition for IR 
observe a 9% lower risk of T2D (HR: 0.91, 95%CI: 0.85, 0.98) when habitually 
consuming a cup of coffee compared to those who do not drink coffee (Figure 6-
1). There are no comparable studies examining coffee intake with IR GRS and 
T2D. However, in a study evaluating coronary risk (n=55,685), a long term 
macrovascular complication of T2D, the authors reported that adopting a healthy 
lifestyle (a score composed of no smoking, no obesity, regular physical activity 
and a healthy diet) can reduce the risk of coronary events regardless of genetic 
predisposition.[236] A healthy diet was defined as adherence to at least half of the 
following: greater consumption of fruits, nuts, vegetables, whole grains, fish and 
dairy products and reduced intake of refined grains, processed meats, 
unprocessed red meats, SSBs, trans fats and sodium.[236] Although in our analysis 
we did not identify a statistically significant association between other foods or 
beverages and T2D risk, interactions with GRS were consistently null, thereby 
indicating a similar interpretation.  
Two nominally significant interactions were observed, whereby among those 
habitually consuming a daily portion of egg and egg products, participants with 
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higher genetic risk for T2D had higher risk of developing T2D than those with a 
lower genetic risk (pinteraction=0.039). This has not been previously reported and 
the high between-country heterogeneity (I2= 80%), with a possible interaction 
evident in France, the UK and Spain, warrants further research in these countries 
in particular. We also found a nominal interaction between SSB intake and those 
with a genetic predisposition for BMI on T2D risk, on both the multiplicative and 
additive scale, where the risk of T2D was highest among those with a higher 
genetic predisposition for BMI and higher SSB intake. This aligns with the 
previously reported interaction between SSB and BMI GRS on measures of 
adiposity,[148,220,237] so further research is of interest.  
Therefore, currently, the consistent findings of no evidence for interactions 
between genetic risk for metabolic diseases and foods and beverages with the 
development of T2D have two main implications. One, these findings provide 
evidence against possible concerns about genetic fatalism or determinism for 
T2D, captured by statements like ‘our genes are our destiny.’[238] And two, these 
findings endorse the message that everyone is susceptible to the health 
consequences of poor dietary habits, such as developing T2D, including those 
with low overall genetic metabolic risk.  This does not preclude future research 
investigating the interaction between other dietary and genetic exposures. 
Strengths and limitations 
With low statistical power being a barrier to investigating gene-diet interactions 
in smaller studies, EPIC-InterAct enabled us to examine our research question 
within a large study with incident T2D that also has dietary and genetic data. This 
is the first published interaction analyses for T2D which has investigated the 
interaction between foods and beverages with three GRS, representing key 
intermediate determinants of and explaining greater variance for T2D. Attempts 
were made to minimise the possibility of spurious interactions through multiple 
approaches: i) taking a systematic approach to selecting foods and beverages 
based on previously reported investigations with T2D, hence avoiding selective 
testing and reporting, ii) accounting for multiple testing to reduce false positive 
reporting, iii) confirming that there is little evidence of dependence between the 
GRS and dietary exposures (Table 6-3)[218] and iv) trying to address potential 
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confounding including population stratification.[126] The consistent findings of no 
interaction under both the multiplicative and additive interaction scales further 
strengthen our null inferences. However, in choosing these 15 foods and 
beverages, the possibility of interactions with other dietary variables or overall 
dietary patterns that reflect potential synergistic interplay between different foods 
and beverages cannot be excluded. A previous analysis in EPIC-InterAct reported 
no evidence for  an interaction between the Mediterranean dietary pattern and 
T2D GRS,[239] but further investigation in other cohorts and with other dietary 
patterns are warranted. Although GRS may improve statistical power,[149] some 
argue that if individual SNPs interact with dietary exposures in opposing 
directions, this can subsequently reduce statistical efficiency.[150] Lastly, these 
findings cannot be generalised to populations of non-European descent, but 
inclusion of eight European countries improved the generalisability to Europeans.     
In conclusion, these findings from the EPIC-InterAct Study in eight European 
countries suggests that the associations of 15 foods and beverages with future risk 
of T2D are not modified by an individual’s genetic predisposition for BMI, insulin 
resistance or T2D.  
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6. Chapter 7 Genome-Environment-Wide-Interaction-
Study of macronutrient intake on incident Type 2 
Diabetes 
 
 
This chapter reports the use of a genome-wide approach to test for the interaction 
between genetic variants and macronutrient intake and risk of developing T2D 
(relating to objective 5, Chapter 2). To my knowledge, this was the first attempt to 
investigate this topic using a fully agnostic approach and has raised important 
issues surrounding method development for such an analysis.  
 
7.1 Abstract 
 
Background: to date, no gene-macronutrient interactions in the development of 
type 2 diabetes (T2D) have been robustly replicated, which invites the 
opportunity for hypothesis-free methods to potentially identify novel interactions 
at unexpected genetic loci to improve our understanding of T2D aetiology. 
Methods: a Genome-Environment-Wide-Interaction-Study (GEWIS) of five 
dietary macronutrients on incident T2D was conducted, in EPIC-InterAct, a 
prospective case-cohort study across 8 European countries (N=21,148 with 9,403 
cases of diabetes). Using Illumina 660W-Quad BeadChip or Illumina HumanCore 
Exome chip arrays, approximately 7.8M genetic variants were examined for 
interaction with the proportion of energy intake from total carbohydrate, total 
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protein, saturated fat, polyunsaturated fat or cereal fibre intake estimates derived 
from self-reported food frequency questionnaires. We used Cox regression to 
estimate the beta coefficients for multiplicative interactions. Genomic inflation 
factor (λgc) was used to evaluate possible systematic bias that may be due to 
population stratification. 
Results: no genetic loci demonstrated significant evidence of interaction with 
the five macronutrients examined in relation to the development of T2D 
(pinteraction ≥ 1.29E-07, with the threshold for significance<5E-08). Highly inflated 
test statistics were observed across all findings from the Illumina 660W-Quad 
BeadChip (λgc≤2.56). Therefore, results must be interpreted in light of this. Post-
hoc analyses were undertaken to investigate the cause of this inflation. The 
specification of a covariate, BMI as a continuous or categorical variable, greatly 
contributed to this inflation.  
Conclusion: further analyses are planned before any conclusions can be made 
about these null findings. After resolution of methodological issues, it is 
anticipated that there would be more widespread use of genome-wide approaches 
for testing gene-diet interactions.  
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7.2 Background 
 
The literature on gene-macronutrient interactions and T2D, including our null 
findings, do not highlight any promising examples using hypothesis-driven 
approaches (i.e. candidate genetic variants or genetic risk scores in Chapters 4 
and 5).[209] Therefore, taking a hypothesis-free approach was the next logical step 
in the systematic interrogation of whether such interactions contribute to the 
aetiology of T2D, with the potential to identify interactions at unexpected genetic 
loci.  
Thus far, hypothesis-free approaches such as GEWIS have been fairly under-
explored, mainly hindered by a lack of statistical power of small sample sizes and 
the large multiple testing burden. Within the literature examining gene-diet 
interactions and T2D, only one study has taken a GEWIS approach. This study 
examined dietary haem iron,[240] whereas none have studied gene-macronutrient 
interactions.[209] In a relatively modest sized US population (n=4,771), the 
association between haem iron intake and T2D did not significantly differ by 
genetic variants, when assessed across 700,000 SNPs as well as specifically with 
SNPs within iron metabolic pathways.[240] Within cancer epidemiology, GEWIS 
approaches to studying gene-diet interactions have recently emerged in the 
literature, with interactions being reported for processed meat,[241] dietary 
pattern[242] and alcohol intake.[151]     
To date, there has been no consensus on the best analytical strategy for 
undertaking a GEWIS, that is, should it be a ‘joint’ test with 1 degree of freedom 
(only examining the interaction term), with 2 degrees of freedom (tests for both 
gene and gene-environment interaction, proposed by Manning and Kraft),[243,244] 
or a ‘stratified’ framework, which compares the main genetic effect between strata 
of a second exposure.[245] Kraft et al. advocate the 2 degrees of freedom tests for 
variants with low or no marginal effect.[244] A recent empirical comparison of joint 
vs stratified tests showed a high correlation between the –log10P values (r>0.75) 
for cohort studies, but recommended a joint approach to retain statistical power 
and if studying low-frequency variants.[245] Some reviews[35,120] have summarised 
alternative methods, which have often been used in addition to the classic joint 
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test with 1 degree of freedom, with variable success. This includes 2 step 
approaches[246] and genome-wide heterogeneity of variance analysis,[247] albeit 
the latter method cannot determine the exposure causing the heterogeneity.   
Therefore, we aimed to characterise gene-macronutrient interactions on T2D risk, 
at the genome-level, using the most basic joint test with 1 degree of freedom. With 
this approach we hope to fill a gap in the literature in using GEWIS to examine 
this research question.  
 
7.3 Method 
 
For the current analyses, the EPIC-InterAct study was used with the main 
methods already described in Chapter 3. In addition, specific methods for this 
piece of work are described below. 
 
Cohort 
Current analyses were based on a subset of EPIC-InterAct with available genome-
wide genotyping, dietary data and data on covariates (9,403 cases and 11,745 
non-cases, a total of 21,148).  
 
Dietary data 
As a first GEWIS of macronutrient intake and T2D, five macronutrients (total 
carbohydrate, total protein, SFA, PUFA and cereal fibre) were prioritised to 
minimise the multiple testing burden and for feasiblity reasons. Macronutrients 
were treated as nutrient densities, being either 5% of total energy intake/day or 
1g/1000kcal/day for cereal fibre. This was to enable comparability and potential 
future harmonisation with previously published literature, which often used these 
units. Total energy intake includes energy from carbohydrate, fat, protein and 
alcohol intake. The outliers were Winsorised at the 1st and 99th percentile. To 
reduce possible multicollinearity in the context of interactions, macronutrient 
variables were centred to the mean.[129]  
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Rationale for macronutrient selection 
 
1. Total carbohydrate intake 
2. Total protein intake 
3. + 4. SFA and PUFA intake: 
• There is no clear association between self-reported intake of total fat, 
SFA, MUFA or PUFA and T2D.[63,224,248,249]  
• The cardiometabolic literature, however, indicates different directions 
of associations between the quality indicators of fat intake (e.g. SFA, 
MUFA, PUFA). SFA and PUFA intake are associated with 
cardiovascular disease but in opposing directions, therefore 
investigating total fat intake would mask these effects.[78,81,250] Also, 
current dietary advice is for replacing SFA with PUFA intake.[208] 
5. Cereal fibre intake: 
• Meta-analysis show that although both total and cereal fibre are 
associated with T2D, cereal fibre (RR for T2D per 10g/d: 0.75, 
95%CI:0.65,0.86) appears to be the driving factor between total fibre 
and T2D (RR for T2D: 0.91, 95%CI: 0.87,0.96).[86] 
 
Genotyping and imputation  
 
Participants were genotyped on the Illumina 660W-Quad BeadChip (referred to 
as ‘GWAS chip’ in this chapter) or Illumina HumanCore Exome Chip (referred to 
as ‘Exome Chip’ in this chapter) arrays and imputed to the Haplotype Reference 
Consortium using IMPUTE v2.3.2. Pre-analysis filtering excluded SNPs with 
minor allele count <10, imputation accuracy of info<0.4 and Hardy-Weinberg-
equilibrium p <10-6. An additive genetic model was assumed for each SNP, where 
the number of risk alleles was 0, 1 or 2 for genotyped SNPs and a continuous 
dosage ranging from 0 to 2 for imputed SNPs. 
Statistical interaction analysis 
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Interactions between each SNP and macronutrient intake on incident T2D were 
analysed using a Prentice-weighted Cox regression model on the basis of the case-
cohort design of EPIC-InterAct, by including the macronutrient, SNP and 
interaction terms in the model (on a multiplicative interaction scale). Both 
macronutrient and genetic exposures were entered as continuous variables. 
Potential confounders relating to both exposures (SNP and/or macronutrient 
intake) have often not been adequately addressed in past interaction analyses and 
may induce both type I and II errors, as Keller, VanderWeele, and Sul have 
empirically demonstrated and discussed.[126–128] Therefore, in balancing this with 
computational efficiency, we adjusted for age at recruitment (continuous 
variable) as the underlying time scale, sex (dichotomised), country (categorised: 
France, Italy, Spain, UK, Netherlands, Germany, Sweden, Denmark), first 3 
principal components for population stratification, total energy intake (TEI) 
(continuous: kcal/day), physical activity (ordinal, treated as continuous: inactive, 
moderately inactive, moderately active, active), level of education (categorical: 
none, completed primary school, technical/professional school, secondary school 
or longer education), smoking status (categorical: never, former or current 
smoker), sex-specific alcohol intake (categorical: none, light drinking (0.1-6g of 
alcohol/d), moderate drinking (men: 6.1-24g, women:6-12g/d) and heavy 
drinking (men>24g, women>12g/d)) based on WHO’s definition of 12g of 
alcohol/drink,[251] and BMI (continuous). Equation 4 below illustrates this, where 
‘SNP’ is the genetic variant and ‘Macro’ is the macronutrient. 
 
f(T2DM)= β0 + βSNPSNP  +βMMacro  +βSNP·MSNPxMacro +  ∑βCCovariate (4) 
 
Chip-specific GEWIS analyses were conducted in Stata v14 (StataCorp LP, Texas, 
USA), using an in-house GWAS programme. The robust command was used to 
calculate the robust standard error of the interaction term and error covariance, 
as advised by Voorman et al., to help minimise exposure misspecification under 
an interaction model.[252] Due to the computational and time intensiveness of 
these analyses, a specialised high-throughput computing system (called high 
performance computing) was used. The University of Cambridge is one of six 
centres in the UK which supports this system.[253] Despite this powerful system, 
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each GEWIS of macronutrient intake takes approximately three days to run and 
equates to £2,000 of computing time and energy. Therefore, decisions relating to 
the analyses were made with consideration of the efficiency of analysis. 
Post analysis quality control included exclusion of rare variants with minor allele 
frequency (MAF) ≤1% and those with missing estimates. Chip-specific results 
were then meta-analysed using the inverse variance-based method within the 
METAL software, originally designed to meta-analyse GWAS findings.[254] This 
resulted in approximately 7.8M SNPs used in our analyses. Between-chip 
heterogeneity was assessed with Cochran’s Q statistic and heterogeneity I2. We 
used pinteraction≤5E-08 as the p-value threshold for significance. 
Quantile- Quantile (QQ) plots were used to examine if the distribution of –log10 p 
values for interaction were consistent with the null distribution (except the 
extreme tail). Deviation from the expected null distribution can suggest large-
scale systematic bias due to population stratification or genotyping error. The 
meta-analysed results (across chips) have been corrected for genomic control 
lambda.  
Chip-specific genomic control inflation lambda (λgc) was calculated by the ratio of 
the observed median chi-squared divided by the expected median chi-squared 
distribution.[255] A value for λgc of less than one is assumed to be from sampling 
error alone, whereas a value above one indicates risk of population stratification 
leading to spurious findings and therefore genomic control correction is usually 
applied. However, as a rule of thumb in GWAS, a λgc >1.1 is considered unusually 
high so applying genomic control correction is insufficient. Thus the underlying 
cause of inflation should be addressed.[256]  
If statistically significant interactions were identified, the following sensitivity 
analyses were planned: 
1. Further adjustment for potential dietary confounders 
a. GEWIS for macronutrient intake: dietary total fibre, magnesium, iron, 
vitamin C, green leafy vegetables, tea, coffee  
b. GEWIS for cereal fibre intake: protein, carbohydrate, saturated fat, 
monounsaturated fat, polyunsaturated fat intake, magnesium, iron, 
vitamin C, green leafy vegetables, tea, coffee 
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2. To assess the possibility of confounding by covariate interaction, interactions 
between covariates and macronutrient as well as between covariates and SNPs 
would be modelled simultaneously.[128] For example, this is exemplified in 
Equation 5: 
 
f(T2DM)= β0 + βSNPSNP  +βMMacro  +βSNPxMSNPxMacro +  ∑βCCovariate +  
∑βSNPxCSNPxCovariate  + ∑βMacroxCMacroxCovariate    (5) 
 
If the strength of the interaction attenuates, distinguishing the covariate 
responsible will aid understanding of the causal pathway, using the approach 
proposed by Waldman[257] 
3. Verification of gene-macronutrient independence[218] 
4. Accounting for isocaloric macronutrient substitution 
 
If interactions were robust to the above analyses, replication would be warranted 
and annotation of the SNPs of interest would be undertaken.  
This methods section reflects the stage of the project that was achieved at the 
time of writing this chapter. In light of highly inflated λgc, post-hoc exploratory 
analyses were undertaken to determine its cause.  
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7.4 Results 
 
The population characteristics of the EPIC-InterAct subset used for this work 
were the same as that used for the replication analysis in Chapter 4 (Table 4-3). 
The main associations between the proportion of energy from macronutrient 
intake (total carbohydrate, protein, SFA, PUFA and cereal fibre) on incident T2D 
are shown in Table 7-1. Total protein intake was positively associated with T2D 
(HR=1.09 per standard deviation; 95%CI: 1.04, 1.14). There were null 
associations for the other macronutrients examined. 
Table 6-1: Association between macronutrient intake and incident type 2 diabetes 
(EPIC-InterAct study) 
Macronutrient intake N (cases/total) Mean (SD) HR (95%CI) per SD 
Total carbohydrate (%TEI) 9403/21148 43.85(6.97) 0.96(0.91,1.01) 
Total protein (%TEI) 9403/21148 17.03(3.04) 1.09(1.04,1.14) 
Saturated fat (%TEI) 9403/21148 13.34(3.34) 1.01(0.92,1.12) 
Polyunsaturated fat (%TEI) 9403/21148 5.55(1.81) 1.02(0.95,1.09) 
Cereal fibre (g/1000kcal) 9400/21139 8.91(4.92) 1.00(0.91,1.10) 
Hazard Ratios (HR) for macronutrients (per SD difference) and Type 2 Diabetes (T2D), adjusted for age 
(=underlying time scale), sex, country, total energy intake, physical activity, education, smoking, sex-specific 
alcohol categories, BMI 
Abbreviations: N- number, SD- standard deviation, HR- hazard ratio, TEI- total energy intake 
 
Among the five macronutrients and more than 7 million SNPs examined, we did 
not observe any gene-macronutrient interactions contributing to T2D aetiology 
that were robust to passing the genome-wide-significance threshold (shown by 
the red horizontal line in the Manhattan plot in Figure 7-1).  
The QQ plots for the chip-specific and post-genomic control meta-analysed 
findings are shown in Figure 7-2. The test statistic inflation ranged from 1.06 to 
2.56, with an average of 1.29. There was overall higher test statistic inflation in 
the GWAS chip analyses, with the PUFA GEWIS most affected (λgc: 2.56), 
followed by carbohydrate GEWIS from the same chip (λgc: 1.54). All GEWIS, 
except that for PUFA and carbohydrate intake were considered at low or 
moderate risk of systematic type I error. 
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Figure 6-1: Manhattan plots of  –log10(P) for the genome-wide interaction (GEWIS) of 
each respective self-reported macronutrient intake on incident Type 2 Diabetes. 
Interaction analyses between macronutrient intake (per 5% total energy intake or per 
g/1000kcal for cereal fibre) and per risk allele of the respective SNP, adjusted for age 
(=underlying time scale), sex, country, total energy intake, physical activity, education, 
smoking, sex-specific alcohol categories, BMI and the first three principal components 
for population stratification.  
None reached genome-wide significance of p≤5E-08, which is indicated by the red 
horizontal line. For each GEWIS, the top SNP has been annotated with the SNP rsid (gene 
name, if applicable) and observed p value.  
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Figure 6-2: QQ plots of –log10(p) for the genome-wide interaction (GEWIS) of the respective self-reported 
macronutrient and incident T2D, by genotyping chip. Meta-analysed –log10(p)  for interaction was undertaken using 
the METAL software and corrected for genomic control.  
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Results from post-hoc exploratory analyses: 
Given highly inflated test statistics (λgc) for some GEWIS, a number of 
exploratory analyses were undertaken to determine the cause of this inflation. 
The PUFA GEWIS was used as the example because it exhibited the highest 
inflation (λgc: 2.56 on the GWAS chip). 
1. No obvious geographical differences in PUFA intake that would have led to 
the highly inflated test statistics (Figure 7-3 shows the country 
distributions by genotyping chip). 
2. No obvious chip-specific problems (in regards to genotyping or 
imputation). No inflation was evident in the GWAS chip for either a GWAS 
(as opposed to a GEWIS) conducted for circulating vitamin C (Zheng et al., 
unpublished) or a GEWIS conducted for BMI and incident T2D, in EPIC-
InterAct (Sharp et al., unpublished) (Figure 7-4). This may suggest that the 
inflation observed in our analysis is specific to GEWIS of dietary factors 
and incident T2D, if not specific to macronutrient intake. Findings from 
the above two checks suggest that there were no obvious differences in 
participant characteristics between chip arrays that would have 
importantly influenced the findings. 
3. Potential multicollinearity was examined for the PUFA GEWIS on the 
GWAS chip. Firstly the effect of reducing the number of covariates of the 
multivariable model from 12 to 8 covariates (excluding physical activity, 
smoking, education and alcohol intake) was examined. This increased the 
λgc from 2.56 to 3.56 (Figure 7-5), with the explanation of this observation 
unclear. In suspecting that the prospective nature of the Cox regression 
may be a reason, all covariates except for age as the underlying time 
variable was dropped from the model to assess the influence of age, 
however, the inflation disappeared (λgc: 1.02) (Figure 7-5). This confirmed 
that age was not the problem. To assess how much each of the 8 covariates 
contributed to this inflation the analysis was performed 5 times, each time 
excluding one covariate (all 3 principal components were dropped 
simultaneously) from the model. The model without BMI abolished the 
inflation (λgc: 0.985), which indicates that BMI had the largest influence 
(Figure 7-6). For computational efficiency, analyses were performed using 
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only chromosome 22, after confirming that the inflation existed uniformly 
across all chromosomes. Given that there was no notable difference in the 
distribution of BMI between genotyping chips, we concluded that at least 
for the PUFA GEWIS findings, conducted on the GWAS chip, the inclusion 
of BMI in the model contributed to high inflation. 
4. Whether the covariate, BMI, may have been misspecified. It was observed 
that treating BMI as a categorical rather than as a continuous variable 
reduced the inflated test statistic. Figure 7-7 shows the GEWIS for PUFA 
and carbohydrate intake, respectively. This was based on analyses 
adopting the most adjusted model, where BMI was treated as WHO cut 
offs (<25, 25-29, ≥30kg/m2), only on the GWAS chip and only for 
chromosome 22.  
 
 
Figure 6-3: PUFA intake distributions within each country, by the GWAS and Exome Chip 
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Figure 6-4: Genotyping chip specific QQ plots of –log10(p) for a) the GWAS of circulating vitamin C (Zheng, 
unpublished) and b) GEWIS of BMI on incident T2D (GWAS chip N=9,100, Exome chip N=13,078) (Sharp, 
unpublished). * indicates in subcohort only (GWAS chip N=3,521, Exome chip N=6,504). 
 
Figure 6-5: QQ plot of –log10(p) for interaction from the PUFA GEWIS on the GWAS chip only. Shows that reducing 
the number of covariates from 12 to 8 increased the inflation (A compared to B) and that age was not inducing the 
inflated test statistics (C). PUFA GEWIS adjusted for A) age (underlying time scale), sex, country, first 3 PC for 
population stratification, total energy intake, physical activity, education, smoking, sex-specific alcohol intake, BMI; B) 
age (underlying time scale), sex, country, first 3 PC for population stratification, total energy intake, BMI; C) age 
(underlying time scale). 
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Figure 6-6: QQ plots of –log10(p) for interaction from the PUFA GEWIS, only on the GWAS chip and on chromosome 
22. Each of the above covariates was dropped one at a time. Abbreviation TEI: total energy intake, PCA: principal 
components for population stratification 
 
 
Figure 6-7: QQ plots of –log10(p) for interaction from the PUFA and carbohydrate GEWIS, only on the GWAS chip 
and on chromosome 22, under the most adjusted model using categorised BMI as a covariate. Analysis adjusted for 
age (underlying time variable), sex, country, TEI, first 3 principal components for population stratification, BMI, 
physical activity, education, smoking and sex-specific alcohol intake. 
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7.5 Discussion 
 
To our knowledge, this was the first macronutrient intake GEWIS for incident 
T2D, using over 7 million SNPs, examined in over 21,000 participants. No 
interactions at genome-wide-significance were identified. For some analyses, the 
high genomic inflation was in a large part due to misspecification of a covariate 
(BMI). This methodological issue has therefore shaped future plans for this piece 
of work and has raised an important consideration for future GEWIS of dietary 
intake.     
The high degree of inflated test statistics observed for the PUFA and carbohydrate 
GEWIS findings resulted in an evaluation of the suitability of QQ plots to assess 
systematic type I error in the setting of a GEWIS. It also led to identifying a gap in 
the literature for methods in evaluating reasons for this beyond population 
stratification. Although assessing QQ plots and the degree of inflation of the 
median test statistic is well accepted in GWAS of a single exposure, Voorman and 
colleagues demonstrated that, in the GEWIS setting high inflation within a QQ 
plot could reflect systematic underestimation of variability in interaction effect 
estimates across the genome, therefore resulting in spurious QQ-plot inflation 
even when there is no problem with population substructure.[252] Theoretically, 
gene-environment interactions are more prone to violating the model assumption 
that the mean value of the outcome is truly linear in the coefficients of the 
exposure variables. This is because, in nutritional epidemiology, we have seen 
that many dietary exposures show non-linear associations with disease, including 
the U-shaped association between alcohol intake and T2D.[251] Therefore, 
Voorman et al., proposed modelling robust estimates of variance to prevent 
misspecification. In all the current analyses, this was done, yet high inflation was 
still evident. In a GEWIS of BMI and T2D within the Nurses’ Health Study, 
Cornelis and colleagues simulated four methods for specifying the main exposure 
(BMI) which resulted in different levels of inflated test statistics.[205] They 
concluded that treating their main exposure (BMI) as a linear continuous variable 
led to variances of the interaction β to be underestimated and therefore inflated 
test statistics. This was rectified by modelling BMI as polynomial, dichotomising 
it or using a robust variance estimator, as suggested by Voorman et al. In our 
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case, categorising our main exposure (proportion of energy from PUFA intake) 
and using a robust variance estimator did not fully eliminate the inflated test 
statistic (λgc: 1.32), in the context of a larger number of T2D cases (N=9,403) than 
that available in the Nurses’ Health Study (N=2,199 cases of T2D). This 
demonstrated how currently proposed methods for controlling test statistic 
inflation in the GEWIS setting,[205,252] if assuming that misspecification of 
exposures may be a contributing factor, is insufficient. In the current analysis 
when the covariate, BMI, was subjected to the same methods adopted by Cornelis 
et al., a decrease in inflation for both the PUFA and carbohydrate GEWIS was 
observed (Figure 7.7). Therefore, although further methodological developments 
are warranted, the findings indicate that future GEWIS of dietary and/or 
macronutrient intake should apply robust variance estimator during analyses and 
if QQ plots indicate inflated test statistics, researchers should evaluate how the 
main exposure(s) and covariate(s) are specified before concluding that population 
stratification may have biased their findings.  
The differences observed for findings between the two genotyping chips is 
difficult to explain and the possibility of collider bias contributing to the role of 
BMI is challenging to assess in this setting.[258] 
The question about whether it is too early to establish a fixed threshold for 
rejecting the null from GEWIS analyses, is still under debate. The conflict 
between a) raising the type II error rate by using stringent thresholds to 
determine whether an interaction is due to chance and b) raising the type I error 
rate when using less conservative approaches, is difficult to balance. In a meta-
analysis of 22 candidate gene-based interaction studies, the authors 
demonstrated that NAT2 slow acetylates are more susceptible to the adverse 
effects of cigarette smoking on bladder cancer risk because they have a reduced 
detoxification capacity for aromatic monoamines, found primarily in tobacco 
smoke.[103] This was identified at a p value for interaction much higher than the 
genome-wide-significance threshold used in the GEWIS setting 
(pinteraction=0.008).[103] Hence, this demonstrates a risk for type II error when 
undertaking a GEWIS because biologically plausible interactions, including this, 
may be overlooked when a stringent threshold for rejecting the null hypothesis is 
applied. However, given the likelihood of ‘winner’s curse,’ and the potential for 
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spurious interactions in the context of many limitations associated with 
observational epidemiology that could lead to misinterpretation at the public 
health interface, a more conservative approach to investigating interactions by 
using the genome-wide-association threshold (pinteraction ≤5E-08) was chosen in 
the current analyses. This appears to be current practice for GEWIS investigating 
various outcomes.[151,241,259] Moreover, enlarging the current dataset by replication 
in comparable studies and then pooling the findings, particularly of the 
interactions that were at sub-genome-wide-significance threshold (pinteraction ≤1E-
06), may offer further insights.  
Strengths and limitations 
This current work has tried to address some of the known methodological 
concerns relating to GEWIS approaches, including potential confounding for both 
exposures and had planned a thorough set of sensitivity analyses to minimise the 
likelihood of type I error. Additionally, an important methodological issue not 
previously reported in the GEWIS literature has been highlighted and may 
pertain specifically to GEWIS of dietary exposures, if not to macronutrient 
exposures. However, it is questionable whether there was sufficient power to 
detect interactions with the small magnitude of effects that were observed. 
Appendix I lists five SNPs for each macronutrient GEWIS that achieved the 
lowest p values for interaction. Among these SNPs with a MAF≥10% the 
interaction beta ranged from 0.07 to 0.62, with all but one SNP demonstrating an 
interaction beta of ≤0.22. Our analyses had <80% power to detect an interaction 
beta of ≤0.25, assuming an MAF≥10% within EPIC-InterAct (N=9,403 incident 
T2D cases, see Figure 7-8).[156] Despite this, EPIC-InterAct is a large prospective 
study with incident T2D (with over 5 times the number of T2D cases as other 
large prospective observational cohorts)[142] and both genetic data and measures 
of self-reported macronutrient intake. It would be worthwhile to consider 
enlarging the discovery dataset by meta-analysing with comparable studies to 
improve statistical power. This would require considerations for harmonisation of 
the genetic and dietary exposures as well as the analysis approach.    
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Figure 6-8: Power calculations for detecting interactions between genetic variants and environmental exposures 
within EPIC-InterAct (software: QUANTO based on assumed population risk of 5%, MAF of 10% and normally 
distributed environmental exposure).[156] Rge: relative risk (magnitude of effect) for the interaction between genetic 
variants and environmental exposure. 
 
Future plans 
Given that a practical method to address the inflation observed for the PUFA and 
carbohydrate GEWIS would be to treat the BMI covariate as a categorical 
variable, this is the plan for when these two macronutrients will be re-analysed.  
As previously mentioned, interrogating interactions at sub-genome-wide-
significance (pinteraction ≤1E-06) via replication in comparable studies and then 
meta-analysis, would be a next step. From the meta-analysis, an option to better 
understand the biology of statistically significant interactions (pinteraction ≤5E-08) 
could be to filter by genes of biological relevance to the macronutrient of interest 
and/or T2D pathophysiology.[260] To begin with, a focused list of genes within a 
pathway for each respective macronutrient will need to be identified. This can be 
informed by genetic variants known to cause protein change (nonsynonymous) or 
have been shown to regulate gene expression using databases such as the 
Genotype-Tissue Expression (GTEx).[261] However, some considerations in using 
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such an approach include the complexity in gene regulation (i.e. whether they are 
trans or cis-regulated genes and if there may be interaction between them) and 
tissue specificity of gene expression.  The selection of appropriate pathways can 
also be related to genes involved in inherited metabolic disorders of nutrient 
metabolism, for instance the mutation in GALT which encodes for the enzyme 
involved in galactose (a carbohydrate) metabolism which results in the condition 
called galactosemia.[262] Another resource is the Kyoto Encyclopedia of Genes and 
Genomes (KEGG), a database of biochemical pathways highlighting enzymes and 
other cofactors that are involved in the digestion, absorption, metabolism, 
distribution and elimination of macronutrients.[263] The genetic variants 
identified from this approach are key candidates to prioritise for future gene-
macronutrient interaction testing under various conditions (e.g. different 
population groups) and methods (e.g. using a recall by genotype RCT study 
design). 
This first attempt to examine gene-macronutrient interactions across the genome 
has highlighted several methodological issues that warrant further investigation 
and development to guide future GEWIS research applied to dietary intake. 
Although much has been learnt from GWAS studies, it must be borne in mind 
that investigating interactions (as distinct from marginal genetic effects in the 
presence of interactions) involves the convergence of two fields of epidemiology 
(nutrition and genetics). Therefore, decisions about multiple testing corrections, 
selection of covariates, interpretation of QQ plots, and how exposure and 
covariates are specified, are some that require not only considerations of the 
conventions taken in both fields but perhaps also the development of novel 
methods and practices specifically targeted to GEWIS in the context of particular 
exposures, such as diet. Although this piece of work remains on-going, several 
gaps in understanding have been identified and warrant further methodological 
research to help with advancements within this field.   
 
 
 
  
 
177 
 
 
7. Chapter 8 General discussion, implications and 
conclusion 
 
 
Within my PhD, the overall aim was to understand the contribution of gene-diet 
interactions to the aetiology of type 2 diabetes (T2D).  In particular, I focused on 
potential interactions with macronutrient intake (Chapters 4, 5 and 7). I have also 
included investigation of the potential interactions with foods and beverages 
(Chapter 6). In the chapter-specific discussions, the potential of this leading to 
genotype-target nutritional interventions to prevent T2D has been evaluated. I 
took a systematic approach in comprehensively investigating gene-macronutrient 
interactions and T2D using three methods (candidate genes, genetic risk scores 
and a genome-environment-wide-interaction study). The following discussion 
will bring everything together. 
 
8.1 Summary of key findings  
 
In chapter 4, a systematic review of the literature on gene-macronutrient 
interactions and T2D was conducted, where 13 publications that reported 8 
unique statistically significant interactions were identified. These were between 
one of the following macronutrients: carbohydrate, fat, saturated fat, dietary 
fibre, and glycaemic load derived from self-report of dietary intake and 
circulating n-3 polyunsaturated fatty acids with genetic variants in or near the 
following genetic loci: TCF7L2, GIPR, CAV2 and PEPD (pinteraction<0.05). Some of 
the key limitations of the published literature on this topic included a lack of 
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reported replication, insufficient correction for multiple testing, inadequate 
adjustment for potential confounders relating to both genetic and dietary 
exposures and that no studies accounted for isocaloric macronutrient 
substitution.  
 
In chapter 4, it was also demonstrated that none of the interactions reported in 
the literature could be replicated in a large prospective cohort study of Europeans 
with incident T2D cases (N=21,148 with 9,403 T2D cases) with a comparable 
population to those of the published studies. This discrepancy in findings likely 
reflects either true heterogeneity between study populations, methods and/or 
analyses, or the possibility of spurious interactions identified in previous 
publications because no studies confirmed their findings via replication. It is 
probable that chance, confounding and/or biases within the published literature 
may have contributed to possible false positive findings.  
 
From the systematic review, I identified two key research gaps: i) the need for 
replication of interactions and ii) there is a paucity of studies investigating gene-
macronutrient interactions using non-candidate gene methods, such as using a 
GRS and GEWIS. 
 
Chapter 5 extended these findings when gene-macronutrient interactions for 
incident T2D were examined using three GRS (based on meta-analyses of GWAS 
for BMI, IR and T2D) and no interactions were identified. This was consistent 
with the null findings reported in Chapter 4.  
 
In chapter 6, using a similar method as for Chapter 5, the investigation was 
extended to include potential interactions between 15 foods and beverages and 
these three GRS (BMI, IR and T2D). Again, no significant evidence for 
interactions were observed for foods or beverages. 
 
Finally, in continuing to examine gene-macronutrient interactions across the 
spectrum of methods, at the hypothesis-free end, a GEWIS was performed. No 
statistically significant interactions were identified at the genome-wide 
significance level for total carbohydrate, protein, saturated fat, polyunsaturated 
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fat and cereal fibre intake on incident T2D. This work highlighted a number of 
challenges using GEWIS to examine interactions with macronutrient intake, 
including the specification of main exposures as well as covariates and which p 
value threshold to use to reject the null hypothesis.  
Taken altogether, this comprehensive approach to the investigation of gene-
macronutrient interactions and incident T2D demonstrates that such interactions 
do not appear to significantly contribute to the aetiology of T2D. Therefore, the 
current results support universal rather than genetically targeted approaches for 
dietary advice on macronutrient consumption for the prevention of T2D. 
 
8.2 Overall strengths and limitations  
 
Specific strengths and limitations pertaining to each project within this PhD have 
been discussed within their respective chapters. The focus of this section is to 
highlight the overall strengths and limitations. 
Strengths 
To my knowledge, the work conducted within this PhD represents the most 
comprehensive and systematic investigation of the contribution of gene-
macronutrient interactions in the aetiology of T2D.  We have taken advantage of 
high-efficiency computation in large genetic datasets to examine this from both 
hypothesis-driven and hypothesis-free angles. The prioritisation of candidate 
genetic variants selected for hypothesis-driven approaches was underpinned by a 
systematic review of the literature and biological plausibility.  
A further strength of this work was the opportunity to examine these research 
questions within EPIC-InterAct, which currently includes a large population of 
incident T2D cases. This played an important role in maximising statistical 
power; often a methodological barrier in studying gene-environment interactions. 
Having had eight countries represented across Europe allowed the investigation 
of the consistency between countries. It also supported a consistent method for 
exposure and outcome assessment and analysis across countries, which 
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minimised heterogeneity. Therefore, these findings can be generalised across 
Europe. 
An attempt was made to reduce the limitations evident in previous studies that 
investigated gene-macronutrient interactions. This included examining both 
multiplicative and additive interactions where appropriate (i.e. interaction 
between GRS and foods and beverages), addressing confounding of both 
exposures when examining ‘interaction’ (as opposed to effect modification), 
addressing multiple testing concerns, transparency in reporting all findings, and 
where appropriate, reporting both effect estimates by strata of the third variable 
as well as the p-value for interaction.  
Finally, the last project using a GEWIS approach presents an example of 
challenges that arise from method development of this technique applied to 
nutrition. Hopefully, the learnings from this work can guide future research using 
this method. 
Limitations 
The current findings and conclusions are limited by the scope of our exposure 
selection and should be interpreted with this caveat in mind. It is impossible to 
have examined every genetic locus and dietary exposure to make a broad 
generalised conclusion that gene-diet interactions do not contribute to T2D 
aetiology. Given that intermediate traits for T2D such as BMI and glycaemic 
markers are more responsive to lifestyle change in part due to their shorter time 
of effect, it can be hypothesised that gene-diet interactions could have more 
noticeable effects on these traits. Although examining these intermediate traits 
would be useful, it was outside the scope of this PhD and thus deserves future 
attention. Additionally, the majority of the analyses within this PhD were 
conducted within one study: EPIC-InterAct. Although a phenotypically rich and 
large study, it does raise issues relating to generalisability and will be discussed in 
section 8.3.5. 
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8.3 Interpretation of gene-macronutrient interaction findings 
 
Within the field of cardiometabolic gene-environment interactions, some people 
have posited that null findings or a lack of replicated interactions could reflect 
methodological limitations of observational epidemiology. This refers to possibly 
bias and/or confounding reducing interaction effects so that they are either 
underestimated or undetectable, even within large population studies.[118]  The 
findings from this PhD indicate that there are no significant gene-macronutrient 
interactions contributing to the aetiology of T2D. However, next, an evaluation of 
the internal validity of these findings will be provided to assess whether 
alternative explanations may explain these in light of epidemiological issues such 
as chance, bias and confounding. This will then be followed by an assessment of 
the finding’s external validity or generalisability.  
8.3.1 Chance and statistical power  
The main study used within this PhD was EPIC-InterAct, which was a subset of 
people from the general population at the time period between recruitment and 
follow-up (see Methods Chapter 3 for details). However, sampling variability can 
influence how accurate and precise the findings are for the general population, 
within this subset of the population. In order to make inferences about the 
general population from this study, the degree to which chance affected the 
findings must be determined.  
The degree of chance findings can be quantified using p-values and confidence 
intervals from hypothesis testing. The p-value is defined as the probability of the 
observed result occurring purely by chance, assuming that there is truly no 
association between the exposure and outcome. Within this thesis, various p-
value thresholds have been used to determine the significance of findings. For 
replication conducted in Chapter 4, the conventional p-value threshold of 0.05 
was used for independent replication. This is an arbitrary cut off meaning that the 
result of 1 in every 20 tests would be wrongly classified as a real interaction when 
in fact it is due to chance (type I error or false positive findings), hence no matter 
how small the cut off is set there is always the possibility of chance. A criticism of 
published research on gene-environment interactions has been the large number 
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of tests conducted and hence the high rates of spurious findings, particularly with 
selective reporting of only those that pass p-value thresholds of 0.05. Therefore, 
in trying to overcome this, an attempt was made to lower the probability of false 
positives. Where multiple independent hypothesis tests were conducted, the 
statistical p-value (e.g. nominal p-value) for interaction was reported but the 
threshold for rejecting the null hypothesis of no interactions was corrected for 
multiple testing using Bonferroni correction or the False Discovery Rate, where 
indicated. However, because some exposures were correlated (e.g. Pearson 
correlation was 0.7 between total and animal protein intake reported in Chapter 
5), this violates the assumption of independence under Bonferroni correction and 
therefore an alternative ‘effective number (Meff) of independent tests,’ was 
calculated to minimise the risk of overlooking possible true hits (type II error or 
false negative findings).[203] This method uses principal component analysis for 
the exposures to calculate the Meff of independent tests. This number was then 
used to correct the p-value threshold for significance. For example, in Chapter 5, 
we investigated the interaction between 3 GRS and 12 macronutrients and found 
that no interactions were considered statistically significant (pinteraction ≥0.20). 
This was based on the p-value threshold of <0.0015 (0.05/33 is the estimated Meff 
number of independent tests). This would mean that less than 2 in every 1000 
tests would be a false positive finding. For our GEWIS, we used the conventional 
genome-wide-significance p-value of 5E-08 because it was hypothesis-free and 
the multiple testing burden was assumed to be similar to a GWAS. Although our 
findings were all null, based on our large sample size and significance threshold 
that accounted for multiple testing, any detected interactions would not have 
been influenced by chance.  
How precise the null estimates are is influenced by sample variability, which 
inherently decreases when increasing the sample size of the study from which the 
inference is based. Therefore, having used a study with the largest sample size to 
date to examine gene-macronutrient interactions on T2D incidence, this 
improves the confidence in making reliable inferences. The 95% confidence 
interval around our effect measures have also been provided as this indicates the 
range of values within which the true effect measure lies, with 95% assurance of 
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accuracy. The narrower the confidence intervals, the greater that estimates are 
precisely reflecting the true estimate.   
Concerns have been raised about the overly-conservative correction that the 
Bonferroni method enforces, with some suggesting the use of an alternative 
method being the ‘False Discovery Rate.’ This estimates the proportion of errors 
due to falsely rejecting the null hypothesis of no interactions (proportion of false 
positives you are willing to accept).[264] However, given the currently high level of 
scepticism within the field of gene-environment interaction regarding spurious 
findings, a false positive interaction finding may inflict more negative 
implications for public health and research than a false negative. This was the 
rationale for choosing a more conservative correction method for the majority of 
the analyses.   
Within genetic epidemiology, where effect sizes of individual SNPs are modest, 
studies with large sample sizes are usually needed to detect whether the effect 
truly exists (preventing a false negative). This problem is further inflated when 
examining the interaction between genetic variants and another exposure, often 
requiring >10,000 individuals if the expected magnitude of the effect is modest 
(interaction HR<1.2) and alleles are commonly distributed in the population 
(MAF>10%).[121] This has been a concern for the interaction field in general.[35,119] 
The statistical power of a study is the probability of rejecting the null hypothesis if 
one truly existed (1-β) and where β is the probability of making a false negative 
error. In a study without adequate power to detect an interaction, a null finding 
may not necessarily mean a true lack of interaction effect, but rather it may 
indicate that the signal was not strong enough to be detected within the sample 
size available. In the first analysis, where an attempt was made to replicate the 
interactions previously reported (Chapter 4), EPIC-InterAct was the study with 
the largest number of incident T2D cases (>5 times that of published studies) to 
have investigated this research question. Therefore, the analyses conducted had 
>80% power to detect 6 of the 8 reported interactions. For the interaction 
analyses using GRS, which included a combination of SNPs, no power 
calculations were performed because i) there have not been any previously 
published studies to determine the expected magnitude of effect and ii) currently 
there is no guidance on how to specify the minor allele frequency (MAF) of a 
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combined GRS. This is a limitation that is acknowledged. In the GEWIS, a 
detailed discussion has already been made about the likelihood of the study being 
underpowered (please see strengths and limitations section of Chapter 7).  
8.3.2 Bias  
 
Bias refers to a systematic error within a study which results in an incorrect 
estimate of the association between exposure and outcomes. Next, different forms 
of bias that have been considered throughout this PhD will be discussed. 
 
Measurement bias; regression dilution bias and misclassification 
To minimise time, expense and participant burden within large epidemiological 
studies, a food frequency questionnaire (FFQ) is often used to assess self-reported 
dietary intake, as was the case with EPIC-InterAct. For example, in the UK 
centres FFQs are limited to 130 items, meaning they are unable to capture all 
intakes and therefore leading to imprecision in estimating macronutrient intake. 
Such imprecision can bias the interaction effect towards the null (regression 
dilution bias) and/or misclassify individuals into categories of exposure. For 
example, within the replication work described in Chapter 4, it is unclear how 
much such a bias may be an alternative explanation for the discrepancy that was 
observed between the null findings from the current work and the previously 
reported interaction for dietary fibre and TCF7L2. In Chapter 4, it was 
demonstrated that the differential measurement bias for dietary fibre intake 
across countries did not materially influence the interaction findings, however, 
the extent to which this impacts on other interactions is unclear. Also, although 
validation studies have shown that FFQs estimate macronutrient intake well, 
these studies have not examined quality markers of macronutrient intake 
including dietary fibre. All self-reported dietary intake, which can also include 
repeated 24 hour recalls and food diaries, may be subject to recall and social 
desirability bias. Moreover, in the estimation of macronutrient intake, conversion 
of food into nutrient data by the use of food composition databases can introduce 
another layer of error. Especially since interaction effects are particularly 
sensitive to loss of statistical power due to measurement bias,[122] future gene-diet 
  
 
185 
interactions should use objective biomarkers of intake, when available and 
feasible. However, currently a limited set of nutritional biomarkers is available for 
macronutrient intake and much work is needed to develop, validate and apply 
biomarkers of diet in nutritional epidemiology. Although statistical methods may 
be used to correct for measurement bias, as discussed in Chapter 4, using a more 
precise tool to begin with is ideal.  
Bias in modelling 
A statistical consideration, already mentioned in the methods chapter, is that how 
dietary exposures are modelled (either continuous or categorical), can influence 
the interaction effect and its variance.[205] To minimise loss of power through 
categorisation, dietary exposures were specified as continuous variables for all 
analyses except the attempt to replicate previously published interactions 
(chapter 4). The consistency of approach for exposure specification also ensured 
that significant interactions were not identified as a result of data dredging.  
Dissemination bias 
Dissemination bias includes publication bias, selective reporting and language 
bias and is known to be prevalent in the interaction literature.[265] 
It is suspected that non-significant interactions are often unpublished, in the 
context of many post-hoc interaction analyses and that many reported 
interactions have not been replicated.[142] This is therefore a limitation of the 
literature underpinning the systematic review, described in Chapter 4. This 
practice is not specific to the field of interactions but has implications for 
interpreting the overall evidence for gene-diet interactions if the totality of 
evidence is skewed towards positive findings and lead to a wasteful use of 
resources in conducting research that has already been conducted but not 
reported. Moreover, from conducting the systematic review, a high level of 
selective reporting was evident, particularly if interactions were null. Throughout 
this PhD, I have strongly advocated for publishing all findings, regardless of their 
results and have included the summary estimates, not just p values for 
interaction, in supplementary tables as a possible resource for future studies. 
However, editor bias in accepting positive findings is a well-recognised problem 
contributing to publication bias that needs to be separately addressed.[266]  
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Tabery offers a fascinating perspective on how our unconscious biases, which 
underpin our beliefs and values placed on finding interactions, could influence 
our expectations of what we find and this, in effect, may result in dissemination 
bias. In his book, ‘Beyond Versus: The struggle to understand the interaction of 
nature and nurture,’ he examined the debate regarding the existence of 
interactions from a philosophical perspective.[267] This debate has played out 
since the 20th century and began with RA Fisher who believed in the independent 
contribution of genetics and environment, whereas Lancelot Hogben advocated 
for the interdependence of gene and environmental factors on the variation of 
phenotypes.[268] More contemporary yet equally controversial examples of a 
similar debate includes the potential existence of the interaction reported by 
Caspi and Moffitt about whether life stress and depression risk may be moderated 
by a genetic variation near the serotonin transporter (5-HT T) gene.[104] The 
commonality between these debates lies in the two perspectives given, which 
include those who take the a) variation-partitioning approach and believe 
interactions are purely statistical so need to be eliminated (sceptics) vs b) the 
view that interactions enable understanding of mechanisms and developmental 
processes that should be understood (advocates).[269] These two distinct 
perspectives to how scientists study interactions and their extremely different 
reasons in doing so may, therefore, contribute to how they interpret and share 
their findings with the scientific community. For variation partitioners, the 
research question is about how much variation can be explained in a population 
by the specific exposures and therefore interactions may present an obstacle. 
Whereas for mechanism-elucidators, interactions aid in understanding the 
developmental process.[269] What I take from Tabery’s explanation is that 
subconscious biases can influence analysis, interpretation, synthesis of data and 
perception of what is seen as ‘true’ in this field despite that quantitative findings 
are generally  perceived as objective. This can also be understood under the 
framework of social constructivism, where each individual perceives the same 
experience through a different lens which is influenced by their past 
experiences.[269] This can lead to dissemination bias and influence the entire 
process of conducting research. So, it may, therefore, be valuable for researchers 
to incorporate reflective practices when studying interactions, such as using a 
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reflective journal to acknowledge their experiences and biases to promote 
transparency.[270] In setting an example, I have declared my biases below: 
As a dietitian, I came into this research with the aim of trying to 
objectively evaluate whether services that claim to provide ‘personalised 
nutrition,’ based on an individual’s genetic profile are scientifically valid. 
This led me to study gene-diet interactions. I cannot deny that I was once 
excited by the prospect of providing more effective dietary interventions 
through knowledge of someone’s genetics. However, my main 
motivations have always been to promote health and protect the interests 
of the public. In addition, given that commercial companies have been 
strong advocates for personalised nutrition, I am aware that I leaned 
more towards being a sceptic rather than an advocate for gene-diet 
interactions. To counterbalance this, throughout my PhD I have made 
both mental and written notes to help me stay mindful of this bias, so I 
hope that my ‘trained’ objectivity is apparent within this thesis. I believe 
everyone is a victim to some form of subconscious bias but it is how 
mindful we are of this that determines how optimally we treat the 
information within our power.  
Gene-environment dependence 
It has been recognised that under gene-diet dependence, a statistical interaction 
can be found for a genetic marker even if there is no interaction between the 
causal variant and the dietary exposure. Dudbridge and Fletcher explain that this 
may occur under three scenarios, including by mediation, pleiotropy and 
confounding.[218] In the analyses conducted within this PhD (Chapter 5 and 6), 
little correlation was observed between the GRS and dietary exposures. This 
therefore minimised potential gene-diet dependence leading to possible spurious 
interaction findings. Understandably, this was not feasible for the GEWIS 
analyses (Chapter 7) given the millions of SNPs examined but could be 
undertaken as a sensitivity analysis.  
8.3.3 Confounding  
As already explained in Chapter 2 on methodological challenges and Chapter 3 on 
which confounders were relevant for ‘interaction’ analysis, key confounders for 
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both genetic and dietary exposures were included in all analyses. In addition to 
confounders of the main genetic and dietary exposures, another potential 
confounder could be related to the interaction effect (i.e. the interaction between 
the genetic exposure and each covariate as well as the interaction between the 
environmental exposures and each covariate). This is shown in Equation 6, 
below, where G= genetic exposure, E= environmental exposure and C= 
covariates. Keller explained that the interaction term will be biased if i) the 
covariate is correlated with the genetic variable and the covariate x environment 
interaction coefficient is non-zero, or ii) the covariate is correlated with the 
environmental variable and the covariate x gene interaction coefficient is non-
zero.[128] Taking a pragmatic approach to avoid the potential overfitting of the 
primary models and loss of power, the method described by Keller and colleagues 
was planned as a sensitivity analysis. Therefore, although the possibility of 
residual confounding from unmeasured confounders remains, the current body of 
work has gone beyond what previous studies have done to minimise the impact of 
confounding on the results. 
 
f(T2DM)=  β0 + βGG + βEE + βcC + βGxEGE + βGxcGC + βExCEC                     (6)                      
 
8.3.4 Type of interaction scale  
In Chapter 3, the difference between the multiplicative and additive interaction 
scales have been explained. Several studies demonstrate that interactions are 
scale-dependent.[139,140] Whilst some endorse testing and reporting all 
interactions on both scales,[141] since additive interactions are only relevant when 
an interaction has public health relevance, a hypothesis-driven approach was 
adopted in deciding which interaction scale to use and when. In the replication 
analysis (Chapter 4), the scale was based on what was applied in the published 
report. In analyses between GRS and macronutrient intake (Chapter 5), a 
multiplicative scale was deemed most appropriate given the aim of those analyses 
was to understand aetiology of T2D, whereas for the interaction analyses between 
GRS and foods and beverages (Chapter 6), both multiplicative and additive 
interactions were tested because of the foreseeable public health potential of any 
  
 
189 
identified interactions. The reason for using multiplicative interactions for the 
GEWIS was similar to that taken for GRS and macronutrients. 
8.3.5 Generalisability 
Given that all the study cohorts examined within this PhD were populations of 
European descent, the question about whether gene-diet interactions exist in 
other ethnic groups remain unanswered. For example, worldwide, China 
currently has the highest prevalence of diabetes (11%)[12] and their post-
globalisation dietary changes represent a potentially insightful population to 
examine how transitional patterns of eating (e.g. from traditional Chinese to 
Western dietary patterns) contribute to rising T2D, under genetic susceptibility. 
Indeed, some gene-macronutrient interactions have been noted in those of 
Chinese[192] and Indian descent.[271] Moreover, most of the analyses from this PhD 
(Chapters 4-7) were conducted within one study population (EPIC-InterAct). This 
limits the generalisability of findings beyond European populations but also non-
EPIC-InterAct European populations. In genetic epidemiology, the practice of in 
silico replication and meta-analyses of several cohorts is more common than for 
studies of gene-diet interactions, with barriers such as heterogeneity in dietary 
assessment discussed in Chapter 4. However, EPIC-InterAct is the most suitable 
study to evaluate the research questions set for this PhD because of the large 
number of incident cases of T2D and detailed genetic and dietary data available. 
As well as this, having eight countries represented in EPIC-InterAct allowed us to 
some extent generalise our findings across Europe. The harmonised assessment 
and analyses within EPIC-InterAct also minimised possible heterogeneity and 
therefore differences in potential bias between countries.  
Nevertheless, having undertaken most of the analyses in EPIC-InterAct is a 
limitation of the current findings. Although enlarging the analyses with other 
similar studies via a meta-analysis (e.g. CHARGE consortium efforts) may be an 
option to address limitations of generalisability and can improve statistical 
power, current approaches like this do not fully address long-standing concerns 
about heterogeneity relating to dietary assessment (e.g. one study uses FFQ whilst 
another uses 24 hour recall) and analysis (e.g. absence of covariates in certain 
studies and possible misclassification if variable definitions differ) between 
pooled studies.[118] In section 8.7, a discussion is made about how future research 
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should determine what constitutes the most valuable form of replication for gene-
diet interactions, whilst considering inherent issues relating to heterogeneity 
between studies and the impact of important subgroup differences where they 
exist. UK Biobank is another cohort that may help with evaluating generalisability 
of interactions in other ethnic groups.   
Another limitation of this work is the scope of interactions that could be 
examined. Whilst the choice in macronutrients was those that have been most 
commonly consumed and researched, we cannot preclude interactions that may 
exist between alternative macronutrient (e.g. monosaccharides, ‘free sugars’) 
and/or genetic exposures. Therefore, for all of the individual projects conducted 
within this PhD, broad generalised conclusions have been avoided and this 
limitation has been highlighted in the respective discussion sections. 
8.4 Assessment of causality  
The main aim of this PhD was to investigate the existence of and then evaluate 
the validity and reliability of gene-diet interactions in the aetiology T2D. Given 
the nature of the findings (i.e. no interactions were identified), next is a brief 
discussion about how causality of interactions would have been evaluated should 
any have been identified. 
In observational epidemiology, where ‘associations’ are examined, the ‘noise’ 
among free-living populations (i.e. chance, bias, confounding) means that care is 
needed when making causal inferences. Even when there is internal validity of the 
findings observed, how it fits within the context of other sources of evidence and 
its biological plausibility needs to be considered to infer ‘causality.’ There are 
three tools/criteria that I would use to aid this assessment, namely the Bradford 
Hill Criteria, Directed Acyclic Graphs (DAG) and Rothman’s sufficient-
component-cause model. In 1965, Sir Austin Bradford-Hill proposed a series of 
criteria for assessing causality in observation research, which was motivated by 
his attempt to understand the role of smoking in the aetiology of lung cancer.[272] 
This includes consideration of the strength of association, specificity, dose-
response, consistency, temporality, biological plausibility, analogy, coherence and 
experimental evidence. Although widely used in medical epidemiology, a key 
criticism of this approach is that it considers a single exposure at a time, which 
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can be at odds for evaluating conditions of multifactorial nature (e.g. T2D), and 
for determinants of health that are distant from the individual’s biology, such as 
education.[165,273]  
In developing a framework for assessing causality of gene-environment 
interactions, Geneletti al., suggested combining the Bradford-Hill criteria with a 
DAG.[165] They advised DAGs to help visualise the complexity of the interaction 
and Hill’s criteria to determine which edges can be considered causal. 
Alternatively, Rothman in 1976 proposed the ‘sufficient-component-cause model’ 
or ‘causal pie.’[134] This overcame the above problems, as it attributes disease 
development to multiple causes, each called a ‘component cause’ and only a 
complete pie is considered a causal pathway, called a ‘sufficient cause.’ Unlike the 
Bradford-Hill criteria, it does not reduce disease development to a single 
‘component cause’ but recognises that multifactorial conditions may arise from 
an accumulation of variable factors that could potentially differ between people 
but must be present simultaneously to cause the disease. This model resonates 
with research on gene-diet interactions, at least with one hypothesis about the 
synergistic impact of the presence of both genetic and dietary risk factors in the 
development of T2D.  
Specifically for Hill’s criterion of consistency, the findings from this PhD 
demonstrated internal consistency for no interaction based on various methods 
used, including weighted and unweighted GRS, combined GRS and single SNPs 
and in some instances on both multiplicative and additive interaction scales. 
However, although replication would strengthen the reliability of either a null or 
positive interaction finding, whether the dynamic nature of interactions lends to 
be replicated or consistent across what may appear to be demographically similar 
populations, is questionable. This will be further discussed in section 8.7 on 
implications.  
Rothman’s sufficient-component-cause model helps to explain the dynamic 
nature of interactions and offers an alternative explanation for the lack of 
interactions identified within this PhD. It is well accepted that whilst some 
dietary effects persist across the lifespan, some are transitory. This is evident with 
nutritional requirements that adapt to critical periods associated with growth and 
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development, including from infancy to adolescence and during pregnancy. 
Several studies have identified exposure modification by age, including the 
differential effect of cigarette smoking on cancer risk in mice at different 
developmental stages,[274] and that high-fat diets consumed by maternal mice had 
a greater impact on cancers in the offspring than high-fat diets consumed by the 
offspring postnatally.[275] Genetic expression also changes over time, observed at 
the day-to-day level, reflecting constantly changing environmental exposures.[276] 
Indeed, higher order multi-way interactions (e.g. sex-specific effects for the 
interaction between IRS1 and macronutrient intake)[195,277,278] have been 
suggested and these pieces of evidence together suggest that gene-environment 
interactions may occur only during critical periods of time and/or are sensitive to 
other factors such as sex and context. Therefore, it may only be possible to detect 
certain interactions in certain populations at certain times. Rothman’s model may 
help to explain why the absence of gene-diet interactions in this PhD does not 
necessarily preclude the existence of these interactions, but rather that the 
current context in which this particular population is studied may be insufficient 
to bring about a detectable interaction.[222] In other words, either another 
modifier (e.g. sex) is present at a higher degree and may mask the gene-diet 
interactions of interest or that only under certain conditions (presence of another 
modifier) will the interactions of interest become apparent. However, 
methodological limitations such as sample size restrictions did not enable this to 
be tested in the current PhD. 
Certainly, several fields including cancer epidemiology and psychiatry are actively 
researching gene-environment interactions, with several theories supporting its 
existence including the diathesis-stress model, differential susceptibility, 
plasticity alleles, biopsychosocial model and evolutionary developmental 
psychology.[202,279] Across all these fields, similar methodological challenges exist 
in the context of the aforementioned limitations of observational studies. 
Therefore, from a fundamental standpoint, interactions between genes and 
environmental factors including dietary, must contribute to the development of 
multifactorial phenotypes (including diseases). None were identified between the 
specific exposures that were examined in this PhD, for the risk of developing T2D 
in this specific population. Therefore, before causality can be examined, it may be 
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more valuable to evaluate the suitability of the current methods and study designs 
used to examine interactions. And if interactions are identified the clinical 
significance of the magnitude of interaction effect will determine its applicability. 
8.5 Clinical utility of genetic risk information  
Apart from the validity of gene-diet interactions, a commonly asked question is 
whether disclosure of genetic risk information would lead to behaviour change 
and subsequent improvement in health outcomes (clinical utility). Certainly, 
genetic risk may be a potent motivator for behaviour change because of its 
biological accuracy and personal salience, which is consistent with the Health 
Belief Model.[280] Early research indeed indicated that the provision of 
personalised genetic information favourably influenced screening behaviours and 
medication adherence for individuals at risk of familial cancers, often involving 
Mendelian inheritance with high penetrance genetic variants.[281] However, this 
cannot be assumed for the adoption of more complex ‘lifestyle’ health-related 
behaviours, such as dietary modification, that are required to be adopted and 
sustained in order to reduce the risk of developing cardiometabolic disorders 
such as obesity, T2D and cardiovascular disease (CVD).  
 
As an adjunct to this PhD, I led on a systematic review and meta-analysis of RCTs 
undertaken in the context of cardiometabolic disorders (obesity, T2D, CVD) to 
investigate: 1) the effect of genetic risk testing and communication on perceived 
and actual motivation to engage in risk reduction lifestyle modification (diet and 
physical activity); 2) the effect of genetic risk testing and communication on 
actual lifestyle modification and 3) clinical outcomes.[282] From 13 RCTs 
(N=8,426 participants) there were no consistent effect of genetic risk on actual 
motivation for weight loss, perceived motivation for dietary change (control 
compared to genetic risk group standardised mean difference (SMD) −0·15; 95% 
CI −1·03, 0·73, P=0·74) or actual change in dietary behaviour. Similar results 
were observed for actual weight loss (control compared to high genetic risk SMD 
0·29 kg; 95% CI −0·74, 1·31, P=0·58). This review found no clear or consistent 
evidence that genetic risk communication alone either raises motivation or 
translates into actual change in dietary intake or physical activity to reduce the 
risk of cardiometabolic disorders in adults.[282] 
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Our findings were consistent with the updated Cochrane Systematic Review for 
dietary (SMD: 0.12, 95%CI: -0.00 to 0.24, p:0.05) and physical activity 
behaviours (SMD: -0.03, 95%CI: -0.14 to 0.07, p:0.54).[283]  The largest 
European-wide internet based RCT on personalised nutrition (Food4Me, 
N=1,269) also did not observe any difference in dietary intake between groups 
who had received personalised dietary advice according to participant’s current 
dietary intake (L1), phenotypic (weight, BMI, waist circumference and blood 
markers) (L2) or genotypic information (L3), after 6 months (e.g. p value for the 
difference between Healthy Eating Index [HEI] in those in L1 compared to those 
in L2+L3= 0.693).[284] Nevertheless, it did demonstrate that simple 
personalisation, including by information on dietary intake, was more effective in 
promoting healthy eating than conventional dietary advice.[284] This suggests that 
the process of personalisation (i.e. tailoring advice) rather than the tool used to 
convey personalisation (e.g. genes) appears more important in promoting healthy 
eating. To ensure public welfare in engaging with genetic susceptibility 
information, policy makers need to enforce stricter regulation of direct to 
consumer services offering personalised nutrition by genotype. 
8.6 Assessing the causality of diet and disease using genetics 
A related area of interest is the application of genetics in nutritional 
epidemiology, which is helping us to understand the aetiology of cardiometabolic 
conditions, including T2D. Mendelian Randomisation (MR) is a statistical 
method that enables inferences to be made about causal relationships within 
observational studies.[285]   Genes associated with a particular exposure are used 
as genetic proxies for the lifetime environmental exposure of interest without the 
complication of reverse causality and confounding, which are known limitations 
of observational nutrition studies.[286]  
I contributed to a meta-analysis of GWAS studies (as part of the CHARGE 
Consortium, unpublished) that investigated genetic variants associated with 
percentage of energy from protein, fat or carbohydrate intake. The associated 
genetic variants were used to develop genetic instruments to examine the 
respective causal relationship between these macronutrient intake exposures and 
BMI, a strong risk factor for T2D. There was reasonably clear evidence to support 
  
 
195 
causality for higher genetically predicted BMI influencing higher genetically 
predicted protein intake (Table 9-1).  A previous report highlighted that the FTO 
locus, a BMI associated locus, was associated with higher protein intake.[287] This 
is a finding we now extend to other BMI-raising alleles suggesting that higher 
BMI is associated with higher reported protein intake and not specific to FTO. An 
alternative explanation of the findings may be that there is a shared biological 
‘soil’ between macronutrients and BMI. Given that most BMI SNPs act through 
the brain and may be involved in energy homeostasis,[28] perhaps these MR 
findings indicate BMI driving cognitive intake preferences possibly via increasing 
TEI, which protein intake may be a marker for. Secondly, all three genetically 
predicted macronutrients were associated with genetically predicted BMI (Table 
8-1). This is because the genetic variant at FGF21 was included in the genetic 
instrument for all three macronutrients given its shared association. Whether this 
reflects substitution of macronutrients as a proportion of TEI is difficult to assess, 
so, causality between any one specific macronutrient group with BMI cannot be 
determined.  
Table 7-1: Mendelian Randomisation results for the relationship between genetically predicted protein 
intake and genetically predicted BMI 
Genetically predicted exposure Genetically predicted 
outcome (IVW MR) 
Effect estimates  
↑ 1 standard deviation in BMI due to a 94-SNP 
polygenic risk score (excluding FTO) 
↑0.58%TEI from protein 
intake 
SE =0.08, Pivw =9.88E-13 
↑ 1% of TEI from protein intake ↑0.09 kg/m2  (BMI) SE =0.03, Pivw =6.92E-04 
↑ 1% of TEI from fat intake ↑0.05 kg/m2  (BMI) SE =0.02, Pivw =6.92E-04 
↑ 1% of TEI from carbohydrate intake ↓0.06 kg/m2  (BMI) SE =0.01, Pivw =1.12E-09 
Note:  97 SNPs were associated with BMI (Locke et al., 2015) but we included 94 SNPs because 2 had no proxies and 
another genetic variant in FTO locus was excluded.  
Abbreviation: TEI- total energy intake, MR- Mendelian randomisation, IVW- inverse variance weighted 
 
8.7 Implications and recommendations  
 
In summary, the findings from this PhD indicate that none of the gene-diet 
interactions examined within this PhD significantly contribute to the 
development of T2D. During this PhD, the inherent limitations to the research 
methods currently adopted for investigating gene-diet interactions is clear. 
Therefore, improvement in methods is a key priority going forward for this field. 
This and the findings from this PhD lead to several important implications for 
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future research to better understand if gene-diet interactions are truly important 
in the aetiology of T2D. 
Firstly, in conducting the systematic review, where the available literature on 
gene-macronutrient interactions and T2D was critiqued, studies were highly 
heterogeneous and this have been previously highlighted as a barrier to 
meaningful quantitative pooling of data.[154] There has been on-going criticism 
about the quality of studies available (from the review in Chapter 4 and many 
others).[105,173,202] Alongside this, in several projects within this PhD, 
methodological decisions were based on judgement using available knowledge 
rather than previously evaluated best practice such as treating macronutrient 
exposures and the interaction term as linear variables. These issues make it 
difficult to derive clear conclusions about gene-diet interactions. Moreover, 
currently there are no published standards in conducting gene-environment 
interactions, unlike the STREGA statement used for evaluating GWAS.[143] 
Despite on-going methodological developments in this field, there needs to be a 
formally agreed upon standard in conducting gene-environment interactions that 
is accepted by the scientific community, to guide more rigorous future research 
and assist more informed evaluation and interpretation of published interaction 
studies. Efforts are emerging, with a proposed set of guidelines for cancer 
epidemiology,[144] so how well this can be applied to other conditions such as 
diabetes will be of interest. I have also provided some suggestions towards this 
goal, from our own work (Appendix A). 
Secondly, it is clear that in observational nutritional epidemiology examining 
macronutrient intake, associations with disease requires isocaloric macronutrient 
substitution modelling for accuracy and findings to be interpretable. This has 
been neglected within studies of gene-macronutrient interactions, at least within 
the cardiometabolic literature. Although findings from this PhD which compare 
analyses with and without isocaloric macronutrient interactions are not 
materially different (Chapter 4 and 5), it is methodologically more accurate to 
apply isocaloric macronutrient substitution. Therefore, it is the hope that this 
work will provide the impetus for future gene-macronutrient interaction research 
to adopt this practice.     
  
 
197 
Thirdly, even with all the challenges of conducting replication, mentioned in 
Chapter 4 including difficulties in finding the appropriate replication population, 
study design, exposure assessment and modelling of covariates to name a few, 
replication adds to the body of evidence necessary to evaluate gene-diet 
interactions and is an important process. By minimising the possibility of chance 
findings (Winner’s curse) this aims to improve the credibility of findings. 
Although the best form of ‘replication,’ is yet to be defined, some examples of 
approaches that may address the issue of heterogeneity are presented next. 
Recently, a study using UK Biobank to examine the interaction between FTO and 
lifestyle factors on the risk of obesity cleverly divided their population into three 
samples.[107] Although intended to better control for population substructure, the 
consistency in methods enabled appropriate replication and consistency in 
findings between those who were classified as ‘British’ and those more ethnically 
diverse. Together, this strengthened the inference of detected interactions. In 
cases where opportunities to access such large and well-phenotyped databases 
may not be possible, suggestions have been made for accompanying interactions 
with findings using complementary methods (e.g. functional studies in vitro) to 
aid interpretation.  
An alternative method may be to conduct individual participant data (IPD) meta-
analysis that enables harmonisation of terminology, analysis method and 
researcher interpretation using raw participant data (one- stage approach). Tools 
such as DataSHaPER and guidelines such as that written by Maelstrom Research 
have been developed to facilitate retrospective harmonisation between studies, 
[288,289] however this process is resource-intensive. Hence, once platforms such as 
InterConnect (http://www.interconnect-diabetes.eu/) are established, with the 
aim of investigating gene-environment interactions in mind, it will be a valuable 
resource for researchers. Studies from the Emerging Risk Factors Collaboration 
adopt an IDP approach to examine lipid, inflammatory and other markers in the 
development of cardiovascular disease, also offer existing examples 
(http://www.phpc.cam.ac.uk/ceu/erfc/erfc-publications/). Therefore, investing 
time and research into deciding what will be the most valid and feasible method/s 
to constitute a ‘replication,’ will be a valuable pursuit that will resolve this 
problem for the interaction field.  
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Although in this PhD no convincing interactions have been identified, I have 
learnt that a rigorously conducted study with null findings declares more 
influence than a positive finding from a less well-conducted study. I agree with 
others that future interaction studies should start off with the expectation to 
disprove their interactions and only when it is robust to a battery of tests, like 
replication or other, should that interaction be confidently accepted. Despite what 
may be considered a conservative approach, this may be necessary to reinstate 
confidence back into research conducted within this field. 
Fourthly, a recurring theme throughout this thesis is the difficulty in accounting 
for the dynamics of gene-diet interactions (e.g. presence of other factors such as 
age, sex, etc), as explained in section 8.4 on causality. Therefore, this means that 
the existence of gene-diet interaction cannot be fully invalidated even if none 
were identified in our case within a particular population at a particular point in 
time. This was explained by how higher order multi-way interactions exist and 
that current epidemiological methods are limited by their sample size and issues 
such as confounding to detect this. Suggestions have been made about how to 
study this, ranging from using long-term follow-up studies with repeated dietary 
assessment, systems biology, experimental studies under strict regulation of other 
environment exposures, and recall by genotype dietary interventions.[96,120]  
Carvalho-Wells and colleagues used the recall by genotype approach when 
investigating ApoE and fat intake on plasma triglyceride and CRP levels, to 
minimise ‘noise’ and improve statistical power by recruiting participants 
according to their ApoE genotype.[115] Additionally, whilst the method of MR has 
predominantly been used to assess the causal role of a single exposure with a 
single outcome, it may help in determining the causality of gene-diet interactions 
with T2D.[290] To my knowledge, no studies have applied the MR framework in 
examining gene-diet interactions and may be worthwhile to investigate. All 
aforementioned approaches are beyond the scope of present thesis and it is up to 
future studies to investigate how best to do this. 
The GEWIS of macronutrient intake and T2D remain on-going and future plans 
for research have already been described in Chapter 7.  
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Lastly, these findings are important for health professionals who are involved in 
nutrition practice (e.g. clinicians and dietitians) to recognise that no change to 
current clinical or public health advice regarding macronutrient intake and T2D 
prevention, is warranted. Present evidence from gene-diet interaction research 
and studies investigating the clinical utility of genetic risk communication on 
behaviour change gives health professionals evidence not to support the use of 
genetically ‘personalised nutrition’ services that are currently commercially 
available. Nutrition practitioners are responsible for correcting misinformation, 
where necessary, so researchers should strive to reach this target audience. For 
example, I have written articles for an international resource database for 
dietitians, called Practice-based Evidence in Nutrition 
(http://www.pennutrition.com/index.aspx). However, health professionals can 
only do so much as to advise the public, it is therefore under the power of 
policymakers to instate stricter regulations on commercial enterprises to protect 
public safety and welfare. Although a balance between regulation and freedom for 
creativity is needed not to stifle meaningful scientific pursuits in this field, honest 
and realistic communication about the current and future scientific potential of 
this research is necessary.  
 
8.8 Conclusion 
 
The totality of the evidence produced from original research during this PhD has 
meaningfully added to the available literature on gene-diet interactions and T2D, 
to suggest that the particular interactions examined within this PhD do not 
contribute to the aetiology of T2D. Despite the benefits of personalisation in 
nutritional therapy, at present on the basis of the lack of empirical evidence for 
robustly validated gene-diet interactions, currently there is no evidence to 
support genetic personalisation of dietary advice to prevent T2D. This body of 
research represents the most comprehensive and systematic investigation of 
gene-macronutrient interactions for the risk of developing T2D to date, and one I 
thoroughly enjoyed contributing to. Considerable methodological limitations still 
exist in this research field, highlighting the urgent need for re-evaluating how 
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interactions should be studied and validated before definitive conclusions can be 
made about their independent contribution to T2D. In keeping with the view 
proposed by Lancelot Hogben relating to the interdependence of Nature and 
Nurture, which underpins the study of gene-environment interactions, it may 
indeed be time to develop novel methods that also stretch beyond the summing of 
its component parts (namely, genetics and nutrition). 
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List of projects  
 
Projects that I led on 
1. Interaction between genetic variants and macronutrient intake on the risk of developing type 2 
diabetes: systematic review and findings from EPIC- InterAct 
 
2. Interplay between genetic predisposition, macronutrient intake and Type 2 Diabetes incidence. 
Analysis across 8 European countries: EPIC-InterAct Study 
 
3. Interplay between genetic predisposition, food and beverage intake for Type 2 Diabetes 
incidence. Analysis across 8 European countries: EPIC-InterAct Study 
 
4. Genome-wide-interaction study of macronutrient intake and incident Type 2 Diabetes: EPIC-
InterAct Study 
 
5. The effect of communicating the genetic risk of cardiometabolic disorders on motivation and 
actual engagement in preventative lifestyle modification and clinical outcome: a systematic 
review and meta-analysis of randomised controlled trials 
 
Projects that I have contributed to and have been discussed within this thesis 
1. Macronutrient intake genome-wide-association-study (CHARGE Consortium) 
 
Projects that I have contributed to but were not discussed within this thesis 
1. Circulating saturated fatty acid genome-wide-association-study (EPIC-InterAct) 
 
2. Genome-wide-interaction study of circulating polyunsaturated fatty acids and C-Reactive-
Protein (CHARGE Consortium) 
 
3. Genetic risk score and dietary pattern interaction analysis for incident Type 2 Diabetes: EPIC-
InterAct 
 
4. Association between circulating vitamin D and Type 2 Diabetes: EPIC-InterAct 
 
5. Circulating fatty acids and trends in EPIC-Norfolk 
 
 
 
 
  
 
202 
 
 
References 
 
1.  Hogben LT. Genetic Principles in Medicine and Social Science. London: Williams & 
Norgate; 1932.  
2.  Tuomi T, Santoro N, Caprio S, Cai M, Weng J, Groop L. The many faces of diabetes: a 
disease with increasing heterogeneity. Lancet 2014;383(9922):1084–94.  
3.  Florez JC. Leveraging Genetics to Advance Type 2 Diabetes Prevention Identifying 
Individuals at Increased Risk. PLoS Med 2016;1–7.  
4.  Hindy G, Sonestedt E, Ericson U, Jing X-J, Zhou Y, Hansson O, et al. Role of TCF7L2 risk 
variant and dietary fibre intake on incident type 2 diabetes. Diabetologia 
2012;55(10):2646–54.  
5.  Morris AP, Voight BF, Teslovich TM, Ferreira T, Segrè A V, Steinthorsdottir V, et al. Large-
scale association analysis provides insights into the genetic architecture and 
pathophysiology of type 2 diabetes. Nat Genet 2012;44(9):981–90.  
6.  WHO. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. 
Geneva: 1999.  
7.  ADA. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014;37 Suppl 
1(January):S81-90.  
8.  WHO, IDF. Definition and diagnosis of diabetes mellitus and intermediate 
hyperglycaemia. Geneva: 2006.  
9.  WHO. Use of Glycated Haemoglobin ( HbA1c ) in the Diagnosis of Diabetes Mellitus. 
Geneva: 2011.  
10.  ADA. Standards of Medical Care in Diabetes - 2017. Diabetes Care 2017;40 (Suppl.:S44-
47).  
11.  NCD-RisC. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-
based studies with 4·4 million participants. Lancet 2016;387:1513–30.  
12.  IDF. International Diabetes Federation. IDF Diabetes Atlas, 7th edn. Belgium: 2015.  
13.  Fowler MJ. Microvascular and Macrovascular Complications of Diabetes. Clin Diabetes 
2014;29(3):116–22.  
14.  Franks PW, Mccarthy MI. Exposing the exposures responsible for type 2 diabetes and 
obesity. Science 2016;354(6308):69–73.  
15.  Bommer C, Heesemann E, Sagalova V, Manne-Goehler J, Atun R, Bärnighausen T, et al. 
The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness 
study. Lancet Diabetes Endocrinol 2017;8587(17):1–8.  
  
 
203 
16.  World Health Organization. Global Report on Diabetes. 2016.  
17.  Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: 
perspectives on the past, present, and future. Lancet 2014;383(9922):1068–83.  
18.  Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis 
and therapy. Lancet 2010;365(9467):1333–46.  
19.  Mozaffarian D. Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and 
Obesity: A Comprehensive Review. Circulation 2016;133:187–225.  
20.  Bell J a, Kivimaki M, Hamer M. Metabolically healthy obesity and risk of incident type 2 
diabetes: a meta-analysis of prospective cohort studies. Obes Rev 2014;15(6):504–15.  
21.  White M. Population Approaches to Prevention of Type 2 Diabetes. PLoS Med 
2016;13(7):10–3.  
22.  Conklin AI, Monsivais P, Khaw K-T, Wareham NJ, Forouhi NG. Dietary diversity, diet cost, 
and incidence of type 2 diabetes in the United Kingdom: a prospective cohort study. PLoS 
Med 2016;13(7):e1002085.  
23.  Stokols D. Translating Social Ecological Theory into guidelines for community health 
promotion. Am J Heal Promot 1996;10(4):282–98.  
24.  NICE. National Institute for Health and Care Excellence. Preventing type 2 diabetes 
overview [Internet]. Flowchart2017 [cited 2017 May 4];Available from: 
https://pathways.nice.org.uk/pathways/preventing-type-2-diabetes 
25.  Almgren P, Lehtovirta M, Isomaa B, Sarelin L, Taskinen MR, Lyssenko V, et al. Heritability 
and familiality of type 2 diabetes and related quantitative traits in the Botnia Study. 
Diabetologia 2011;54(11):2811–9.  
26.  Willemsen G, Ward KJ, Bell CG, Christensen K, Bowden J, Dalgård C, et al. The 
Concordance and Heritability of Type 2 Diabetes in 34,166 Twin Pairs From International 
Twin Registers: The Discordant Twin (DISCOTWIN) Consortium. Twin Res Hum Genet 
2015;18(6):762–71.  
27.  Mahajan A, Go M, Zheng W, Below J, Gaulton K, Ferreira T. Genome-wide trans-ancestry 
meta-analysis provides insight into the genetic architecture of type 2 diabetes 
susceptibility. Nat Genet 2014;46(3):234–44.  
28.  Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. Genetic studies of body 
mass index yield new insights for obesity biology. Nature 2015;518:197–206.  
29.  Scott R a, Lagou V, Welch RP, Wheeler E, Montasser ME, Luan J, et al. Large-scale 
association analyses identify new loci influencing glycemic traits and provide insight into 
the underlying biological pathways. Nat Genet 2012;44(9):991–1005.  
30.  Lotta L, Gulati P, Day FR, Payne F, Ongen H, van de Bunt M, et al. Integrative genomic 
analysis implicates limited peripheral adipose storage capacity in the pathogenesis of 
human insulin resistance. Nat Genet 2016;49(1):17–26.  
31.  Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh P-R, et al. An atlas of genetic 
correlations across human diseases and traits. Nat Genet 2015;47(11):1236–41.  
32.  Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, et al. 
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat 
Genet 2006;38(3):320–3.  
33.  Wang J, Kuusisto J, Vänttinen M, Kuulasmaa T, Lindström J, Tuomilehto J, et al. Variants 
of transcription factor 7-like 2 (TCF7L2) gene predict conversion to type 2 diabetes in the 
Finnish Diabetes Prevention Study and are associated with impaired glucose regulation 
  
 
204 
and impaired insulin secretion. Diabetologia 2007;50(6):1192–200.  
34.  Fuchsberger C, Flannick J, Teslovich T, Mahajan A, Agarwala V, Gaulton K. The genetic 
architecture of type 2 diabetes. Nature 2016;536(7614):41–7.  
35.  Thomas D. Gene-environment-wide association studies: emerging approaches. Nat Rev 
Genet 2010;11(4):259–72.  
36.  Prevention D. Long-term effects of lifestyle intervention or metformin on diabetes 
development and microvascular complications over 15-year follow-up: the Diabetes 
Prevention Program Outcomes Study. Lancet Diabetes Endocrinol 2015;3(11):866–75.  
37.  Li G, Zhang P, Wang J, An Y, Gong Q, Gregg EW, et al. Cardiovascular mortality , all-cause 
mortality, and diabetes incidence after lifestyle intervention for people with impaired 
glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. 
Lancet Diabetes Endocrinol 2014;8587(14):1–9.  
38.  Lindström J, Peltonen M, Eriksson JG, Ilanne-Parikka P, Aunola S, Keinänen-Kiukaanniemi 
S, et al. Improved lifestyle and decreased diabetes risk over 13 years: Long-term follow-
up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia 
2013;56(2):284–93.  
39.  Knowler W, Barrett-Connor E, Flowler S, Hamman R, Lachin J, Walker E, et al. Reduction 
in the incidence of type 2 diabetess with lifestyle intervention or metformin. N Engl J Med 
2002;346(6):393–403.  
40.  WHO/FAO. Diet, nutrition and the prevention of chronic diseases. Report of a joint 
WHO/FAO Expert Consultation. 2003.  
41.  Dyson P a, Kelly T, Deakin T, Duncan  a, Frost G, Harrison Z, et al. Diabetes UK evidence-
based nutrition guidelines for the prevention and management of diabetes. Diabet Med 
2011;28(11):1282–8.  
42.  Ley SH, Hamdy O, Mohan V, Hu FB. Prevention and management of type 2 diabetes: 
dietary components and nutritional strategies. Lancet 2014;383(9933):1999–2007.  
43.  Martinez-Gonzalez MA, Salas-Salvado J, Estruch R, Corella D, Fito M, Ros E. Benefits of the 
Mediterranean Diet: Insights From the PREDIMED Study. Prog Cardiovasc Dis 
2015;58(1):50–60.  
44.  Cooper AJ, Forouhi NG, Ye Z. Fruit and vegetable intake and type 2 diabetes : EPIC-
InterAct prospective study and meta-analysis. Eur J Clin Nutr 2012;66(10):1082–92.  
45.  Aune D, Norat T, Romundstad P, Vatten LJ. Whole grain and refined grain consumption 
and the risk of type 2 diabetes: A systematic review and dose-response meta-analysis of 
cohort studies. Eur J Epidemiol 2013;28(11):845–58.  
46.  Afshin A, Micha R, Khatibzadeh S, Mozaffarian D. Consumption of nuts and legumes and 
risk of incident ischemic heart disease , stroke , and diabetes : a systematic review and. 
Am J Clin Nutr 2014;100:278–89.  
47.  Gijsbers L, Ding EL, Malik VS, Goede J De, Geleijnse JM, Soedamah-muthu SS. 
Consumption of dairy foods and diabetes incidence : a dose-response meta-analysis of 
observational studies. Am J Clin Nutr 2016;103:1111–24.  
48.  Aune D, Orat T, Romundstad P, Vatten LJ. Dairy products and the risk of type 2 diabetes : 
a systematic review and dose-response meta-analysis of cohort studies. Am J Clin Nutr 
2013;98:1066–83.  
49.  Ding M, Bhupathiraju SN, Chen M, Van Dam RM, Hu FB. Caffeinated and decaffeinated 
coffee consumption and risk of type 2 diabetes: A systematicreview and a dose-response 
meta-analysis. Diabetes Care 2014;37(2):569–86.  
  
 
205 
50.  Yang J, Mao Q-X, Xu H-X, Ma X, Zeng C-Y. Tea consumption and risk of type 2 diabetes 
mellitus: a systematic review and meta-analysis update. BMJ Open 2014;4(7):e005632.  
51.  Wallin A, Di Giuseppe D, Orsini N, Patel PS, Forouhi NG, Wolk A. Fish consumption, 
dietary long-chain n-3 fatty acids, and risk of type 2 diabetes: systematic review and 
meta-analysis of prospective studies. Diabetes Care 2012;35(4):918–29.  
52.  Tamze M, Virtanen J, Gaziano JM. Egg consumption and risk of type 2 diabetes: a meta-
analysis of prospective studies. Br J Nutr 2016;103(2):474–80.  
53.  Imamura F, O’Connor L, Ye Z, Mursu J, Hayashino Y, Bhupathiraju SN, et al. Consumption 
of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and 
incidence of type 2 diabetes: systematic review, meta-analysis, and estimation of 
population attributable fraction. BMJ 2015;351:1–12.  
54.  Hu E a, Pan A, Malik V, Sun Q. White rice consumption and risk of type 2 diabetes: meta-
analysis and systematic review. BMJ 2012;344(March):e1454.  
55.  Pan A, Sun Q, Bernstein AM, Schulze MB, Manson JE, Willett WC, et al. Red meat 
consumption and risk of type 2 diabetes : 3 cohorts of US adults and an updated meta-
analysis. Am J Clin Nutr 2011;194:1088–96.  
56.  Jacobs DR, Tapsell LC. Food, not nutrients, is the fundamental unit in nutrition. Nutr Rev 
2007;65(10):439–50.  
57.  Carlberg C, Campbell MJ. Vitamin D receptor signaling mechanisms: Integrated actions of 
a well-defined transcription factor. Steroids 2013;78(2):127–36.  
58.  Johnston BC, Kanters S, Bandayrel K, Wu P, Naji F, Siemieniuk RA., et al. Comparison of 
Weight Loss Among Named Diet Programs in Overweight and Obese Adults. JAMA 
2014;312(9):923–33.  
59.  Lindström J, Peltonen M, Eriksson JG, Louheranta A, Fogelholm M, Uusitupa M, et al. 
High-fibre, low-fat diet predicts long-term weight loss and decreased type 2 diabetes risk: 
the Finnish Diabetes Prevention Study. Diabetologia 2006;49(5):912–20.  
60.  Martinez JA, Navas-Carretero S, Saris WHM, Astrup A. Personalized weight loss strategies-
the role of macronutrient distribution. Nat Rev Endocrinol 2014;10(12):749–60.  
61.  Hooper L, Abdelhamid A, Moore HJ, Douthwaite W, Skeaff CM, Summerbell CD. Effect of 
reducing total fat intake on body weight: systematic review and meta-analysis of 
randomised controlled trials and cohort studies. BMJ 2012;345:1–15.  
62.  Tobias DK, Chen M, Manson JAE, Ludwig DS, Willett W, Hu FB. Effect of low-fat diet 
interventions versus other diet interventions on long-term weight change in adults: A 
systematic review and meta-analysis. Lancet Diabetes Endocrinol 2015;3(12):968–79.  
63.  Alhazmi A, Stojanovski E, McEvoy M, Garg ML. Macronutrient Intakes and Development 
of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Cohort Studies. J Am Coll 
Nutr 2012;31(4):243–58.  
64.  Mansoor N, Vinknes KJ, Veierød MB, Retterstøl K. Effects of low-carbohydrate diets v. 
low-fat diets on body weight and cardiovascular risk factors: a meta-analysis of 
randomised controlled trials. Br J Nutr 2016;115:466–79.  
65.  Hu T, Mills KT, Yao L, Demanelis K, Eloustaz M, Yancy WS, et al. Systematic Reviews and 
Meta- and Pooled Analyses Effects of Low-Carbohydrate Diets Versus Low-Fat Diets on 
Metabolic Risk Factors : A Meta-Analysis of Randomized Controlled Clinical Trials. Am J 
Epidemiol 2012;176(7):S45-54.  
66.  South Beach Diet [Internet]. 2017;Available from: 
http://www.southbeachdiet.com/diet/dr-agatston/index.jsp 
  
 
206 
67.  Real Meal Revolution: Home of Banting [Internet]. 2017;Available from: 
https://realmealrevolution.com/ 
68.  Naude CE, Schoonees A, Senekal M, Young T, Garner P, Volmink J. Low Carbohydrate 
versus Isoenergetic Balanced Diets for Reducing Weight and Cardiovascular Risk: A 
Systematic Review and Meta-Analysis. PLoS One 2014;9(7):e100652.  
69.  Shai I, Schwarzfuchs D, Henkinm Y, Shahar D, Witkow S, Greenberg I. Weight Loss with a 
Low-Carbohydrate, Mediterranean, or Low-Fat Diet. N Engl J Med 2008;359(3):229–41.  
70.  Schulze MB, Schulz M, Heidemann C, Schienkiewitz A, Hoffmann K, Boeing H. 
Carbohydrate intake and incidence of type 2 diabetes in the European Prospective 
Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Br J Nutr 2008;99(5):1107–
16.  
71.  Rietman A, Schwarz J, Tomé D, Kok FJ, Mensink M. High dietary protein intake, reducing 
or eliciting insulin resistance? Eur J Clin Nutr 2014;68(9):973–9.  
72.  Santesso N, Akl E a, Bianchi M, Mente  a, Mustafa R, Heels-Ansdell D, et al. Effects of 
higher- versus lower-protein diets on health outcomes: a systematic review and meta-
analysis. Eur J Clin Nutr 2012;66(7):780–8.  
73.  Wycherley TP, Moran LJ, Clifton PM, Noakes M, Brinkworth GD. Effects of energy-
restricted high-protein, low-fat compared with standard-protein, low-fat diets: a meta-
analysis of randomized controlled trials 1–3. Am J Clin Nutr 2012;96(2):1281–98.  
74.  Schwingshackl L, Hoffmann G. Long-term effects of low-fat diets either low or high in 
protein on cardiovascular and metabolic risk factors: a systematic review and meta-
analysis. Nutr J 2013;12:48.  
75.  Shang X, Scott D, Hodge AM, English DR, Giles GG, Ebeling PR, et al. Dietary protein intake 
and risk of type 2 diabetes: results from the Melbourne Collaborative Cohort Study and a 
meta-analysis of prospective studies. Am J Clin Nutr 2016;104(5):1352–65.  
76.  Sluijs I, Beulens JWJ, van der A DL, Spijkerman AMW, Grobbee DE, van der Schouw YT. 
Dietary intake of total, animal, and vegetable protein and risk of type 2 diabetes in the 
European Prospective Investigation into Cancer and Nutrition (EPIC)-NL study. Diabetes 
Care 2010;33(1):43–8.  
77.  Ericson U, Sonestedt E, Gullberg B, Hellstrand S, Hindy G, Wirfält E, et al. High intakes of 
protein and processed meat associate with increased incidence of type 2 diabetes. Br J 
Nutr 2013;109(6):1143–53.  
78.  Imamura F, Micha R, Wu JHY, de Oliveira Otto MC, Otite FO, Abioye AI, et al. Effects of 
Saturated Fat, Polyunsaturated Fat, Monounsaturated Fat, and Carbohydrate on Glucose-
Insulin Homeostasis: A Systematic Review and Meta-analysis of Randomised Controlled 
Feeding Trials. PLoS Med 2016;13(7):1–18.  
79.  Chowdhury R, Warnakula S, Kunutsor S, Crowe F, Ward HA, Johnson L, et al. Association 
of Dietary , Circulating , and Supplement Fatty Acids With Coronary Risk : A Systematic 
Review and Meta-analysis. Ann Intern Med 2014;160:398–406.  
80.  de Souza RJ, Mente A, Maroleanu A, Cozma AI, Ha V, Kishibe T, et al. Intake of saturated 
and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, 
and type 2 diabetes: systematic review and meta-analysis of observational studies. BMJ 
2015;351:1–16.  
81.  Mozaffarian D, Micha R, Wallace S. Effects on Coronary Heart Disease of Increasing 
Polyunsaturated Fat in Place of Saturated Fat: A Systematic Review and Meta-Analysis of 
Randomized Controlled Trials. PLoS Med 2010;7(3):1–10.  
  
 
207 
82.  Li Y, Hruby A, Bernstein AM, Ley SH, Wang DD, Chiuve SE, et al. Saturated Fats Compared 
with Unsaturated Fats and Sources of Carbohydrates in Relation to Risk of Coronary Heart 
Disease A Prospective Cohort Study. J Am Coll Cardiol 2015;66(14):1538–48.  
83.  Forouhi NG, Imamura F, Sharp SJ, Koulman A, Schulze MB, Zheng J, et al. Association of 
Plasma Phospholipid n-3 and n-6 Polyunsaturated Fatty Acids with Type 2 Diabetes: The 
EPIC-InterAct Case-Cohort Study. PLoS Med 2016;13(7):1–17.  
84.  Viguiliouk E, Stewart SE, Jayalath VH, Ng AP, Mirrahimi A, de Souza RJ, et al. Effect of 
replacing animal protein with plant protein on glycemic control in diabetes: A systematic 
review and meta-analysis of randomized controlled trials. Nutrients 2015;7(12):9804–24.  
85.  Malik VS, Li Y, Tobias DK, Pan A, Hu FB. Dietary Protein Intake and Risk of Type 2 Diabetes 
in US Men and Women. Am J Epidemiol 2016;183(8):715–28.  
86.  The InterAct Consortium. Dietary fibre and incidence of type 2 diabetes in eight European 
countries: the EPIC-InterAct Study and a meta-analysis of prospective studies. 
Diabetologia 2015;58(7):1394–408.  
87.  Smith CE, Tucker KL. Health benefits of cereal fibre: a review of clinical trials. Nutr Res 
Rev 2011;24:118–31.  
88.  Gibb RD, McRorie JW, Russell DA, Hasselblad V, D'Alessio DA. Psyllium fiber improves 
glycemic control proportional to loss of glycemic control : a meta-analysis of data in 
euglycemic subjects , patients at risk of type 2 diabetes mellitus , and patients being 
treated for type 2 diabetes mellitus. Am J Clin Nutr 2015;102:1604–14.  
89.  Yao B, Fang H, Xu W, Yan Y, Xu H, Liu Y, et al. Dietary fiber intake and risk of type 2 
diabetes: a dose-response analysis of prospective studies. Eur J Epidemiol 2014;29(2):79–
88.  
90.  Rylander R. Letters to the Editor: high protein, low carbohydrate and mineral balance. Am 
J Clin Nutr 2011;93:1152–6.  
91.  Calton JB. Prevalence of micronutrient deficiency in popular diet plans. J Int Soc Sports 
Nutr 2010;7(1):24.  
92.  Müller M, Kersten S. Nutrigenomics : goals and strategies. Nat Rev Genet 
2003;4(April):315–22.  
93.  Hunter DJ. Gene-environment interactions in human diseases. Nat Rev Genet 
2005;6(4):287–98.  
94.  Williams RA, Mamotte CDS, Burnett JR. Phenylketonuria: an inborn error of phenylalanine 
metabolism. Clin Biochem Rev 2008;29(1):31–41.  
95.  Franks PW, Pearson E, Florez JC. Gene-environment and gene-treatment interactions in 
type 2 diabetes: progress, pitfalls, and prospects. Diabetes Care 2013;36(5):1413–21.  
96.  Franks PW, Paré G. Putting the Genome in Context: Gene-Environment Interactions in 
Type 2 Diabetes. Curr Diab Rep 2016;16(7):57.  
97.  Gibney MJ, Walsh MC. The future direction of personalised nutrition: my diet, my 
phenotype, my genes. Proc Nutr Soc 2013;72(2):219–25.  
98.  Ferguson LR, De Caterina R, Görman U, Allayee H, Kohlmeier M, Prasad C, et al. Guide and 
Position of the International Society of Nutrigenetics/Nutrigenomics on Personalised 
Nutrition: Part 1 - Fields of Precision Nutrition. J Nutrigenet Nutrigenomics 2016;9:12–27.  
99.  Martínez JA. Perspectives on personalized nutrition for obesity. J Nutrigenet 
Nutrigenomics 2014;7(1):1–3.  
100.  MRC. Stratified Medicine Initiative- call for proposals for disease-focused partnerships to 
  
 
208 
stratify for patient benefit [Internet]. [cited 2017 Mar 16];Available from: 
https://www.mrc.ac.uk/funding/browse/smi/stratified-medicine-initiative-disease-
focused-partnerships-for-patient-benefits/ 
101.  The White House Factsheet: President Obama’s Precision Medicine Initiative [Internet]. 
[cited 2017 Mar 16];Available from: https://obamawhitehouse.archives.gov/the-press-
office/2015/01/30/fact-sheet-president-obama-s-precision-medicine-initiative 
102.  Rhea M, Bettles C. Future Changes Driving Dietetics Workforce Supply and Demand: 
Future Scan 2012-2022. J Acad Nutr Diet 2012;112(3):S10–24.  
103.  García-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, et al. NAT2 
slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the 
Spanish Bladder Cancer Study and meta-analyses. Lancet 2005;366(9486):649–59.  
104.  Caspi A, Sugden K, Moffitt T, Taylor A, Craig IW, Harrington H, et al. Influence of life stress 
on depression: moderation by a polymorphism in the 5-HTT gene. Science 
2003;301(5631):386–9.  
105.  Duncan LE, Keller MC. A Critical Review of the First 10 Years of Candidate Gene-by -
Environment Interaction Research in Psychiatry. Am J Psychiatry 2011;168:1041–9.  
106.  Kilpeläinen TO, Qi L, Brage S, Sharp SJ, Sonestedt E, Demerath E, et al. Physical activity 
attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 
adults and 19,268 children. PLoS Med 2011;8(11):e1001116.  
107.  Young AI, Wauthier F, Donnelly P. Multiple novel gene-by-environment interactions 
modify the effect of FTO variants on body mass index. Nat Commun 2016;7(12724):1–12.  
108.  Celis-Morales C, Marsaux CFM, Livingstone KM, Navas-Carretero S, San-Cristobal R, 
O’Donovan CB, et al. Physical activity attenuates the effect of the FTO genotype on 
obesity traits in European adults: The Food4Me study. Obesity 2016;24(4):962–9.  
109.  Livingstone KM, Celis-Morales C, Papandonatos GD, Erar B, Florez JC, Jablonski K a, et al. 
FTO genotype and weight loss: systematic review and meta-analysis of 9563 individual 
participant data from eight randomised controlled trials. BMJ 2016;354(4707):1–11.  
110.  Qi Q, Bray G a, Smith SR, Hu FB, Sacks FM, Qi L. Insulin receptor substrate 1 gene 
variation modifies insulin resistance response to weight-loss diets in a 2-year randomized 
trial: the Preventing Overweight Using Novel Dietary Strategies (POUNDS LOST) trial. 
Circulation 2011;124(5):563–71.  
111.  Uusitupa M. Gene-diet interaction in relation to the prevention of obesity and type 2 
diabetes: evidence from the Finnish Diabetes Prevention Study. Nutr Metab Cardiovasc 
Dis 2005;15(3):225–33.  
112.  Florez J, Jablonski K, Bayley N, Pollin T, Bakker PIW De, Ph D, et al. TCF7L2 Polymorphisms 
and Progression to Diabetes in the Diabetes Prevention Program. N Engl J Med 
2006;355(3):241–50.  
113.  Jablonski KA, Mcateer JB, Bakker PIW De, Franks PW, Pollin TI, Hanson RL, et al. Common 
Variants in 40 Genes Assessed for Diabetes Incidence and Response to Metformin and 
Lifestyle Intervention in the Diabetes Prevention Program. Diabetes 2010;59:2672–81.  
114.  Qi B, Bray GA, Hu FB, Sacks FM, Qi L. Weight-loss diets modify glucose-dependent 
insulinotropic polypeptide receptor rs2287019 genotype effects on changes in body 
weight, fasting glucose, and insulin resistance: The preventing overweight using novel 
dietary strategies trial. Am J Clin Nutr 2012;95(2):506–13.  
115.  Carvalho-Wells AL, Jackson KG, Lockyer S, Lovegrove JA, Minihane AM. APOE genotype 
influences triglyceride and C-reactive protein responses to altered dietary fat intake in UK 
  
 
209 
adults. Am J Clin Nutr 2012;96(6):1447–53.  
116.  Fallaize R, Celis-Morales C, Macready AL, Marsaux CF, Forster H, O’Donovan C, et al. The 
effect of the apolipoprotein E genotype on response to personalized dietary advice 
intervention: findings from the Food4Me randomized controlled trial. Am J Clin Nutr 
2016;104(3):827–36.  
117.  Harrington JM, Phillips CM. Nutrigenetics: bridging two worlds to understand type 2 
diabetes. Curr Diab Rep 2014;14(4):477.  
118.  Kilpeläinen TO. Common Sources of Bias in Gene–Lifestyle Interaction Studies of 
Cardiometabolic Disease. Curr Nutr Rep 2013;2(4):251–7.  
119.  Cornelis MC, Hu FB. Gene-environment interactions in the development of type 2 
diabetes: recent progress and continuing challenges. Annu Rev Nutr 2012;32(April):245–
59.  
120.  Aschard H, Lutz S, Maus B, Duell EJ, Fingerlin TE, Chatterjee N, et al. Challenges and 
opportunities in genome-wide environmental interaction (GWEI) studies. Hum Genet 
2012;131(10):1591–613.  
121.  Luan JA, Wong MY, Day NE, Wareham NJ. Sample size determination for studies of gene-
environment interaction. Int J Epidemiol 2001;30(5):1035–40.  
122.  Wong M, Day N, Luan J, Chan K, Wareham N. The detection of gene-environment 
interaction for continuous traits: should we deal with measurement error by bigger 
studies or better measurement? Int J Epidemiol 2003;32(1):51–7.  
123.  Wei W-H, Hemani G, Haley CS. Detecting epistasis in human complex traits. Nat Rev 
Genet 2014;15(11):722–33.  
124.  Franks PW. Gene × environment interactions in type 2 diabetes. Curr Diab Rep 
2011;11(6):552–61.  
125.  Dudbridge F. Power and predictive accuracy of polygenic risk scores. PLoS Genet 
2013;9(3):e1003348.  
126.  Sul JH, Bilow M, Yang W-Y, Kostem E, Furlotte N, He D, et al. Accounting for Population 
Structure in Gene-by-Environment Interactions in Genome-Wide Association Studies 
Using Mixed Models. PLoS Genet 2016;12(3):e1005849.  
127.  VanderWeele TJ, Ko YA, Mukherjee B. Environmental confounding in gene-environment 
interaction studies. Am J Epidemiol 2013;178(1):144–52.  
128.  Keller MC. Gene × environment interaction studies have not properly controlled for 
potential confounders: The problem and the (simple) solution. Biol Psychiatry 
2014;75(1):18–24.  
129.  Shieh G. Clarifying the role of mean centring in multicollinearity of interaction effects. Br J 
Math Stat Psychol 2011;64(3):462–77.  
130.  Kutz G. Nutrigenetic Testing. Tests Purchased from Four Web Sites Mislead Consumers. 
USA: 2006.  
131.  Green R, Farahany N. The FDA is overcautious on consumer genomics. Nature 
2014;505:286–7.  
132.  Hogarth S, Javitt G, Melzer D. The current landscape for direct-to-consumer genetic 
testing: legal, ethical, and policy issues. Annu Rev Genomics Hum Genet 2008;9:161–82.  
133.  ACCE Model Process for Evaluating Genetic Tests [Internet]. CDC [cited 2015 May 
9];Available from: http://www.cdc.gov/genomics/gtesting/ACCE/ 
  
 
210 
134.  Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. 3rd Ed. USA: Lippincott 
Williams & Wilkins; 2008.  
135.  VanderWeele TJ. Explanation in Causal Inference: Methods for Mediation and Interaction. 
USA: Oxford University Press; 2015.  
136.  VanderWeele TJ, Robins JM. Four types of effect modification: a classification based on 
directed acyclic graphs. Epidemiology 2007;18(5):561–8.  
137.  Knol MJ, Van Der Tweel I, Grobbee DE, Numans ME, Geerlings MI. Estimating interaction 
on an additive scale between continuous determinants in a logistic regression model. Int J 
Epidemiol 2007;36(5):1111–8.  
138.  Knol MJ, VanderWeele TJ, Groenwold RHH, Klungel OH, Rovers MM, Grobbee DE. 
Estimating measures of interaction on an additive scale for preventive exposures. Eur J 
Epidemiol 2011;26(6):433–8.  
139.  Clayton DG. Prediction and interaction in complex disease genetics: Experience in type 1 
diabetes. PLoS Genet 2009;5(7):1–6.  
140.  Markowitz SB, Levin SM, Miller A, Morabia A. Asbestos, Asbestosis, Smoking, and Lung 
Cancer. New Findings from the North American Insulator Cohort. Am J Respir Crit Care 
Med 2013;188(1):90–6.  
141.  Knol MJ, VanderWeele TJ. Recommendations for presenting analyses of effect 
modification and interaction. Int J Epidemiol 2012;41(2):514–20.  
142.  Cornelis MC. Gene-Diet Interactions in Type 2 Diabetes. Curr Nutr Rep 2014;3(4):302–23.  
143.  Little J, Higgins JPT, Ioannidis JPA, Moher D, Gagnon F, von Elm E, et al. Strengthening the 
reporting of genetic association studies (STREGA): an extension of the STROBE Statement. 
Hum Genet 2009;125(2):131–51.  
144.  Boffetta P, Winn DM, Ioannidis JP, Thomas DC, Little J, Smith GD, et al. Recommendations 
and proposed guidelines for assessing the cumulative evidence on joint effects of genes 
and environments on cancer occurrence in humans. Int J Epidemiol 2012;41(May):686–
704.  
145.  Little J, Manolio T, Melzer D, Minelli C, Pharoah P, Sanderson S, et al. The HuGENet TM 
HuGE Review Handbook , version 1.0. 2006.  
146.  Pearson TA, Manolio TA. How to interpret a genome-wide association study. JAMA 
2008;299(11):1335–44.  
147.  Holmes M V., Newcombe P, Hubacek JA., Sofat R, Ricketts SL, Cooper J, et al. Effect 
modification by population dietary folate on the association between MTHFR genotype, 
homocysteine, and stroke risk: A meta-analysis of genetic studies and randomised trials. 
Lancet 2011;378(9791):584–94.  
148.  Qi Q, Chu AY, Kang JH, Jensen MK, Curhan GC, Pasquale LR, et al. Sugar-sweetened 
beverages and genetic risk of obesity. N Engl J Med 2012;367(15):1387–96.  
149.  Dudbridge F. Polygenic Epidemiology Genetic Epidemiology. Genet Epidemiol 
2016;40:268–72.  
150.  Aschard H. A perspective on interaction effects in genetic association studies. Genet 
Epidemiol 2016;40(8):678–88.  
151.  Gong J, Hutter CM, Newcomb PA, Ulrich CM, Bien SA, Campbell PT, et al. Genome-Wide 
Interaction Analyses between Genetic Variants and Alcohol Consumption and Smoking 
for Risk of Colorectal Cancer. PLoS Genet 2016;12(10):e1006296.  
152.  Budin-Ljøsne I, Soye KJ, Tassé AM, Knoppers BM, Harris JR. Genotype-driven recruitment: 
  
 
211 
a strategy whose time has come? BMC Med Genomics 2013;6(1):19.  
153.  Nettleton JA, Follis JL, Ngwa JS, Smith CE, Ahmad S, Tanaka T, et al. Gene × dietary 
pattern interactions in obesity: Analysis of up to 68 317 adults of European ancestry. Hum 
Mol Genet 2015;24(16):4728–38.  
154.  Palla L, Higgins JPT, Wareham NJ, Sharp SJ. Challenges in the use of literature-based 
meta-analysis to examine gene-environment interactions. Am J Epidemiol 
2010;171(11):1225–32.  
155.  Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European Prospective 
Investigation into Cancer and Nutrition (EPIC): study populations and data collection. 
Public Health Nutr 2002;5(6B):1113–24.  
156.  Langenberg C, Sharp S, Forouhi NG, Franks PW, Schulze MB, Kerrison N, et al. Design and 
cohort description of the InterAct Project: an examination of the interaction of genetic 
and lifestyle factors on the incidence of type 2 diabetes in the EPIC Study. Diabetologia 
2011;54(9):2272–82.  
157.  Prentice RL. A case-cohort design for epidemiologic cohort studies and disease 
prevention trials. Biometrika 1986;73(1):1–11.  
158.  Slimani N, Deharveng G, Unwin I, Southgate DAT, Vignat J, Skeie G, et al. The EPIC 
nutrient database project (ENDB): a first attempt to standardize nutrient databases 
across the 10 European countries participating in the EPIC study. Eur J Clin Nutr 
2007;61(9):1037–56.  
159.  Kroke A, Klipstein-grobusch K, Voss S, Möseneder J, Thielecke F, Noack R, et al. Validation 
of a self-administered food-frequency questionnaire administered in the European 
Prospective Investigation into Cancer and Nutrition (EPIC) Study: comparison of energy, 
protein, and macronutrient intakes estimated with the doubly labeled water,. Am J Clin 
Nutr 1999;70:439–47.  
160.  Bingham S, Welch A, Day K, Cassidy A. Comparison of dietary assessment methods in 
nutritional epidemiology: weighed Records V. 24 H Recalls , Food-Frequency and 
estimated-diet records. Br J Nutr 1994;72:619–43.  
161.  Bingham S, Cassidy  A, Cole TJ, Welch A, Runswick SA, Black AE, et al. Validation of 
weighed records and other methods of dietary assessment using the 24 h urine nitrogen 
technique and other biological markers. Br J Nutr 1995;73:531–50.  
162.  Forouhi NG, Koulman A, Sharp SJ, Imamura F, Kröger J, Schulze MB, et al. Differences in 
the prospective association between individual plasma phospholipid saturated fatty acids 
and incident type 2 diabetes: the EPIC-InterAct case-cohort study. Lancet Diabetes 
Endocrinol 2014;8587(14):1–9.  
163.  Wang LY, Summerhill K, Rodriguez-Canas C, Mather I, Patel P, Eiden M, et al. 
Development and validation of a robust automated analysis of plasma phospholipid fatty 
acids for metabolic phenotyping of large epidemiological studies. Genome Med 
2013;5(4):39.  
164.  Onland-Moret NC, van der A DL, van der Schouw YT, Buschers W, Elias SG, van Gils CH, et 
al. Analysis of case-cohort data: a comparison of different methods. J Clin Epidemiol 
2007;60(4):350–5.  
165.  Geneletti S, Gallo V, Porta M, Khoury MJ, Vineis P. Assessing causal relationships in 
genomics: From Bradford-Hill criteria to complex gene-environment interactions and 
directed acyclic graphs. Emerg Themes Epidemiol 2011;8(1):5.  
166.  Kirkwood BR, Sterne JA. Essential Medical Statistics. Oxford, UK: Blackwell Publishing 
  
 
212 
Company; 2013.  
167.  Rhee JJ, Sampson L, Cho E, Hughes MD, Hu FB, Willett WC. Comparison of methods to 
account for implausible reporting of energy intake in epidemiologic studies. Am J 
Epidemiol 2015;181(4):225–33.  
168.  Willett WC. Nutritional epidemiology. 3rd ed. New York: Oxford University Press; 2013.  
169.  Zheng J-S, Arnett DK, Lee Y-C, Shen J, Parnell LD, Smith CE, et al. Genome-wide 
contribution of genotype by environment interaction to variation of diabetes-related 
traits. PLoS One 2013;8(10):e77442.  
170.  Wirstrom T, Hilding A, Hu H, Ostenson C-G, Bjorklund A. Consumption of whole grain 
reduces risk of deteriorating glucose tolerance, including progression to prediabetes. Am 
J Clin Nutr 2013;97:179–87.  
171.  Fisher E, Boeing H, Fritsche A, Doering F, Joost H-G, Schulze MB. Whole-grain 
consumption and transcription factor-7-like 2 ( TCF7L2) rs7903146: gene-diet interaction 
in modulating type 2 diabetes risk. Br J Nutr 2009;101(4):478–81.  
172.  Cornelis MC, Qi L, Kraft P, Hu FB. TCF7L2 , dietary carbohydrate and risk of type 2 
diabetes in US. Am J Clin Nutr 2009;89:1256–62.  
173.  Franks PW, Mesa J-L, Harding AH, Wareham NJ. Gene-lifestyle interaction on risk of type 
2 diabetes. Nutr Metab Cardiovasc Dis 2007;17(2):104–24.  
174.  Price AL, Zaitlen NA, Reich D, Patterson N. New approaches to population stratification in 
genome-wide association studies. Nat Rev Genet 2010;11(7):459–63.  
175.  Hu FB, Stampfer MJ, Rimm E, Ascherio A, Rosner BA, Spiegelman D, et al. Dietary fat and 
coronary heart disease: a comparison of approaches for adjusting for total energy intake 
and modeling repeated dietary measurements. Am J Epidemiol 1999;149(6):531–40.  
176.  Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of 
Observational Studies in Epidemiology A proposal for reporting. JAMA 
2000;283(15):2008–12.  
177.  Stewart L, Moher D, Shekelle P. Why prospective registration of systematic reviews 
makes sense. Syst Rev 2012;1(7):1–4.  
178.  Lunn J, Theobald H. The health effects of dietary unsaturated fatty acids. 2006.  
179.  SACN. Draft Carbohydrates and Health report. 2014.  
180.  Fardet A. New hypotheses for the health-protective mechanisms of whole-grain cereals: 
what is beyond fibre? Nutr Res Rev 2010;23(1):65–134.  
181.  Moura FF De, Lewis KD, Falk MC. Applying the FDA Definition of Whole Grains to the 
Evidence for Cardiovascular Disease Health Claims. J Nutr 2009;139:2220S–2226S.  
182.  Corella D, Tai ES, Sorlí J V, Chew SK, Coltell O, Sotos-prieto M, et al. Association between 
the APOA2 promoter polymorphism and body-weight in Mediterranean and Asian 
populations. Replication of a gene-saturated fat interaction. Int J Obes (Lond) 
2011;35(5):666–75.  
183.  Pisabarro RE, Sanguinetti C, Stoll M, Prendez D. High Incidence of Type 2 Diabetes in 
Peroxisome Proliferator – Activated Receptor y2 Pro12Ala Carriers Exposed to a High 
Chronic Intake of Trans Fatty Acids and Saturated Fatty Acids. Diabetes Care 
2004;27(9):2251–2.  
184.  Sterne JA, Higgins JPT, Reeves BC. A Cochrane Risk Of Bias Assessment Tool : for Non- 
Randomized Studies of Interventions ( ACROBAT-NRSI ). 2014.  
  
 
213 
185.  Salanti G, Amountza G, Ntzani EE, Ioannidis JP a. Hardy-Weinberg equilibrium in genetic 
association studies: an empirical evaluation of reporting, deviations, and power. Eur J 
Hum Genet 2005;13(7):840–8.  
186.  Fisher E, Schreiber S, Joost H, Boeing H, Do F. A Two-Step Association Study Identifies 
CAV2 rs2270188 Single Nucleotide Polymorphism Interaction with Fat Intake in Type 2 
Diabetes Risk. J Nutr 2011;141:177–81.  
187.  Slimani N, Bingham S, Runswick S, Ferrari P, Day NE, Welch A., et al. Group level 
validation of protein intakes estimated by 24-hour diet recall and dietary questionnaires 
against 24-hour urinary nitrogen in the European Prospective Investigation into Cancer 
and Nutrition (EPIC) calibration study. Cancer Epidemiol Biomarkers Prev 2003;12(8):784–
95.  
188.  Hoffmann K, Kroke A, Klipstein-Grobusch K, Boeing H. Standardization of dietary intake 
measurements by nonlinear calibration using short-term reference data. Am J Epidemiol 
2002;156(9):862–70.  
189.  Villegas R, Goodloe RJ, McClellan BE, Boston J, Crawford DC. Gene-carbohydrate and 
gene-fiber interactions and type 2 diabetes in diverse populations from the National 
Health and Nutrition Examination Surveys ( NHANES ) as part of the Epidemiologic 
Architecture for Genes Linked to Environment ( EAGLE ) study. BMC Genet 
2014;15(69):1–8.  
190.  Zheng J-S, Arnett DK, Parnell LD, Smith CE, Li D, Borecki IB, et al. Modulation by dietary 
fat and carbohydrate of IRS1 association with type 2 diabetes traits in two populations of 
different ancestries. Diabetes Care 2013;36(9):2621–7.  
191.  Mansego ML, Martínez F, Martínez-Larrad MT, Zabena C, Rojo G, Morcillo S, et al. 
Common variants of the liver fatty acid binding protein gene influence the risk of type 2 
diabetes and insulin resistance in Spanish population. PLoS One 2012;7(3):e31853.  
192.  Zheng J-S, Huang T, Li K, Chen Y, Xie H, Xu D, et al. Modulation of the Association between 
the PEPD Variant and the Risk of Type 2 Diabetes by n-3 Fatty Acids in Chinese Hans. J 
Nutrigenet Nutrigenomics 2015;8(1):36–43.  
193.  Nelson TL, Fingerlin TE, Moss LK, Barmada MM, Ferrell RE, Norris JM. The peroxisome 
proliferator-activated receptor gamma coactivator-1 Alpha Gene (PGC-1a) is not 
associated with Type 2 diabetes mellitus or body mass index among hispanic and non 
hispanic whites from Colorado. Exp Clin Endocrinol diabetes 2007;115:268–75.  
194.  Sonestedt E, Lyssenko V, Ericson U, Gullberg B, Wirfält E, Groop L, et al. Genetic variation 
in the glucose-dependent insulinotropic polypeptide receptor modifies the association 
between carbohydrate and fat intake and risk of type 2 diabetes in the Malmo Diet and 
Cancer cohort. J Clin Endocrinol Metab 2012;97(5):E810-8.  
195.  Ericson U, Rukh G, Stojkovic I, Sonestedt E, Gullberg B, Wirfa E, et al. Sex-specific 
interactions between the IRS1 polymorphism and intakes of carbohydrates and fat on 
incident type 2 diabetes. Am J Clin Nutr 2013;97:208–16.  
196.  Lamri A, Abi Khalil C, Jaziri R, Velho G, Lantieri O, Vol S, et al. Dietary fat intake and 
polymorphisms at the PPARG locus modulate BMI and type 2 diabetes risk in the 
D.E.S.I.R. prospective study. Int J Obes 2012;36(2):218–24.  
197.  Cho YS, Chen C-H, Hu C, Long J, Ong RTH, Sim X, et al. Meta-analysis of genome-wide 
association studies identifies eight new loci for type 2 diabetes in east Asians. Nat Genet 
2012;44(1):67–72.  
198.  Nelson TL, Fingerlin TE, Moss LK, Barmada MM, Ferrell RE, Norris JM. Association of the 
peroxisome proliferator-activated receptor gamma gene with type 2 diabetes mellitus 
  
 
214 
varies by physical activity among non-Hispanic whites from Colorado. Metabolism 
2007;56(3):388–93.  
199.  Simonds NI, Ghazarian AA, Pimentel CB, Schully SD, Ellison GL, Gillanders EM, et al. 
Review of the Gene-Environment Interaction Literature in Cancer: What Do We Know? 
Genet Epidemiol 2016;40(5):356–65.  
200.  Franks PW, Shungin D. The interplay of lifestyle and genetic susceptibility in Type 2 
diabetes risk. Diabetes Manag 2011;1(3):299–307.  
201.  Hoggart CJ, Clark TG, Iorio M De, Whittaker JC, Balding DJ. Genome-Wide Significance for 
Dense SNP and Resequencing Data. Genet Epidemiol 2008;32:179–85.  
202.  Hutter CM, Mechanic LE, Chatterjee N, Kraft P, Gillanders EM, Abnet CC, et al. Gene-
environment interactions in cancer epidemiology: A national cancer institute think tank 
report. Genet Epidemiol 2013;37:643–57.  
203.  Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a 
correlation matrix. Heredity (Edinb) 2005;95(3):221–7.  
204.  Knol MJ, Le Cessie S, Algra A, Vandenbroucke JP, Groenwold RHH. Overestimation of risk 
ratios by odds ratios in trials and cohort studies: Alternatives to logistic regression. CMAJ 
2012;184(8):895–9.  
205.  Cornelis MC, Tchetgen EJT, Liang L, Qi L, Chatterjee N, Hu FB, et al. Gene-Environment 
Interactions in Genome-Wide Association Studies : A Comparative Study of Tests Applied 
to Empirical Studies of Type 2 Diabetes. Am J Epidmiol 2012;175(3):191–202.  
206.  Midthune D, Carroll RJ, Freedman LS, Kipnis V. Measurement error models with 
interactions. Biostatistics 2016;17:277–90.  
207.  Scott RA, Chu AC, Grarup N, Manning AK, Hivert M-F, Shungin D, et al. No interactions 
between previously associated 2-hour glucose gene variants and physical activity or BMI 
on 2-hour glucose levels. Diabetes 2012;61(5):1291–6.  
208.  Van Horn L, Carson JAS, Appel LJ, Burke LE, Economos C, Karmally W, et al. 
Recommended Dietary Pattern to Achieve Adherence to the American Heart 
Association/American College of Cardiology (AHA/ACC) Guidelines: A Scientific Statement 
from the American Heart Association. Circulation 2016;134(22):e505–29.  
209.  Li SX, Imamura F, Ye Z, Schulze MB, Zheng J. Interaction between genes and 
macronutrient intake on the risk of developing type 2 diabetes: systematic review and 
findings from EPIC- InterAct. Am J Clin Nutr 2017;106(1):263–75.  
210.  White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and 
guidance for practice. Stat Med 2011;30(July 2010):377–99.  
211.  Sterne J a C, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple 
imputation for missing data in epidemiological and clinical research: potential and pitfalls. 
BMJ 2009;338(July):b2393.  
212.  Sluijs I, Beulens JWJ, Schouw YT Van Der, A DL Van Der, Buckland G, Kuijsten A, et al. 
Dietary Glycemic Index , Glycemic Load, and Digestible Carbohydrate Intake Are Not 
Associated with Risk of Type 2 Diabetes in Eight European Countries. J Nutr 2013;143:93–
9.  
213.  van Nielen M, Feskens EJM, Mensink M, Sluijs I, Molina E, Amiano P, et al. Dietary protein 
intake and incidence of type 2 diabetes in Europe: the EPIC-InterAct Case-Cohort Study. 
Diabetes Care 2014;37(7):1854–62.  
214.  Rukh G, Sonestedt E, Melander O, Hedblad B, Wirfält E, Ericson U, et al. Genetic 
susceptibility to obesity and diet intakes: Association and interaction analyses in the 
  
 
215 
Malmö Diet and Cancer Study. Genes Nutr 2013;8(6):535–47.  
215.  Ankarfeldt MZ, Larsen SC, Ängquist L, Husemoen LLN, Roswall N, Overvad K, et al. 
Interaction between genetic predisposition to adiposity and dietary protein in relation to 
subsequent change in body weight and waist circumference. PLoS One 
2014;9(10):e110890.  
216.  Goni L, Cuervo M, Milagro FI, Martínez JA. A genetic risk tool for obesity predisposition 
assessment and personalized nutrition implementation based on macronutrient intake. 
Genes Nutr 2015;10(1):445.  
217.  Wang T, Huang T, Zheng Y, Rood J, Bray GA, Sacks FM, et al. Genetic variation of fasting 
glucose and changes in glycemia in response to 2-year weight-loss diet intervention: the 
POUNDS LOST trial. Int J Obes 2016;40(7):1164–9.  
218.  Dudbridge F, Fletcher O. Gene-environment dependence creates spurious gene-
environment interaction. Am J Hum Genet 2014;95(3):301–7.  
219.  Jacobs DR, Gross MD, Tapsell LC. Food synergy: An operational concept for understanding 
nutrition. In: Am J Clin Nutr. 2009. page 1543–8. 
220.  Brunkwall L, Chen Y, Hindy G, Rukh G, Ericson U, Barroso I, et al. Sugar-sweetened 
beverage consumption and genetic predisposition to obesity in 2 Swedish cohorts. Am J 
Clin Nutr 2016;104(3):809–15.  
221.  The InterAct Consortium. Investigation of gene–diet interactions in the incretin system 
and risk of type 2 diabetes: the EPIC-InterAct study. Diabetologia 2016;59(12):2613–21.  
222.  VanderWeele TJ, Richardson TS. General theory for interactions in sufficient cause 
models with dichotomous exposures. Ann Stat 2012;40(4):2128–61.  
223.  Patel PS, Sharp SJ, Jansen E, Luben RN, Khaw K, Wareham NJ, et al. Fatty acids measured 
in plasma and erythrocyte-membrane phospholipids and derived by food-frequency 
questionnaire and the risk of new-onset type 2 diabetes : a pilot study in the European 
Prospective Investigation into Cancer and Nutrition ( EPIC )–Norfolk. Am J Clin Nutr 
2010;92:1214–22.  
224.  Kröger J, Zieteman V, Enzenback C, Weikert C, Jansen EHJM, Döring F, et al. Erythrocyte 
membrane phospholipid fatty acids , desaturase activity , and dietary fatty acids in 
relation to risk of type 2 diabetes in the European Prospective Investigation into Cancer 
and nutrition (EPIC)-Potsdam Study. Am J Clin Nutr 2011;93(1):127–42.  
225.  Qi L, Cornelis MC, Zhang C, Dam RM Van, Hu FB. Genetic predisposition , Western dietary 
pattern , and the risk of type 2 diabetes in men. Am J Clin Nutr 2009;89:1453–8.  
226.  Bingham S, Day N. Using biochemical markers to assessthe validity of prospective dietary 
assessment methods and the effect of energy adjustment. Am J Clin Nutr 1997;65:1130S–
7S.  
227.  Food Standards Agency. Food portion sizes. 2nd ed. UK: HMSO; 2002.  
228.  Newson R, ALSPAC study team. Multiple-test procedures and smile plots. Stata J 
2003;3(2):109–32.  
229.  Schwingshackl L, Schwedhelm C, Hoffmann G, Lampousi A-M, Knüppel S, Iqbal K, et al. 
Food groups and risk of type 2 diabetes mellitus: a systematic review and meta-analysis 
of prospective studies. Eur J Epidemiol 2017;32:363–75.  
230.  Sluijs I, Forouhi NG, Beulens JWJ, Schouw YT Van Der, Agnoli C, Arriola L, et al. The 
amount and type of dairy product intake and incident type 2 diabetes : results from the 
EPIC-InterAct Study. Am J Clin Nutr 2012;96:382–90.  
  
 
216 
231.  Bendinelli B, Palli D, Masala G, Sharp SJ, Schulze MB, Guevara M, et al. Association 
between dietary meat consumption and incident type 2 diabetes: The EPIC-InterAct 
study. Diabetologia 2013;56(1):47–59.  
232.  Patel PS, Forouhi NG, Kuijsten A, Schulze MB, Woudenbergh GJ Van, Ardanaz E, et al. The 
prospective association between total and type of fish intake and type 2 diabetes in 8 
European countries : EPIC-InterAct Study. Am J Clin Nutr 2012;95:1445–53.  
233.  The InterAct Consortium. Consumption of sweet beverages and type 2 diabetes incidence 
in European adults: results from EPIC-InterAct. Diabetologia 2013;56(7):1520–30.  
234.  Li M, Fan Y, Zhang X, Hou W, Tang Z. Fruit and vegetable intake and risk of type 2 
diabetes mellitus: meta-analysis of prospective cohort studies. BMJ Open 
2014;4(11):e005497.  
235.  Qi Q, Chu AY, Kang JH, Liang L, Curhan GC, Pasquale LR, et al. Fried food consumption , 
genetic risk , and body mass index : gene-diet interaction analysis in three US cohort. 
2014;1610(March):1–12.  
236.  Khera A V., Emdin C a., Drake I, Natarajan P, Bick AG, Cook NR, et al. Genetic Risk, 
Adherence to a Healthy Lifestyle, and Coronary Disease. N Engl J Med 
2016;(November):NEJMoa1605086.  
237.  Olsen NJ, A ngquist L, Larsen SC, Linneberg A, Skaaby T, Husemoen LLN, et al. Interactions 
between genetic variants associated with adiposity traits and soft drinks in relation to 
longitudinal changes in body weight and waist circumference. Am J Clin Nutr 
2016;104(3):816–26.  
238.  Halliday JL. Genetics and public health--evolution, or revolution? J Epidemiol Community 
Heal 2004;58(11):894–9.  
239.  Langenberg C, Sharp SJ, Franks PW, Scott R a, Deloukas P, Forouhi NG, et al. Gene-
Lifestyle Interaction and Type 2 Diabetes: The EPIC InterAct Case-Cohort Study. PLoS Med 
2014;11(5):e1001647.  
240.  Pasquale LR, Loomis SJ, Aschard H, Kang JH, Cornelis MC, Qi L, et al. Exploring genome-
wide - dietary heme iron intake interactions and the risk of type 2 diabetes. Front Genet 
2013;4:7.  
241.  Figueiredo JC, Hsu L, Hutter CM, Lin Y, Campbell PT, Baron J a., et al. Genome-Wide Diet-
Gene Interaction Analyses for Risk of Colorectal Cancer. PLoS Genet 2014;10(4).  
242.  Melkonian SC, Daniel CR, Hildebrandt M a T, Tannir NM, Ye Y, Chow WH, et al. Joint 
association of genome-wide association study-identified susceptibility loci and dietary 
patterns in risk of renal cell carcinoma among non-hispanic whites. Am J Epidemiol 
2014;180(5):499–507.  
243.  Manning AK, Hivert M, Scott R a., Grimsby JL, Bouatia-Naji N, Chen H. A genome-wide 
approach accounting for body mass index identifies genetic variants influencing fasting 
glycemic traits and insulin resistance. Nat Genet 2012;44(6):659–69.  
244.  Kraft P, Yen YC, Stram DO, Morrison J, Gauderman WJ. Exploiting gene-environment 
interaction to detect genetic associations. Hum Hered 2007;63(2):111–9.  
245.  Sung YJ, Winkler TW, Manning AK, Aschard H, Gudnason V, Harris TB, et al. An Empirical 
Comparison of Joint and Stratified Frameworks for Studying G × E Interactions: Systolic 
Blood Pressure and Smoking in the CHARGE Gene-Lifestyle Interactions Working Group. 
Genet Epidemiol 2016;40:404–15.  
246.  Hsu L, Jiao S, Dai JY, Hutter C, Peters U, Kooperberg C. Powerful Cocktail Methods for 
Detecting Genome-wide Gene- Environment Interaction. Genet Epidemiol 
  
 
217 
2012;36(3):183–94.  
247.  Yang J, Loos RJF, Powell JE, Medland SE, Speliotes EK, Chasman DI, et al. FTO genotype is 
associated with phenotypic variability of body mass index. Nature 2012;490(7419):267–
72.  
248.  Alhazmi A, Stojanovski E, McEvoy M, Garg ML. Macronutrient intake and type 2 diabetes 
risk in middle-aged Australian women. Results from the Australian Longitudinal Study on 
Women’s Health. Public Health Nutr 2014;17(7):1587–94.  
249.  Wolfram G, Bechthold A, Boeing H, Ellinger S, Hauner H, Kroke A, et al. Evidence-Based 
Guideline of the German Nutrition Society: Fat Intake and Prevention of Selected 
Nutrition-Related Diseases. Ann Nutr Metab 2015;67(3):141–204.  
250.  Hooper L, Martin N, Abdelhamid A, G DS. Reduction in saturated fat intake for 
cardiovascular disease (Review). Cochrane Database Syst Rev 2015;(6):1–150.  
251.  Beulens JWJ, van der Schouw YT, Bergmann MM, Rohrmann S, Schulze MB, Buijsse B, et 
al. Alcohol consumption and risk of type 2 diabetes in European men and women: 
influence of beverage type and body size The EPIC-InterAct study. J Intern Med 
2012;272(4):358–70.  
252.  Voorman A, Lumley T, McKnight B, Rice K. Behavior of QQ-plots and Genomic Control in 
studies of gene-environment interaction. PLoS One 2011;6(5):e19416.  
253.  EPSRC. Six High Performance Computing centres to be officially launched [Internet]. 
[cited 2017 Aug 2];Available from: 
https://www.epsrc.ac.uk/newsevents/news/sixhpccentresofficiallylaunch/ 
254.  Willer CJ, Li Y, Abecasis GR. METAL: Fast and efficient meta-analysis of genomewide 
association scans. Bioinformatics 2010;26(17):2190–1.  
255.  Dadd T, Weale ME, Lewis CM. A critical evaluation of genomic control methods for 
genetic association studies. Genet Epidemiol 2009;33(4):290–8.  
256.  Winkler TW, Day FR, Croteau-Chonka DC, Wood AR, Locke AE, Mägi R, et al. Quality 
control and conduct of genome-wide association meta-analyses. Nat Protoc 
2014;9(5):1192–212.  
257.  Waldman ID. Gene-environment interactions reexamined: Does mother’s marital stability 
interact with the dopamine receptor D2 gene in the etiology of childhood attention-
deficit/hyperactivity disorder? Dev Psychopathol 2007;19(2007):1117–28.  
258.  Day FR, Loh PR, Scott R a., Ong KK, Perry JRB. A Robust Example of Collider Bias in a 
Genetic Association Study. Am J Hum Genet 2016;98(2):392–3.  
259.  Fan Q, Verhoeven VJM, Wojciechowski R, Barathi V a, Hysi PG, Guggenheim J a, et al. 
Meta-analysis of gene-environment-wide association scans accounting for education level 
identifies additional loci for refractive error. Nat Commun 2016;7:11008.  
260.  Wang K, Li M, Hakonarson H. Analysing biological pathways in genome-wide association 
studies. Nat Rev Genet 2010;11(12):843–54.  
261.  Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, et al. The Genotype-Tissue 
Expression (GTEx) project. Nat Genet 2013;45(6):580–5.  
262.  Acosta PB, editor. Nutritional management of patients with inherited metabolic 
disorders. USA: Jones and Bartlett Publishers; 2010.  
263.  Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and 
interpretation of large-scale molecular data sets. Nucleic Acids Res 2012;40(Database 
issue):D109-14.  
  
 
218 
264.  Hochberg Y, Benjaminit Y. Controlling the False Discovery Rate: A Practical and Powerful 
Approach to Multiple Controlling the False Discovery Rate: a Practical and Powerful 
Approach to Multiple Testing. Source J R Stat Soc 1995;57(1):289–300.  
265.  Delgado-Rodriguez M. Bias. J Epidemiol Community Heal 2004;58(8):635–41.  
266.  Teixeira da Silva JA. Negative results: negative perceptions limit their potential for 
increasing reproducibility. J Negat Results Biomed 2015;14(12):1–4.  
267.  Tabery J. Beyond Versus: The struggle to Understand the Interaction of Nature and 
Nurture. USA: MIT Press; 2014.  
268.  Tabery J. R. A. Fisher, Lancelot Hogben, and the Origin(s) of Genotype-Environment 
Interaction. J Hist Biol 2008;41:717–61.  
269.  Tabery J. Debating interaction: the history, and an explanation. Int J Epidemiol 
2015;44(4):1117–23.  
270.  Ortlipp M. Keeping and Using Reflective Journals in the Qualitative Research Process. 
Qual Rep 2008;13(4):695–705.  
271.  Vimaleswaran KS, Bodhini D, Lakshmipriya N, Ramya K, Anjana RM, Sudha V, et al. 
Interaction between FTO gene variants and lifestyle factors on metabolic traits in an 
Asian Indian population. Nutr Metab (Lond) 2016;13:39.  
272.  Hill AB. The environment and disease: association or causation? Proc R Soc Med 
1965;58:295–300.  
273.  Lucas RM, McMichael AJ. Association or causation: evaluating links between 
“environment and disease”. Bull World Health Organ 2005;83(10):792–5.  
274.  Balansky R, Ganchev G, Iltcheva M, Nikolov M, Steele VE, De Flora S. Differential 
carcinogenicity of cigarette smoke in mice exposed either transplacentally, early in life or 
in adulthood. Int J Cancer 2012;130(5):1001–10.  
275.  Lo C-Y, Hsieh P-H, Chen H-F, Su H-M. A maternal high-fat diet during pregnancy in rats 
results in a greater risk of carcinogen-induced mammary tumors in the female offspring 
than exposure to a high-fat diet in postnatal life. Int J cancer 2009;125(4):767–73.  
276.  Chen R, Mias GI, Li-Pook-Than J, Jiang L, Lam HYK, Chen R, et al. Personal omics profiling 
reveals dynamic molecular and medical phenotypes. Cell 2012;148(6):1293–307.  
277.  Wenten M, Gauderman WJ, Berhane K, Lin PC, Peters J, Gilliland FD. Functional variants 
in the catalase and myeloperoxidase genes, ambient air pollution, and respiratory-related 
school absences: An example of epistasis in gene-environment interactions. Am J 
Epidemiol 2009;170(12):1494–501.  
278.  Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF, et al. Multifactor-
dimensionality reduction reveals high-order interactions among estrogen-metabolism 
genes in sporadic breast cancer. Am J Hum Genet 2001;69(1):138–47.  
279.  Manuck SB, McCaffery JM. Gene-Environment Interaction. Annu Rev Psychol 
2014;65(1):41–70.  
280.  Strecher VJ, Rosenstock IM. The health belief model. In: Cambridge handbook of 
psychology, health and medicine. Cambridge: Cambridge University Press; 1997. page 
113–117. 
281.  Schneider KI, Schmidtke J. Patient compliance based on genetic medicine: a literature 
review. J Community Genet 2014;5(1):31–48.  
282.  Li SX, Ye Z, Whelan K, Truby H. The effect of communicating the genetic risk of 
cardiometabolic disorders on motivation and actual engagement in preventative lifestyle 
  
 
219 
modification and clinical outcome: a systematic review and meta-analysis of randomised 
controlled trials. Br J Nutr 2016;116(5):924–34.  
283.  Hollands GJ, French DP, Griffin SJ, Prevost AT, Sutton S, King S, et al. The impact of 
communicating genetic risks of disease on risk- reducing health behaviour : systematic 
review with meta-analysis. BMJ 2016;352(1102):1–11.  
284.  Celis-Morales C, Livingstone KM, Marsaux CFM, Macready AL, Fallaize R, O’Donovan CB, 
et al. Effect of personalized nutrition on health-related behaviour change: evidence from 
the Food4me European randomized controlled trial. Int J Epidemiol 2017;46(2):578–88.  
285.  Haycock PC, Burgess S, Wade KH, Bowden J, Relton C, Smith GD. Best (but oft-forgotten) 
practices: The design, analysis, and interpretation of Mendelian randomization studies. 
Am J Clin Nutr 2016;103(4):965–78.  
286.  Burgess S, Butterworth A, Malarstig A, Thompson SG. Use of Mendelian randomisation to 
assess potential benefit of clinical intervention. BMJ 2012;345(November):1–6.  
287.  Qi Q, Kilpeläinen TO, Downer MK, Tanaka T, Smith CE, Sluijs I, et al. FTO genetic variants, 
dietary intake, and body mass index: insights from 177,330 individuals. Hum Mol Genet 
2014;1–12.  
288.  Fortier I, Burton PR, Robson PJ, Ferretti V, Little J, L’Heureux F, et al. Quality, quantity and 
harmony: The DataSHaPER approach to integrating data across bioclinical studies. Int J 
Epidemiol 2010;39(5):1383–93.  
289.  Fortier I, Raina P, Van den Heuvel ER, Griffith LE, Craig C, Saliba M, et al. Maelstrom 
Research guidelines for rigorous retrospective data harmonization. Int J Epidemiol 
2017;46(1):103–15.  
290.  Smith GD. Mendelian Randomization for Strengthening Causal Inference in Observational 
Studies: Application to Gene x Environment Interactions. Perspect Psychol Sci 
2011;6(3):314–314.  
 
 
 
 
 
 
 
 
 
  
 
220 
 
 
 
 
 
Appendices 
 
 	
  
 
221 
Appendix A: Checklist for critiquing gene-diet interaction studies 
 
Purpose: to highlight the key concepts within a research paper about gene-diet 
interactions or nutrigenetics that readers need to be mindful of when assessing the 
quality of the study.  
Additionally, like any epidemiological study, the validity of the study depends on whether 
it is robust to confounding, bias and/or chance (see STROBE and/or Cochrane RCT 
quality checklists). 
Concept Rationale Assessment 
notes 
Study design: if it is 
prospective or 
retrospective 
Retrospective study designs e.g. cross-sectional or case-control 
studies make it difficult to determine the temporal sequence of 
events and therefore whether diet led to disease or the other way 
around (reverse causality). More about the general issues relating 
to different study designs can be found in textbooks on 
epidemiology. 
 
Sample size large 
enough? 
A key determinant of a GWAS. 
 
Common genetic variants (that occur frequently in the population) 
often have small effects on the outcome of interest for polygenic 
conditions and therefore studies with large sample sizes are 
needed.  
 
If available, a sample size calculation may help you determine 
whether the sample size was large enough. 
 
How well is the dietary 
exposure measured? 
Is it a subjective (e.g. self-report) or objective (e.g. nutritional 
biomarker, via observation or dietary intervention) measure of 
dietary intake?  
 
Has this tool been validated?  
 
 
How good is the 
genotyping and 
imputation, where 
relevant? (quality 
control of the study) 
Look for information about genotyping performance. The sample 
and SNP call rate should be >95%. Those <95% are normally 
removed from further analysis because of the possibility of high 
genotyping errors contributing to bias. 
 
More on this can be found in the paper by Pearson, JAMA, 2008 
 
If some SNPs are imputed (estimated from the genotyped SNPs), 
authors should provide the average quality score or information 
metric.  
 
Appropriateness of 
interaction scale: 
additive or 
multiplicative 
interaction? 
An interaction on the multiplicative scale does not imply one on 
the additive scale. Vice versa. Also, a lack of interaction on the 
multiplicative scale does not preclude a lack of interaction on the 
additive scale.  
 
Most interaction studies are under the multiplicative scale because 
of ease of analysis. 
 
Additive interactions should be investigated to understand an issue 
of public health relevance. Whereas a multiplicative interaction 
 
  
 
222 
should be assessed where such relevance may not yet be so 
obvious but may serve to help understand disease aetiology. 
Have important 
confounders been 
addressed? 
For interaction analyses, it is important to control for two sets of 
confounders related to genes and disease as well as to diet and 
disease. Therefore, for the latter, confounders may include physical 
activity, socio-economic status (e.g. education level), smoking, 
alcohol intake and total energy intake 
 
An important confounder for gene-disease associations is 
population stratification (or population structure: how ethnically 
diverse is the population under study)? This is often adjusted in the 
analysis using eigenvectors or principal components for population 
stratification.  
 
Often authors will report whether their genotypes are in Hardy-
Weinberg equilibrium. If not (with p-value statistically significantly 
deviating from equilibrium), this may indicate genotyping or 
genotype calling errors or peculiarities in the data. 
 
Were stringent 
corrections applied to 
multiple testing?  
To reduce the likelihood of false positive/chance findings, often a 
problem with multiple tests, Bonferroni correction is commonly 
done. However, other less conservative approaches may have also 
been considered. Authors should have described this in their 
methods and discussed their results taking this into account. 
 
If there is an 
interaction, is both the 
overall p-value for 
interaction across 
strata and the strata-
specific effect 
estimates presented? 
An interaction is present when there are a statistically significant 
difference in effect estimates between strata of either genotype or 
the dietary exposure category (e.g. is there a significant difference 
between the association between the highest compared to lowest 
quartile of fibre intake and disease?) 
 
Have the results been 
replicated in an 
independent 
population? Is there 
consistency in findings 
across different types 
of studies? 
To provide insurance against errors or biases that can affect an 
individual study, replication of GWAS studies is now mandatory. 
However, replication for gene-diet interactions is more challenging 
because of differences in population characteristics and methods 
in dietary intake. Therefore, whilst it will be preferable that studies 
also include independent replication, the inclusion of other tests 
e.g. functional tests can also help elucidate the validity of the 
interaction. This concurs with the Bradford Hill criteria of 
‘consistency,’ of findings. 
 
Is there evidence of a 
functional role of the 
genetic variants? 
Many GWAS associated genetic variants have been in non-coding 
regions of the DNA (introns- regions that do not code for a 
protein). To understand what its effect on disease is, further 
studies examining the role of the genetic variant is often 
conducted.  
 
Is the interaction biologically plausible? Although given much of 
human biology is unknown, this needn’t be major criteria. 
 
Are the strata-specific 
effects of clinical 
value? 
Additive interaction may be undertaken to assess this  
Overall Make an overall impression statement, including where the study 
does well or can see improvement in. 
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Appendix B: Example of a Food Frequency Questionnaire (centre: EPIC-
Norfolk) 
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Appendix C: Example of a search strategy for the systematic review of 
gene-macronutrient interactions and T2D 
 
EMBASE (Ovid) 
Date: 6-10-15 
No. Query Result 
1 exp Genotype/ 324549 
2 exp Alleles/ 146253 
3 exp genetic variability/ 185093 
3 exp genetic polymorphism/ or exp genetic heterogeneity/ 361288 
4 Genetic Predisposition.mp. or exp genetic predisposition/ 129174 
5 exp genetic association/ 119908 
6 (genotype or 'gene' or 'genetic risk score' or GWAS).ab,ti. 1948179 
7 exp genetic polymorphism/ or exp genetic heterogeneity/ 324073 
8 1 or 2 or 3 or 4 or 5 or 6 or 7 2368293 
9 exp non insulin dependent diabetes mellitus/ 167582 
10 diabetogenic.mp. 8417 
11 9 or 10 175577 
12 exp carbohydrate diet/ 14648 
13 exp glycemic index/ 3492 
14 ('glycaemic index' or 'glycemic load' or 'glycaemic load' or GI 
or GL).ab,ti. 
71757 
15 exp dietary fiber/ 16438 
16 exp sugar intake/ 4969 
17 ('free sugar*' or 'added sugar*').ab,ti. 2039 
18 exp fat intake/ 44614 
19 ('fatty acid*' or 'saturated fat*' or 'monounsaturated fat*' or 
'polyunsaturated fat*' or 'trans fat*' or 'dietary 
cholesterol').ab,ti. 
231922 
20 ('alpha-linolenic acid' or ALA or 'linolenic acid*' or 'linoleic 
acid*' or LA or n-3 or n-6 or omega-3 or omega-6).ab,ti. 
321990 
21 exp protein intake/ 126 
22 dietary protein quality.mp. 100 
23 exp caloric intake/ 44733 
24 exp low carbohydrate diet/ or exp carbohydrate intake/ 19153 
25 exp atherogenic diet/ or exp high fiber diet/ or exp lipid 
diet/ or exp low calory diet/ or exp cholesterol diet/ or exp 
low fat diet/ or exp protein diet/ 
54183 
26 (macronutrient or 'dietary fat' or 'dietary protein' or 'dietary 
carbohydrate').ab,ti. 
26536 
27 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 
23 or 24 or 25 or 26 
740148 
28 8 and 11 and 27 2152 
29 limit 28 to human 1509 
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Appendix D: EPIC-InterAct gene-macronutrient interactions and incident 
T2D, under the ‘Modified Analyses’ 
 
 
Figure 1: EPIC-InterAct analyses for the hazard ratio (HR) for incident T2D per A allele (GIPR rs10423928), by 
categories of macronutrient exchange  
Pooled HR for T2D, with adjustment for age (=underlying time scale), sex, centre, eigenvectors (first 5 principal 
components for population stratification),  physical activity, education, smoking, sex-specific alcohol categories, total 
energy intake (TEI), season, dietary factors (fibre, magnesium, iron, vitamin C, coffee, tea, leafy vegetables and 
artificially sweetened beverage) and BMI. 
Models substituted for the following were further adjusted for other macronutrients* SFA, MUFA and PUFA; ^ 
protein; & carbohydrate; $ protein 
Pinteraction: estimated by treating rs10423928 and macronutrients as continuous variables 
Heterogeneity I2 between countries was low to moderate: total Carbohydrate: 0% and total fat: 29%.  
Statistical test: multiplicative interaction analysis using Prentice-weighted Cox regression 
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Figure 2: EPIC-InterAct analysis for the hazard ratio (HR) of incident T2D per 1%TEI substitution in macronutrient, 
stratified by CAV2 rs2270188 genotype 
Pooled HR for T2D, with adjustment for age (=underlying time scale), sex, centre, eigenvector (first 5 principal 
components for population stratification), physical activity, education, smoking, sex-specific alcohol categories, total 
energy intake (TEI), season, dietary factors (fibre, magnesium, iron, vitamin C, coffee, tea, leafy vegetables and 
artificially sweetened beverage) and BMI. 
Models substituted for the following were further adjusted for other macronutrients * carbohydrate; ^ protein; & 
PUFA, protein and carbohydrate; $ MUFA, protein and carbohydrate 
Pinteraction:  estimated by treating macronutrients and rs2270188 as continuous variables. 
There was modest heterogeneity (I2) between countries for total fat: 48% and SFA: 58%. 
Statistical test: multiplicative interaction analysis using Prentice-weighted Cox regression 
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Figure 3: EPIC-InterAct analysis for the hazard ratio (HR) of incident T2D per A allele of rs3786897 (PEPD), stratified 
by levels of circulating n-3 PUFA.  
Pooled HR for T2D, with adjustment for age (=underlying time scale), sex, centre, eigenvectors (first 5 principal 
components for population stratification), physical activity, education, smoking, sex-specific alcohol categories, season 
of blood collection, BMI 
Pinteraction: estimated by treating circulating n-3 PUFA and PEPD rs3786897 as a continuous variable. 
Abbreviation: TPFA: total phospholipid fatty acid 
Statistical test: multiplicative interaction analysis using Prentice-weighted Cox regression 
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Appendix E: Summary effect sizes for all studies from the systematic review of gene-macronutrient interactions and 
T2D 
Table: Summary effect sizes for all studies (if information were available) 
Gene and 
SNP 
Study 
(n=cases/total) 
Interaction results (G x macronutrient)*  
  Nutrients assessed Effect size 95%CI P-value P value for 
interaction^ 
Quality (risk of bias) 
TCF7L2 
rs7903146 
Hindy et al., 2012 
(MDCS cohort 
n=1649/24799) 
CHO 
 
OR: 1.37 
 
1.14,1.64 
 
9.0x10-4 
 
0.91 
 
Moderate 
Large sample size with 
validated measurement 
tools and adjustment for 
confounders. Multiple 
testing not accounted for (4 
tests). 
Fat OR: 1.36 1.13,1.64 9.4x10-4 0.47  
PRO OR: 1.51 1.29,1.77 3.5x10-7 0.70  
Fibre OR: 1.56 1.31,1.86 8.3x10-7 0.049  
      
OR= odds per T allele at the 5th quintile of macronutrient intake  
rs7903146 
rs4506565 
 
Wirstrom et al., 
2013  (SDPP 
cohort 
n=165/5477) 
Cereal fibre     Moderate 
Exposure is not 
comprehensively measured 
and study with small sample 
size.    
rs7903146 OR: 1.10 0.76,1.59 NA 0.005   
rs4506565 OR: 1.07 0.74,1.54 NA 0.006  
OR= odds per T allele per 5g increase of fibre/d  
rs12255372 Cornelis et al., 
2009 (NHS CC 
n=1140/3055) 
CHO 
 
OR: 1.48 
 
1.20,1.82 
 
NA 0.18 
 
Moderate 
Well conducted study. 
GI OR: 1.54 1.24,1.92  0.06*  
Cereal fibre OR: 1.18 0.92,1.49  0.14  
GL OR: 1.68 1.35,2.09  0.03*  
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    After adjusting for 
family history  
(p for interaction 
GI: 0.14; GL: 0.13) 
 
OR= odds per T allele at the 3rd tertile of macronutrient intake 
 
 
GIPR 
rs10423928 
Sonestedt et al., 
2012 (MDCS 
cohort 
n=1541/24840) 
CHO 
 
HR: 1.14 
 
0.98,1.32 
 
0.09 
 
0.001 
 
Moderate 
Large sample size, validated 
measurement tools and 
comprehensive analyses, 
with adjustment for key 
confounders. Multiple 
testing not accounted for (5 
tests). 
Fat HR: 0.82 0.71,0.96 0.01 0.002  
PRO HR: 1.02 0.88,1.17  0.83  
Fibre HR: 1.01 0.87,1.18  0.22  
Sucrose HR: 1.02 0.88,1.19  0.75  
HR= hazard per A allele at the 3rd tertile of macronutrient intake  
IRS1 
rs2943641 
Ericson et al., 
2013 (MDCS 
cohort 
n=1567/24841) 
CHO 
Fat 
PRO 
Fibre 
 
 
HR: 0.80 
HR: 0.78 
HR: 0.99 
HR: 0.87 
 
 
0.61,1.08 
0.59,1.02 
0.75,1.30 
0.65,1.16 
0.75 
0.89 
0.65 
0.96 
0.59$ 
0.4$ 
0.28 
0.92 
$(interaction 
detected for 
IRS1xdietxsex. P 
for interaction 
both fat and 
carbohydrate: 
0.01)  
Moderate 
Large sample size with 
comprehensive dietary 
measurement. Multiple 
testing was not accounted 
for 
 
 
 
HR= hazard for TT genotype with the 3rd tertile of macronutrient intake  
 
rs7578326 
rs2943641 
Zheng et al., 2013 
(GOLDN, BPRHS 
cross-sectional 
CHO 
Fat 
SFA 
NA 
 
 
NA  NS, NA 
 
Moderate 
Conducted replication and 
meta-analysis. Well 
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n=419/1664) MUFA 
SFA: CHO ratio 
GI  
GL 
 
 
 
 
 
 
 
 
adjusted for confounding.  
Small sample size. 
PPARG 
Pro12Ala/rs18
01282 
 
1431C>T 
Lamri et al., 2012 
(DESIR cohort 
n=191/4676) 
Fat 
 
 
 
 
 
 
 
 
NA NA  NS, NA 
 
 
 
 
Serious 
Dietary questionnaire with 
limited food items may 
cause measurement bias  
and misclassification of fat 
intake. Residual 
confounding is likely due 
to lack of adjustments for 
key confounders (total 
energy intake, physical 
activity, etc). 
Ala+ HR: 0.67 0.28,1.58  0.05  
ProPro HR: 1.73 1.19,2.52    
T+ HR: 0.58 0.25,1.36 0.21   
CC HR: 1.85 1.27,2.71 0.36   
HR: hazard for Ala/T allele carriers of the ProPro/CC homozygotes at the 3rd tertile of fat intake  
    
Pro12Ala Cornelis et al., 
2009 (NHS CC 
n=1140/3055) 
CHO NA 
 
 
NA  NS, NA Moderate 
Well conducted study. 
  GI NA NA  NS, NA  
  GL NA NA  NS, NA  
  Fibre NA NA  NS, NA  
Pro12Ala 
 
Nelson et al., 2007 
(GENI study: 
PUFA 
 
NA NA NA NS, NA Serious 
Family based association 
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 family based 
association 
analysis 
n=736/1318) 
 
 
test conducted. Several 
key confounders (energy 
intake, BMI, physical 
activity, etc) not 
considered and possible 
reporting bias. 
  SFA NA NA NA NS, NA  
  MUFA NA NA NA NS, NA  
  PUFA: SFA ratio 
 
 
 
NA NA NA NS, NA  
Pro12Ala Fisher et al., 2011 
(EPIC-Potsdam CC 
576, case-cohort 
806/2864) 
 
 
Fat  NA  
  
  
 
 
 
 
NA 
 
 
 
 0.32 Moderate 
Robust assessment, using 
a novel interaction 
analysis approach that 
maximises power. 
Multiple testing was not 
accounted for in 
exploratory analysis (256 
tests). 
63 SNPs  SFA  NA   NA  0.08  
  MUFA  NA   NA  0.29  
  PUFA  NA   NA  0.07  
  (per 1 %E increase 
in nutrient) 
     
APOA2 
−265T>C 
Corella et al., 2011 
(PREDIMED, SNHS 
cross-sectional 
n=825/2830) 
SFA (Singapore, 
Asian) 
 
OR: 3.1  
  
  
 
0.87,11.02 
 
 
 
0.08  
 
 
 
NS, NA 
 
Moderate 
Potential reporting bias 
evident. 
SFA (Spain, 
European) 
higher 
 
NA 0.045 NS, NA 
 
 
OR= odds for CC genotype at the highest category of SFA intake (high vs low)  
CAV2 Fisher et al., 2011 Fat HR: 1.06 1.02,1.11 0.002 0.02 Moderate 
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rs2270188 
 
63 SNPs 
(EPIC-Potsdam CC 
576, case-cohort 
2864) 
       Robust assessment, using 
a novel interaction 
analysis approach that 
maximises power. 
Multiple testing was not 
accounted for in 
exploratory analysis (256 
tests). 
SFA HR: 1.12 1.05,1.19 0.0006 0.002  
MUFA NA NA NA   
PUFA NA NA NA   
HR= hazard for TT genotype for each 1%E increase in macronutrient intake  
FABP1/2/3/4 
rs2197076 
 
12 SNPs 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mansego et al., 
2012 (Hortega, 
Segovia 
replication cross-
sectional 
n=174/2022) 
Fat 
 
OR: 1.85 
 
 
1.03,3.84 
 
 0.03274 
 
 
Serious 
Replication conducted. 
The interaction was 
neither examined in 1/3 of 
the population (without 
reason) nor examined in 
SNPs without the main 
effect on T2D. Most 
confounders were not 
accounted for and 
selective reporting was 
evident. 
SFA NA NA  NA  
PUFA    (not statistically 
significant after 
multiple testing 
corrections) 
 
OR= odds per A allele at the highest category of fat intake (high vs low)  
PGC-1α 
 
Gly482Ser 
Thr612Met 
Nelson et al., 2007 
(GENI study: 
family-based 
association 
PUFA 
 
NA NA NA NS, NA Serious 
Family-based association 
test conducted. Several 
key confounders (energy 
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Thr528Thr 
 
analysis 
n=736/1318) 
intake, BMI, physical 
activity, etc) not 
considered and possible 
reporting bias. 
  SFA NA NA NA NS, NA  
  MUFA NA NA NA NS, NA  
  PUFA: SFA ratio NA NA NA NS, NA  
PEPD 
rs3786897 
 
9 SNPs 
examined 
Zheng et al., 2015  
(case-control, 
n=622/915) 
Circulating 
erythrocyte 
membrane 
phospholipid n-3 
PUFA 
OR: low n-3 PUFA 
 
 
 
 
 0.027 Serious 
Several likely confounders 
may explain the 
associations observed that 
were not adjusted for 
(BMI, blood lipid status, 
etc) and incomplete 
reporting of participant 
characteristics. 
   GG vs AA: 1.88 
 
1.07,3.31 
 
   
   GG vs GA: 2.40 1.40,4.12    
   high n-3 PUFA 
 
    
   GG vs AA: 0.59 
 
0.30,1.13 
 
   
   GG vs GA : 0.65 0.35,1.19    
GRS  
15 SNPs, 
weighted 
score 
Villegas et al., 
2014 (NHANES 
cross-sectional 
n=1337/13120) 
CHO  NA 
 
 
 
NA  NS, NA Serious 
Dietary measurement tool 
was not validated and how 
T2D status was obtained 
was not described, 
therefore bias may be 
likely. The study reported 
a lack of statistical power 
to detect interactions. 
  Fibre  NA NA  NS, NA  
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Abbreviations: CHO: carbohydrate, PRO: protein, GL: glycemic load, GI: glycemic index, NS: not significant, NA: not available, MT: multiple testing, h: highest category, CC: case-control 
study, MDCS: Malmo Diet and Cancer Study, SDPP: Stockholm Diabetes Prevention Program, NHS: Nurse’s Health Study, GOLDN: Genetics of Lipid Lowering Drugs and Diet Network, 
BPRHS: Boston Puerto Rican Health Study, GENI: Gene Environment Interactions study, EPIC: European Prospective Investigation into Cancer and Nutrition-Potsdam, PREDIMED: 
Prevención con Dieta Mediterránea trial, SNHS: , Singapore National Health Survey, NHANES: National Health and Nutrition Examination Survey. 
*Interaction results: multiplicative model between gene and macronutrient. Gene is per risk allele (additive model) unless otherwise specified eg. TT genotype (codominant). Nutrient is 
with the highest category of macronutrient intake (categorical variable) or per X grams/%E of macronutrient (continuous variable). An example is given where there are available results. 
^ p for interaction: represents the significance level for interaction across all categories of intake, under the additive genetic model, unless otherwise specified.  
Gene-T2DM association: all by trait-increasing allele (additive model), except where specified otherwise. 
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Appendix F: Multiplicative models for the interaction between macronutrient and genetic risk scores (unweighted) 
with isocaloric macronutrient substitution: EPIC-InterAct Study 
 
Macronutrient 
intake (5% total 
energy intake) 
Model (*sub= 
substituted) 
GRS for body mass index (per 6.3 risk 
alleles)% 
GRS for insulin resistance (per 4.5 risk 
alleles) GRS for type 2 diabetes (per 4.3 risk alleles) 
  
Beta (95% CI) P I2 (%) Beta (95% CI) P I2 (%) Beta (95% CI) P I2 (%) 
Carbohydrate model 1 0.004(-0.024,0.032) 0.779 34.3 -0.003(-0.028,0.023) 0.847 23.2 -0.003(-0.025,0.02) 0.815 1.3 
 
model 2 -0.003(-0.032,0.026) 0.849 34.5 -0.009(-0.042,0.023) 0.586 44.9 -0.008(-0.031,0.015) 0.502 0.0 
 
model 3 -0.001(-0.033,0.032) 0.961 44.5 -0.006(-0.035,0.022) 0.665 29.0 -0.007(-0.032,0.017) 0.555 5.4 
 
model 4 
   
0.004(-0.023,0.03) 0.785 0.0 0.005(-0.029,0.039) 0.774 26.5 
 
model 5:sub with 
PUFA -0.027(-0.141,0.087) 0.642 29.2 0.012(-0.138,0.161) 0.878 39.5 0.076(-0.033,0.184) 0.172 0.0 
 
model 5:sub with 
MUFA 0.012(-0.046,0.071) 0.680 0.0 0.033(-0.07,0.137) 0.528 41.4 -0.013(-0.108,0.083) 0.797 32.5 
           Total protein model 1 -0.003(-0.065,0.059) 0.923 11.0 0.05(-0.007,0.108) 0.084 0.0 -0.048(-0.112,0.015) 0.136 13.7 
 
model 2 0.001(-0.079,0.081) 0.980 38.1 0.047(-0.013,0.106) 0.125 0.0 -0.046(-0.115,0.023) 0.194 18.5 
 
model 3 -0.008(-0.071,0.056) 0.815 4.0 0.056(-0.005,0.117) 0.074 0.0 -0.041(-0.123,0.04) 0.319 36.9 
 
model 4 
   
0.048(-0.022,0.117) 0.180 0.0 -0.05(-0.128,0.028) 0.213 15.1 
 
model 5:sub with 
carbohydrate 0(-0.038,0.037) 0.991 57.2 0.005(-0.022,0.032) 0.727 0.0 0.005(-0.028,0.037) 0.767 20.9 
 
model 5:sub with 
PUFA -0.034(-0.147,0.08) 0.561 29.2 0.014(-0.138,0.166) 0.857 41.5 0.068(-0.04,0.177) 0.215 0.0 
 
model 5:sub with 
MUFA 0.012(-0.046,0.071) 0.676 0 0.024(-0.087,0.136) 0.671 49.4 -0.023(-0.111,0.064) 0.601 23.8 
        
 
  Animal protein model 1 0.009(-0.059,0.076) 0.805 37.3 0.027(-0.025,0.08) 0.306 0 -0.041(-0.113,0.03) 0.258 41.0 
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model 2 0.007(-0.063,0.078) 0.835 35.1 0.022(-0.033,0.077) 0.437 0 -0.036(-0.107,0.036) 0.329 35.1 
 
model 3 0.005(-0.059,0.07) 0.873 21.2 0.036(-0.031,0.103) 0.289 24.4 -0.032(-0.116,0.052) 0.460 49.5 
 
model 4 
   
0.026(-0.038,0.091) 0.425 0 -0.048(-0.136,0.039) 0.278 38.6 
 
model 5:sub with 
carbohydrate 0(-0.037,0.037) 0.992 56.7 0.006(-0.021,0.032) 0.687 0 0.003(-0.028,0.033) 0.872 12.9 
 
model 5:sub with 
plant protein -0.041(-0.179,0.096) 0.556 0 0.07(-0.106,0.247) 0.434 12.5 0(-0.18,0.179) 0.996 12.3 
  
       
  Plant protein model 1 -0.041(-0.168,0.087) 0.533 0.0 0.059(-0.112,0.231) 0.499 32.8 0.025(-0.154,0.205) 0.780 40.0 
 
model 2 -0.059(-0.191,0.073) 0.384 0 0.066(-0.11,0.242) 0.463 31.5 0.01(-0.176,0.196) 0.917 40.6 
 
model 3 -0.06(-0.197,0.076) 0.384 0.0 0.094(-0.07,0.259) 0.260 19.3 0.01(-0.171,0.191) 0.916 34.3 
 
model 4 
   
0.079(-0.084,0.243) 0.342 3.6 -0.009(-0.192,0.173) 0.921 15.6 
 
model 5:sub with 
carbohydrate 0.001(-0.037,0.038) 0.974 57.2 0.002(-0.026,0.031) 0.869 7.6 0.003(-0.028,0.034) 0.855 14.7 
           Total fat model 1 0.008(-0.017,0.033) 0.552 0.0 -0.005(-0.037,0.028) 0.772 32.0 0.017(-0.009,0.044) 0.188 0.0 
 
model 2 0.012(-0.014,0.037) 0.375 0.0 -0.004(-0.041,0.033) 0.833 41.7 0.016(-0.011,0.043) 0.248 0.0 
 
model 3 0.01(-0.017,0.036) 0.471 0.0 -0.007(-0.04,0.025) 0.653 22.5 0.016(-0.012,0.045) 0.267 5.9 
 
model 4 
   
-0.004(-0.048,0.041) 0.869 41.2 0.011(-0.021,0.043) 0.497 0.0 
 
model 5:sub with 
carbohydrate 0.001(-0.032,0.034) 0.955 44.3 0(-0.028,0.029) 0.986 9.3 0.004(-0.03,0.037) 0.833 23.6 
 
model 5:sub with 
total protein -0.008(-0.074,0.059) 0.821 10.9 0.049(-0.021,0.119) 0.168 0 -0.057(-0.138,0.024) 0.167 19.7 
 
model 5:sub with 
plant protein -0.058(-0.197,0.08) 0.407 0 0.066(-0.116,0.248) 0.475 16.1 -0.014(-0.21,0.183) 0.892 24.0 
 
model 5:sub with 
animal protein 0.004(-0.061,0.069) 0.898 21.2 0.034(-0.035,0.103) 0.335 9.1 -0.05(-0.134,0.034) 0.247 33.3 
           SFA model 1 0.022(-0.03,0.073) 0.407 12.2 -0.019(-0.068,0.03) 0.444 0 0.047(-0.003,0.096) 0.066 0 
 
model 2 0.033(-0.018,0.085) 0.208 8.5 -0.021(-0.073,0.03) 0.412 0 0.045(-0.006,0.096) 0.085 0 
 
model 3 0.031(-0.019,0.08) 0.228 0 -0.027(-0.08,0.025) 0.311 0 0.046(-0.007,0.1) 0.09 2.9 
 
model 4    -0.015(-0.089,0.058) 0.687 22.8 0.027(-0.034,0.089) 0.384 0 
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model 5:sub with 
carbohydrate 0.001(-0.036,0.038) 0.957 54.4 0.003(-0.024,0.03) 0.85 0 0.001(-0.031,0.033) 0.941 18.7 
 
model 5:sub with 
plant protein -0.045(-0.183,0.094) 0.526 0 0.064(-0.114,0.243) 0.479 13.4 -0.004(-0.185,0.178) 0.966 13.7 
 
model 5:sub with 
animal protein 0.002(-0.061,0.064) 0.96 14.1 0.027(-0.039,0.092) 0.425 0 -0.052(-0.14,0.037) 0.25 38.8 
 
model 5:sub with 
total protein -0.01(-0.072,0.052) 0.753 0 0.046(-0.025,0.116) 0.206 0 -0.054(-0.135,0.028) 0.195 19.7 
 
model 5:sub with 
PUFA -0.031(-0.146,0.083) 0.593 29.6 0.006(-0.142,0.153) 0.939 37.9 0.075(-0.033,0.183) 0.173 0 
 
model 5:sub with 
MUFA 0.013(-0.046,0.072) 0.671 0 0.035(-0.073,0.143) 0.528 45.3 -0.008(-0.105,0.089) 0.869 33.7 
  
       
  MUFA model 1 0.01(-0.046,0.066) 0.724 0 -0.001(-0.079,0.077) 0.982 35.7 0.002(-0.075,0.08) 0.95 34.0 
 
model 2 0.015(-0.043,0.072) 0.617 0 -0.005(-0.083,0.073) 0.902 31.7 0.001(-0.083,0.084) 0.987 38.9 
 
model 3 0.014(-0.044,0.073) 0.634 0 -0.003(-0.088,0.083) 0.949 38.5 -0.003(-0.092,0.087) 0.954 43.8 
 
model 4    0.023(-0.087,0.133) 0.685 48.5 -0.016(-0.097,0.065) 0.699 15.3 
 
model 5:sub with 
plant protein -0.045(-0.183,0.094) 0.527 0 0.054(-0.137,0.246) 0.576 21.9 -0.01(-0.197,0.177) 0.916 17.5 
 
model 5:sub with 
animal protein 0(-0.066,0.066) 0.996 22.4 0.031(-0.036,0.098) 0.37 3.1 -0.052(-0.136,0.032) 0.226 33.2 
  
       
  PUFA model 1 -0.042(-0.124,0.039) 0.309 0 -0.019(-0.129,0.092) 0.742 32.9 0.036(-0.05,0.123) 0.408 0 
 
model 2 -0.039(-0.141,0.064) 0.459 21.9 -0.025(-0.119,0.068) 0.598 7.97 0.044(-0.047,0.134) 0.342 0 
 
model 3 -0.042(-0.155,0.072) 0.471 30.5 -0.019(-0.109,0.071) 0.676 1.1 0.044(-0.048,0.136) 0.351 0 
 
model 4    0.01(-0.139,0.16) 0.895 40.4 0.072(-0.039,0.182) 0.204 2.2 
 
model 5:sub with 
plant protein -0.046(-0.185,0.092) 0.51 0 0.065(-0.111,0.241) 0.467 11.5 -0.004(-0.198,0.189) 0.964 22.1 
 
model 5:sub with 
animal protein 0.002(-0.059,0.064) 0.938 12.2 0.028(-0.038,0.093) 0.41 0 -0.05(-0.135,0.036) 0.255 35.3 
 
model 5:sub with 
MUFA 0.018(-0.04,0.077) 0.544 0 0.034(-0.076,0.144) 0.545 47.5 -0.01(-0.109,0.089) 0.842 36.2 
  
       
  Total dietary model 1 0.005(-0.005,0.015) 0.346 0 0(-0.011,0.012) 0.95 20.9 0.001(-0.009,0.011) 0.86 0 
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fibre 
 
model 2 0.005(-0.006,0.015) 0.382 0 -0.003(-0.017,0.012) 0.723 36.5 0.001(-0.01,0.011) 0.919 0 
 
model 3 0.005(-0.006,0.015) 0.385 0 -0.004(-0.017,0.01) 0.602 28.6 0.002(-0.009,0.013) 0.76 0 
 
model 4 
   
0(-0.015,0.016) 0.951 24.5 0.001(-0.011,0.013) 0.875 0 
     
    
  Vegetable fibre model 1 -0.001(-0.026,0.024) 0.921 0 -0.008(-0.045,0.03) 0.688 44.7 0.003(-0.023,0.03) 0.81 0 
 
model 2 0.004(-0.026,0.033) 0.802 11.4 -0.013(-0.054,0.029) 0.553 51.1 0.002(-0.025,0.029) 0.897 0 
 
model 3 -0.002(-0.033,0.029) 0.903 10.6 -0.009(-0.048,0.031) 0.66 41.1 0.007(-0.021,0.035) 0.618 0 
 
model 4   
 
-0.011(-0.042,0.02) 0.49 2.1 0.013(-0.019,0.044) 0.433 0 
     
    
  Fruit fibre model 1 0.006(-0.012,0.024) 0.53 0 0(-0.026,0.027) 0.981 40.1 -0.003(-0.029,0.022) 0.79 33.7 
 
model 2 0.005(-0.016,0.027) 0.637 16.2 -0.003(-0.031,0.025) 0.83 43.1 -0.004(-0.034,0.026) 0.799 45.4 
 
model 3 0.004(-0.015,0.023) 0.662 0 -0.006(-0.036,0.025) 0.721 47.1 -0.002(-0.036,0.033) 0.928 54.5 
 
model 4   
 
0.001(-0.042,0.045) 0.948 66.5 -0.001(-0.043,0.041) 0.965 60.2 
     
    
  Cereal fibre model 1 -0.003(-0.019,0.013) 0.695 0 0.003(-0.014,0.02) 0.742 0 0.002(-0.017,0.022) 0.829 17.0 
 
model 2 -0.006(-0.023,0.01) 0.452 0 -0.001(-0.018,0.017) 0.925 0 0.006(-0.012,0.024) 0.52 5.5 
 
model 3 -0.006(-0.023,0.011) 0.472 0 -0.002(-0.021,0.016) 0.795 4.2 0.006(-0.011,0.024) 0.476 0 
  model 4       -0.008(-0.029,0.014) 0.489 5.5 0.006(-0.016,0.028) 0.606 9.8 
Abbreviations: SFA- saturated fatty acid, MUFA- monounsaturated fatty acid, PUFA- polyunsaturated fatty acid, GRS- genetic risk score 
Macronutrients are represented by per 5% of total energy intake and dietary fibre by per g/1000kcal. 
Beta-coefficient for the interaction between each of the genetic risk score with the following macronutrients on incident T2D are adjusted for the following covariates. 
Macronutrient 
Model 1: age (=underlying time scale), sex, centre, total energy (TEI), first 5 principal component (PC) for population stratification 
Model 2: model 1 + lifestyle factors- physical activity, education, smoking, sex-specific alcohol categories 
Model 3: model 2+ dietary covariates (dietary fibre, magnesium, iron, vitamin C, leafy vegetables, tea, coffee) 
Model 4: model 3+ BMI 
Model 5: model 4+ isocaloric macronutrient substitution 
Dietary fibre 
Model 1: age (=underlying time scale), sex, centre, TEI, first 5 PC for population stratification 
Model 2: model 1 + lifestyle factors- physical activity, education, smoking, sex-specific alcohol categories 
Model 3: model 2+ dietary covariates (carbohydrate, SFA, MUFA, PUFA intake, magnesium, iron, vitamin C, leafy vegetable, tea, coffee ) 
Model 4: model 3+ BMI 
fibre subtypes: last model includes mutual adjustment 
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& There is no adjustment for BMI for interactions models with BMI GRS 
Example of interpretation: the beta-coefficient of the interaction between total fat and BMI GRS was 0.001 for incident T2D, when fat replaced carbohydrate intake. However, this was 
not statistically significant because the 95% confidence interval is -0.032 and 0.034. 
Isocaloric macronutrient substitution: α for significant interaction< 6.17E-4 (0.05/81 tests) 
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Appendix G: Individual SNP and macronutrient interactions and incident 
T2D, with p-value for interaction<0.05  
Please note that these interactions are based on isocaloric macronutrient substitution 
modelling detailed in Appendix F. 
GRS: genetic risk score 
snp: single nucleotide polymorphism 
macro: macronutrient intake 
submacro: macronutrient being substituted for (this is being replaced) 
beta: beta coefficient 
se: standard error 
lci: lower confidence interval 
uci: upper confidence interval 
p_int: pvalue for interaction 
i_sq: I squared for heterogeneity 
p_het: pvalue for heterogeneity 
 Threshold for p value for interaction after Bonferroni correction< 9.4E-06 
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GRS snp macro submacro beta se lci uci p_int i_sq p_het
T2D rs3802177 mufa5Ew pufa5Ew -0.194 0.053 -0.298 -0.089 2.954E-04 0.000 0.948
T2D rs3802177 mufa5Ew prot5Ew -0.189 0.053 -0.293 -0.085 3.782E-04 0.000 0.877
T2D rs3802177 mufa5Ew sfa5Ew -0.188 0.053 -0.293 -0.084 4.283E-04 0.000 0.795
BMI rs17724992 prot5Ew fat5Ew -0.179 0.051 -0.279 -0.079 4.473E-04 0.000 0.533
BMI rs17724992 prot5Ew sfa5Ew -0.178 0.051 -0.278 -0.077 0.001 0.000 0.543
T2D rs3802177 mufa5Ew cho5Ew -0.184 0.053 -0.288 -0.080 0.001 0.000 0.653
IR rs6937438 pufa5Ew prot5Ew -0.279 0.084 -0.443 -0.115 0.001 0.000 0.469
IR rs6937438 pufa5Ew sfa5Ew -0.277 0.084 -0.441 -0.112 0.001 0.000 0.437
IR rs6937438 pufa5Ew cho5Ew -0.274 0.084 -0.439 -0.110 0.001 0.000 0.461
BMI rs3849570 cho5Ew sfa5Ew -0.057 0.018 -0.092 -0.023 0.001 0.000 0.579
BMI rs3849570 cho5Ew fat5Ew -0.057 0.018 -0.091 -0.022 0.001 0.000 0.696
BMI rs3849570 cho5Ew protp5Ew -0.056 0.018 -0.091 -0.022 0.001 0.000 0.580
BMI rs3849570 cho5Ew prot5Ew -0.055 0.017 -0.089 -0.021 0.001 0.000 0.658
BMI rs3849570 cho5Ew prota5Ew -0.055 0.017 -0.089 -0.021 0.002 0.000 0.676
BMI rs1928295 prot5Ew sfa5Ew 0.133 0.044 0.046 0.221 0.003 0.000 0.877
BMI rs1928295 prot5Ew fat5Ew 0.130 0.044 0.044 0.217 0.003 0.000 0.794
IR rs2249105 fb_fruit_kcalwfruit 0.044 0.016 0.013 0.075 0.005 0.000 0.816
T2D rs6878122 pufa5Ew sfa5Ew -0.239 0.089 -0.413 -0.066 0.007 8.402 0.365
BMI rs4256980 prota5Ew pufa5Ew -0.110 0.041 -0.191 -0.029 0.008 0.000 0.691
BMI rs17724992 prota5Ew mufa5Ew -0.140 0.053 -0.243 -0.037 0.008 17.576 0.291
BMI rs9540493 protp5Ew prota5Ew -0.269 0.101 -0.467 -0.071 0.008 0.000 0.882
T2D rs6878122 pufa5Ew cho5Ew -0.246 0.093 -0.428 -0.064 0.008 13.219 0.327
BMI rs17724992 prota5Ew sfa5Ew -0.142 0.054 -0.248 -0.037 0.008 20.478 0.267
BMI rs1928295 prota5Ew mufa5Ew 0.106 0.040 0.027 0.185 0.009 0.000 0.652
BMI rs1928295 prota5Ew pufa5Ew 0.106 0.040 0.027 0.185 0.009 0.000 0.592
IR rs17402950 fb_cereal_kcalwfruit -0.091 0.035 -0.160 -0.023 0.009 0.000 0.537
BMI rs4256980 prota5Ew fat5Ew -0.108 0.041 -0.189 -0.027 0.009 0.000 0.751
T2D rs6878122 pufa5Ew prot5Ew -0.265 0.102 -0.466 -0.065 0.009 24.812 0.231
BMI rs17724992 prota5Ew pufa5Ew -0.136 0.053 -0.240 -0.033 0.010 18.324 0.285
BMI rs1928295 prota5Ew sfa5Ew 0.104 0.040 0.024 0.183 0.010 0.000 0.683
BMI rs17724992 prota5Ew fat5Ew -0.143 0.056 -0.253 -0.033 0.011 26.509 0.217
BMI rs3101336 cho5Ew prota5Ew 0.043 0.017 0.010 0.077 0.011 0.000 0.675
BMI rs3101336 cho5Ew prot5Ew 0.043 0.017 0.010 0.076 0.011 0.000 0.623
BMI rs4256980 prot5Ew fat5Ew -0.115 0.045 -0.204 -0.026 0.011 0.000 0.744
BMI rs12446632 fb_kcalw fruitw 0.027 0.011 0.006 0.048 0.011 0.000 0.707
BMI rs3101336 cho5Ew protp5Ew 0.043 0.017 0.010 0.077 0.011 0.000 0.658
BMI rs4256980 prota5Ew mufa5Ew -0.104 0.042 -0.186 -0.023 0.012 0.000 0.652
BMI rs9540493 protp5Ew sfa5Ew -0.255 0.102 -0.454 -0.056 0.012 0.000 0.779
BMI rs9540493 protp5Ew pufa5Ew -0.254 0.102 -0.453 -0.055 0.012 0.000 0.707
BMI rs6091540 fb_veg_kcalwfruit 0.066 0.026 0.014 0.118 0.012 19.607 0.274
BMI rs1928295 prota5Ew fat5Ew 0.101 0.040 0.022 0.180 0.012 0.885 0.422
BMI rs7899106 pufa5Ew prot5Ew 0.336 0.135 0.072 0.600 0.013 0.000 0.815
BMI rs3101336 cho5Ew sfa5Ew 0.043 0.017 0.009 0.077 0.013 0.000 0.779
BMI rs7164727 fb_kcalw fruitw 0.020 0.008 0.004 0.036 0.013 0.000 0.899
T2D rs780094 mufa5Ew prot5Ew -0.122 0.049 -0.219 -0.026 0.013 0.000 0.435
BMI rs9540493 protp5Ew fat5Ew -0.250 0.101 -0.449 -0.052 0.013 0.000 0.681
BMI rs4256980 prot5Ew sfa5Ew -0.112 0.046 -0.202 -0.022 0.014 0.000 0.669
T2D rs2943640 prot5Ew sfa5Ew 0.134 0.055 0.026 0.241 0.015 3.893 0.400
BMI rs9540493 protp5Ew mufa5Ew -0.248 0.102 -0.448 -0.049 0.015 0.000 0.822
BMI rs2112347 fb_cereal_kcalwfruit -0.035 0.014 -0.063 -0.007 0.015 10.756 0.347
BMI rs4256980 prota5Ew sfa5Ew -0.101 0.042 -0.182 -0.019 0.016 0.000 0.728
BMI rs3101336 cho5Ew fat5Ew 0.041 0.017 0.008 0.075 0.016 0.000 0.751
T2D rs163184 fb_kcalw fruitw 0.022 0.009 0.004 0.041 0.017 7.170 0.375
T2D rs12427353 fb_cereal_kcalwfruit -0.048 0.020 -0.088 -0.008 0.019 12.708 0.331
BMI rs7715256 prot5Ew fat5Ew -0.102 0.044 -0.189 -0.015 0.021 0.000 0.922
BMI rs11126666 cho5Ew fat5Ew 0.044 0.019 0.006 0.081 0.022 0.000 0.600
IR rs308971 prot5Ew fat5Ew -0.225 0.098 -0.418 -0.032 0.022 32.020 0.172
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GRS snp macro submacro beta se lci uci p_int i_sq p_het
BMI rs12885454 mufa5Ew prot5Ew -0.100 0.044 -0.185 -0.014 0.022 0.000 0.630
BMI rs1167827 fb_veg_kcalwfruit -0.060 0.026 -0.111 -0.008 0.023 30.928 0.181
BMI rs7899106 pufa5Ew cho5Ew 0.310 0.136 0.043 0.577 0.023 0.000 0.780
BMI rs7715256 prot5Ew sfa5Ew -0.100 0.045 -0.187 -0.012 0.025 0.000 0.757
T2D rs2943640 prot5Ew fat5Ew 0.132 0.059 0.016 0.248 0.026 15.231 0.310
BMI rs492400 fb_kcalw fruitw -0.018 0.008 -0.033 -0.002 0.026 0.000 0.638
IR rs308971 prot5Ew sfa5Ew -0.221 0.099 -0.416 -0.026 0.026 31.916 0.173
BMI rs10132280 fb_fruit_kcalwfruit -0.035 0.016 -0.066 -0.004 0.026 6.174 0.383
BMI rs9540493 cho5Ew prota5Ew -0.040 0.018 -0.075 -0.005 0.026 8.880 0.361
IR rs731839 protp5Ew prota5Ew -0.268 0.122 -0.507 -0.029 0.028 0.000 0.837
IR rs11130329 protp5Ew prota5Ew 0.437 0.199 0.047 0.828 0.028 27.652 0.208
BMI rs11057405 mufa5Ew pufa5Ew -0.180 0.082 -0.341 -0.019 0.029 0.000 0.701
BMI rs2365389 pufa5Ew prot5Ew 0.141 0.065 0.015 0.268 0.029 0.000 0.806
BMI rs9540493 cho5Ew prot5Ew -0.041 0.019 -0.078 -0.004 0.029 15.152 0.311
IR rs7227237 pufa5Ew prot5Ew 0.193 0.089 0.019 0.366 0.029 0.000 0.698
IR rs11130329 protp5Ew mufa5Ew 0.401 0.185 0.038 0.763 0.030 18.978 0.280
T2D rs10203174 fb_fruit_kcalwfruit 0.096 0.044 0.009 0.182 0.030 56.636 0.024
BMI rs1516725 mufa5Ew prot5Ew -0.137 0.063 -0.261 -0.013 0.031 0.000 0.724
IR rs2943645 prot5Ew sfa5Ew 0.127 0.059 0.012 0.242 0.031 14.153 0.319
IR rs11130329 protp5Ew pufa5Ew 0.430 0.199 0.039 0.821 0.031 27.585 0.208
IR rs308971 prota5Ew fat5Ew -0.215 0.100 -0.411 -0.020 0.031 43.961 0.086
BMI rs2112347 protp5Ew prota5Ew -0.216 0.100 -0.413 -0.020 0.031 0.000 0.778
BMI rs11057405 mufa5Ew sfa5Ew -0.178 0.083 -0.340 -0.016 0.031 0.000 0.697
BMI rs7899106 pufa5Ew sfa5Ew 0.297 0.138 0.026 0.567 0.032 0.000 0.734
BMI rs11126666 cho5Ew protp5Ew 0.041 0.019 0.004 0.078 0.032 0.000 0.702
BMI rs3736485 cho5Ew prota5Ew -0.037 0.017 -0.071 -0.003 0.032 3.069 0.406
T2D rs459193 pufa5Ew prot5Ew -0.173 0.081 -0.332 -0.014 0.032 0.000 0.659
IR rs459193 pufa5Ew prot5Ew -0.173 0.081 -0.332 -0.014 0.032 0.000 0.659
BMI rs758747 prota5Ew mufa5Ew -0.097 0.045 -0.186 -0.008 0.033 0.000 0.453
IR rs7227237 pufa5Ew sfa5Ew 0.189 0.089 0.015 0.363 0.033 0.000 0.716
BMI rs2112347 fb_veg_kcalwfruit -0.045 0.021 -0.087 -0.004 0.033 4.548 0.395
BMI rs11126666 cho5Ew sfa5Ew 0.041 0.019 0.003 0.079 0.033 0.000 0.685
IR rs9492443 fb_veg_kcalwfruit 0.055 0.026 0.004 0.105 0.033 0.000 0.879
BMI rs2365389 pufa5Ew cho5Ew 0.138 0.065 0.011 0.265 0.033 0.000 0.859
BMI rs1167827 fb_fruit_kcalwfruit -0.029 0.014 -0.056 -0.002 0.033 0.000 0.589
IR rs11130329 protp5Ew sfa5Ew 0.407 0.192 0.032 0.783 0.034 22.975 0.246
BMI rs2033529 fb_kcalw fruitw 0.018 0.008 0.001 0.034 0.034 0.000 0.851
BMI rs7239883 prot5Ew sfa5Ew 0.096 0.045 0.007 0.185 0.034 0.000 0.795
BMI rs12885454 mufa5Ew pufa5Ew -0.093 0.044 -0.180 -0.007 0.034 0.000 0.532
BMI rs7164727 fb_cereal_kcalwfruit 0.030 0.014 0.002 0.058 0.035 6.473 0.380
BMI rs758747 prota5Ew fat5Ew -0.095 0.045 -0.184 -0.007 0.035 0.000 0.507
BMI rs2033732 protp5Ew fat5Ew -0.252 0.120 -0.487 -0.018 0.035 0.000 0.495
IR rs308971 prota5Ew mufa5Ew -0.216 0.102 -0.417 -0.015 0.035 45.999 0.073
T2D rs2943640 protp5Ew pufa5Ew 0.251 0.119 0.017 0.485 0.035 0.000 0.534
BMI rs11126666 cho5Ew prot5Ew 0.040 0.019 0.003 0.076 0.036 0.000 0.578
BMI rs13107325 prota5Ew pufa5Ew -0.168 0.080 -0.325 -0.011 0.036 0.000 0.612
BMI rs2112347 protp5Ew mufa5Ew -0.212 0.101 -0.410 -0.014 0.036 0.000 0.676
IR rs7227237 pufa5Ew cho5Ew 0.186 0.088 0.012 0.359 0.036 0.000 0.715
T2D rs780094 mufa5Ew pufa5Ew -0.111 0.053 -0.215 -0.007 0.036 5.329 0.389
IR rs731839 protp5Ew sfa5Ew -0.257 0.122 -0.497 -0.017 0.036 0.000 0.833
BMI rs11126666 cho5Ew prota5Ew 0.039 0.019 0.003 0.076 0.036 0.000 0.601
T2D rs2943640 protp5Ew prota5Ew 0.248 0.119 0.016 0.481 0.036 0.000 0.611
BMI rs11057405 mufa5Ew prot5Ew -0.170 0.081 -0.330 -0.010 0.037 0.000 0.719
T2D rs780094 mufa5Ew sfa5Ew -0.111 0.053 -0.214 -0.007 0.037 5.075 0.391
T2D rs2943640 protp5Ew fat5Ew 0.248 0.119 0.015 0.481 0.037 0.000 0.572
T2D rs3802177 protp5Ew pufa5Ew 0.263 0.127 0.015 0.511 0.037 0.000 0.968
BMI rs2365389 pufa5Ew sfa5Ew 0.135 0.065 0.008 0.262 0.038 0.000 0.814
T2D rs11634397 pufa5Ew prot5Ew -0.164 0.079 -0.320 -0.009 0.038 0.000 0.867
BMI rs7239883 prot5Ew fat5Ew 0.094 0.045 0.005 0.182 0.038 0.000 0.779
BMI rs6091540 fb_kcalw fruitw 0.018 0.009 0.001 0.035 0.038 0.000 0.591
IR rs308971 prota5Ew sfa5Ew -0.203 0.098 -0.396 -0.011 0.038 40.995 0.105
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GRS snp macro submacro beta se lci uci p_int i_sq p_het
BMI rs10733682 cho5Ew prot5Ew 0.039 0.019 0.002 0.076 0.038 15.983 0.304
IR rs11130329 protp5Ew fat5Ew 0.406 0.196 0.022 0.790 0.038 26.203 0.220
IR rs3864041 fb_cereal_kcalwfruit 0.044 0.021 0.002 0.085 0.038 37.562 0.130
BMI rs2033732 protp5Ew mufa5Ew -0.249 0.120 -0.485 -0.013 0.038 0.000 0.633
T2D rs2075423 fb_cereal_kcalwfruit 0.035 0.017 0.002 0.068 0.039 8.408 0.365
BMI rs1516725 mufa5Ew pufa5Ew -0.132 0.064 -0.258 -0.007 0.039 0.000 0.873
BMI rs11057405 mufa5Ew cho5Ew -0.170 0.082 -0.331 -0.008 0.039 0.000 0.721
BMI rs2112347 protp5Ew pufa5Ew -0.208 0.101 -0.406 -0.010 0.040 0.000 0.711
BMI rs543874 fb_veg_kcalwfruit -0.053 0.026 -0.103 -0.003 0.040 0.922 0.422
BMI rs12885454 mufa5Ew cho5Ew -0.091 0.044 -0.177 -0.004 0.040 0.000 0.586
T2D rs10278336 fb_veg_kcalwfruit -0.055 0.027 -0.107 -0.002 0.040 19.091 0.279
BMI rs10733682 cho5Ew prota5Ew 0.038 0.019 0.002 0.075 0.040 15.642 0.307
BMI rs758747 prota5Ew pufa5Ew -0.093 0.045 -0.181 -0.004 0.040 0.000 0.508
BMI rs10733682 cho5Ew sfa5Ew 0.036 0.018 0.002 0.071 0.041 6.244 0.382
BMI rs758747 prota5Ew sfa5Ew -0.093 0.045 -0.182 -0.004 0.041 0.000 0.506
T2D rs2943640 protp5Ew mufa5Ew 0.243 0.119 0.010 0.477 0.041 0.000 0.602
BMI rs1516725 mufa5Ew cho5Ew -0.130 0.064 -0.255 -0.005 0.041 0.000 0.857
BMI rs2112347 protp5Ew sfa5Ew -0.206 0.101 -0.404 -0.008 0.041 0.000 0.755
BMI rs758747 prot5Ew fat5Ew -0.100 0.049 -0.197 -0.004 0.041 0.000 0.747
IR rs308971 prota5Ew pufa5Ew -0.203 0.099 -0.397 -0.008 0.041 42.777 0.093
IR rs731839 protp5Ew pufa5Ew -0.249 0.122 -0.489 -0.010 0.041 0.000 0.757
T2D rs3802177 cho5Ew prota5Ew 0.047 0.023 0.002 0.092 0.041 7.864 0.369
BMI rs16851483 cho5Ew prota5Ew -0.073 0.036 -0.143 -0.003 0.042 0.000 0.669
T2D rs780094 mufa5Ew cho5Ew -0.112 0.055 -0.219 -0.004 0.042 8.556 0.364
BMI rs9540493 cho5Ew protp5Ew -0.038 0.019 -0.074 -0.001 0.042 11.755 0.339
BMI rs2365389 protp5Ew pufa5Ew -0.281 0.138 -0.551 -0.011 0.042 39.244 0.117
BMI rs13078960 pufa5Ew prot5Ew 0.157 0.077 0.006 0.308 0.042 0.000 0.564
IR rs7973683 cho5Ew fat5Ew -0.040 0.019 -0.078 -0.001 0.042 0.000 0.694
BMI rs9540493 cho5Ew sfa5Ew -0.036 0.018 -0.071 -0.001 0.042 5.137 0.391
T2D rs11634397 pufa5Ew cho5Ew -0.161 0.080 -0.317 -0.005 0.043 0.000 0.849
T2D rs2943640 protp5Ew sfa5Ew 0.241 0.119 0.008 0.475 0.043 0.000 0.575
IR rs6066149 protp5Ew prota5Ew -0.274 0.135 -0.539 -0.009 0.043 0.000 0.532
BMI rs1516725 mufa5Ew sfa5Ew -0.130 0.064 -0.255 -0.004 0.043 0.000 0.848
BMI rs2365389 protp5Ew fat5Ew -0.263 0.130 -0.517 -0.008 0.043 33.496 0.161
T2D rs780094 pufa5Ew sfa5Ew 0.204 0.101 0.006 0.402 0.043 31.397 0.177
BMI rs13107325 prota5Ew fat5Ew -0.162 0.080 -0.319 -0.005 0.043 0.000 0.694
BMI rs2365389 protp5Ew mufa5Ew -0.278 0.138 -0.549 -0.008 0.044 39.794 0.114
IR rs11130329 fb_kcalw fruitw 0.035 0.017 0.001 0.068 0.044 38.063 0.126
BMI rs12885454 mufa5Ew sfa5Ew -0.089 0.044 -0.176 -0.002 0.044 0.000 0.534
IR rs1045241 prota5Ew sfa5Ew 0.105 0.052 0.003 0.208 0.044 0.000 0.633
BMI rs13107325 prota5Ew mufa5Ew -0.161 0.080 -0.318 -0.004 0.045 0.000 0.674
BMI rs2033732 protp5Ew prota5Ew -0.241 0.120 -0.477 -0.006 0.045 0.000 0.590
IR rs3864041 protp5Ew sfa5Ew 0.241 0.120 0.006 0.477 0.045 0.000 0.875
BMI rs2365389 protp5Ew sfa5Ew -0.280 0.140 -0.553 -0.006 0.045 40.412 0.109
IR rs731839 protp5Ew fat5Ew -0.244 0.122 -0.483 -0.005 0.045 0.000 0.770
BMI rs13078960 pufa5Ew sfa5Ew 0.155 0.077 0.003 0.307 0.045 0.000 0.727
BMI rs10733682 cho5Ew protp5Ew 0.036 0.018 0.001 0.071 0.046 9.665 0.355
IR rs3864041 protp5Ew pufa5Ew 0.240 0.120 0.004 0.475 0.046 0.000 0.793
BMI rs2820292 pufa5Ew cho5Ew 0.133 0.067 0.002 0.265 0.046 0.000 0.750
T2D rs849135 prot5Ew fat5Ew 0.101 0.051 0.002 0.201 0.046 0.000 0.670
T2D rs11634397 pufa5Ew sfa5Ew -0.158 0.079 -0.313 -0.002 0.047 0.000 0.820
T2D rs3802177 protp5Ew mufa5Ew 0.250 0.126 0.003 0.498 0.048 0.000 0.974
BMI rs2820292 pufa5Ew sfa5Ew 0.133 0.067 0.001 0.264 0.048 0.000 0.803
BMI rs16851483 cho5Ew prot5Ew -0.071 0.036 -0.141 -0.001 0.048 0.000 0.656
BMI rs2033732 protp5Ew sfa5Ew -0.238 0.121 -0.475 -0.002 0.048 0.000 0.474
T2D rs11257655 pufa5Ew sfa5Ew 0.251 0.127 0.002 0.501 0.048 37.663 0.129
BMI rs3736485 cho5Ew prot5Ew -0.034 0.017 -0.069 0.000 0.049 5.429 0.388
BMI rs16851483 cho5Ew fat5Ew -0.071 0.036 -0.142 0.000 0.049 0.000 0.808
IR rs7973683 cho5Ew prota5Ew -0.039 0.020 -0.077 0.000 0.049 0.000 0.663
BMI rs977747 prota5Ew sfa5Ew -0.096 0.049 -0.191 0.000 0.049 22.840 0.248
IR rs1045241 prota5Ew mufa5Ew 0.103 0.052 0.000 0.206 0.049 0.000 0.687
BMI rs11727676 protp5Ew fat5Ew 0.379 0.193 0.001 0.757 0.049 0.000 0.713
BMI rs758747 prot5Ew sfa5Ew -0.097 0.050 -0.194 0.000 0.050 0.000 0.708
T2D rs11257655 pufa5Ew cho5Ew 0.256 0.130 0.000 0.511 0.050 39.751 0.114
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Appendix H: Individual SNP and food and beverage interactions and 
incident T2D, with p-value for interaction<0.05  
Please note that these interactions are based on model 4 detailed in Table 6-4.  
GRS: genetic risk score 
snp: single nucleotide polymorphism 
beta: beta coefficient 
se: standard error 
lci: lower confidence interval 
uci: upper confidence interval 
p_int: pvalue for interaction 
i_sq: I squared for heterogeneity 
p_het: pvalue for heterogeneity 
T2D: type 2 diabetes 
IR: insulin resistance 
BMI: body mass index 
ssb: sugar sweetened beverage 
 
 Threshold for p value for interaction after Bonferroni correction< p<1.71E-05 
Please note: 
All foods and beverages are per 100g or 100ml, except for nuts and seeds which is per 30g 
This analysis includes 7 of the 8 countries. France was excluded because of the spurious 
interactions arising, likely due to low sample size. 
We also checked the analysis by merging France with Germany and the results were very similar. 
 
 
  
 
256 
 
GRS snp Food or beverage beta se lci uci p_int i_sq p_het
T2D rs6878122 wholegrain -0.201 0.052 -0.303 -0.098 1.269E-04 0.000 0.499
BMI rs2820292 coffee 0.027 0.007 0.012 0.042 3.028E-04 0.000 0.449
T2D rs11063069 tea 0.045 0.013 0.020 0.071 4.941E-04 0.000 0.704
T2D rs10278336 green leafy vegetables -0.261 0.083 -0.423 -0.098 0.002 0.000 0.817
BMI rs10132280 fruit -0.047 0.015 -0.077 -0.018 0.002 0.000 0.696
BMI rs13107325 nuts and seeds 0.840 0.271 0.310 1.371 0.002 0.000 0.440
IR rs1045241 fruit -0.057 0.018 -0.093 -0.021 0.002 0.000 0.805
BMI rs3736485 nuts and seeds -0.375 0.124 -0.619 -0.131 0.003 0.000 0.766
T2D rs459193 tea -0.038 0.013 -0.063 -0.013 0.003 0.000 0.880
T2D rs7177055 ssb -0.071 0.024 -0.119 -0.024 0.003 0.000 0.517
BMI rs2033732 rice -0.393 0.134 -0.655 -0.130 0.003 0.000 0.956
T2D rs2334499 ssb 0.088 0.031 0.027 0.149 0.005 34.113 0.168
BMI rs1441264 ssb 0.061 0.022 0.018 0.103 0.005 0.000 0.850
IR rs11577194 rice -0.352 0.127 -0.600 -0.103 0.005 0.000 0.536
T2D rs6795735 fish 0.567 0.207 0.162 0.972 0.006 0.000 0.605
BMI rs3849570 egg and egg products 0.402 0.147 0.113 0.691 0.006 0.000 0.704
BMI rs4740619 fish 0.480 0.178 0.131 0.829 0.007 0.000 0.815
T2D rs7177055 tea 0.033 0.012 0.009 0.057 0.007 0.250 0.422
BMI rs7164727 wholegrain 0.121 0.046 0.031 0.212 0.009 1.809 0.411
T2D rs7756992 root vegetables -0.316 0.121 -0.553 -0.079 0.009 1.767 0.411
BMI rs3849570 fish 0.477 0.185 0.114 0.841 0.010 0.000 0.987
IR rs8101064 processed meat -0.612 0.241 -1.084 -0.140 0.011 0.000 0.684
IR rs754814 green leafy vegetables -0.223 0.088 -0.396 -0.050 0.011 0.000 0.924
BMI rs205262 coffee 0.020 0.008 0.004 0.037 0.012 0.000 0.470
T2D rs7177055 red meat -0.222 0.089 -0.397 -0.047 0.013 0.000 0.942
BMI rs2836754 fruit 0.037 0.015 0.008 0.066 0.013 0.000 0.796
BMI rs7599312 ssb 0.053 0.022 0.011 0.095 0.014 0.000 0.596
BMI rs16907751 green leafy vegetables -0.282 0.116 -0.510 -0.055 0.015 0.000 0.936
IR rs4804311 legumes -0.451 0.186 -0.816 -0.085 0.016 0.000 0.479
T2D rs10830963 nuts and seeds -0.371 0.154 -0.673 -0.070 0.016 0.000 0.898
T2D rs13389219 ssb 0.065 0.027 0.012 0.119 0.016 23.648 0.249
T2D rs849135 fermented dairy -0.075 0.031 -0.137 -0.014 0.017 0.000 0.457
BMI rs9914578 nuts and seeds -0.385 0.163 -0.705 -0.066 0.018 0.000 0.697
BMI rs7599312 tea 0.024 0.010 0.004 0.044 0.019 0.000 0.675
BMI rs9374842 ssb 0.063 0.027 0.011 0.116 0.019 22.663 0.256
T2D rs11717195 egg and egg products 0.456 0.195 0.075 0.838 0.019 2.037 0.409
BMI rs2080454 red meat -0.168 0.072 -0.310 -0.026 0.020 0.000 0.763
T2D rs1496653 ssb -0.077 0.033 -0.142 -0.012 0.021 17.238 0.298
BMI rs3810291 legumes 0.363 0.157 0.055 0.670 0.021 7.275 0.370
IR rs10195252 ssb 0.057 0.025 0.008 0.106 0.022 13.853 0.324
IR rs6066149 tea 0.052 0.023 0.007 0.096 0.024 43.827 0.099
BMI rs13078960 nuts and seeds 0.324 0.144 0.042 0.607 0.024 0.000 0.621
BMI rs9540493 egg and egg products 0.321 0.142 0.041 0.600 0.024 0.000 0.656
T2D rs11651052 ssb -0.057 0.025 -0.106 -0.007 0.025 5.262 0.387
IR rs645040 fish -0.618 0.275 -1.158 -0.079 0.025 14.291 0.321
BMI rs6091540 root vegetables 0.235 0.104 0.030 0.439 0.025 0.000 0.997
T2D rs243088 legumes -0.314 0.140 -0.588 -0.039 0.025 0.000 0.469
BMI rs12566985 nuts and seeds 0.286 0.128 0.035 0.538 0.025 0.000 0.633
BMI rs16907751 processed meat -0.310 0.139 -0.582 -0.038 0.025 15.906 0.309
T2D rs10401969 legumes 0.675 0.304 0.078 1.271 0.027 0.000 0.734
IR rs683135 fermented dairy 0.094 0.043 0.011 0.178 0.027 31.238 0.190
BMI rs12286929 egg and egg products 0.307 0.139 0.035 0.580 0.027 0.000 0.600
IR rs132985 fermented dairy 0.066 0.030 0.007 0.124 0.028 0.000 0.843
IR rs683135 tea 0.037 0.017 0.004 0.070 0.028 23.774 0.248
BMI rs2820292 legumes 0.550 0.250 0.060 1.040 0.028 37.236 0.158
T2D rs11063069 rice 0.342 0.156 0.036 0.648 0.028 0.000 0.672
T2D rs6878122 green leafy vegetables -0.176 0.081 -0.335 -0.018 0.029 0.000 0.835
BMI rs9641123 ssb 0.048 0.022 0.005 0.091 0.029 0.000 0.466
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GRS snp Food or beverage beta se lci uci p_int i_sq p_het
T2D rs13233731 green leafy vegetables 0.284 0.132 0.025 0.543 0.031 12.941 0.331
T2D rs7177055 coffee -0.020 0.009 -0.037 -0.002 0.032 0.000 0.450
BMI rs2075650 processed meat -0.246 0.115 -0.472 -0.021 0.032 0.000 0.507
T2D rs1552224 wholegrain 0.149 0.070 0.013 0.285 0.032 0.000 0.905
BMI rs543874 ssb 0.056 0.026 0.005 0.107 0.033 0.000 0.866
BMI rs3849570 red meat 0.154 0.072 0.013 0.296 0.033 0.000 0.467
BMI rs9914578 green leafy vegetables -0.268 0.126 -0.514 -0.022 0.033 6.431 0.379
BMI rs6804842 egg and egg products 0.301 0.141 0.024 0.577 0.033 0.000 0.802
T2D rs2261181 nuts and seeds 0.911 0.428 0.072 1.750 0.033 60.030 0.020
BMI rs3101336 egg and egg products -0.307 0.144 -0.590 -0.025 0.033 0.000 0.808
T2D rs1801282 fruit 0.065 0.030 0.005 0.124 0.034 15.950 0.308
BMI rs1928295 ssb -0.042 0.020 -0.080 -0.003 0.034 0.000 0.747
BMI rs10132280 root vegetables 0.230 0.109 0.017 0.444 0.034 0.000 0.732
IR rs9881942 egg and egg products -0.340 0.161 -0.655 -0.024 0.035 0.000 0.756
IR rs731839 fermented dairy 0.069 0.033 0.005 0.133 0.035 0.000 0.804
BMI rs4256980 tea 0.031 0.015 0.002 0.060 0.035 25.466 0.234
T2D rs1359790 ssb 0.122 0.058 0.008 0.236 0.035 76.633 0.000
BMI rs2365389 wholegrain -0.090 0.043 -0.174 -0.006 0.036 0.000 0.620
T2D rs6795735 red meat 0.169 0.080 0.011 0.326 0.036 0.000 0.785
BMI rs12401738 ssb 0.047 0.023 0.003 0.091 0.036 8.460 0.364
IR rs498313 green leafy vegetables -0.237 0.113 -0.459 -0.015 0.037 4.368 0.393
BMI rs1167827 processed meat 0.224 0.108 0.013 0.435 0.037 38.178 0.138
IR rs498313 fish -0.455 0.220 -0.886 -0.025 0.038 0.000 0.779
T2D rs10830963 root vegetables -0.230 0.112 -0.449 -0.012 0.039 0.000 0.796
BMI rs1558902 legumes -0.262 0.127 -0.511 -0.013 0.039 0.000 0.640
BMI rs17094222 fish 0.549 0.266 0.027 1.071 0.039 14.466 0.319
T2D rs10278336 rice 0.265 0.129 0.013 0.517 0.039 0.000 0.571
BMI rs1516725 tea -0.029 0.014 -0.057 -0.001 0.040 0.000 0.872
T2D rs12427353 wholegrain -0.128 0.062 -0.250 -0.006 0.040 0.000 0.553
IR rs2699429 fish 0.416 0.203 0.019 0.814 0.040 0.000 0.482
IR rs2126259 legumes -0.509 0.248 -0.995 -0.024 0.040 0.000 0.691
BMI rs7243357 ssb -0.056 0.027 -0.109 -0.002 0.040 0.000 0.620
BMI rs4256980 red meat -0.148 0.072 -0.289 -0.006 0.040 0.000 0.784
IR rs17402950 wholegrain -0.252 0.124 -0.495 -0.010 0.041 12.991 0.331
IR rs3861397 fermented dairy 0.065 0.032 0.002 0.128 0.042 0.000 0.707
BMI rs11165643 green leafy vegetables -0.155 0.076 -0.304 -0.005 0.043 0.000 0.669
BMI rs2176040 nuts and seeds 0.270 0.133 0.009 0.531 0.043 0.000 0.453
IR rs132985 egg and egg products 0.422 0.208 0.014 0.831 0.043 29.194 0.205
BMI rs11126666 red meat -0.161 0.079 -0.316 -0.005 0.043 0.000 0.774
BMI rs17001654 fish -0.493 0.244 -0.972 -0.015 0.043 0.000 0.928
IR rs498313 nuts and seeds 0.462 0.230 0.011 0.914 0.045 42.676 0.106
IR rs2126259 fish 0.698 0.348 0.016 1.380 0.045 0.000 0.442
IR rs11130329 legumes 0.971 0.483 0.024 1.919 0.045 50.035 0.075
BMI rs12429545 coffee -0.020 0.010 -0.040 0.000 0.045 0.000 0.424
IR rs6822892 fish -0.420 0.210 -0.830 -0.009 0.045 0.000 0.847
T2D rs17168486 tea 0.057 0.029 0.001 0.113 0.045 51.205 0.056
BMI rs6091540 processed meat -0.170 0.085 -0.336 -0.003 0.046 0.000 0.891
T2D rs10923931 fermented dairy 0.137 0.069 0.002 0.271 0.046 37.788 0.140
BMI rs11191560 ssb 0.073 0.037 0.001 0.146 0.047 8.405 0.364
T2D rs7202877 rice -0.546 0.276 -1.086 -0.006 0.048 33.410 0.173
IR rs132985 fish -0.515 0.261 -1.027 -0.004 0.048 23.666 0.249
IR rs2434612 red meat -0.191 0.097 -0.380 -0.001 0.048 0.000 0.647
BMI rs12940622 green leafy vegetables -0.153 0.078 -0.305 -0.001 0.049 0.000 0.844
BMI rs12446632 coffee -0.021 0.011 -0.042 0.000 0.049 0.000 0.576
BMI rs3101336 rice 0.231 0.117 0.001 0.461 0.049 0.000 0.526
T2D rs10401969 tea 0.035 0.018 0.000 0.069 0.049 0.965 0.417
T2D rs13233731 red meat 0.215 0.110 0.000 0.431 0.050 40.426 0.122
BMI rs7899106 ssb 0.147 0.075 0.000 0.294 0.050 52.242 0.051
IR rs6937438 fermented dairy 0.068 0.035 0.000 0.135 0.050 0.000 0.551
IR rs7005992 ssb 0.085 0.044 0.000 0.171 0.050 39.576 0.128
IR rs2126259 green leafy vegetables -1.086 0.555 -2.174 0.001 0.050 69.477 0.003
BMI rs2207139 wholegrain -0.140 0.072 -0.281 0.000 0.050 31.884 0.185
BMI rs2836754 fish -0.379 0.194 -0.759 0.001 0.050 0.000 0.453
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Appendix I:  Top 5 SNPs for each macronutrient from a genome-
environment-wide- interaction-study for the risk of developing Type 2 
Diabetes 
 
Table: Top five hits from the GEWIS of each respective macronutrient intake and incident T2D (EPIC-
InterAct) 
Macro- 
nutrient SNP 
Chromosome: 
position: effect 
allele: other allele Gene (in/near) 
Effect 
allele 
freq- 
uency β SE p 
Carbohydrate rs3112356 7:135396031_A_G SLC13A4 0.23 0.12 0.03 2.42E-06 
 
rs8138283 22:49841479_A_G C22orf34 0.66 0.10 0.02 5.14E-06 
 
rs116950933 8:145959416_G_A LOC107986986 0.02 -0.55 0.12 5.89E-06 
 
rs2359460 3:23111674_A_G intergenic 0.91 0.15 0.03 6.17E-06 
 
rs4902166 14:63123208_G_T intergenic 0.85 -0.14 0.03 6.87E-06 
Protein  rs61810167 1:163082778_T_C RGS5 0.99 -1.97 0.39 3.93E-07 
 
rs186453404  14:87109364_T_C intergenic 0.99 -0.97 0.20 1.44E-06 
 
rs10999966  10:73468137_G_A CDH23 0.04 0.50 0.11 1.67E-06 
 
rs141413593  17:75763769_C_G intergenic 0.96 -0.54 0.11 2.35E-06 
 
rs11786114 8:102321001_C_T RNU7-67P 0.03 -0.63 0.13 2.84E-06 
SFA rs73652097 9:81385044_T_C intergenic 0.88 -0.32 0.07 1.41E-06 
 
rs7725760 5:39556805_A_G intergenic 0.78 -0.22 0.05 1.97E-06 
 
rs12338311  9:81385696_A_G intergenic 0.88 -0.31 0.07 1.98E-06 
 
 rs142865342 21:46284404_C_T PTTG1IP 0.01 0.90 0.19 2.30E-06 
 
rs2962495 5:39574354_A_G CCDC11P1 0.23 0.22 0.05 2.96E-06 
PUFA rs11003372 10:54840408_G_A intergenic 0.22 0.62 0.13 1.33E-06 
 
rs12099307 11:125990750_G_T intergenic 0.07 0.68 0.15 4.99E-06 
 
rs12099306 11:125990749_G_C intergenic 0.07 0.68 0.15 5.06E-06 
 
rs146302320  8:140889848_G_A TRAPPC9 0.01 1.02 0.23 6.27E-06 
 
rs72793267 10:52965186_C_T PRKG1 0.05 1.02 0.23 6.77E-06 
Cereal fibre rs4689848 4:7751894_C_T AFAP1-AS1 0.33 -0.07 0.01 1.29E-07 
 
rs4689849 4:7752174_C_T AFAP1-AS1 0.34 -0.07 0.01 2.32E-07 
 
rs11721409 4:7753417_C_T AFAP1-AS1 0.34 -0.07 0.01 7.30E-07 
 
 rs4018903  3:193900347_A_G intergenic 0.54 -0.08 0.02 7.64E-07 
 
rs6855176 4:7753403_C_G AFAP1-AS1 0.34 -0.07 0.01 7.74E-07 
Effect estimates for the interaction between macronutrient intake (per 5% total energy intake or per g/1000kcal for 
cereal fibre) and per risk allele of the respective SNP on incident T2D. Abbreviations: SFA- saturated fat, MUFA- 
monounsaturated fat, PUFA- polyunsaturated fat, N- number, SE- standard error, p- value for interaction 
 
